

Recent Results in Cancer Research
P.M. Schlag · H.-J. Senn *Series Editors*

Janusz A. Z. Jankowski
Editor

Inflammation and Gastrointestinal Cancers

Indexed in PubMed/Medline

 Springer

Recent Results in Cancer Research

Volume 185

Managing Editors

P. M. Schlag, Berlin, Germany

H.-J. Senn, St. Gallen, Switzerland

Associate Editors

P. Kleihues, Zürich, Switzerland

F. Stiefel, Lausanne, Switzerland

B. Groner, Frankfurt, Germany

A. Wallgren, Göteborg, Sweden

Founding Editor

P. Rentsch, Geneva, Switzerland

For further volumes:

<http://www.springer.com/series/392>

Janusz A. Z. Jankowski
Editor

Inflammation and Gastrointestinal Cancers

Prof. Dr. Janusz A. Z. Jankowski
Department of Oncology
University of Oxford
Old Road Campus
Headington
OX3 7DG
UK
e-mail: janusz.jankowski@clinpharm.ox.ac.uk

ISSN 0080-0015

ISBN 978-3-642-03502-9

e-ISBN 978-3-642-03503-6

DOI 10.1007/978-3-642-03503-6

Springer Heidelberg Dordrecht London New York

© Springer-Verlag Berlin Heidelberg 2011

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover design: eStudio Calamar, Berlin/Figueres

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Contents

Basic Concepts of Inflammation and its Role in Carcinogenesis	1
1 Introduction	2
2 Overview of Inflammation.....	2
3 Cancer and Inflammation.....	5
3.1 Cancer Initiation Events.....	8
3.2 Cancer Promotion Events	9
4 Inflammatory Infiltrate in the Tumour Microenvironment	10
4.1 Macrophages.....	11
4.2 Mast Cells.....	13
4.3 Neutrophils	15
4.4 T Cells	16
5 Genetic Influences of Inflammation and Cancer.....	18
6 Concluding Remarks	24
References.....	24
Inherited Syndromes Predisposing to Inflammation and GI Cancer	35
1 Introduction	36
2 Role of Inflammation in Mendelian Gastrointestinal Disease	
Polyposis Syndromes	37
2.1 Polyposis Syndromes: Familial Adenomatous Polyposis.....	37
2.2 Polyposis Syndromes: Peutz-Jeughers Syndrome.....	38
2.3 Polyposis Syndromes: Juvenile Polyposis Syndrome.....	39
2.4 Polyposis Syndromes: Lynch Syndrome or Hereditary	
Non-Polyposis Colon Cancer.....	39
3 Non-Mendelian Association of Inflammation and Cancer.....	41
3.1 Oesophageal Cancer.....	41
3.2 Coeliac Disease Inflammation and Cancer Sequence	42
3.3 Inflammatory Bowel Disease and Cancer.....	43
3.4 Gastric Cancer and Inflammatory Genes	44
4 Conclusion	44
References.....	45

Stem Cells and Inflammation in the Intestine	51
1 The Colonic Crypt.....	52
1.1 Multi-Potential Stem Cells are Housed Within a Basal Niche: The Crypt Hierarchy	53
1.2 Stem Cell Number.....	53
1.3 Lineage Progenitors.....	55
1.4 Determinants of Cell Fate.....	56
1.5 Stem Cell Dynamics: Colonic Crypts are Clonal Populations	57
1.6 Mechanisms of Fixation.....	58
2 The Effects of Inflammation on Stem Cells and their Niche	59
3 Concluding Remarks	60
References.....	61
Acid Reflux and Oesophageal Cancer	65
1 Inflammation in GI Cancer.....	67
2 Gastro-Oesophageal Reflux Disease.....	68
3 Inflammation and Gastro-Oesophageal Reflux Disease	69
4 Inflammation and Barrett's Metaplasia.....	70
4.1 TNF- α	71
4.2 COX-2.....	71
4.3 NF- κ B	72
4.4 Interleukins	72
4.5 p53	73
4.6 CDX1 and CDX2	73
4.7 p16	74
4.8 Reactive Oxygen Species.....	74
4.9 Polymorphisms in Inflammatory Agents.....	74
5 Anti-Inflammatory Therapies and Clinical Management of Oesophageal Adenocarcinoma.....	76
5.1 Proton Pump Inhibitors	76
5.2 Non-Steroidal Anti-Inflammatories	76
6 Clinical Trials and Future Treatment of Acid Reflux and Oesophageal Cancer.....	77
6.1 Current Treatment for Oesophageal Adenocarcinoma	77
6.2 Anti-TNF Therapy.....	77
6.3 Aspirin and PPI's	77
6.4 Surveillance of Barrett's Patients	78
6.5 Other Studies	79
References.....	79
<i>Helicobacter pylori</i> and Gastric Cancer	83
1 Introduction	84
2 Pathogenesis	85
2.1 Bacterial Factors.....	87

2.2	Host Factors.....	90
2.3	Environmental Factors	91
3	Treatment.....	92
4	Conclusion	93
	References.....	93
	Inflammatory Bowel Disease and Colon Cancer	99
1	Introduction	100
2	Genetic Epidemiology of IBD Aetiology	101
2.1	Genetic Variation in Inflammation-Related Genes.....	101
3	Comparison of Carcinogenesis Pathways in Sporadic and Colitis-Associated Colorectal Cancer.....	104
3.1	Genetic Instability	104
3.2	Role of Inflammation in Cancer Epigenetics.....	106
4	Mutator Phenotype versus Clonal Expansion	107
5	Field Cancerisation.....	108
6	Screening and Detection	109
6.1	Endoscopic Screening	109
6.2	Biomarkers.....	109
7	Chemoprevention.....	109
8	Future Perspectives	110
8.1	Biological Therapies and Cancer.....	110
8.2	Stem Cell Therapy	110
	References.....	111
	Primary Sclerosing Cholangitis	117
1	Introduction	118
2	Epidemiology.....	118
3	Aetiopathogenesis.....	119
4	Clinical Features and Diagnosis	120
5	Malignancies in PSC.....	122
5.1	Cholangiocarcinoma.....	122
5.2	Other Malignancies in PSC	123
5.3	Chemoprevention.....	125
5.4	Treatment.....	126
	References.....	128
	Chronic Inflammation and Hepatocellular Carcinoma	135
1	Introduction	136
2	Hepatitis B virus	136
3	Hepatitis C virus	138
4	Signalling Pathways Linking Inflammation and HCC Development.....	138

5	Obesity	142
6	Liver Regeneration and Carcinogenesis	143
7	Conclusions	146
	References.....	146
	Gastrointestinal Cancer: Current Screening Strategies	149
1	Introduction	150
2	Oesophageal Cancer	150
3	Screening for Oesophageal Squamous Cancer	151
4	Screening for Oesophageal Adenocarcinoma (Barrett's Cancers)	152
5	Screening for Adenocarcinoma and Lymphoma of the Stomach	153
6	Small Intestine Inflammation: Crohns Disease.....	154
7	Inflammatory Bowel Disease: Colorectal Adenocarcinoma.....	155
8	Conclusions	156
	References.....	156
	Targeted Drug Therapies and Cancer	159
1	Cell Signalling Networks and Potential Targets.....	160
2	Targeted Therapies in Gastrointestinal Cancers	160
	2.1 Tyrosine Kinase Cell Receptor Families.....	160
	2.2 VEGF Inhibitor	164
	2.3 Small Molecule TK Inhibitor	165
3	Network Interactions and Resistance to Targeted Therapies	167
4	Conclusion	168
	References.....	168
	Genetics of Inflammation in the Gastrointestinal Tract and How it Can Cause Cancer	173
1	<i>Helicobacter pylori</i> and Gastric Cancer.....	174
2	Role of IL-1 β in Gastric Cancer Risk.....	175
3	Confirmation of the Role of IL-1 β in Gastric Cancer Pathogenesis.....	177
4	Tumour Necrosis Alpha (TNF- α).....	177
5	Interleukin-8	177
6	COX-2 and MMP-9	178
7	Role of Innate Immune Response Genes.....	179
8	Genome-Wide Association Studies and Gastric Cancer.....	180
9	Overall Contribution of a Host Pro-Inflammatory Genetic Makeup to Pathogenesis of Gastric Cancer	180
10	Conclusion	181
	References.....	181

Endoscopic Methods	185
1 Endoscopic Methods	186
2 Inflammation and Cancer.....	186
3 Fundamental Endoscopic Principles	186
3.1 Preparation.....	186
3.2 Basic Concepts	187
3.3 Philosophy of Endoscopy	187
3.4 Oesophageal Cancer.....	187
3.5 Treatment.....	190
4 The Stomach.....	191
4.1 Treatment.....	192
5 The Colon.....	193
6 Endoscopic Resection of DALMS	194
7 Conclusions	195
References.....	195

Basic Concepts of Inflammation and its Role in Carcinogenesis

Stephen G. Maher and John V. Reynolds

Abstract

While the normal inflammatory cascade is self-limiting and crucial for host protection against invading pathogens and in the repair of damaged tissue, a wealth of evidence suggests that chronic inflammation is the engine driving carcinogenesis. Over a period of almost 150 years the link between inflammation and cancer development has been well established. In this chapter we discuss the fundamental concepts and mechanisms behind normal inflammation as it pertains to wound healing. We further discuss the association of inflammation and its role in carcinogenesis, highlighting the different stages of cancer development, namely tumour initiation, promotion and progression. With both the innate and adaptive arms of the immune system being central to the inflammatory process, we examine the role of a number of immune effectors in contributing to the carcinogenic process. In addition, we highlight the influences of host genetics in altering cancer risk.

Contents

1	Introduction.....	2
2	Overview of Inflammation.....	2
3	Cancer and Inflammation.....	5
3.1	Cancer Initiation Events.....	8
3.2	Cancer Promotion Events.....	9

S. G. Maher · J. V. Reynolds (✉)
Department of Surgery, Institute of Molecular Medicine,
Trinity College Dublin and St. James's Hospital,
Dublin 8, Ireland
e-mail: reynoldsjv@stjames.ie

S. G. Maher
e-mail: maherst@tcd.ie

J. A. Z. Jankowski (ed.), *Inflammation and Gastrointestinal Cancers*,
Recent Results in Cancer Research 185, DOI: 10.1007/978-3-642-03503-6_1,
© Springer-Verlag Berlin Heidelberg 2011

4	Inflammatory Infiltrate in the Tumour Microenvironment.....	10
4.1	Macrophages.....	11
4.2	Mast Cells.....	13
4.3	Neutrophils.....	15
4.4	T Cells.....	16
5	Genetic Influences of Inflammation and Cancer.....	18
6	Concluding Remarks.....	24
	References.....	24

1 Introduction

The nineteenth century saw much advancement in the biological sciences. Darwin published his theories on evolution in *The Origin of Species*, Koch developed his postulates on microbial infection, Pasteur developed the first vaccine, and Mendel studied the genetics of inheritance. Although less heralded, it was also an era when the first report of an association between inflammation and cancer was recorded. In 1863, Rudolf Virchow hypothesised that immune cell infiltrate reflected the origins of cancer at sites of chronic inflammation (Balkwill and Mantovani 2001).

The cellular basis for inflammation and cancer is now well understood. Under normal physiological conditions, inflammation is usually associated with tissue injury and arises via innate immunity. The innate immune system, comprised of macrophages, mast cells, dendritic cells, granulocytes (neutrophils, eosinophils and basophils) and the innate lymphocytes (natural killer (NK) and $\gamma\delta$ T cells), is a non-specific first line defence against invading pathogens. Following wounding, the cells of the innate immune system converge at the site of damage. Macrophages engulf and consume pathogens, mast cells release histamine, and the granulocytes produce cytokines and chemokines that promote inflammation. Dendritic cells in the area pick up antigens from pathogens and present them to naïve T cells in the lymph nodes for the development of an adaptive immune response, while NK cells destroy host cells that have been infected with the invading pathogen (Fig. 1). The physiological response to cancer has many parallels with inflammation and wound healing. During normal tissue injury, cell proliferation is enhanced while the tissue regenerates; the proliferation and inflammation subside once the assaulting agent/pathogen is removed or the tissue is repaired. In contrast, as occurs with tumours, proliferating cells that sustain DNA damage and/or mutagenic assault continue to proliferate in microenvironments rich in inflammatory cells and growth/survival factors that support their growth. Because of this, tumours are likened to wounds that fail to heal.

2 Overview of Inflammation

Inflammation is a complex biological response. To understand the role that inflammation plays in carcinogenesis it is important to understand what inflammation is, and how it contributes to physiological and pathological processes,




Fig. 1 Normal wound healing. During the wound healing process activated platelets from the circulatory system produce clotting proteins and form a plug. Platelets release chemotactic factors, recruiting leucocyte populations from the periphery to the site of injury. Mast cells release vasoactive amines, which mediate vasodilation and vascular constriction. Neutrophils secrete antimicrobial peptides and together with macrophages phagocytose invading pathogens. Tissue-resident macrophages secrete an array of cytokines that attract immune cells to the wound and activate cells involved in the repair process. The inflammatory process continues until invading pathogens are neutralised and the wound is repaired

including wound healing and infection. Inflammation can be defined by the four Latin words *calor*, *dolor*, *rubor* and *tumor*, meaning heat, pain, redness, and swelling, all of which reflect the effects of cytokines and other inflammatory mediators on the local blood vessels. Dilation and increased permeability of the blood vessels during inflammation lead to increased core blood flow and vascular leakage, and account for the heat, redness and swelling. Cytokines alter the adhesive properties of the endothelium, causing circulating leucocytes to stick to the blood vessel wall and migrate between the endothelial cells to the site of injury along chemokine gradients. The migration of cells into the tissue and their local actions account for the pain.

Inflammation is a fundamental adaptation to the loss of cellular and tissue homeostasis with many important roles, including host defence, but also tissue remodelling and repair, and the regulation of metabolism (Hotamisligil 2006; Medzhitov 2008; Nathan 2002). The complexity of the inflammatory response requires that many of its functions are controlled in a coordinate manner in some situations, but independently in others. This is achieved via multiple mechanisms, including alterations in the composition of immune cells in tissues, changes in cellular responsiveness to inflammatory stimuli, regulation of signalling pathways and control at the level of gene expression (Medzhitov and Hornig 2009). Thus, the different mechanisms regulating the inflammatory responses can be divided into cell-specific, signal-specific and gene-specific mechanisms.

Upon injury to tissue, a multifactorial network of chemical signals initiate and maintain a host response designed to destroy invading pathogens at the site and repair the damaged tissue. This involves the activation and directed migration of leucocytes (neutrophils, monocytes and eosinophils) from the venous system to the site of damage. Chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leucocyte populations, recruit downstream effector cells and dictate the natural evolution of the inflammatory response. Mast cells and tissue-resident macrophages are the first host tissue cells to become activated in response to injury, and orchestrate the series of events that follow (Coussens and Werb 2002; Mantovani et al. 2008). Residing along blood vessel walls, mast cells are activated via Fc receptors and by components of the complement system (C3a and C5a) and danger signals that are generated by the presence of bacteria or immune complexes. Activated mast cells release preformed and newly synthesised inflammatory mediators, such as vasoactive amines (e.g., histamine), cytokines and proteases complexed to highly sulphated proteoglycans, as well as lipid mediators, which promote the early vascular response observed in inflammation (Marshall 2004). This response is characterised by transient arteriolar constriction followed by dilatation of veins and capillaries, and an increase in vascular permeability (Le Bitoux and Stamenkovic 2008).

Macrophages are also activated by Fc crosslinking and C3a and C5a fragments, and by mediators released by damaged cells and the chemotactic fMLP (N-formyl-methionyl-leucyl-phenylalanine) peptide, a component of bacterial cell walls. Macrophages produce an array of proinflammatory cytokines, including IL-1 and TNF- α . These cytokines work in synergy, with similar effects of the vasculature, including endothelial cell (EC) activation and expression of members of the selectin family of adhesion proteins, such as L-, E- and P-selectin as well as ICAM-1 on the EC surface. L-, E-, P-selectin recognise sialylated and fucosylated oligosaccharides on the E-selectin ligand (ESL) and P-selectin glycoprotein ligand-1 (PSGL-1) expressed on the surface of neutrophils, monocytes, and certain lymphocyte subsets (Hidalgo et al. 2007; Le Bitoux and Stamenkovic 2008). The interaction between the selectins on ECs and their cognate ligands facilitates leucocyte adhesion through $\alpha_4\beta_1$ and $\alpha_4\beta_7$ integrins binding to endothelial vascular cell-adhesion molecule-1 (VCAM-1) and MadCAM-1, respectively, and rolling across the vascular endothelium. Neutrophils and monocytes are activated by chemokines, CXCL8 being one example, through G-protein coupled receptors on their surface. These molecules originate from the activated ECs and macrophages, which are stimulated to produce them in response to proximal cell-cell contact. The activated neutrophils arrest on the endothelium and subsequently extravasate into the tissue by a process known as diapedesis (Muller 2009). Following extravasation, the activated leucocytes migrate towards the site of injury and to the provisional extracellular matrix that forms a scaffold upon which fibroblasts and endothelial cells proliferate and migrate, thus providing a nexus for reconstitution of the normal microenvironment (Coussens and Werb 2002). At the wound, neutrophils engulf and breakdown invading pathogens. Within hours, the local activated endothelial adhesion receptors and chemokine/cytokine repertoire adapt

to recruit additional leucocyte subpopulations. Following the initial wave of neutrophils, infiltration by monocytes, which differentiate into macrophages in tissues, is guided by chemotactic factors (Kamei and Carman 2010). Activated macrophages are the main source of lipid mediators, growth factors and cytokines, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming growth factor (TGF) β , which profoundly affect endothelial, epithelial and mesenchymal cells in the local tissue/wound microenvironment. The infiltrate also releases proteolytic factors, such as matrix metalloproteinases (MMPs) and cathepsins, which participate in the subsequent breakdown of extracellular matrix components.

By nature, the inflammatory cascade is self-limiting, and as the etiologic agents are gradually diminished, the balance of cytokines, chemokines, growth factors and lipid mediators, shifts from inflammation-driven tissue remodelling to tissue repair. A key factor in this process is a switch from the production of proinflammatory prostaglandins to antiinflammatory lipoxins (Serhan and Savill 2005). The production of lipoxins results in the recruitment of monocytes, which, following differentiation into macrophages, remove cellular debris at the site of injury and coordinate repair.

During a normal inflammatory reaction, if the acute inflammatory response fails to eliminate the cause of injury, the inflammatory response may persist but acquires new features. Monocytes and macrophages, and in some cases lymphocytes, replace the infiltrating neutrophils. If this remains insufficient to clear the tissue of the pathogen a chronic inflammatory state develops. Depending on the pathogen and type of host response, the inflammation may be granulomatous or lymphocytic in nature, with the formation of tertiary lymphoid tissues. The profile of cytokine/chemokines persisting at an inflammatory site is important in the development of chronic disease. Being well established in the literature, chronic inflammation is associated with carcinogenesis.

3 Cancer and Inflammation

Cancer results from the expansion of a clonal population of cells from within a tissue. Over the last number of decades, studies on different types of cancer have led to the development of models characterising their growth. This characterisation process has revealed the essential features of cancer development, termed the 'hallmarks of cancer' (Hanahan and Weinberg 2000). Exposure of tissue to physical injury, ischemia, toxins, or infectious agents, induces inflammation. Inflammatory reactions can stimulate antitumour immune responses, but also have the capacity to promote tumour development. There is a vast amount of epidemiological and clinical data supporting an increased risk of certain cancers in the setting of chronic inflammation. Basic research has shown that many of the processes involved in inflammation (e.g., leucocyte migration, local vascular dilation and enhanced permeability and angiogenesis), when found in association with tumours, are more likely to contribute to

tumour growth, progression and metastasis, than to elicit an effective host anti-tumour immune response.

Through epidemiological studies it is now estimated that about 15–20% of all cancers are attributable, or are associated with, chronic inflammation due to infectious agents, chemical and physical agents and autoimmune reactions (Karin 2008; Kuper et al. 2000). Primary examples are hepatocellular carcinoma and viral hepatitis (Fattovich et al. 2004), gastric adenocarcinoma and gastric lymphoma with *Helicobacter pylori* infection (Roder 2002), colitis-associated cancer and oesophageal adenocarcinoma from Barrett's oesophagus (Ekblom 1998) (Table 1). Intriguingly, inflammation is an integral component at all three stages of tumour development: initiation, promotion and progression (Fig. 2). Inflammation, resulting from tissue injury, contributes to tumour initiation events by stimulating the release of a variety of chemokines and cytokines, which alert the vasculature to allow inflammatory cells and mediators access into the tissue microenvironment. These inflammatory mediators may cause oxidative damage, induce DNA mutations, and other changes in the microenvironment, making it more conducive to cellular transformation, increased cell survival and proliferation. However, the precise mechanism whereby chronic inflammation contributes to tumour progression remains unclear. Tumour cells produce various chemotactic factors that attract inflammatory cells, which then secrete an array of soluble mediators, stimulating further proliferation of the initiated cell, tissue disruption in the stroma, and tumour growth. Leucocyte infiltration, and particularly macrophages, can lead to enhanced angiogenesis, predominantly via VEGF, which is associated with a poor prognosis for a number of tumours. The role of inflammation in the metastatic spread of a tumour is much less well-defined than its role in cancer initiation and progression. Soluble mediators produced by tumour-associated leucocytes promote cell motility, induce angiogenesis, vascular dilatation and the extravasation of tumour cells. Inflammation continues to play a role at metastatic sites by creating a new cytokine milieu conducive to tumour growth.

While the body has a strong reaction to wounding and infection in terms of the humoral and cellular responses, overall its response to tumours is relatively weak. This may be linked to the fact that most tumour antigens are recognised as 'self'. There are a number of factors that determine the repertoire of immune infiltrate found in the tumour microenvironment, with hypoxia being a dominant driving force. Once tumours grow 2 mm beyond the nearest blood supply the oxygen tension drops dramatically, and the tumour cells begin to activate and express hypoxia-responsive genes (Denko et al. 2003). The hypoxic tumour environment favours the infiltration of immune infiltrate dependent on the glycolytic pathway for survival, such as macrophages and granulocytes. These infiltrating cells generate reactive oxygen species (ROS) upon local activation. These ROS are immunosuppressive, mediating their effects through nuclear factor kappa B (NF κ B) activation, the major inflammatory transcription factor. The activation of NF κ B in the tumour cells themselves can lead to the expression of cytokines, TNF- α among others, which can ultimately drive tumour growth (Balkwill and Coussens 2004; Greten et al. 2004; Pikarsky et al. 2004). As tumours become

Table 1 Agents associated with inflammation and cancer. Adapted from Coussens and Werb (2002) and Hold and El-Omar (2008)

Agents	Inflammation/Cancer Association
Viral	
HIV	Kaposi's sarcoma Squamous cell carcinoma Non-Hodgkin's lymphoma
HBV/HCV	Hepatitis/hepatocellular carcinoma
EBV	Nasopharyngeal carcinoma Malignant lymphoma
HHV8	Kaposi's sarcoma Squamous cell carcinoma Non-Hodgkin's lymphoma
HTLV-1	T cell lymphoma Leukaemia
HPV	Cervical carcinoma Ovarian carcinoma Anogenital carcinoma Penile carcinoma
CMV	Gastric carcinoma
Bacterial	
<i>H. pylori</i>	Gastritis/gastric carcinoma
<i>C. trachomatis</i>	Cervical carcinoma
<i>E. coli</i>	Prostate dysplasia/atypical hyperplasia
Parasitic	
Chinese liver fluke	Cholangiocarcinoma
Schistosomiasis	Chronic cystitis/bladder carcinoma
Liver fluke (<i>Opisthorchis viverrini</i>)	Cholangiocarcinoma/colon cancer
Chemical	
Asbestos	Malignant mesothelioma
Fumes, smoking, etc.	Lung cancer
Other inflammatory	
Chronic pancreatitis	Pancreatic carcinoma
Chronic prostatitis	Prostate carcinoma
Endometriosis	Endometrial adenocarcinoma
Pelvic inflammatory disease	Ovarian cancer
Inflammatory bowel disease	Colorectal cancer
Thyroiditis	Papillary thyroid carcinoma
Primary sclerosing cholangitis	Cholangiocarcinoma
Chronic cholecystitis	Gall bladder carcinoma




Fig. 2 The stages of tumourigenesis. During chronic inflammation, cells of the innate immune system, such as the macrophage, mediate tumour initiation events via production of DNA-damaging reactive oxygen and nitrogen species (ROS/RNS). Macrophages also produce proinflammatory cytokines, such as IL-1 and TNF- α , which can recruit and stimulate other immune effectors through the activation of the NF κ B transcription factor. These immune effectors, such as T cells, produce an array of factors, facilitating angiogenesis and tissue remodelling. As healthy cells progress through the tumour initiation stage and onto the promotion stage they acquire new mutations and dysregulations, leading to tumour progression, which is associated with the 6 hallmarks of cancer. Adapted from Waldner and Neurath (2009)

dependent on these soluble factors the microenvironment is adjusted or programmed so that the release of these factors is continual. Thus, cell proliferation, differentiation, angiogenesis, cell migration and matrix remodelling are all 'reprogrammed' to benefit the tumour.

3.1 Cancer Initiation Events

The vast majority of tumours arise due to one or several genetic mutations that lead to the production of proteins with altered tertiary structure, frequently leading to dysregulation of normal biological function. Although inflammation is a vital response for the resolution of infection, repair of damaged tissue and in the suppression of tumour formation, chronic inflammation is also clearly correlated with increased risk of cancer development. Peyton Rous was the first to recognise that cancers develop from *subthreshold neoplastic states* induced by viral or chemical carcinogens that induce somatic changes (Rous and Kidd 1941). These states, now known as 'initiation' events, involve DNA alterations, which are irreversible and

can exist in a benign state in otherwise normal tissue indefinitely, until the occurrence of a second type of stimulatory event, the ‘promotion’ event. Hereditary mutations can also act as initiation events. While normal inflammatory processes are self-limiting, there are a number of reasons why acute inflammation may develop into a chronic state: the inflammatory stimulus may persist (such as that in colonic ulcerative colitis, Crohn’s disease or gastroesophageal reflux disease), or there is dysregulation in the control mechanisms that normally switch off the proinflammatory reaction. In addition, it may also be due to the persistence of initiation factors.

One of the major advances in beginning to understand the relationship between inflammation and cancer came from murine models of chemically-induced cancer, showing that the carcinogenic process could be broken into a number of sequential steps including initiation, promotion and progression (Foulds 1954; Hecker 1967; Philip et al. 2004; Rous and Beard 1935; Rous and Kidd 1941). From this data, a working hypothesis was proposed. During the course of life, humans accumulate somatic mutations in different cell types within the various tissues. These mutations are induced by exposure to undetectable or trace amounts of carcinogens, or can arise spontaneously. These are referred to as ‘initiation events’. Subsequently, inflammation can act as a ‘promoter’ to either induce more mutations in these cells, for example through exposure to ROS, or drive the mutated cells to proliferate. Inflammation may also provide the damaged cells with a growth advantage, this has been referred to as a ‘Darwinian selection’ (Klein and Klein 1985).

The molecular basis for the increased risk of cancer, in the background of chronic inflammation, is largely considered to be two-fold. Firstly, macrophages in the tissue microenvironment produce a number of factors, including ROS and reactive nitrogen species (RNS). These reactive species lead to DNA damage in the surrounding epithelial cells. Secondly, enhanced proliferation signals, necessary for tissue regeneration, mediated by cytokines released from immune cells increase the number of cells at risk of mutation. Combining both of these signals, DNA damage and proliferation, provides an environment favourable to carcinogenesis. ROS and RNS can induce significant permanent genetic damage, stimulating recombination events, resulting in the production of aberrant protein species and dysregulated cellular signalling (Fig. 3). Under normal conditions it is estimated that reactive species induce approximately 10,000 oxidative lesions per cell per day, with any number of these being potentially mutagenic (Loft and Poulsen 1996). ROS can also activate certain signalling cascades and transcription factors, including NF κ B, which triggers pro-survival and anti-apoptotic mechanisms.

3.2 Cancer Promotion Events

The precise mechanisms and signals stimulated by inflammation for the promotion of tumour progression are largely unclear. Tumour promotion can result from exposure of ‘initiated’ cells to damage, be this via chemical irritants, factors




Fig. 3 The role of reactive oxygen species in tumourigenesis. Various exogenous and endogenous stimuli can result in the generation of DNA- and protein-damaging reactive oxygen species (ROS). Polymorphisms in DNA repair and oxidative enzyme genes, encoding proteins with altered functional activity, can alter cellular efficacy in regulating ROS-mediated damage. ROS can promote genomic instability and mutation, as well as damage RNA and protein, resulting in altered gene expression. When these factors combine, inflamed pre-malignant tissue acquires a propensity to tumourigenesis. Adapted from Klaunig et al. (2010) and Kundu and Surh (2008)

released at the site of tissue damage, partial organ resection, hormones, chronic irritation or inflammation. Functionally, many tumour promoters induce cell proliferation, recruit inflammatory cells, increase production of ROS leading to oxidative DNA damage, and reduce DNA repair. Induced oncogenes such as c-Myc have also been reported by TNF- α stimulates in Barrett's metaplasia (Tselepis et al. 2003). Subversion of cell death and/or repair programmes occurs in chronically inflamed tissues, thus resulting in DNA replication and proliferation of cells that have lost normal growth control. Chronic inflammation appears to be due to persistence of the initiating factors or a failure of the mechanisms required to resolve the inflammatory response. It is this sustained inflammatory response that ultimately confers increased risk for carcinogenic progression.

4 Inflammatory Infiltrate in the Tumour Microenvironment

The presence of inflammatory infiltrate within tumour microenvironments is taken as evidence that the host is not ignorant of a developing tumour, and attempts to interfere with its progression (Whiteside 2008; Zitvogel et al. 2006). There have been numerous studies linking inflammatory infiltrate with improved prognosis or increased survival (Baxevanis et al. 1994; Galon et al. 2006; Kornstein et al. 1983; Naito et al. 1998; Pages et al. 2005). The microenvironment of tumours, including the stroma scaffolding, contains a myriad of leucocytes. These leucocytes produce proinflammatory mediators; cytokines, chemokines and growth factors that promote tumour growth and alter the inflammatory status of the tumour, and some of the key players are discussed below.

4.1 Macrophages

Macrophages make up the major component of the total cellular infiltrate within most tumours (Mantovani et al. 1992). These tumour-associated macrophages (TAMs) are originally derived from monocytes, which enter into the tumour via chemotaxis mediated mainly by monocyte chemotactic proteins (MCPs) released from the microenvironment. Many tumours produce colony-stimulating factors that enhance the survival of TAMs. This was shown by Pollard et al. who found that knocking out the CSF-1 gene in mice engineered to develop breast cancer, significantly decreased the rate of progression to malignancy and metastatic spread in these animals (Lin et al. 2001). IL-2-, interferon- γ and IL-12-activated TAMs can promote tumour cell death, or disrupt the tumour vasculature. However, TAMs also produce growth factors and angiogenic factors as well as extracellular matrix (ECM)-degrading proteases. As early as the 1970s it was noted that TAMs promoted tumour growth both *in vitro* and *in vivo* and that a high frequency infiltration of macrophages into tumours was associated with a poor prognosis. For example, genes associated with leucocyte or macrophage infiltration, such as *CD68*, herald poor prognosis for breast carcinomas and lymphomas (Dave et al. 2004). In addition, functional single nucleotide polymorphisms in IL-1 and TNF- α are associated with an increased risk of cancer progression (Balkwill and Mantovani 2001). Consequently, TAMs can promote tumour cell proliferation, matrix-remodelling, angiogenesis, invasion and metastasis.

Toll-like receptors (TLRs) are central to direct pathogen recognition by innate immune cells, and represent a critical link between innate and adaptive immunity. Macrophages, and mast cells, express a range of TLRs, which include TLR-1, -2, -3, -4, -6 and -9. Macrophages are directly activated by TLRs upon interaction with pathogen-associated molecular patterns (PAMPS), such as lipopolysaccharide (LPS) on gram-negative bacteria via TLR-4, peptidoglycan on gram-positive bacteria via TLR-2 and viral dsRNA via TLR-3. Polarised macrophages can be classed as either M1 or M2, similar to the T_H nomenclature used for cells of the T cell lineage. M1 macrophages are stimulated by IFN- γ or bacterial wall products like LPS, as well as cytokines such as TNF- α and GM-CSF. M2 macrophages are induced by IL-4 and IL-13. The M1 macrophage phenotype is IL-12^{high}, IL-23^{high}, IL-10^{low}, and they efficiently produce TNF- α , IL-1, IL-6, ROS and RNS. The M2 phenotype is IL-12^{low}, IL-23^{low}, IL-10^{high}. M1 macrophages act as inducers and effectors in T cell T_H1 responses and mediate resistance against tumours. Conversely, M2 macrophages promote tumour proliferation and progression, stromal deposition, tissue repair and remodelling, angiogenesis, lymphangiogenesis, and have suppressive effects on adaptive immune capacity (Albini et al. 2005; De Palma et al. 2005; Nakao et al. 2005; Wyckoff et al. 2004). Most macrophages found in the tumour microenvironment are skewed to the M2 phenotype (Biswas et al. 2006).

In the development of melanoma, activated macrophages produce TGF- β , TNF- α and IL-1- α and ECM-degrading proteases (Torisu et al. 2000). TAMs also

produce cytokines such as IL-10, which downregulates the anti-tumour responses of cytotoxic lymphocytes (CTLs) and is correlated with poor prognosis (Bingle et al. 2002). Other studies have shown that tumour accumulation of TAMs is associated with the increased production of proangiogenic factors including VEGF and PDGF (Birkwell and Mantovani 2001). Hypoxic areas within tumour micro-environments stimulate macrophage infiltration and result in macrophage-mediated production of proangiogenic factors, such as VEGF, TNF- α , bFGF, and CXCL8. The role of CXCL8 in angiogenesis remains unclear, with some reports of anti-angiogenic activity, as well as some describing pro-angiogenic activity.

In gastrointestinal cancers, there are a number of essential elements for carcinogenesis and the metastatic phenotype, which include TNF- α , IL-1, macrophage CSF-1 and CCL2, COX-2, the master inflammatory transcription factor NF κ B, and a number of enzymes involved in tissue remodelling (Balkwill et al. 2005; Balkwill and Mantovani 2001; Coussens and Werb 2002; Koehne and Dubois 2004; Mantovani et al. 2008; Pikarsky et al. 2004; Voronov et al. 2003; Wyckoff et al. 2004).

VEGF stimulates lymphangiogenesis by stimulating its cognate receptors expressed on the surface of endothelial cells. Consistent with what is known about TAMs, it has been shown recently in renal cell carcinoma, that VEGF levels were higher in more aggressive (high grade, larger tumours, or symptomatic) RCC. Indeed, patients with symptoms, large tumours, or high grade tumours displayed higher levels of TAMs (Toge et al. 2009). VEGF levels and TAM numbers were higher in patients with recurrence compared to those without recurrence. While VEGF, TAMs, CD34 expression, tumour stage and grade were identified as prognostic factors in a univariate analysis, only TAMs acted as an independent prognostic factor by multivariate analysis (Toge et al. 2009). Using a CT26 colon cancer cell line and RAW 264.7 macrophage model it has been shown that CT26-stimulated macrophages upregulate SDF-1 α and VEGF, and that these cytokines contribute to CT26 migration *in vitro* (Green et al. 2009). CSF-1 was revealed as the major chemoattractant for RAW 264.7 macrophages in this system. Interestingly, Green et al. found in the CAM (chick chorioallantoic membrane) model of tumour progression and angiogenesis that RAW 264.7 macrophages localised specifically to the tumour periphery, where they were found to increase CT26 tumour growth, microvessel density, vascular disruption and lung metastasis. They suggest that these cells home to actively invading areas of the tumour, but not the hypoxic core of the mass. Supporting this observation, they found that hypoxia downregulated CSF-1 production in several cell lines and decreased RAW 264.7 macrophage migration *in vitro* (Green et al. 2009). In breast cancer, TAM infiltration is associated with the levels of macrophage chemoattractant protein-1 (MCP-1) (Ueno et al. 2000). MCP-1 expression levels also correlated with the expression of several other proangiogenic factors, including VEGF, TNF- α , CXCL8 and thymidine phosphorylase (TP).

Proinflammatory TNF- α is a key downstream mediator in inflammation. Despite the name, TNF- α is important in early events in tumours, regulating a cascade of cytokines, chemokines, adhesion molecules, MMPs and pro-angiogenic activities.

While high-dose, locally-administered TNF- α can result in an acute and dramatic regression of tumours (Lejeune et al. 1998), it may be surprising that two independent studies demonstrated that the TNF signalling pathway was required for the induction of skin tumours (Moore et al. 1999; Sukanuma et al. 1999). Using a syngeneic TNF knockout mouse model, Sukanuma et al. showed that all the animals were virtually protected against two-stage carcinogenesis when DMBA was used as a tumour initiator and when TPA was used as a promoter. Thus, TNF- α may be one of the ways in which inflammation acts as a tumour promoter. The role of TNF- α in the promotion of tumour progression is a classic example of how tumours usurp a normal inflammatory process to promote their own growth and survival. These data suggest that blocking antibodies that have significant therapeutic efficacy in other inflammatory diseases, such as rheumatoid arthritis, may have applications in therapy for cancer.

4.2 Mast Cells

Mast cells are one of the first host tissue cells to become activated in response to injury. Mast cells originate from haematopoietic stem cells in the bone marrow, and terminally differentiate in their target tissues (Chen et al. 2005; Galli 1990). Tissue-resident mast cells are primarily found in areas of the body regularly exposed to pathogens and parasites, such as the airway, gut and skin. Activated mast cells release preformed and newly synthesised inflammatory mediators, such as vasoactive histamine, cytokines and proteases, as well as lipid mediators, which promote transient arteriolar constriction followed by dilatation of veins and capillaries, and an increase in vascular permeability (Le Bitoux and Stamenkovic 2008). Since the late nineteenth century mast cells have been recognised to infiltrate the leading edge of tumours, at the interface between normal and tumour tissue. The effects of mast cells on tumours can be divided into two general categories, direct and indirect. Direct effects of mast cells include mast cell-mediated tumour cell cytotoxicity, whereas the indirect effects include angiogenesis, tissue remodelling and immune cell recruitment. Mast cells are recognised as an early and persistent infiltration into the tumour environment, even before significant tumour growth and angiogenesis has been established. Many of the theories behind mast cell functions in tumours are based upon their known roles in wound healing and infection. It is well established that, *in vitro*, mast cells migrate towards supernatants derived from tumourigenic cell lines, but not primary or non-tumour forming lines. In addition, to tumour-specific homing, progenitor mast cells constitutively home to mucosal tissues, such as the gut and airway (Abonia et al. 2005; Gurish et al. 2001), and mast cell accumulation also occurs at sites of healing and infection. Therefore, the tissue site of tumour development and localised inflammation also likely contribute to mast cell recruitment via tumour-mediated pathways (Maltby et al. 2009).

Mast cells in close proximity to tumour tissue are frequently observed to associate with the vasculature, suggesting that they may indeed play a role in

angiogenesis via the production of pro-angiogenic factors including VEGF, TNF- α , histamine and bFGF. It has been suggested that the infiltration of mast cells into the environment of a developing tumour triggers an 'angiogenic switch'. Early in its development, a tumour is heavily reliant on mast cells to orchestrate pro-angiogenic events, whereas at later stages the tumour has become autonomous in its growth and becomes mast cell-independent (Coussens et al. 1999). In one study, mast cells localised to blood vessels during the hyperplastic stage of tumour growth in a transgenic murine model, where animals were engineered to express HPV16 genes in basal keratinocytes, promoting early tumour development. It was found that mast cell accumulation was greatest near angiogenic lesions, during periods of intense angiogenesis, but remained absent within the interior tumour microenvironment. Indeed, the absence of mast cells in the interior of these tumours may be linked to a lack of staining due to degranulation, but the preponderance of data available on mast cell localisation to vascular regions would suggest otherwise.

Mast cells are critical mediators of tissue remodelling, a process central to wound repair and the growth of tumours. They perform this function through the production of proteases, which destroy protein in the extracellular matrix. These proteases possess chymase, tryptase and carboxypeptidase activities. Mast cell-mediated destruction of the extracellular matrix is considered to aid tumour dissemination and to facilitate tumour growth via stimulation of angiogenesis; destruction of the extracellular matrix results in the release of factors such as FGF and SCF, thereby increasing endothelial cell migration and neovascularisation (Maltby et al. 2009).

Mast cells are loaded with enzyme-containing granules that promote inflammation. Activation of mast cells occurs through cell surface receptor crosslinking by an array of ligands. Mast cells also display complement fragment receptors for C3a and C5a, as well as C4a, immunological by-products of an infection, which mediate indirect mast cell activation. Mast cells also express receptors for the Fc portions of both IgE and IgG. Activation of mast cells stimulates two potential outcomes: an immediate response involving the exocytosis of preformed mediators contained within granules, or a subsequent upregulation in the production of *de novo* synthesised proinflammatory molecules. *De novo* synthesised mediators include lipid mediators, such as leukotriene (LT) C₄, LTB₄ and prostaglandin D₂, which are involved in allergic and proinflammatory responses (Bischoff 2007; Marshall 2004). While anaphylactic degranulation is responsible for the pathology of immediate type I hypersensitivity and innate immune responses, piecemeal degranulation is thought to play a role in chronic inflammatory disorders and cancers. The production of these proinflammatory cytokines also occurs in parallel to the production of chemokines. Mast cells have long been recognised to recruit and activate T and B cell populations and to recruit eosinophils and neutrophils. They produce T_h2-skewing cytokines, such as IL-4, IL-5 and IL-13, as well as T_h1-skewing cytokines, such as IFN- γ , IL-12 and IL-18. Activated mast cells produce several of the CC- and CXC-chemokines, such as CCL5 and CXCL8, which recruit immune cells to sites of infection (Marshall 2004). Mast cells have

also been shown to express MHC class II molecules and CD28, and to activate T cells *in vitro* (Nakae et al. 2006; Vincent-Schneider et al. 2001). Their location at tissue boundaries makes them one of the first immune cells to encounter invading pathogens, and as such they have been suggested to play a role in initiating immune responses. Furthermore, it has been hypothesised that mast cells may precipitate early tumour rejection by stimulating early T and NK cell responses, perhaps via their antigen presentation capacity, however, this remains both controversial and unclear.

4.3 Neutrophils

There are two pools of neutrophils in circulation; the circulating pool and the marginate pool. The circulating pool consists of neutrophils that circulate freely, while the marginated pool consists of neutrophils that are sequestered to the microvascular endothelium. The marginated pool can be mobilised to the circulating pool upon receipt of acute inflammation signals, in the form of cytokines, such as IL-6. Neutrophils are recruited to sites of inflammation and tumours from the circulating pool (Friedman 2002; Tazzyman et al. 2009). In response to tissue injury, activated neutrophils arrest on the endothelium and subsequently extravasate into the tissue. The extravasation process is often accompanied by plasma fluid and protein leakage (Sarelius et al. 2006). The associated swelling at sites of inflammation is attributable to this vascular leakage. While the leakage itself is largely considered to be due to mechanical disruption mediated by transmigration of neutrophils across the endothelial barrier, an emerging paradigm emphasises a dynamic and reversible interaction between the endothelium and vasoactive mediators released from neutrophils during adhesion and migration (Yuan et al. 2002). Vascular endothelial cells respond to neutrophil activation through a Src- and RhoA-dependent endothelial cell-cell interaction, which is characterised by VE-cadherin and β -catenin phosphorylation and disorganisation of adherens junctions. This response is coupled with MLC phosphorylation-dependent cytoskeletal contraction (Kumar et al. 2009; Tinsley et al. 2002; Yuan et al. 2002). It has also been shown that oxidants and cytokines released by neutrophils cause endothelial hyperpermeability by activating the contractile machinery and opening cell-cell junctions through associated signalling pathways. Cytokines derived from activated leucocytes, such as neutrophils, mediate the upregulation of endothelial adhesion molecules, such as ICAM-1, VCAM-1 and E-selectin. These molecules interact with their ligands on activated leucocytes to mediate rolling and arrest on the endothelial surface, followed by subsequent diapedesis. Following extravasation, the activated neutrophils chemotax towards the site of injury via interaction of chemokines, or tumour/stroma-derived CXCL8, with G-protein coupled receptors on their surface. At the wound, neutrophils engulf and break down invading pathogens.

Neutrophils have long been known to play an important role in normal physiological angiogenesis. For example, neutrophils act as the source for VEGF

during the proliferation and growth of the endometrium during the menstrual cycle. There is now an abundance of evidence showing that neutrophils may play an important role in both tumour and inflammatory angiogenesis. In an *in vivo* corneal model, neutrophil depletion significantly attenuated inflammatory angiogenesis, and reduced the protein levels of VEGF, MIP-1 alpha and MIP-2 in the cornea (Gong and Koh 2009). In a mouse model of multistage carcinogenesis, Nozawa et al. (2006) showed that MMP-9-expressing neutrophils are predominantly found inside angiogenic islet dysplasias and tumours. Transient neutrophil depletion reduced VEGF–VEGF receptor interaction, a surrogate marker of MMP-9 activity, markedly reducing the frequency of the initial angiogenic switching stages in dysplasias that occur during pancreatic islet carcinogenesis. These studies highlight the importance of neutrophils in the angiogenic process. Many different tumour types, and indeed their stromal compartments, are rich sources of CXCL8, a potent chemoattractant for neutrophils. Expression of CXCL8 can be upregulated by tumour microenvironmental conditions, such as hypoxia and acidosis (Kennedy et al. 1997; Xie 2001). Elevated levels of the CXCL1 and CXCL6 chemokines has been detected in gastrointestinal tumours, which are both chemotactic for neutrophils (Cuenca et al. 1992; Eck et al. 2003; Gijsbers et al. 2005; Proost et al. 1993). Elevated neutrophil infiltration has been observed in numerous different cancer types. In colon cancer, neutrophil numbers are higher in adenocarcinoma tumour samples compared with normal tissue biopsies. Interestingly, their density is highest in invasive and ulcerated areas (Nielsen et al. 1996). Neutrophil infiltration into tumours is associated with increased mutation frequency leading to tumorigenesis, presumably through the production of copious amounts of DNA-damaging ROS (Sandhu et al. 2000). As neutrophils interact with the vascular endothelium and extracellular matrix they release MMPs, which cleave proteins allowing for cellular migration to sites of inflammation. Disruption of the basement membrane and extracellular matrix in this way is thought to facilitate tumour metastasis. Thus, while the effects of neutrophils are largely mediated in host defence, clearly they can also be hijacked by the growing tumour.

4.4 T Cells

As one of the major elements of the adaptive immune response, T cells play an important role in inflammation and tumourigenesis. Tumour-infiltrating lymphocytes (TILs) containing various proportions of CD3⁺ CD4⁺ and CD3⁺ CD8⁺ T cells are a major component of the tumour microenvironment. TILs in medullary breast carcinomas form lymph node-like structures, suggesting that the immune response is operating *in situ* (Coronella et al. 2002). They also act as a source of tumor antigen-specific lymphocytes, which have been used in many studies in adoptive transfers following IL-2-mediated clonal expansion in culture (Whiteside 2008; Zhou et al. 2004). The accumulation of tumour antigen-specific T cell populations may be evidence of host-mediated tumour immunosurveillance, however, these T cells are largely ineffective in controlling tumour growth.

This may be due, in part, to regulatory T cells (T_{reg}), both naturally-occurring and antigen-specific. T_{reg} are a subset of regulatory T cells that serve to limit proliferation of other T cell subsets through either contact-dependent mechanisms or through the release of IL-10 and TGF- β . In addition, antigen-specific T cell responses may be ineffective due to an immunosuppressive environment within the established tumour.

Predominantly consisting of 'self', and lacking co-stimulatory and danger signals, tumours are generally considered as poorly immunogenic, and by failing to activate antigen-presenting cells may 'passively' anergise effector T cells. In ovarian cancer, tumour cells and TAMs attract pre-existing T_{reg} cells to the tumour site via production of CCL22 (Curiel et al. 2004). An ever increasing amount of evidence indicates that effector T cells can be converted into T_{reg} cells, *de novo*, either within the tumour microenvironment or in local draining lymph nodes by antigen-presenting cells tolerised by the tumour environment (Colombo and Piconese 2007; Saurer and Mueller 2009; Zou 2005, 2006). Many cancer types overexpress COX-2, a key enzyme involved in the biosynthesis of PGE₂ (Baratelli et al. 2005). Indeed, a positive feedback loop for tumour-mediated immunosuppression is evident with respect to COX-2. PGE₂ can upregulate indoleamine 2,3 dioxygenase, an enzyme that catalyzes the degradation of tryptophan resulting in the generation of immunosuppressive metabolites, in dendritic cells (Braun et al. 2005), as well as directly induce FOXP3 in CD4⁺ and CD25⁻ T cells (Baratelli et al. 2005).

The differential activation of T cell subsets has been related to the various morphological aspects of the inflammation observed in inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). UC has been characterised by atypical Th₂ cells producing TGF- β and IL-5, leading to a diffuse mucosal inflammation with superficial ulcerations continuously extending from the distal rectum to various degrees of the colon. The immune response in CD is reflective of transmural inflammation, affecting virtually any part of the GI tract, mediated by a Th₁ type response with T cells producing IL-2, IL-12, IFN- γ and Th₁₇ cells producing IL-17 (Fuss et al. 1996; Neurath 2007; Podolsky 2002; Waldner and Neurath 2009; Xavier and Podolsky 2007).

NF κ B activation in immune cells drives the expression of numerous pro-inflammatory cytokines, such as TNF α , IL-1 and IL-6 (Atreya et al. 2008). IL-6 has been implicated in playing a central role in the pathogenesis of IBD, with raised serum levels of IL-6 detected in CD patients (Mitsuyama et al. 1991; Yamamoto et al. 2000). In addition, increased levels of IL-6 have also been shown in patients presenting with colorectal cancer, indicating it as a cytokine likely to be involved in inflammation-related tumorigenesis. In cancer, associated with colitis one of the potential downstream signalling targets of IL-6 produced from CD4⁺ T cells is STAT3 (Becker et al. 2004), the constitutive activation of which is well established as being a feature of tumour promotion in many cancer types (Aggarwal et al. 2009; Devarajan and Huang 2009; Yu et al. 2009). Indeed, constitutive activation of STAT3 in some melanoma cell lines inhibits TNF- α and IL-1 β production and induces tolerogenic factors, such as IL-10, which inhibits the

functional maturation of dendritic cells, and may therefore lead to the tolerisation of tumour-infiltrating lymphocytes (Drake et al. 2006; Kreis et al. 2007; Oble et al. 2009). Waldner and Neurath (2009) suggest that while CD4⁺ T cell infiltration has been shown to support host anti-tumour responses in cases of sporadic cancers (Yu and Fu 2006), the opposite might be true of inflammation-related cancer. In support of this are the findings of Osawa et al. who showed that an anti-inflammatory Th₂ response promotes tumour growth in a mouse model of colon cancer (Osawa et al. 2006).

While most cancer data suggests the occurrence of immunosurveillance, particularly in GI cancers, the fact that GI malignancy is relatively high in incidence and mortality also suggests that the anti-tumour immune response is insufficient, which is probably true for most cancer types. Failure to eradicate the tumour is thought to be attributable to immunoselection, whereby non-immunogenic tumour cells are positively selected, and immunosubversion, a dynamic process involving tumour-mediated immunosuppression (Zou 2005). CD8⁺ T cells play a central role in the immunosurveillance of cancer. The presentation of tumour-specific antigens displayed on dendritic cells to CD8⁺ T cells, through MHC class I interactions and co-stimulatory signals, results in T cell activation and the subsequent release of effectors, such as anti-proliferative IFN- γ and cytotoxic perforins and granzymes (A/B), which induce tumour cell apoptosis (Maher et al. 2002). T cell infiltration of tumours with either CD4⁺ or CD8⁺ T cells, or both, has been associated with improved prognosis in multiple cancers, including colorectal cancer (Baeten et al. 2006; Chiba et al. 2004; Pages et al. 2009) and oesophageal cancer (Hosch et al. 1997; Ma et al. 1999; Schumacher et al. 2001). While the role for CD4⁺ cells in colorectal cancers is relatively well-defined, the role of CD8⁺ T cells and T_{reg} is less obvious. Since both these T cell types are involved in both intestinal inflammation and immunosurveillance, they can either promote or suppress tumour proliferation, which has significant implications for the immunotherapy of inflammation-associated malignancy.

5 Genetic Influences of Inflammation and Cancer

It is well established that tumour initiating events arise as mutations in the DNA, occurring spontaneously or as a result of carcinogens (as discussed in Sects. 3 and 3.1). Most leucocytes have the capacity to produce ROS, including nitric oxide, superoxide anion, hydroxyl radicals and hydrogen peroxide. In addition, RNS, such as nitrogen oxides and peroxy nitrates, are also formed and can react to generate mutagenic DNA adducts (Marnett 2000; Valko et al. 2006). NO can mediate its tumorigenic effects through a number of mechanisms, such as the induction of ssDNA or dsDNA breaks, deoxyribonucleotide or deoxyribose modifications, DNA cross-linking or damage to proteins. These alterations can result in altered gene transcription, signal transduction, genomic instability, as well as replication errors (Cooke et al. 2003). Evidence also suggests that mitochondrial DNA damage can contribute to tumour initiation and promotion, and mutations

and altered expression of mitochondrial genes encoding complexes I, III, IV and V have been demonstrated in several different cancer types (Penta et al. 2001). Mutations to the DNA can also result in the aberrant expression and function of cellular repair effectors, such as p53 (Ohshima 2003).

ROS are a natural element of the normal cellular metabolic process, but can induce significant DNA damage at the heightened levels observed during the inflammatory process. While the vast majority of the DNA-damaging effects of ROS are non-specific, many studies have demonstrated that ROS can specifically activate certain intracellular signalling pathways, contributing to tumour development. ROS can be divided into oxygen free radicals (superoxide, hydroxyl ion and NO) and non-radicals (H_2O_2). H_2O_2 can be catalysed to produce hydroxyl ions, which can induce *K-ras*. NO can induce the proto-oncogene p21 and the tumour suppressor p53. One of the major redox sensitive transcription factors is NF κ B, which as previously mentioned is a key player in inflammatory mediator signalling.

The NF κ B transcription factor was discovered in 1986 and has since been shown to be ubiquitously expressed in all human cell types (Sen and Baltimore 1986; Singh et al. 1986). NF κ B is largely considered to be the primary inflammation-associated transcription factor, as it is activated in response to multiple proinflammatory cytokines and pathogens. NF κ B exists in the cytoplasm in either a homodimeric or heterodimeric form. The NF κ B family consists of 5 subunits, including p65, p50, C-Rel, RelB and p52, however, NF κ B exists mainly in the form of a p50/p65 heterodimer. In the cytoplasm, NF κ B is found in an inactive state bound to the inhibitor I κ B. Upon appropriate stimulation, IKK (I κ B kinase), a complex of two catalytic subunits IKK α and IKK β as well as a regulatory protein called NEMO (NF κ B essential modulator), is activated and subsequently phosphorylates I κ B, targeting it for polyubiquitination and ultimately proteasomal degradation. Once released from I κ B, the NF κ B dimer translocates to the nucleus where it binds to κ B-regulatory elements within gene promoter regions, initiating the transcription of >200 genes (See Table 2) (Karin 2006; Karin and Greten 2005).

NF κ B is an exquisitely redox sensitive transcription factor (Mercurio and Manning 1999) (See Fig. 4). It is now well established that ROS can activate NF κ B, with the level of cellular antioxidants, such as glutathione and thioredoxin, serving to regulate the NF κ B signalling capacity of ROS. However, the precise mechanisms whereby ROS activate NF κ B are not yet fully understood. The process by which cellular ROS are regulated is highly complex and diverse; therefore, the mechanism by which NF κ B is activated by ROS may be equally complex. As an example, it has been shown that three cell-specific pathways lead to NF κ B activation in response to IL-1 (Bonizzi et al. 1999).

There is a vast amount of evidence supporting the role for NF κ B in the tumour initiation, promotion and progression process (Lu and Stark 2004). The genes for NF κ B p65, C-Rel, RelB and p52 are located at sites of recurrent translocations and genomic rearrangements in various cancers (Bargou et al. 1997; Gilmore and Morin 1993; Mathew et al. 1993). Numerous studies have shown that NF κ B is constitutively activated in a number of cancers, including breast, hepatocellular, oesophageal, colorectal cancer, acute lymphoid leukaemias, multiple myelomas,

Table 2 Genes regulated by NF κ B activation. Adapted from Wu and Kral (2005)

Class of molecule	Target gene
Cytokines	IL-1, IL-2, IL-6, IL-8, IL-9, IL-11, IL-12, IL-15, IFN- γ , LT- α , LT- β , TNF- α , TNF- β
Immune response	Ig ϵ chain, Ig κ chain, IL-2 receptor, MHC class I, MHC class II, T cell receptor, β 2-microglobulin
Growth factors	Colony-stimulating factors (CSFs), PDGF, Thrombospondin, VEGF, IGFBP1, IGFBP2
Transcription factors	p53, c-Myc, I κ B, c-Rel, IRF1, IRF2
Enzymes	Collagenase I, Lysozyme, Xanthine Oxidase, Transglutaminase
Adhesion molecules	ELAM-1, ICAM-1, VCAM-1, E-selectin
Acute phase proteins	Complement factor B, C4, CRP, angiotensinogen, urokinase-type plasminogen activator
Apoptosis-associated	IAPs, Fas, Bcl-2

prostate, colon, pancreatic, ovarian, melanoma, NSCLC, SCC, thyroid carcinoma, fibrosarcoma and gastric carcinoma (Aggarwal et al. 2006; Bharti et al. 2004; Dejardin et al. 1999; Deng et al. 2002; Greten et al. 2004; Herrmann et al. 1997; Hideshima et al. 2002; Higgins et al. 1993; Hold and El-Omar 2008; Ivarsson et al. 2000; Kordes et al. 2000; Krappmann et al. 1999; Luo et al. 2005; Mori et al. 1999; Mukhopadhyay et al. 1995, 2001; Okamoto et al. 2007; Palayoor et al. 1999; Pikarsky et al. 2004; Sanda et al. 2005; Shah et al. 2001; Shishodia and Aggarwal 2004; Tamatani et al. 2001; Visconti et al. 1997; Wang et al. 1999; Yamanaka et al. 2004; Yang and Richmond 2001), presumably through its actions as a cell survival factor. In cell lines, overexpression of activated NF κ B promotes cellular proliferation, whereas suppression of NF κ B blocks proliferation. In several tumour types NF κ B is activated in an autocrine fashion through the release of cytokines such as TNF- α (cutaneous T cell lymphoma (Giri and Aggarwal 1998; O'Connell et al. 1995), Barrett's oesophagus (Tselepis et al. 2002), IL-1 α (head and neck squamous cell carcinomas and melanomas (Kimura et al. 1998; Wolf et al. 2001)), IL-1 β (pancreatic carcinoma (Arlt et al. 2002)), GM-CSF or G-CSF (lung cancer (Uemura et al. 2004)), BAFF and APRIL (B cell lymphomas (He et al. 2004; Kern et al. 2004)). NF κ B regulates gene such as IL-1, IL-2, IL-6, IL-8, IL-12, IFN- γ and TNF- α . It also regulates cell-adhesion molecules such as ICAM-1, VCAM-1, ELAM-1 and E-selectin, regulators of the cell cycle, such as p21 and cyclin D1, enzymes, such as COX-2, iNOS and 5-Lox, anti-apoptotic molecules, such as the caspases, IAPs, survivin, Bcl-2 and Bcl-x1, as well as other transcription factors,




Fig. 4 Schematic representation of reactive oxygen intermediate generation systems and mechanisms of activation of NFκB. The principle reactive oxygen intermediates are the superoxide anion (O_2^-), hydrogen peroxide (H_2O_2) and the hydroxyl radical ($OH\cdot$). The xanthine oxidase enzyme can split molecular oxygen (O_2) leading to the generation of O_2^- . Other enzymes involved in the formation of O_2^- include lipoxygenase, cyclooxygenase, NADPH oxidase and cytochrome P450. Mitochondrial leakage is also a source of intracellular superoxide. The superoxide anion can be converted by the enzyme superoxide dismutase to H_2O_2 and molecular oxygen. The hydroxyl radical is formed through the metal catalysed Fenton/Haber-Weiss reaction. O_2^- , H_2O_2 and $OH\cdot$ can each activate NFκB, leading to the transcription of certain genes, including those encoding enzymes involved in redox regulation. Receptor-mediated cellular activation, as well as stress-induced (via environmental toxins, inflammation and γ - or UV-irradiation), result in the generation of O_2^- , H_2O_2 , and $OH\cdot$. GSH = reduced glutathione; GSSG = oxidised glutathione; NADPH = nicotinamide dinucleotide phosphate; NO = nitric oxide; OX = oxidation; RED = reduction; TRX = thioredoxin. Adapted from Mercurio and Manning (1999)

including p53, c-Myc and API (Abdel-Latif et al. 2009; Wu and Kral 2005). The involvement of NFκB in the angiogenic process appears to be less clear than originally thought; while it is true that NFκB mediates the transcription of promoters of angiogenesis, such as VEGF, IL-6, MMPs and MCP-1, there is evidence demonstrating a suppressive role for NFκB in angiogenesis (Kisseleva et al. 2006; Shen and Tergaonkar 2009). Kisseleva et al. showed in an *in vivo* IκBα-mutant mouse model that tumour vascularisation was markedly increased. Furthermore, known angiostatic agents, such as the 16 kDa prolactin fragment, angiostatin and

Neovastat, are closely associated with the activity of NF κ B (Gingras et al. 2004; Shen and Tergaonkar 2009; Tabruyn and Griffioen 2007, 2008; Tabruyn et al. 2007). As cancer therapeutics aim to suppress NF κ B activation and inhibit angiogenesis, these data suggest a cautionary note regarding the use of potential anti-cancer agents that block NF κ B (Shen and Tergaonkar 2009; Tabruyn and Griffioen 2007, 2008).

In addition to being constitutively activated in pre-malignant and cancerous tissues, including oesophageal (Abdel-Latif et al. 2004), NF κ B is also found in an activated state in inflamed gut specimens for IBD patients, with macrophages and epithelial cells as the main sources (Neurath et al. 1996). In a study by Rogler et al. the level of activated NF κ B significantly correlated with the severity of intestinal inflammation observed in IBD patients (Rogler et al. 1998). The increased expression of NF κ B in macrophages from IBD specimens is accompanied by an increased capacity of these cells to produce TNF- α , IL-1 and IL-6 (Neurath et al. 1996), which may ultimately be involved in promoting the progression to cancer in these patients.

It is now well recognised that gene polymorphisms contribute significantly to disease susceptibility and severity. This is particularly true for cancer. Single nucleotide polymorphisms, or SNPs, are naturally-occurring variations in the genetic code that occur in a relatively high percentage of the population (>1%). SNP analysis is particularly useful for studies trying to identify mutations that play a role in multifactorial diseases, such as cancer, which can have complex biological as well as environmental components (Risch 2000). Following completion of the human genome project, and analysis of the relative frequencies of SNPs in the genome, it is estimated that there may be as many as 10 million SNPs in the human genome. Many of these SNPs lie in non-coding regions of the genome, and many of those that lie in the coding sequence may result in synonymous amino acids. Indeed, with the expanding research into the field of non-coding micro-RNAs, which regulate gene expression at the translational level (Lynam-Lennon et al. 2009), the involvement of SNPs in the non-coding regions of the genome is likely to herald a new era in SNP analysis and its association with disease. However, specific non-synonymous SNPs in the coding regions of the genome have been shown to correlate with and influence the inter-individual variation in the magnitude of inflammatory responses, obviously having ramifications for tumourigenesis.

Cytochrome P450 (CYP) represents a family of monooxygenases that coordinate phase I metabolism of many endogenous and exogenous factors, including carcinogenic agents, drugs and xenobiotics (Lewis et al. 2004). The primary CYPs that metabolise carcinogens in humans are CYP1A1, CYP2A6, CYP1B1 and CYP2E1 (Gonzalez 1993). Polymorphisms have been identified in most of these carcinogen-associated CYP genes, which result in proteins with altered expression level and/or activity (Guengerich 1994; Guengerich et al. 1991). The alterations in proteins derived from these polymorphic CYP genes likely has an impact on the cellular capacity to metabolise carcinogens, which may ultimately alter cellular DNA repair mechanisms, altering cancer susceptibility.

Given that ROS are a key element in mediating DNA damage ultimately promoting tumour initiation, promotion and progression, it is not surprising that polymorphisms in specific genes, such as those involved in the DNA repair mechanism or in antioxidant genes, should have an effect on inflammation-related tumorigenesis. Antioxidants represent a major mechanism for protecting cells from oxidative stress, particularly in the context of chronic inflammation. Many of the antioxidant genes are known to be polymorphic, including Manganese superoxide dismutase (MnSOD or SOD2), myeloperoxidase (MPO), catalase (CAT), glutathione peroxidase (GPX), glutathione S-transferase (GSTM1, GSTT1, GSTP1), epoxide hydrolase (EPHX1) and NAD(P)H quinone oxidoreductase (NQO1) (Klaunig et al. 2009). The variant allele of MnSOD is associated with an increased risk of lung (Liu et al. 2004), breast (Bewick et al. 2008), prostate (Kang et al. 2007) and ovarian cancer (Olson et al. 2004), as well as non-Hodgkin's lymphoma (Wang et al. 2006). Catalase is another antioxidant enzyme that catalyses the conversion of hydrogen peroxide to water and oxygen (Hunt et al. 1998). While there are polymorphisms in the CAT gene present with high population penetrance, no study has yet identified an association of this SNP with tumorigenesis. GPX1, a gene encoding a glutathione peroxidase enzyme, protects against oxidative damage by reducing cellular H₂O₂ levels and an array of peroxides (Arthur 2000). A P198L polymorphism in GPX1 is somewhat a population-inconsistent SNP associated with bladder (Ichimura et al. 2004), lung (Raaschou-Nielsen et al. 2007), prostate (Arsova-Sarafinovska et al. 2008) and breast cancer (Ravn-Haren et al. 2006).

One of the major and most studied forms of oxidative DNA lesions is 8-hydroxyguanine (oh⁸G) (Shinmura and Yokota 2001), a lesion induced by ROS. The oh⁸G lesion is repaired by a number of base repair enzymes, including OGG1, NEIL1, APE1 and MUTYH (Evans et al. 2004), with polymorphisms applicable to each of these enzymes. The OGG1 gene encodes a DNA glycosylase/AP (apurinic/aprimidinic) lyase that can directly remove oh⁸G lesions from damaged DNA (Shinmura and Yokota 2001). OGG1 is highly polymorphic within the human population. In many cancers, including lung, esophageal, gastric and prostate, OGG1 is somatically mutated and confers increased risk. Polymorphisms within this gene alter glycosylase activity and function, impairing the cellular capacity to excise and repair ROS-mediated DNA damage. Thus, OGG1 polymorphisms may alter individual susceptibility to cancer development (Shinmura and Yokota 2001).

CD is characterised by a destructive inflammation of the intestine, with an imbalanced immune response to luminal microbiological or nutritional antigens appearing to play a major causative role (Niessner and Volk 1995). It has been shown that a polymorphism in the NF κ B inhibitor α (NF κ BIA) gene is associated with CD in patients who lack a predisposing allele of the CARD15 gene, a gene involved in the recognition of muramyl dipeptide derived from LPS and the activation of NF κ B (Klein et al. 2004). It has been shown that polymorphisms in the *IL-1 β* gene increase the risk of gastric cancer by 2–3-fold in patients infected

with *H. pylori* (El-Omar et al. 2000; El-Omar et al. 2003; Klein et al. 2004). Furthermore, SNPs in the *TNF- α* and *IL-10* genes are additional risk factors for non-cardia gastric cancer (El-Omar et al. 2003).

6 Concluding Remarks

As we have learned, the physiological response to cancer has significant overlap with the response to tissue injury in the context of inflammation. While acute inflammation associated with tissue damage and wound healing is normally self-limiting and chronic inflammation within a pre-malignant environment, be this due to infection, physical or chemical trauma, favours neoplastic progression. Cancer cells can educate immune infiltrate to produce factors important for tumour growth and metastasis. Consequently, the sustained activation of immune cells within the tumour microenvironment results in a persistence of proinflammatory factors, which ultimately promote tumour growth and survival. The nature and intensity of the inflammatory infiltrate varies as the tumour progresses, a process dependent on the local milieu that is created and shaped by the tumour. The dissection of the molecular basis for inflammation-driven carcinogenesis has identified a number of key mediators in this process, such as the cytokines *TNF- α* and *IL-1*, transcription factors such as *STAT3* and *NF κ B*, and even altered susceptibility driven by host genetics. It is apparent that our comprehension of inflammation and its role in the carcinogenic process is far from complete. Only in fully understanding the relationship between inflammation and cancer will we be able to adequately manipulate the process. Ultimately the challenge ahead is to reinstate the normal inflammatory process, by increasing tumour suppressive factors and decreasing tumour promoting factors.

References

- Abdel-Latif MM, Kelleher D, Reynolds JV (2009) Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. *J Surg Res* 153:172–180
- Abdel-Latif MM, O’Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV (2004) NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. *Ann Surg* 239:491–500
- Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, Kuziel WA, Koni PA, Gurish MF (2005) Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. *Blood* 105:4308–4313
- Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? *Ann N Y Acad Sci* 1171:59–76
- Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? *Biochem Pharmacol* 72:1605–1621
- Albini A, Tosetti F, Benelli R, Noonan DM (2005) Tumor inflammatory angiogenesis and its chemoprevention. *Cancer Res* 65:10637–10641
- Arlt A, Vorndamm J, Muerkoster S, Yu H, Schmidt WE, Folsch UR, Schafer H (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. *Cancer Res* 62:910–916

- Arsova-Sarafinovska Z, Matevska N, Petrovski D, Banev S, Dzikova S, Georgiev V, Sikole A, Sayal A, Aydin A, Suturkova L, Dimovski AJ (2008) Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. *Cell Biochem Funct* 26:771–777
- Arthur JR (2000) The glutathione peroxidases. *Cell Mol Life Sci* 57:1825–1835
- Atreya I, Atreya R, Neurath MF (2008) NF-kappaB in inflammatory bowel disease. *J Intern Med* 263:591–596
- Baeten CI, Castermans K, Hillen HF, Griffioen AW (2006) Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. *Clin Gastroenterol Hepatol* 4:1351–1357
- Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* 7:211–217
- Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. *Nature* 431:405–406
- Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? *Lancet* 357:539–545
- Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. *J Immunol* 175:1483–1490
- Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B (1997) Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. *J Clin Invest* 100:2961–2969
- Baxevasis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M (1994) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. *Cancer* 74:1275–1282
- Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. *Immunity* 21:491–501
- Bewick MA, Conlon MS, Lafrenie RM (2008) Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. *Breast Cancer Res Treat* 111:93–101
- Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. *Blood* 103:3175–3184
- Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J Pathol* 196:254–265
- Bischoff SC (2007) Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. *Nat Rev Immunol* 7:93–104
- Biswas SK, Gangi L, Paul S, Schioppa T, Sacconi A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). *Blood* 107:2112–2122
- Bonizzi G, Piette J, Schoonbroodt S, Greimers R, Havard L, Merville MP, Bours V (1999) Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. *Mol Cell Biol* 19:1950–1960
- Braun D, Longman RS, Albert ML (2005) A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. *Blood* 106:2375–2381
- Chen CC, Grimbaldston MA, Tsai M, Weissman IL, Galli SJ (2005) Identification of mast cell progenitors in adult mice. *Proc Natl Acad Sci USA* 102:11408–11413
- Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y, Satomi S (2004) Intraepithelial CD8+ T-cell-count becomes a prognostic factor

- after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. *Br J Cancer* 91:1711–1717
- Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. *Nat Rev Cancer* 7:880–887
- Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003) Oxidative DNA damage: mechanisms, mutation, and disease. *Faseb J* 17:1195–1214
- Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. *J Immunol* 169:1829–1836
- Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. *Genes Dev* 13:1382–1397
- Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* 420:860–867
- Cuenca RE, Azizkhan RG, Haskill S (1992) Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. *Surg Oncol* 1:323–329
- Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 10:942–949
- Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med* 351:2159–2169
- De Palma M, Venneri MA, Galli R, Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie₂ identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell* 8:211–226
- Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, Bours V (1999) Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. *Oncogene* 18:2567–2577
- Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, Hung MC (2002) beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. *Cancer Cell* 2:323–334
- Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ (2003) Investigating hypoxic tumor physiology through gene expression patterns. *Oncogene* 22:5907–5914
- Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. *Curr Mol Med* 9:626–633
- Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. *Adv Immunol* 90:51–81
- Eck M, Schmausser B, Scheller K, Brandlein S, Muller-Hermelink HK (2003) Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. *Clin Exp Immunol* 134:508–515
- Ekbom A (1998) Risk of cancer in ulcerative colitis. *J Gastrointest Surg* 2:312–313
- El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 404:398–402
- El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH (2003) Increased risk of noncardia

- gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 124:1193–1201
- Evans MD, Dizdaroglu M, Cooke MS (2004) Oxidative DNA damage and disease: induction, repair and significance. *Mutat Res* 567:1–61
- Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 127:S35–S50
- Foulds L (1954) The experimental study of tumor progression: a review. *Cancer Res* 14:327–339
- Friedman AD (2002) Transcriptional regulation of granulocyte and monocyte development. *Oncogene* 21:3377–3390
- Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W (1996) Disparate CD4⁺ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN- γ , whereas ulcerative colitis LP cells manifest increased secretion of IL-5. *J Immunol* 157:1261–1270
- Galli SJ (1990) New insights into 'the riddle of the mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. *Lab Invest* 62:5–33
- Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 313:1960–1964
- Gijssbers K, Gouwy M, Struyf S, Wuyts A, Opendakker G, Penninckx F, Ectors N, Geboes K, Van Damme J (2005) GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. *Exp Cell Res* 303:331–342
- Gilmore TD, Morin PJ (1993) The I kappa B proteins: members of a multifunctional family. *Trends Genet* 9:427–433
- Gingras D, Nyalendo C, Di Tomasso G, Annabi B, Beliveau R (2004) Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. *Biochem Biophys Res Commun* 320:205–212
- Giri DK, Aggarwal BB (1998) Constitutive activation of NF- κ B causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. *J Biol Chem* 273:14008–14014
- Gong Y, Koh DR (2009) Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. *Cell Tissue Res* 82:495–515
- Gonzalez FJ (1993) Molecular biology of human xenobiotic-metabolizing cytochromes P450: role of vaccinia virus cDNA expression in evaluating catalytic function. *Toxicology* 82:77–88
- Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, Gonias SL, Klemke RL (2009) Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. *PLoS One* 4:e6713
- Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKK β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 118:285–296
- Guengerich FP (1994) Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. *Toxicol Lett* 70:133–138
- Guengerich FP, Kim DH, Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. *Chem Res Toxicol* 4:168–179
- Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, Parker CM, Austen KF (2001) Intestinal mast cell progenitors require CD49 β 7 (alpha4beta7 integrin) for tissue-specific homing. *J Exp Med* 194:1243–1252
- Hanahan D, Weinberg RA (2000) The hallmarks of cancer. *Cell* 100:57–70
- He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. *J Immunol* 172:3268–3279
- Hecker E (1967) Phorbol esters from croton oil. Chemical nature and biological activities. *Naturwissenschaften* 54:282–284

- Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, Brisbay S, McDonnell TJ (1997) Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. *Exp Cell Res* 237:101–109
- Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS (2007) Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. *Immunity* 26:477–489
- Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. *J Biol Chem* 277:16639–16647
- Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R (1993) Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. *Proc Natl Acad Sci USA* 90:9901–9905
- Hold GL, El-Omar EM (2008) Genetic aspects of inflammation and cancer. *Biochem J* 410:225–235
- Hosch SB, Meyer AJ, Schneider C, Stoecklein N, Prenzel KL, Pantel K, Broelsch CE, Izbicki JR (1997) Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer. *J Gastrointest Surg* 1:316–323
- Hotamisligil GS (2006) Inflammation and metabolic disorders. *Nature* 444:860–867
- Hunt CR, Sim JE, Sullivan SJ, Featherstone T, Golden W, Von Kapp-Herr C, Hock RA, Gomez RA, Parsian AJ, Spitz DR (1998) Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. *Cancer Res* 58:3986–3992
- Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, Kato T (2004) Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. *J Urol* 172:728–732
- Ivarsson K, Ekerydh A, Fyhr IM, Janson PO, Brannstrom M (2000) Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. *Acta Obstet Gynecol Scand* 79:777–784
- Kamei M, Carman CV (2010) New observations on the trafficking and diapedesis of monocytes. *Curr Opin Hematol* 17:43–52
- Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB (2007) Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. *Cancer Epidemiol Biomarkers Prev* 16:1581–1586
- Karin M (2006) Nuclear factor-kappaB in cancer development and progression. *Nature* 441:431–436
- Karin M (2008) The IkappaB kinase—a bridge between inflammation and cancer. *Cell Res* 18:334–342
- Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 5:749–759
- Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, Varia MA (1997) Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. *Int J Radiat Oncol Biol Phys* 37:897–905
- Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. *Blood* 103:679–688
- Kimura H, Inukai Y, Takii T, Furutani Y, Shibata Y, Hayashi H, Sakurada S, Okamoto T, Inoue J, Oomoto Y, Onozaki K (1998) Molecular analysis of constitutive IL-1alpha gene expression in human melanoma cells: autocrine stimulation through NF-kappaB activation by endogenous IL-1alpha. *Cytokine* 10:872–879
- Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C (2006) NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. *J Clin Invest* 116:2955–2963

- Klaunig JE, Kamendulis LM, Hocevar BA (2010) Oxidative stress and oxidative damage in carcinogenesis. *Toxicol Pathol* 38:96–109
- Klein G, Klein E (1985) Evolution of tumours and the impact of molecular oncology. *Nature* 315:190–195
- Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen JT, Schmiegel WH, Griga T (2004) A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. *Int J Colorectal Dis* 19:153–156
- Koehne CH, Dubois RN (2004) COX-2 inhibition and colorectal cancer. *Semin Oncol* 31:12–21
- Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C (2000) Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. *Leukemia* 14:399–402
- Kornstein MJ, Brooks JS, Elder DE (1983) Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. *Cancer Res* 43:2749–2753
- Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C (1999) Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. *Oncogene* 18:943–953
- Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I (2007) Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. *Mol Cancer Res* 5:1331–1341
- Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY (2009) Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. *Expert Rev Mol Med* 11:e19
- Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. *Mutat Res* 659:15–30
- Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. *J Intern Med* 248:171–183
- Le Bitoux MA, Stamenkovic I (2008) Tumor-host interactions: the role of inflammation. *Histochem Cell Biol* 130:1079–1090
- Lejeune FJ, Ruegg C, Lienard D (1998) Clinical applications of TNF-alpha in cancer. *Curr Opin Immunol* 10:573–580
- Lewis DF, Lake BG, Dickins M (2004) Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. *Drug Metabol Drug Interact* 20:111–142
- Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J Exp Med* 193:727–740
- Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC (2004) MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. *Cancer Lett* 214:69–79
- Loft S, Poulsen HE (1996) Cancer risk and oxidative DNA damage in man. *J Mol Med* 74:297–312
- Lu T, Stark GR (2004) Cytokine overexpression and constitutive NFkappaB in cancer. *Cell Cycle* 3:1114–1117
- Luo JL, Kamata H, Karin M (2005) IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. *J Clin Invest* 115:2625–2632
- Lynam-Lennon N, Maher SG, Reynolds JV (2009) The roles of microRNA in cancer and apoptosis. *Biol Rev Camb Philos Soc* 84:55–71
- Ma Y, Xian M, Li J, Kawabata T, Okada S (1999) Interrelations of clinicopathological variables, local immune response and prognosis in esophageal squamous cell carcinoma. *Apmis* 107:514–522
- Maher S, Toomey D, Condron C, Bouchier-Hayes D (2002) Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. *Immunol Cell Biol* 80:131–137
- Maltby S, Khaizia K, McNagny KM (2009) Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. *Biochim Biophys Acta* 1796:19–26
- Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. *Immunol Today* 13:265–270

- Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. *Lancet* 371:771–783
- Marnett LJ (2000) Oxyradicals and DNA damage. *Carcinogenesis* 21:361–370
- Marshall JS (2004) Mast-cell responses to pathogens. *Nat Rev Immunol* 4:787–799
- Mathew S, Murty VV, Dalla-Favera R, Chaganti RS (1993) Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. *Oncogene* 8:191–193
- Medzhitov R (2008) Origin and physiological roles of inflammation. *Nature* 454:428–435
- Medzhitov R, Hornig T (2009) Transcriptional control of the inflammatory response. *Nat Rev Immunol* 9:692–703
- Mercurio F, Manning AM (1999) NF-kappaB as a primary regulator of the stress response. *Oncogene* 18:6163–6171
- Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, Arima N, Oriishi T, Harada K, Fujisaki K et al (1991) Colonic mucosal interleukin-6 in inflammatory bowel disease. *Digestion* 50:104–111
- Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. *Nat Med* 5:828–831
- Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N (1999) Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. *Blood* 93:2360–2368
- Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB (2001) Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. *Oncogene* 20:7597–7609
- Mukhopadhyay T, Roth JA, Maxwell SA (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. *Oncogene* 11:999–1003
- Muller WA (2009) Mechanisms of transendothelial migration of leukocytes. *Circ Res* 105:223–230
- Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res* 58:3491–3494
- Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, Galli SJ (2006) Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. *J Immunol* 176:2238–2248
- Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, Ono M (2005) Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. *J Clin Invest* 115:2979–2991
- Nathan C (2002) Points of control in inflammation. *Nature* 420:846–852
- Neurath MF (2007) IL-23: a master regulator in Crohn disease. *Nat Med* 13:26–28
- Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. *Nat Med* 2:998–1004
- Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Dano K (1996) 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. *Int J Cancer* 65:57–62
- Niessner M, Volk BA (1995) Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). *Clin Exp Immunol* 101:428–435
- Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. *Proc Natl Acad Sci USA* 103:12493–12498
- Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. *Cancer Immunol* 9:3

- O'Connell MA, Cleere R, Long A, O'Neill LA, Kelleher D (1995) Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78. *J Biol Chem* 270:7399–7404
- Ohshima H (2003) Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. *Toxicol Lett* 140–141:99–104
- Okamoto T, Sanda T, Asamitsu K (2007) NF-kappa B signaling and carcinogenesis. *Curr Pharm Des* 13:447–462
- Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB (2004) Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. *Gynecol Oncol* 93:615–620
- Osawa E, Nakajima A, Fujisawa T, Kawamura YI, Toyama-Sorimachi N, Nakagama H, Dohi T (2006) Predominant T helper type 2-inflammatory responses promote murine colon cancers. *Int J Cancer* 118:2232–2236
- Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molitor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. *N Engl J Med* 353:2654–2666
- Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. *J Clin Oncol* 27:5944–5951
- Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. *Oncogene* 18:7389–7394
- Penta JS, Johnson FM, Wachsmann JT, Copeland WC (2001) Mitochondrial DNA in human malignancy. *Mutat Res* 488:119–133
- Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. *Semin Cancer Biol* 14:433–439
- Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* 431:461–466
- Podolsky DK (2002) Inflammatory bowel disease. *N Engl J Med* 347:417–429
- Proost P, De Wolf-Peeters C, Conings R, Opendakker G, Billiau A, Van Damme J (1993) Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. *J Immunol* 150:1000–1010
- Raaschou-Nielsen O, Sorensen M, Hansen RD, Frederiksen K, Tjonneland A, Overvad K, Vogel U (2007) GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. *Cancer Lett* 247:293–300
- Ravn-Haren G, Olsen A, Tjonneland A, Dragsted LO, Nexø BA, Wallin H, Overvad K, Raaschou-Nielsen O, Vogel U (2006) Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. *Carcinogenesis* 27:820–825
- Risch NJ (2000) Searching for genetic determinants in the new millennium. *Nature* 405:847–856
- Roder DM (2002) The epidemiology of gastric cancer. *Gastric Cancer* 5(Suppl 1):5–11
- Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V (1998) Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. *Gastroenterology* 115:357–369
- Rous P, Beard JW (1935) The progression to carcinoma of virus-induced rabbit papillomas (shope). *J Exp Med* 62:523–548
- Rous P, Kidd JG (1941) Conditional neoplasms and subthreshold neoplastic states: a study of the tar tumors of rabbits. *J Exp Med* 73:365–390. Available at <http://www.nature.com/nature/journal/v420/n6917/full/nature01322.html-B9#B9>

- Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB, Ueda R, Okamoto T (2005) Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. *Clin Cancer Res* 11:1974–1982
- Sandhu JK, Privora HF, Wenckebach G, Birnboim HC (2000) Neutrophils, nitric oxide synthase, and mutations in the mutatest murine tumor model. *Am J Pathol* 156:509–518
- Sarelius IH, Kuebel JM, Wang J, Huxley VH (2006) Macromolecule permeability of in situ and excised rodent skeletal muscle arterioles and venules. *Am J Physiol Heart Circ Physiol* 290:H474–H480
- Saurer L, Mueller C (2009) T cell-mediated immunoregulation in the gastrointestinal tract. *Allergy* 64:505–519
- Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. *Cancer Res* 61:3932–3936
- Sen R, Baltimore D (1986) Multiple nuclear factors interact with the immunoglobulin enhancer sequences. *Cell* 46:705–716
- Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. *Nat Immunol* 6:1191–1197
- Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. *J Cell Biochem* 82:110–122
- Shen HM, Tergaonkar V (2009) NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. *Apoptosis* 14:348–363
- Shinmura K, Yokota J (2001) The OGG1 gene encodes a repair enzyme for oxidatively damaged DNA and is involved in human carcinogenesis. *Antioxid Redox Signal* 3:597–609
- Shishodia S, Aggarwal BB (2004) Nuclear factor-kappaB: a friend or a foe in cancer? *Biochem Pharmacol* 68:1071–1080
- Singh H, Sen R, Baltimore D, Sharp PA (1986) A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. *Nature* 319:154–158
- Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. *Cancer Res* 59:4516–4518
- Tabruyn SP, Griffioen AW (2007) A new role for NF-kappaB in angiogenesis inhibition. *Cell Death Differ* 14:1393–1397
- Tabruyn SP, Griffioen AW (2008) NF-kappa B: a new player in angiostatic therapy. *Angiogenesis* 11:101–106
- Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, Griffioen AW, Martial JA, Struman I (2007) The angiostatic 16 K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. *Mol Endocrinol* 21:1422–1429
- Tamatani T, Azuma M, Aota K, Yamashita T, Bando T, Sato M (2001) Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. *Cancer Lett* 171:165–172
- Tazzyman S, Lewis CE, Murdoch C (2009) Neutrophils: key mediators of tumour angiogenesis. *Int J Exp Pathol* 90:222–231
- Tinsley JH, Ustinova EE, Xu W, Yuan SY (2002) Src-dependent, neutrophil-mediated vascular hyperpermeability and beta-catenin modification. *Am J Physiol Cell Physiol* 283:C1745–C1751
- Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I (2009) Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. *Int J Urol* 16:801–807
- Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kumano M (2000) Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. *Int J Cancer* 85:182–188
- Tselepis C, Perry I, Dawson C, Hardy R, Darnton J, McConkey C, Stuart R, Wright NA, Harrison RF, Jankowski J (2002) Tumour necrosis factor-alpha in Barrett's metaplasia: a novel mechanism of action. *Oncogene* 39:6071–6081

- Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Harper E, Harrison R, Attwood S, Jankowski JAZ (2003) Upregulation of the oncogene c-myc in Barrett's adenocarcinoma. *Gut* 52:174–180
- Uemura Y, Kobayashi M, Nakata H, Harada R, Kubota T, Taguchi H (2004) Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells. *Int J Cancer* 109: 826–832
- Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. *Clin Cancer Res* 6:3282–3289
- Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chem Biol Interact* 160:1–40
- Vincent-Schneider H, Thery C, Mazzeo D, Tenza D, Raposo G, Bonnerot C (2001) Secretory granules of mast cells accumulate mature and immature MHC class II molecules. *J Cell Sci* 114:323–334
- Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M, Fusco A (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF κ B p65 protein expression. *Oncogene* 15:1987–1994
- Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN (2003) IL-1 is required for tumor invasiveness and angiogenesis. *Proc Natl Acad Sci USA* 100:2645–2650
- Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. *Semin Immunopathol* 31:249–256
- Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, Lan Q, Welch R, Chanock SJ, Rothman N (2006) Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. *Carcinogenesis* 27:1828–1834
- Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. *Clin Cancer Res* 5:119–127
- Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. *Oncogene* 27:5904–5912
- Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N, Van Waes C (2001) IL (interleukin)-1 α promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. *Clin Cancer Res* 7:1812–1820
- Wu JT, Kral JG (2005) The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. *J Surg Res* 123:158–169
- Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. *Cancer Res* 64:7022–7029
- Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 448:427–434
- Xie K (2001) Interleukin-8 and human cancer biology. *Cytokine Growth Factor Rev* 12:375–391
- Yamamoto M, Yoshizaki K, Kishimoto T, Ito H (2000) IL-6 is required for the development of Th1 cell-mediated murine colitis. *J Immunol* 164:4878–4882
- Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, Noshiro H, Yao T, Tsuneyoshi M, Tanaka M, Katano M (2004) Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. *Anticancer Res* 24:1071–1075
- Yang J, Richmond A (2001) Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. *Cancer Res* 61:4901–4909
- Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 9:798–809
- Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? *Lab Invest* 86:231–245

- Yuan SY, Wu MH, Ustinova EE, Guo M, Tinsley JH, De Lanerolle P, Xu W (2002) Myosin light chain phosphorylation in neutrophil-stimulated coronary microvascular leakage. *Circ Res* 90:1214–1221
- Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2004) Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. *J Immunol* 173:7622–7629
- Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. *Nat Rev Immunol* 6:715–727
- Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat Rev Cancer* 5:263–274
- Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol* 6:295–307

Inherited Syndromes Predisposing to Inflammation and GI Cancer

Shane Duggan, David Prichard, Murat Kirca
and Dermot Kelleher

Abstract

Cancers arising within the gastrointestinal (GI) tract are commonly associated with an immune component at their inception and later in their maintenance. While many of the immune factors and immune cell types surrounding these lesions have been highlighted, the underlying pre-dispositions in immunosupported carcinogenesis are not well characterised. Inherited Mendelian GI disorders such as polyposis syndromes, while classically due to germline mutations in non-immune genes, commonly demonstrate alterations in key immune and inflammatory genes. In some cases immune based therapies have been shown to provide at least some benefit in animal models of these syndromes. The advent of genome wide association studies has begun to powerfully examine the genetic nature of complex non-Mendelian GI diseases highlighting polymorphisms within immune related genes and their potential to provide the niche in which GI cancers may originate. Here in the role in which Mendelian and non-Mendelian genetics of immune related factors supporting GI malignancy will be presented and discussed.

Contents

1	Introduction.....	36
2	Role of Inflammation in Mendelian Gastrointestinal Disease Polyposis Syndromes	37
	2.1 Polyposis Syndromes: Familial Adenomatous Polyposis	37

S. Duggan · D. Prichard · M. Kirca · D. Kelleher
Department of Clinical Medicine and Institute of Molecular Medicine,
Trinity College Dublin, Dublin 2, Ireland

D. Prichard · M. Kirca · D. Kelleher (✉)
Department of Gastroenterology, Institute of Molecular Medicine,
Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
e-mail: Dermot.kelleher@tcd.ie

2.2	Polyposis Syndromes: Peutz-Jeghers Syndrome	38
2.3	Polyposis Syndromes: Juvenile Polyposis Syndrome	39
2.4	Polyposis Syndromes: Lynch Syndrome or Hereditary Non-Polyposis Colon Cancer	39
3	Non-Mendelian Association of Inflammation and Cancer	41
3.1	Oesophageal Cancer	41
3.2	Coeliac Disease Inflammation and Cancer Sequence	42
3.3	Inflammatory Bowel Disease and Cancer	43
3.4	Gastric Cancer and Inflammatory Genes	44
4	Conclusion	44
	References	45

1 Introduction

Chronic inflammation has long been established as an aetiological factor in the genesis of neoplasia within the gastrointestinal tract (Secher et al. 2010; Itzkowitz and Yio 2004; Grivennikov et al. 2010). Recent data suggests that even in the absence of an overt macroscopic inflammatory reaction, the activation of pathways involved in inflammation may result in mutagenic and neoplastic consequences. As the gastrointestinal tract represents the largest interface between host environment, innate immune response and immune surveillance, the potential for disturbances resulting in pro-carcinogenic inflammation within this organ is high. Both innate and adaptive immune responses may play a role and there is a substantial literature regarding the potential role for toll-like receptors (TLRs) in the pathogenesis of inflammation and cancer.

In recent years great strides have been made with respect to the molecules involved in epithelial and inflammatory cell response to bacterial infection and innate immunity. It is now understood that such cells are capable of sensing microbial products and components of the outer membrane of Gram-negative bacteria, such as lipo-polysaccharide (LPS), through specific receptors known as toll-like receptors (TLR) (Conroy et al. 2008). These receptors recognise pathogen-associated molecular patterns (PAMPs) of infectious agents such as flagellin (TLR5) (Im et al. 2009) viral RNA (TLR7) (Diebold et al. 2004) and LPS (TLR2 and 4) (Kirschning et al. 1998; Chow et al. 1999). Mutations within the genes encoding these receptors are known to affect responsiveness to infectious agents (Etokebe et al. 2010). The gastro-intestinal system is exposed to many of these agents due to the constant presence of bacteria in the intestinal microflora. It is a commonly held concept that intestinal diseases may initially result from aberrant responses to normal microflora or new bacterial infection that colonises and triggers disease onset. Furthermore, there is growing evidence for the involvement of TLRs in cancer development and in the potential use of TLR agonists in its treatment (Conroy et al. 2008).

Mendelian genetic disorders such as the polyposis syndromes are clearly associated with the pathogenesis of gastrointestinal malignancy. However, more complex genetic approaches including genome-wide association studies (GWAS) have identified a wide diversity of genes involved in the pathogenesis of

gastrointestinal diseases such as inflammatory bowel disease and coeliac disease, many of which are involved in the control of inflammation. Such genetic changes may promote inflammation and regeneration and may also affect fundamental cellular processes such as apoptosis which can impact on survival of cells with malignant potential. While there is evidence to suggest that basic inflammatory processes, including for example cyclo-oxygenase products, may be implicated in the pathogenesis of even the polyposis syndromes, there is now considerable interest in the mechanisms involved in malignant change in non-Mendelian inflammatory diseases of the gastrointestinal tract, which have a heritable component.

2 Role of Inflammation in Mendelian Gastrointestinal Disease Polyposis Syndromes

The polyposis syndromes comprise a heterogeneous group of diseases, all autosomally inherited, although with variable penetrance. Lynch syndrome (Hereditary Non-Polyposis Colon Cancer, HNPCC) is the most commonly occurring of these syndromes, accounting for approximately 3% of all colorectal cancer (CRC). Familial adenomatous polyposis (FAP) occurs with a lower frequency estimated to be between 1:6850 and 1:23790. These two conditions are characterised by the adenoma to carcinoma sequence of progression. Peutz-Jeghers Syndrome (PJS) and Juvenile Polyposis Syndrome (JPS) are rarer conditions in which cancer develops through the dysplastic transformation of hamartomatous lesions. An inflammatory infiltrate is a component of the majority of adenomas and carcinomas seen in the colon, although the relative inflammatory response varies among sporadic tumours and hereditary syndromes (Michel et al. 2008).

2.1 Polyposis Syndromes: Familial Adenomatous Polyposis

Familial Adenomatous Polyposis (FAP) and its associated syndromes (Gardner's, Turcot's and Attenuated FAP) are characterised by autosomal dominant pedigrees. The phenotype is characterised by hundreds to thousands of colonic polyps which harbour malignant potential. There is also an increased risk of developing adenocarcinoma in the ampulla of Vater and stomach, as well as extra-intestinally, in the liver (hepatoblastoma), thyroid (follicular) and brain (medulloblastoma) (Lynch and de la Chapelle 2003).

Germline mutations in the adenomatous polyposis coli (APC) gene on chromosome 5 is the underlying cause of this disease, however, the penetrance of mutations in this gene vary from 20 to 100% in different pedigrees (Lynch and de la Chapelle 2003). The APC protein plays a critical tumour suppressing role by antagonising Wnt induced cell proliferation through binding and phosphorylating proteins such as beta-catenin, resulting in its destruction. Primarily, without the degradation of beta-catenin, this protein can activate TCF-4 and *lef-1* transcription

factors, which upregulate the MYC oncogene and contribute to the development of CRC via aberrant progression of the cell cycle. APC has further roles in cell migration, adhesion chromosome separation, spindle assembly and apoptosis, the disruption of which may also promote tumour initiation and progression.

Both human and murine studies suggest a significant role for cyclooxygenase-2 (COX-2) in this syndrome. COX-2 is upregulated in FAP-associated cancers (Hsi et al. 1999). This inducible cyclooxygenase enzyme is involved in the creation of prostaglandins from arachidonic acids. Prostaglandins act through G-protein coupled receptors to promote and propagate localised inflammation and mitogenesis in both a paracrine and autocrine manner (Khan et al. 2001; Sinicrope et al. 1999). Prostaglandins may also transactivate a number of pathways in cancer cells such as EGFR signalling further promoting metaplasticity (Wu et al. 2010). COX-2 knockout mice with mutated *Apc* genes result in a significant reduction in the size and number of colonic polyps (Oshima et al. 1996). COX-2 inhibitors have been used in an attempt to prevent adenoma and carcinoma progression in both murine and human studies. Trials with the COX inhibitor Sulindac demonstrated adenoma regression initially, although effects of COX-2 inhibition were transient and appeared to result in the hyper-proliferation of colonic adenomas after prolonged regular use (46 months) (Tonelli et al. 2000). Later trials using COX-2 preferential inhibitors such as celecoxib or rofecoxib demonstrated significant chemo-preventative effects (Steinbach et al. 2000; Bertagnolli et al. 2006; Baron et al. 2006) but widespread use of these drugs in this setting has been precluded due to an increased level of cardiovascular disease (Arber and Levin 2008; Solomon et al. 2005; Bresalier et al. 2005). Polymorphisms in COX-2 do not have significant effect in the FAP phenotype either in the colon or on extra-gastrointestinal manifestations (Humar et al. 2000; Peters et al. 2009). The functional COX-2 promoter polymorphism at -1195G associated with low COX-2 expression has recently been associated with FAP in a small clinical cohort but with a p-value approaching in-significance and cannot be explained with respect to COX-2 overexpression within this disease setting (Peters et al. 2009; Eisinger et al. 2006).

2.2 Polyposis Syndromes: Peutz-Jeghers Syndrome

Peutz-Jeghers Syndrome (PJS) results from a germline mutation in the *LKB1* gene now more commonly referred to as serine/threonine kinase 11 (STK11). This gene codes for a serine/threonine kinase which plays a role in cell cycle, apoptosis and cellular polarity. The phenotype is characterised by melanin hyperpigmentation of the buccal membrane and the presence of multiple hamartomatous polyps throughout the intestine. Neoplastic transformation of these gastrointestinal polyps may occur through a dysplasia—neoplasia pathway. COX-2 is also upregulated in polyps and cancers associated with this disease indicative of an inflammatory component to this disease (De Leng et al. 2003; Rossi et al. 2002). Immunohistochemical studies of PJS demonstrate a statistically significant correlation between the expression of total *LKB1* (wild type and mutant) and COX-2,

although the underlying molecular connection between them remains unknown (Wei et al. 2003; Shackelford et al. 2009). COX-2 inhibition in mouse models significantly reduces polyps burden (Udd et al. 2004) and similar effects have also been reported in humans (Udd et al. 2004).

2.3 Polyposis Syndromes: Juvenile Polyposis Syndrome

Multiple juvenile polyps occur in Juvenile Polyposis Syndrome (JPS) both in colon and elsewhere, predisposing to an increased risk of dysplastic and neoplastic change. 50–60% of patients with this disease have mutations in SMAD4 or BMPR1A, both of which are associated with the TGF- β signalling pathway (Geboes et al. 2007; Daniels and Montgomery 2007; Howe et al. 2004). While initially thought to be linked to PTEN mutations and alterations in Akt/PKB signalling, this has subsequently been questioned and has been shown to carry similar mutations and phenotypes to Cowden syndrome (Eng and Peacocke 1998; Lynch et al. 1997). Similar to sporadic and FAP-associated adenomas and carcinomas, the levels of COX-2 are higher in these polyps than in surrounding tissue, although the defining germ-line mutation exerts no effect on the expression of COX-2 (Brazowski et al. 2005; Kurland et al. 2007; van Hattem et al. 2009).

Numerous studies have documented an inflammatory cell infiltrate, especially in the lamina propria (Weller and McColl 1966; Fenoglio-Preiser and Hutter 1985). Furthermore, Kim et al. demonstrated in mouse models that SMAD4 inactivation in lymphocytes leads to the development of cancer, whereas inactivation in epithelial tissue does not exert this effect. This finding proposes a putative mechanistic link between alterations in SMAD4 signalling within the tumour setting and the propagation of cancer through inflammatory processes.

2.4 Polyposis Syndromes: Lynch Syndrome or Hereditary Non-Polyposis Colon Cancer

Lynch Syndrome or HNPCC, an autosomal dominant disease resulting in the development of multiple gastrointestinal and non-gastrointestinal tumours (Lynch and de la Chapelle 2003), is defined by mutations in DNA mismatch repair genes (Parsons et al. 1993). Mutations lead to the development of colonic, gastric, small bowel, and pancreatico-biliary tumours and extra-intestinally to endometrial, ovarian and urological tumours (Lynch and de la Chapelle 2003). The mismatch repair system includes the proteins hMLH1, hMSH2, hPMS1, hMSH6, and hMLH3. A mutation in any of these genes results in the characteristic development of high levels of microsatellite instability (MSI-H). Germ-line mutations in HNPCC affected individuals (of which MLH1 and MSH2 account for approximately 90%) (Lynch and de la Chapelle 2003; Lynch et al. 2009) are followed by further somatic mutations through failure of mismatch repair occurring in short repeat regions (and often in other MMR genes resulting in a self-fulfilling

prophecy), primary genetic damage or hypermethylation of the promoter regions of these genes (Peltomaki 2001). Genes commonly mutated as a result of MMR loss of function include TGF- β , IGF, caspase 5, and Bax, all of which are involved in cell proliferation or apoptosis.

MSI-H tumours are associated with high level of inflammatory cell infiltrate in both pre-cancerous adenomas and the tumours. The magnitude of this infiltration is thought to be associated with the reduced metastatic potential associated with this phenotype and the more favourable clinical outcomes seen in patients with MSI-H tumours with a strong Crohn's like reaction (CLR) (Buckowitz et al. 2005; Gafa et al. 2000; Gryfe et al. 2000; Watson et al. 1998). Between 10–15% of sporadic colorectal cancers may additionally be MSI-H positive postulating that these tumours in the same fashion may respond favourably. This inflammatory component is influenced by the expression of pro-inflammatory genes and the production of frameshift mutated peptides, which act as immunogenic tumour specific antigens (Watson et al. 1998; Ripberger et al. 2003; Schwitalle et al. 2004; Linnebacher et al. 2001). This may be in contrast to the general assumption that inflammation directly promotes carcinogenesis. However a direct immunogenic response to tumour antigens may be classified as a secondary response subsequent to the development of a tumour containing tumour-resident macrophages, tumor-infiltrating cytotoxic (CD8+) lymphocytes and natural killer cells.

Array studies of MSI-H tumours have shown that MSI-H tumour cells express mRNA of genes associated with inflammation and apoptosis at levels higher than those seen in microsatellite stable (MSS) tumours. TGF- β , IGF, and MLH1 were all down regulated in the MSI-H tumours confirming their denoted status. Validation of the array data confirmed the greater expression of inflammatory genes such as β -catenin, Interleukin 8, Toll-like receptor 2, Interleukin 1 β , and Interleukin 18 as well as the apoptotic related genes granulysin, caspase 2, granzyme A, survivin, and Human Natural killer Cell enhancing factor (NKEF) (Banerjea et al. 2009). Enhanced expression of these genes is a reflection of the observed immunogenic response and presence of infiltrating cytotoxic T-lymphocytes. The mechanism through which this form of tumour immunity differs from that observed in other diseases and provides for a better prognosis in MSI tumours is unclear.

Further enhancing the immune response to MSI-H tumours is the relatively low level of T-regulatory cells compared to sporadic and FAP-associated CRC independent of APC mutation status (Sinicrope et al. 1999; Saurer and Mueller 2009; Drescher et al. 2009). T-regulatory cells play an important role in limiting the activation of the inflammatory system, maintaining immune homeostasis and tolerance to self antigens. Their presence is thought to be associated with a poorer prognosis, although this hypothesis is currently being questioned (Mougiakakos et al. 2010; Wang 2008; Franke et al. 2008). Immunohistochemistry and PCR techniques have demonstrated that the intra-tumoral lymphocytes in MSI-H tumours are predominantly CD3+ CD8+ Granzyme B secreting cells, indicating a cytotoxic T-cell phenotype further supported by good correlation between the CD8+ and IL-2R α + cells (Saurer and Mueller 2009; Phillips et al. 2004).

Reinforcing this hypothesis is the higher perforin/CD3 mRNA ratio seen in MSI-H tumours when compared to MSS tumours (Le Gouvello et al. 2008).

3 Non-Mendelian Association of Inflammation and Cancer

3.1 Oesophageal Cancer

The incidence of adenocarcinoma of the distal oesophagus has increased in Western countries over the past three decades, whereas the incidence of squamous-cell carcinoma (SCC) has decreased slightly (Blot and McLaughlin 1999). Obesity, gastro-oesophageal reflux of acid and bile; and Barrett's oesophagus may be contributory factors (Chak et al. 2009; Lagergren et al. 1999; Theisen et al. 2000; Nehra et al. 1999; Sikkema et al. 2010; Hage et al. 2004). The risk of SCC of the oesophagus and the head and neck has been linked to smoking and alcohol consumption (Lee et al. 2007). The familial aggregation of Barrett's oesophagus (BO) may represent a complex genetic trait. Many studies report a strong family link in patients with Barrett's oesophagus and oesophageal adenocarcinoma (OAC). A strong familial expression of BO was seen, spanning one to four generations with two to seven affected members per family. Subsequent, reports of 24 members of 3 generations in a Spanish family showed 6 cases of OAC and 4 cases of BO (Fahmy and King 1993; Munitiz et al. 2008). Further studies have confirmed that individuals with BO and OAC are more likely to have a positive family history (Chak et al. 2002). Furthermore, Mendelian inheritance of familial BO may be more common than previously thought, inherited in an autosomal dominant fashion with incomplete penetrance (Sappati Biyyani et al. 2007).

It is hypothesised that malignancy of the lower oesophagus is supported and propagated through the maintenance of chronic inflammation and dysregulated cytokine expression. A histopathological inflammatory gradient has been observed within BO lesions (Jankowski et al. 2000; Fitzgerald et al. 2002; Tselepis et al. 2002). Cytokines such as IL-6 and IL-1B have been demonstrated to affect lower oesophageal sphincter function, implicating inflammatory mediators in the cyclical increase and propagation of oesophageal disease (Cao et al. 2006). The proinflammatory cytokines IL-8 and IL-1 α are elevated throughout the oesophageal cancer sequence (metaplasia-dysplasia-adenocarcinoma) in conjunction with increased NF-kappaB activation and resistance to chemotherapeutic treatment strategies (O'Riordan et al. 2005). The exact contributions of underlying genetic pre-dispositions or local genetic abnormalities that play in the development of oesophageal malignancy remains an elusive paradigm.

A number of multicentre studies have begun to examine genetic predispositions associated with risk of oesophageal complications, assessing gene associated SNPs with roles in regulation of inflammation and redox response, both important in initial disease onset. The IL-12 (A + 1188C) genotype, associated with increased expression of IL-12p70, has been linked with increased risk of BO development from within a population with gastro-oesophageal reflux disease. However this study did

not report any association between SNPs within IL-2, IL-6, or IL-8 and development of BO (Moons et al. 2008). Interestingly, observations regarding polymorphisms associated with COX-2 have differed between Barrett's associated adenocarcinoma and oesophageal squamous-cell carcinoma (OSCC). Case-control analysis showed a 1.72-fold and 2.24-fold excess risk of developing oesophageal squamous-cell cancer for the COX-2 -1195AA or -765CC genotype carriers compared with noncarriers of OSCC (Zhang et al. 2005). To date few COX-2 polymorphisms have been associated with development of BO or Barrett's associated adenocarcinoma, however (Kristinsson et al. 2009; Ferguson et al. 2008). Future studies utilising more comprehensive GWAS approaches may shed light on underlying polymorphisms in Barrett's associated OAC, rather than the current candidate gene approaches which have largely been negative in their associations. However, a growing number of positive associations have been observed between cytokine polymorphisms, for example in IL-1B and TNF α with patient survival and/or treatment in those suffering from OAC (Deans et al. 2009; Deans et al. 2007; Azim et al. 2007). A large multi-center case-control study conducted in 14 centres examined genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract (UADT) (Canova et al. 2009). SNPs within CYP2A6, MDM2, TNF α , and GASC1 were of notable significance with strong associations to UADT cancers in particular oesophageal cancers. GASC1 variants were strongly associated with increased risk of oesophageal squamous-cell carcinoma (P trend = 0.008). The rare variant of CYP2A6 -47A > C (rs28399433) and of two SNPs in the TNF α gene were associated with a decreased UADT cancer risk (Canova et al. 2009). Taken together, candidate gene approaches to the association of inherited polymorphisms in inflammatory mediators with oesophageal diseases have had limited success. While inflammation plays a vital role in the inception of BO and the propagation of OAC, the underlying genetic predispositions within the inflammatory context remain to be identified. There has recently been two SNPs identified which predispose to Barrett's metaplasia. These are located on autosomal chromosomes (J. Jankowski, personnel correspondence). These are significant to genome wide significance level.

3.2 Coeliac Disease Inflammation and Cancer Sequence

Coeliac disease is a common intestinal inflammatory disorder, characterised by intolerance to dietary gluten and related proteins from barely and rye. Traditionally this disease is thought to be a Th1-mediated disease utilising HLA-DQ2 and DQ8 in antigen presentation (e.g., gluten) to CD4⁺T cells in the intestine. These wheat peptides are deamidated by tissue transglutaminase (TTG) leading to higher affinity for DQ2. Coeliac disease is classically associated with an increased risk (50-fold) of enteropathy associated T-cell lymphoma (Verbeek et al. 2008; Catassi et al. 2005; Gao et al. 2009) and other types of non-Hodgkins lymphomas (NHL), specifically B-cell NHLs (Gao et al. 2009; Smedby et al. 2005). Coeliac disease is also associated with the development of adenocarcinoma of the duodenum and

cancer of the oesophagus (Diosdado et al, 2010). Recent GWAS studies have identified numerous novel non-HLA loci in addition to classical HLA loci upon replication of the top 1020 most strongly associated SNPs (Hunt et al. 2008; Dubois et al. 2010). The HLA-DQ2A1/B1 locus showed the highest level of coeliac association ($P < 10^{-50}$). The majority of the newly identified loci were of an immune-related origin (IL2/IL21, IL18RAP, IL12A, CCR1/CCR3 cluster locus (Hunt et al. 2008); and regions containing BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ETS1, ICOSLG, RUNX3, THEMIS, TNFRSF14, and ZMIZ1 (Dubois et al. 2010)) and a number of these are shared by other autoimmune and inflammatory disorders (IL2-IL21, IL18RAP, CCR3, and SH2B3) (Hunt et al. 2008). Follow-up replication studies of celiac GWAS data specifically focused on SNPs within immune pathways and SNPs overlapping with other autoimmune disorders such as T1D, RA and CD in Wellcome Trust Case Control Consortium (WTCCC) GWAS data. These studies identified 2 further novel genome-wide coeliac disease association loci on chromosome 6q23.3 and 2p16.1 (Trynka et al. 2009). The strongest association between celiac disease and other autoimmune disorders was observed in 60 kb region of strong linkage disequilibrium proximal to *tumour necrosis factor inducible protein A20* (TNFAIP3) on chromosome 6q23.3. Intriguingly this gene has also been strongly implicated in the pathogenesis of Hodgkin's disease and other B-cell lymphomas and further studies are required to determine whether this gene plays a role in celiac-associated lymphomata (Kato et al. 2009; Schmitz et al. 2009). The second novel coeliac disease association loci on chromosome 2p16.1 is located within the second intron of *v-rel reticuloendotheliosis viral oncogene homolog* (REL). The REL protein in conjunction with other members of the family (RELA (p65), RELB NFKB1, and NFKB2) form the core transcription factors in the mediation of NF- κ B inflammatory pathway signalling and in anti-apoptotic signalling.

The discovery of coeliac-associated SNPs proximal to the gene RGS1 may have particular interest with respect to coeliac-associated lymphoma development (Piovan et al. 2007; Han et al. 2006). Chemokine receptor signalling and B-cell activation and proliferation are known to be regulated by RGS1 (Piovan et al. 2007; Han et al. 2006). Indeed, mouse model studies have demonstrated the involvement of RGS1 in B-cell movement to and from lymph nodes (Han et al. 2006; Moratz et al. 2004). It can be postulated that mutations affecting RGS1 expression and localisation may impact upon lymphoma development in celiac patients. Further work is necessary to demonstrate the mechanisms involved in the pathogenesis of both celiac disease and celiac disease-associated malignancy.

3.3 Inflammatory Bowel Disease and Cancer

Studies indicate that 5–20% of inflammatory bowel disease (IBD) is hereditary with genetic factors having a greater impact in Crohn's Disease (CD) than in Ulcerative colitis (UC) (Spehlmann et al. 2008; Halfvarson et al. 2003; Binder 1998). The hereditary genetics of IBD appear to have little direct impact on the risk of

carcinogenesis (Triantafyllidis et al. 2009). Colon cancer typically occurs in ulcerative colitis in patients who have a long history of inflammation and is typically associated with a pan-colitis. The primary risk factor for CRC in IBD is thought to be chronic inflammation with the risk increasing with the duration, extent and severity of colitis and the presence of Primary Sclerosing Cholangitis (PSC) (Itzkowitz and Yio 2004; Triantafyllidis et al. 2009). Candidate gene approaches have highlighted the polymorphic association of inflammatory molecules such as TNF α , IL10 and IL2/21 axis, with UC and colorectal cancer (Franke et al. 2008; Garrity-Park et al. 2008; Festen et al. 2009). Genome-wide Association Studies have highlighted SNPs associated with cell death, immunity and inflammation specific for both Crohn's Disease and Ulcerative Colitis, or general to both (Cho 2008; Anderson et al. 2009; Fisher et al. 2008). Shared disease susceptibility loci discovered for UC and CD included many genes with known immune functions (IL23R, IL12B, HLA, NKX2-3 and MST1 (Fisher et al. 2008); IL18RAP, IL12B, JAK2, STAT3, HLA-DRB1 and HLA-DQA (Anderson et al. 2009) in addition to further disease specific immune-related loci. Emerging roles for the involvement of the T helper-(Th)17 differentiation pathway and innate immunity have been suggested from the susceptibility loci identified through these GWAS studies (Anderson et al. 2009; Fisher et al. 2008; Raelson et al. 2007; Rioux et al. 2007; Duerr et al. 2006). Proto-oncogenes such as MYC and Sp1 have been shown to be induced in UC through inflammatory mechanisms, implicating chronic inflammation in disease onset (Macpherson et al. 1992; Maggio-Price et al. 2005; Brentnall et al. 2009). At this point, further studies are required to delineate between the roles of genetic and environmental factors in the pathogenesis of IBD-associated malignancy.

3.4 Gastric Cancer and Inflammatory Genes

Gastric cancer (GC) typically occurs on a background of life-long *H. pylori* infection associated with chronic inflammation, gastric atrophy, and achlorhydria (Argent et al. 2008; Niwa et al. 2010; Polk and Peek 2010; Waghray et al. 2010). Interleukin 1 is probably the most potent suppressant of gastric acid secretion known and is directly associated with the development of achlorhydria (Furuta et al. 2002; Uehara et al. 1989; Saperas et al. 1992; Kondo et al. 1994). Polymorphisms in the IL1-1 gene cluster known to be associated with enhanced IL-1 activity have been associated strongly with the development of gastric cancer (Waghray et al. 2010; El-Omar et al. 2001). Polymorphisms in TLR9 have also been linked with the development of gastric atrophy and hypochlorhydria in *H. pylori* infected patients (Ng et al. 2010). Patients carrying TLR4 + 896G polymorphism display a significantly increased odds ratio (11-fold; 95% CI = 2.5–48) of developing GC (Hold et al. 2007). However this SNP in conjunction with TLR4 + 1196T, which is also GC associated, have distinct ethnic dependencies. Hence inflammatory activity can be directly linked to the pathogenesis of gastric cancer through its role in the suppression of gastric acid, a scenario which permits the generation of potentially oncogenic compounds such as nitrites within the gastric mucosa.

4 Conclusion

The involvement of inflammatory genes in both pathogenesis and outcome is a subject of emerging detail with respect to gastro-intestinal carcinogenesis. It is understood that chronic GI inflammatory conditions with an inherited component predispose to cancer development but the exact mechanisms through which this occurs may only be postulated. Further detailed genetic studies coupled to functional analysis of identified genes and the analysis of external environmental influences may permit a more detailed dissection of the pathways involved in inflammation-cancer sequences in the gastrointestinal tract.

References

- Anderson CA et al (2009) Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. *Gastroenterology* 136:523–529 e3
- Arber N, Levin B (2008) Chemoprevention of colorectal neoplasia: the potential for personalized medicine. *Gastroenterology* 134:1224–1237
- Argent RH et al (2008) Toxigenic *Helicobacter pylori* infection precedes gastric hypochlorhydria in cancer relatives, and *H. pylori* virulence evolves in these families. *Clin Cancer Res* 14:2227–2235
- Azim K et al (2007) Genetic polymorphisms and the risk of infection following esophagectomy. positive association with TNF-alpha gene -308 genotype. *Ann Surg* 246:122–128
- Banerjea A et al (2009) Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. *Colorectal Dis* 11:601–608
- Baron JA et al (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. *Gastroenterology* 131:1674–1682
- Bertagnolli MM et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. *N Engl J Med* 355:873–884
- Binder V (1998) Genetic epidemiology in inflammatory bowel disease. *Dig Dis* 16:351–355
- Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. *Semin Oncol* 26:2–8
- Brazowski E et al (2005) Characteristics of familial juvenile polyps expressing cyclooxygenase-2. *Am J Gastroenterol* 100:130–138
- Brentnall TA et al (2009) Proteins that underlie neoplastic progression of ulcerative colitis. *Proteomics Clin Appl* 3:1326–1337
- Bresalier RS et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 352:1092–1102
- Buckowitz A et al (2005) Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. *Br J Cancer* 92:1746–1753
- Canova C et al (2009) Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. *Cancer Res* 69:2956–2965
- Cao W et al (2006) IL-1beta signaling in cat lower esophageal sphincter circular muscle. *Am J Physiol Gastrointest Liver Physiol* 291:G672–G680
- Catassi C et al (2005) Association of celiac disease and intestinal lymphomas and other cancers. *Gastroenterology* 128:S79–S86
- Chak A et al (2002) Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. *Gut* 51:323–328

- Chak A et al (2009) Assessment of familiarity, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. *Am J Gastroenterol* 104:1913–1921
- Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 8:458–466
- Chow JC et al (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. *J Biol Chem* 274:10689–10692
- Conroy H et al (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. *Oncogene* 27:168–180
- Daniels J, Montgomery E (2007) Non-neoplastic colorectal polyps. *Curr Diagn Pathol* 13:467–478
- De Leng WW et al (2003) Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. *Clin Cancer Res* 9:3065–3072
- Deans C et al (2007) Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. *Ann Surg Oncol* 14:329–339
- Deans DA et al (2009) Cancer cachexia is associated with the IL10–1082 gene promoter polymorphism in patients with gastroesophageal malignancy. *Am J Clin Nutr* 89:1164–1172
- Diebold SS et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 303:1529–1531
- Diosdado B et al (2010) High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. *Clin Cancer Res* 16:1391–1401
- Drescher KM et al (2009) Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. *Fam Cancer* 8:231–239
- Dubois PC et al (2010) Multiple common variants for celiac disease influencing immune gene expression. *Nat Genet* 42:295–302
- Duerr RH et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 314:1461–1463
- Eisinger AL et al (2006) The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. *J Biol Chem* 281:20474–20482
- El-Omar EM et al (2001) The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. *Nature* 412:99
- Eng C, Peacocke M (1998) PTEN and inherited hamartoma-cancer syndromes. *Nat Genet* 19:223
- Etokebe GE et al (2010) Toll-like receptor 2 (P631H) mutant impairs membrane internalization and is a dominant negative allele. *Scand J Immunol* 71:369–381
- Fahmy N, King JF (1993) Barrett's esophagus: an acquired condition with genetic predisposition. *Am J Gastroenterol* 88:1262–1265
- Fenoglio-Preiser CM, Hutter RVP (1985) Colorectal polyps: pathologic diagnosis and clinical significance. *CA Cancer J Clin* 35:322–344
- Ferguson HR et al (2008) Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 17:727–731
- Festen EA et al (2009) Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. *Gut* 58:799–804
- Fisher SA et al (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. *Nat Genet* 40:710–712
- Fitzgerald RC et al (2002) Inflammatory gradient in Barrett's oesophagus: implications for disease complications. *Gut* 51:316–322
- Franke A et al (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. *Nat Genet* 40:1319–1323
- Furuta T et al (2002) Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. *Gastroenterology* 123:92–105

- Gafa R et al (2000) Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. *Cancer* 89:2025–2037
- Gao Y et al (2009) Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. *Gastroenterology* 136:91–98
- Garrity-Park MM et al (2008) Tumor necrosis factor- α polymorphisms in ulcerative colitis-associated colorectal cancer. *Am J Gastroenterol* 103:407–415
- Geboes K et al (2007) Non-adenomatous colorectal polyposis syndromes. *Curr Diagn Pathol* 13:479–489
- Grivnickov SI et al (2010) Immunity, inflammation, and cancer. *Cell* 140:883–899
- Gryfe R et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med* 342:69–77
- Hage M et al (2004) Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. *Scand J Gastroenterol* 39:1175–1179
- Halfvarson J et al (2003) Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. *Gastroenterology* 124:1767–1773
- Han JI et al (2006) RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization. *J Leukoc Biol* 79:1357–1368
- Hold GL et al (2007) A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. *Gastroenterology* 132:905–912
- Howe JR et al (2004) The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. *J Med Genet* 41:484–491
- Hsi LC et al (1999) Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. *Carcinogenesis* 20:2045–2049
- Humar B et al (2000) Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large swiss familial adenomatous polyposis kindred. *Int J Cancer* 87:812–817
- Hunt KA et al (2008) Newly identified genetic risk variants for celiac disease related to the immune response. *Nat Genet* 40:395–402
- Im J et al (2009) Induction of IL-8 expression by bacterial flagellin is mediated through lipid raft formation and intracellular TLR5 activation in A549 cells. *Mol Immunol* 47:614–622
- Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *Am J Physiol Gastrointest Liver Physiol* 287:G7–G17
- Jankowski J, Harrison RF, Perry I, Balkwill F, Tselepis C (2000) Barrett's esophagus. *Lancet* 356:2079–2085
- Kato M et al (2009) Frequent inactivation of A20 in B-cell lymphomas. *Nature* 459:712–716
- Khan KN et al (2001) Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. *Scand J Gastroenterol* 36:865–869
- Kirschning CJ et al (1998) Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. *J Exp Med* 188:2091–2097
- Kondo S et al (1994) Interleukin-1 beta inhibits gastric histamine secretion and synthesis in the rat. *Am J Physiol* 267:G966–G971
- Kristinsson JO et al (2009) Cyclooxygenase-2 polymorphisms and the risk of esophageal adenocarcinoma. *World J Gastroenterol* 15:3493–3497
- Kurland JE et al (2007) Cyclooxygenase-2 expression in polyps from a patient with juvenile polyposis syndrome with mutant BMPR1A. *J Pediatr Gastroenterol Nutr* 44:318–325
- Lagergren J et al (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 340:825–831
- Le Gouvello S et al (2008) High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. *Gut* 57:772–779
- Lee CH et al (2007) Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking. *Eur J Cancer* 43:1188–1199

- Linnebacher M et al (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. *Int J Cancer* 93:6–11
- Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. *N Engl J Med* 348:919–932
- Lynch ED et al (1997) Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. *Am J Hum Genet* 61:1254–1260
- Lynch HT et al (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet* 76:1–18
- Macpherson AJ et al (1992) Increased expression of c-myc proto-oncogene in biopsies of ulcerative colitis and Crohn's colitis. *Gut* 33:651–656
- Maggio-Price L et al (2005) Dual infection with *Helicobacter bilis* and *Helicobacter hepaticus* in p-glycoprotein-deficient *mdr1a*^{-/-} mice results in colitis that progresses to dysplasia. *Am J Pathol* 166:1793–1806
- Michel S et al (2008) High density of FOXP3-positive T-cells infiltrating colorectal cancers with microsatellite instability. *Br J Cancer* 99:1867–1873
- Moons LM et al (2008) A pro-inflammatory genotype predisposes to Barrett's esophagus. *Carcinogenesis* 29:926–931
- Moratz C et al (2004) Regulation of chemokine-induced lymphocyte migration by RGS proteins. *Methods Enzymol* 389:15–32
- Mougiakakos D et al (2010) Regulatory T-cells in cancer. *Adv Cancer Res* 107:57–117
- Munitiz V et al (2008) High risk of malignancy in familial Barrett's esophagus: presentation of one family. *J Clin Gastroenterol* 42:806–809
- Nehra D et al (1999) Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. *Gut* 44:598–602
- Ng MT et al (2010) Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with *Helicobacter pylori*-induced gastric disease. *Infect Immun* 78:1345–1352
- Niwa T et al (2010) Inflammatory processes triggered by *Helicobacter pylori* infection cause aberrant DNA methylation in gastric epithelial cells. *Cancer Res* 70:1430–1440
- O'Riordan JM et al (2005) Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. *Am J Gastroenterol* 100:1257–1264
- Oshima M et al (1996) Suppression of intestinal polyposis in *Apc delta716* knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* 87:803–809
- Parsons R et al (1993) Hypermutability and mismatch repair deficiency in RER + tumor cells. *Cell* 75:1227–1236
- Peltomaki P (2001) Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum Mol Genet* 10:735–740
- Peters WH et al (2009) COX-2 polymorphisms in patients with familial adenomatous polyposis. *Oncol Res* 17:347–351
- Phillips SM et al (2004) Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. *Br J Surg* 91:469–475
- Piovan E et al (2007) Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis. *Cancer Res* 67:8605–8614
- Polk DB, Peek RM Jr (2010) *Helicobacter pylori*: gastric cancer and beyond. *Nat Rev Cancer* 10:403–414
- Raelson JV et al (2007) Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. *Proc Natl Acad Sci USA* 104:14747–14752
- Rioux JD et al (2007) Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet* 39:596–604
- Ripberger E et al (2003) Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. *J Clin Immunol* 23:415–423

- Rossi DJ et al (2002) Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. *Proc Natl Acad Sci USA* 99:12327–12332
- Saperas E et al (1992) Interleukin-1 beta acts at hypothalamic sites to inhibit gastric acid secretion in rats. *Am J Physiol* 263:G414–G418
- Sappati Biyyani RS et al (2007) Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. *Dis Esophagus* 20:53–57
- Saurer L, Mueller C (2009) T-cell-mediated immunoregulation in the gastrointestinal tract. *Allergy* 64:505–519
- Schmitz R et al (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B-cell lymphoma. *J Exp Med* 206:981–989
- Schwitalle Y et al (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. *Cancer Immun* 4:14
- Secher T et al (2010) Remote control of intestinal tumorigenesis by innate immunity. *Cancer Res* 70:1749–1752
- Shackelford DB et al (2009) mTOR and HIF-1 α -mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. *Proc Natl Acad Sci USA* 106:11137–11142
- Sikkema M et al (2010) Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 8:235–244 quiz e32
- Sinicropo FA et al (1999) Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. *Gastroenterology* 117:350–358
- Smedby KE et al (2005) Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T-cell lymphoma. *Gut* 54:54–59
- Solomon SD et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 352:1071–1080
- Spehlmann ME et al (2008) Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. *Inflamm Bowel Dis* 14:968–976
- Steinbach G et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 342:1946–1952
- Theisen J et al (2000) Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. *J Gastrointest Surg* 4:50–54
- Tonelli F et al (2000) Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? *J Surg Oncol* 74:15–20
- Triantafyllidis JK et al (2009) Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. *Anticancer Res* 29:2727–2737
- Trynka G et al (2009) Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. *Gut* 58:1078–1083
- Tselepis C, Perry I, Dawson C, Hardy R, Darnton J, McConkey C, Stuart R, Wright NA, Harrison RF, Jankowski J (2002) Tumour necrosis factor- α in Barrett's metaplasia: a novel mechanism of action. *Oncogene* 39:6071–6081
- Udd L et al (2004) Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. *Gastroenterology* 127:1030–1037
- Uehara A et al (1989) Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin. *Biochem Biophys Res Commun* 162:1578–1584
- van Hattem WA et al (2009) Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. *Clin Gastroenterol Hepatol* 7:93–97
- Vanbeek WH et al (2008) Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. *Scand J Gastroenterol* 43:1322–1328
- Waghray M et al (2010) Interleukin-1 β promotes gastric atrophy through suppression of Sonic Hedgehog. *Gastroenterology* 138:562–572 e1-2

- Wang R-F (2008) CD8+ regulatory T-cells, their suppressive mechanisms, and regulation in cancer. *Hum Immunol* 69:811–814
- Watson P et al (1998) Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. *Cancer* 83:259–266
- Wei C et al (2003) Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome. *J Histochem Cytochem* 51:1665–1672
- Weller RO, McColl I (1966) Electron microscope appearances of juvenile and Peutz-Jeghers polyps. *Gut* 7:265–270
- Wu WK et al (2010) Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. *Cancer Lett* 295:7–16
- Zhang X et al (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. *Gastroenterology* 129:565–576

Stem Cells and Inflammation in the Intestine

Adam Humphries, Trevor A. Graham and Stuart A. C. McDonald

Abstract

Knowledge of stem cell biology in the intestine is increasing exponentially and it is one of the current hot topics 'of the day'. Yet it is only recently that molecules such as *Lgr5* and *Bmi1* have been shown to reliably mark stem cells and have revealed the stem cell location throughout the murine gastrointestinal tract. However, there is a scarcity of meaningful work within their human counterpart. Nevertheless, recent studies have demonstrated the processes of niche succession, where one stem cell takes over the entire population of stem cells within a crypt; and monoclonal conversion, whereby the entire crypt becomes a clonal population of cells, are present in the human crypt. This work has also shown how crypts themselves divide and expand in the human colon.

Contents

1	The Colonic Crypt.....	52
1.1	Multi-Potential Stem Cells are Housed Within a Basal Niche: The Crypt Hierarchy	53
1.2	Stem Cell Number.....	53
1.3	Lineage Progenitors.....	55
1.4	Determinants of Cell Fate.....	56
1.5	Stem Cell Dynamics: Colonic Crypts are Clonal Populations.....	57
1.6	Mechanisms of Fixation.....	58

A. Humphries · T. A. Graham
Histopathology Unit, London Research Institute, Cancer Research UK,
London, UK

S. A. C. McDonald (✉)
Centre for Digestive Diseases, Blizard Institute of Cell and Molecular Science,
Barts and the London School of Medicine and Dentistry, 2 Newark Street,
Whitechapel, London, E1 2AT, UK
e-mail: stuart.mcdonald@cancer.org.uk

J. A. Z. Jankowski (ed.), *Inflammation and Gastrointestinal Cancers*,
Recent Results in Cancer Research 185, DOI: 10.1007/978-3-642-03503-6_3,
© Springer-Verlag Berlin Heidelberg 2011

2	The Effects of Inflammation on Stem Cells and their Niche	59
3	Concluding Remarks	60
	References.....	61

Chronic inflammation in the intestine has been shown to be a significant risk factor for carcinogenesis (Saleh and Trinchieri 2011). If cancer is seen as a disease of stem cells, exposure of stem cells to inflammation must have a profound contributing effect on this. Increased cellular turnover, exposure to inflammatory mediators and cycles of damage and repair all contribute to a state of stem cell instability increasing the likelihood of a carcinogenic event.

In this chapter, we review the structure of the stem cell compartment within the intestine and discuss stem cell biology within normal and inflamed conditions. We discuss how the intestine adapts to inflammatory damage and the mechanisms of epithelial repair. Furthermore, we examine how field cancerisation (a process whereby an area of epithelium is conditioned to be predisposed to tumourigenesis) is affected by chronic inflammation. Finally, we ask if stem cell therapies have been effective in treating inflammatory disorders such as Crohn's disease (CD) and ulcerative colitis (UC).

1 The Colonic Crypt

The human colonic epithelium consists of a single layer of columnar cells that form the functional unit of the gut—the *crypt*—via finger-like projections into the underlying connective tissue, with a population of approximately 2,000 cells per crypt. Unlike the small bowel, there are no villi to be found and the main physiological function of the colon is salt and water absorption. Hence, the predominant terminally differentiated epithelial cells are columnar absorptive cells known as *colonocytes*, and mucous-secreting *goblet* cells. *Endocrine* cells, also known as *neuroendocrine* or *enteroendocrine* cells, that secrete a variety of peptide hormones in an endocrine or paracrine manner, are the other main cell type, although these are seen less frequently. *Paneth* cells are occasionally found in the colonic epithelium, the true function of these granular epithelial cells is still unclear although they are thought to have an important role in innate immunity and secrete a number of defensins and anti-microbial peptides (Salzman et al. 2007). There is emerging evidence that they can be very long-lived and are found in abundance at the base of the small intestinal crypt, although in the large bowel are only occasionally found in the ascending colon and some disease states.

The concept that these differentiated cells arise from a single multipotential stem cell through a number of *committed progenitors* was first formulated by Cheng and Leblond (1974) as the *Unitarian Hypothesis* in 1974, and is well founded in animals (Ponder et al. 1985; de Dombal et al. 1990). The first few generations of stem cell divisions are known as *transit-amplifying* cells, these divide rapidly to significantly increase the number of progeny that result from a

single stem cell division, as cells then move up the crypt from the base towards the luminal surface where they become committed to a certain lineage—*committed progenitor* cells, as further migration up the crypt axis occurs. Cells are increasingly differentiated until when they reach the luminal surface terminal differentiation has occurred. Once at the luminal surface, differentiated cells are shed 5–7 days after their initial conception in the lower crypt.

1.1 Multi-Potential Stem Cells are Housed Within a Basal Niche: The Crypt Hierarchy

All the experimental evidence to date supports the theory, originally proposed by Williams et al. (1992), that, within the colonic crypt, adult tissue-specific multi-potential stem cells are positioned at the base of the colonic crypt within a *stem cell niche*. The *niche* is a micro-environment that consists of the stem cells themselves and a sheath of surrounding mesenchymal cells, of the myofibroblast lineage—*pericryptal myofibroblasts*, separated by the basal lamina. Interactions between the pericryptal myofibroblasts and niche stem cells via paracrine secretion of cytokines and growth factors are important for maintaining the various cell phenotypes. Indeed, it is likely that the niche micro-environment created by the surrounding stromal/mesenchymal cells plays a more important role in maintaining basal crypt cells in the undifferentiated or ‘stem-like’ state than the intrinsic genetic programming within the stem cells themselves. An interesting recent study by Mathur et al. (2010) has demonstrated that in *Drosophila*, the niche may initially be made of progenitor cells which, through BMP 2/4 homologue signalling from peripheral cells, maintain themselves in an undifferentiated state. When peripheral cells are lost, this allows the progenitor cells to respond to notch and begin to differentiate: yet one progenitor remains to form an intestinal stem cell. This is interesting as the current dogma is that stem cells move away from the niche to differentiate whereas this system shows a niche physically breaking down to initiate differentiation, suggesting that niches are transient.

1.2 Stem Cell Number

Most of the evidence for the structure of the colonic crypt comes from murine labelling experiments using somatic mutagens or chimeric mice, where one strain carries a demonstrable marker. Much of the work has been done on the small intestine, although the principles have been applied to the colon as many similarities exist. Debate continues to exist over the number of stem cells housed within the niche and the properties of niche dynamics.

Stem cells within a niche can either expand asymmetrically or symmetrically: (i) an asymmetric stem cell division yields two daughter cells, one of which remains within the niche as a stem cell and the other leaving the niche being

destined for differentiation, these are also known as q divisions (Meineke et al. 2001), (ii) symmetrical stem cell divisions either produce two stem cells that remain within the niche— p divisions, or two daughter cells that exit the niche and differentiate— r divisions, with the resulting extinction of that stem cell line (Loeffler et al. 1993; Kim and Shibata 2002). It is by this process of symmetrical r divisions, in addition to random apoptosis of stem cells, that one stem cell line can, stochastically or by a selective advantage incurred as a result of a mutation, come to dominate a niche, a process known as *niche* or *clonal succession*. The progeny of this stem cell will then go on to occupy the whole crypt—termed *monoclonal conversion*.

The theory that the intestinal crypt is supported by a number of stem cells residing within a niche, rather than a single stem cell, initially came from a mouse study by Williams et al. (1992). They marked cells via mutagen-induced loss of the X-linked enzyme glucose-6-phosphate dehydrogenase (G6PD) in crypt cells and compared the time-course of mutated phenotypes in both the small and large intestine. A short time after administration of the mutagen a high frequency of partially-mutated crypts were observed, over time a rapid increase in wholly-mutated crypts was observed that reached a plateau at the same time that partially-mutated crypts disappeared. The time taken for the appearance of wholly-mutated crypts in the large intestine was approximately 4 weeks, but 21 weeks in the small intestine, the authors suggested their results were consistent with several stem cells supporting a crypt niche and that the number of stem cells may differ between the small and large colon, with a greater number of niche stem cells in the small intestine to explain the time differences observed. The theory that the intestinal crypt is maintained by a stem cell niche housing multiple stem cells has since been supported by many further studies in both the mouse and human.

Evidence from the mouse points to 4–6 basal stem cells in the colonic crypt (Bjerknes and Cheng 1999; Cai et al. 1997; Potten et al. 1997), and a hierarchical structure to the stem cell compartment has been proposed (Bjerknes and Cheng 1999; Cai et al. 1997; Potten et al. 1997). Cai et al. (1997) utilised the sensitivity of stem cells to very small dose of radiation in order to reduce crypt stem cell numbers to different extents and then measured the regenerative ability of the crypt cells to estimate the numbers of clonogenic cells. The authors concluded that, in the mouse, each colonic crypt consists of approximately 300–450 cells with 4–6 ultimate–lineage ancestor stem cells at the base, a further two tiers of cells above this retain clonogenic stem cell properties and have the ability to repopulate the crypt epithelium and regenerate the lower tier stem cells if the lower cells are damaged.

It is not possible to morphologically differentiate stem cells from other cells within the crypt and, although a number of stem cell markers have been proposed for the intestine none have been proven to specifically mark stem cells. Recent approaches in the mouse model have utilised the ability of stem cells, once clonally marked, to re populate the crypt with clonal progeny of all cell lineages—*clonal replacement* or *monoclonal conversion*—as a marker of multipotentiality. Barker et al. (2007) demonstrated that *Lgr5*

(leucine-rich-repeat-containing G-protein-coupled receptor 5), an intestinal *Wnt* target gene, was exclusively expressed at the colonic crypt base in mice, and that these cells were capable of producing all differentiated cell lineages and were thus multipotential i.e., stem cells.

Further insights supporting the existence of a stem cell niche in the human colon have been provided by studying methylation patterns at CpG islands in individual crypts, a random process known to increase with age (Ahuja et al. 1998; Issa 2000). Quantitative analysis of these patterns in non-expressed genes in the human colon supported the theory that colonic crypts are maintained by stem cell niches containing multiple cells—possibly greater than eight stem cells, rather than a single immortal stem cell, and that successive niche succession cycles take place in colonic crypts which is a natural consequence of the existence of symmetric cell divisions (Kim and Shibata 2002; Yatabe et al. 2001; Nicolas et al. 2007). Modelling studies based on the CpG island methylation patterns estimated that the niche succession time, i.e., the time for a single stem cell line to come to dominate the niche, to be 220 days (95% interquartile range of 2–1,900 days) (Yatabe et al. 2001). Thus, clonal succession is a characteristic of a niche.

1.3 Lineage Progenitors

Little is currently known about the intermediate progenitor cell types in the crypt, Bjercknes and Cheng (1999) used chemical mutagenesis to randomly mark crypt cells by somatic mutation of the *Dib-1* locus in SWR and F1 mice, thus they were able to identify and study the dynamics of mutant clones containing only mucus cells, only columnar cells and clones that contained a mixture of cell types. The authors concluded that both short and long-lived mucus and columnar cell progenitors exist in the crypt, with long-lived progenitors located in the lower-third of the crypt and short-lived progenitors seen higher-up the crypt axis. In this study, over 90% of persisting mutant clones containing a mixture of cell types were seen to arise from a crypt base columnar cell—supporting this as the location for the stem cell.

Therefore, within the human colonic crypt, multiple stem cells reside within a niche—possibly >8 in number, stem cells may undergo symmetric or asymmetric divisions to produce daughter cells that leave the crypt and form the population of transit-amplifying cells. Cells then become committed to a certain lineage, and in the lower part of the crypt a population of long-lived committed precursors exist, with their progeny subsequently undergoing further differentiation and migrating to the luminal surface. The exact life-span of committed progenitor cells in the human crypt is unknown, although it is thought this could be many years. Within the niche, the processes of niche succession and monoclonal conversion enable a single stem cell line and its progeny to completely populate the crypt, with successive niche succession cycles taking place over the life-time of a crypt.

1.4 Determinants of Cell Fate

There are a number of key regulatory signal pathways that are thought to be important in organising the architecture of the crypt, maintaining the stem cell phenotype and controlling cell migration and differentiation. Although most of the work done on evaluating these pathways has been done on the small intestine, similar control mechanisms are thought to be in operation in the colon.

1.4.1 Cellular Proliferation

High levels of *Wnt* signalling are found at the crypt base, the location of the stem cell niche, and this is thought to be crucial for maintaining cells in the proliferative and undifferentiated state (Crosnier et al. 2006). Mutations in adenomatous polyposis coli (*APC*) result in overactivation of *Wnt* signalling and formation of multiple polyps that consist of huge numbers of giant crypts that grow without limit (Morin et al. 1997). *Notch* genes encode trans-membrane receptors that are also important in regulating communication between cells, inhibition of *Notch* results in a large loss of proliferative crypt cells (van Es and Clevers 2005) and thus both *Wnt* and *Notch* pathway activation appears to be required in combination in order to maintain the stem cell phenotype at the crypt base.

1.4.2 Cellular Segregation

Wnt signalling has been shown to control the expression of the *EphB* receptors and *Ephrin* ligands—*Ephrin B1* and *Ephrin B2* that are involved in maintaining cellular boundaries. *Wnt* switches on expression of *EphB2* and *EphB3* receptors and inhibits *Ephrin B1* production, this restricts these cells to the crypt base; as one moves up the crypt axis there is increased *EphrinB1* ligand expression and loss of *Wnt* signalling/*EphB* receptor expression and so this serves to prevent downward migration of cells due to repulsion between *EphB* and *EphrinB1*.

1.4.3 Cellular Differentiation

Wnt signalling is thought to have a variety of important roles, being not just essential for cellular proliferation but also having a role in determining cell fate. Blocking of *Wnt* signalling results in the loss of secretory cell lineages, but enterocyte differentiation appears to be unaffected (Pinto et al. 2003); in cases of excessive *Wnt* activation then increased numbers of Paneth cell committed precursors are observed (Andreu et al. 2005). *Notch* signalling also has an inhibitory effect on secretory differentiation and it is thought that cells escaping *Notch* inhibition are able to commit to a secretory lineage and production of *Notch Delta/Jagged* ligands by these cells also results in lateral inhibition of neighbouring cells from following the same lineage pathway (Crosnier et al. 2006). *Math-1* was first identified as a transcription factor important for the differentiation of neuronal cells (Akazawa et al. 1995), and has since been shown to be expressed in the gut epithelium with *Math-1* protein being required for secretory cell differentiation (Yang et al. 2001). *Hes-1* is a *Notch* signalling component and a negative regulator of secretory cell differentiation—deletion of *Hes-1* results in increased numbers of

secretory cell types and elevated *Math-1* expression (Jensen et al. 2000). Thus, in summary, *Wnt* signalling drives the *Notch* pathway, those cells that become committed to the secretory lineage escape *Notch* activation via expressing the *Delta/Jagged* ligands with subsequent inhibition of *Hes-1* and increased *Math-1* expression; *Notch*-activated cells are under lateral inhibition from committed secretory progenitors, activated *notch* signalling up-regulates *Hes-1* with resulting suppression of *Math-1* and commitment to an absorptive fate.

1.5 Stem Cell Dynamics: Colonic Crypts are Clonal Populations

There is a large body of evidence to support the theory that adult individual crypts are monoclonal, containing cell populations ultimately derived from a single multipotential stem cell, and we have already discussed how *niche succession* with subsequent *monoclonal conversion* is inherent to the dynamics of a stem cell niche.

Studies utilising mouse chimeras have given valuable insights into the clonal evolution of intestinal crypts. Utilising differential binding of the lectin *Dolichos biflorus* agglutinin (DBA) to B6-derived and not SWR-derived cells, Schmidt et al. (1988) created C57BL/6 J Lac (B6) ↔ SWR mouse aggregation chimeras in order to assess crypt clonality in the developing mouse small intestine. Mixed crypts containing cells of both genotypes were seen in the neonatal period, but by day 14 these had all disappeared and only crypts containing cells of a single genotype were observed. Thus, intestinal crypts are polyclonal at birth but by day 14 all crypts are monoclonal, with crypts undergoing an apparent purification during the rapid growth and high rates of crypt fission occurring at this time.

In the human, the chance finding of an individual who had undergone a prophylactic colectomy for Familial Adenomatous Polyposis Coli (FAP), and was also an XO/XY mosaic, enabled non-isotopic *in situ* hybridisation studies to show that colonic crypts were comprised exclusively of either XO or XY cells (Novelli et al. 1996). Thus, crypts are clonal and derived from a multipotential stem cell. Additional studies on human tissue in individuals heterozygous for the naturally occurring polymorphisms for the G6PD Mediterranean mutation (563 C > T) and the gene encoding for the enzyme O-acetyl transferase (OAT) as clonal markers have confirmed the conclusion that human intestinal crypts are clonal populations (Novelli et al. 2003; Campbell et al. 1996). Recently it has been shown that colonic stem cells and their progeny contain non-pathogenic mutations in their mitochondrial DNA, specifically mutations in the cytochrome *c* oxidase (COX) gene—a component of complex IV of the respiratory chain, that are relatively common (Taylor et al. 2003). The mitochondrial genome is prone to mutation due to a lack of protective histones and poor DNA repair mechanisms. Mutations can expand stochastically within a cell and over time cells will become either *homoplasmic*—all the mitochondria in the cell are mutated, or *heteroplasmic*—the cell contains a mixture of mutated and wild-type mitochondria. This stochastic

expansion is a lengthy process, and for a mutated cellular phenotype to be observed homoplasmy or a high degree of heteroplasmy must be present, thus stem cells are the only cells that have a sufficient life-span to accumulate these mitochondrial mutations to a level that results in a biochemical deficiency. Two-colour enzyme histochemistry can be used to simultaneously detect the mtDNA-encoded COX and nuclear DNA-encoded succinate dehydrogenase (SDH), a component of complex II of the respiratory chain. Three different types of crypts are observed: wild-type brown crypts, wholly-mutated crypts and partially-mutated crypts containing both mutant and wild-type cells. Laser micro-dissection on wholly-mutated crypts followed by PCR coupled with mtDNA sequencing confirm the presence of conserved clonal mitochondrial mutations within crypts (Taylor et al. 2003; Greaves et al. 2006), confirming that crypts are clonal populations as here a crypt has been repopulated from a single mutated stem cell via *niche succession* and *monoclonal conversion*. The existence of crypts containing two cell populations, one wild-type and one mutated, demonstrates that human intestinal crypts contain at least two stem cells and has enabled the dynamic analysis of clonal expansion and identification of the stem cell niche in human colonic tissue. Thus we now have evidence in human tissue of niche succession and monoclonal conversion ‘in action’, and that multiple stem cells maintain a crypt.

The time taken for the progeny of a mutated stem cell to colonise the crypt is known as the *clonal stabilisation time* (Campbell et al. 1996). We have already discussed that this has been shown to differ between the small and large intestine in the mouse, being only 28 days in the colon as opposed to 12 weeks in the small bowel (Williams et al. 1992; Park et al. 1995). Campbell et al. (1996), by using loss of O-acetylation of sialomucins after pelvic irradiation in patients heterozygous for O-acetyltransferase gene activity as a clonal marker, estimated the clonal stabilisation time in humans to be approximately one year; this was supported by modelling studies using methylation patterns of CpG islands that gave an estimated niche succession time of 220 days (Yatabe et al. 2001) in human crypts.

1.6 Mechanisms of Fixation

The processes of niche succession and monoclonal conversion allow mutations to be fixed in a number of ways:

1.6.1 Genetic Drift

Due to the small number of stem cells within the colonic niche, they are prone to genetic drift, therefore a single stem cell clone can come to dominate the niche as a result of stochastic non-selective events. As a result neutral mutations that do not affect the fitness if a cell can, over time, become fixed within the population (Kimura 1968).

1.6.2 Natural Selection

Occasionally mutations in a stem cell, especially those involving a tumour suppressor gene such as *APC*, bestow a selective growth advantage to the recipient cell. This allows the processes of niche succession and monoclonal conversion to occur rapidly so that the mutated stem cell progeny occupy the whole crypt. These mutations often result in what is termed a *selective sweep* where natural selection rapidly drives the advantageous allele to fixation (Nowell 1976; Cairns 1975).

1.6.3 Hitchhiking

Although tumourigenesis involves the accumulation of mutations that result in a growth advantage to the cell, not all confer an immediate selective advantage in isolation but in combination with others they contribute to a malignant phenotype. These mutations may become established merely by being linked to or *hitchhiking* with an allele that does provide a selective advantage (Maley et al. 2004; Smith and Haigh 1974).

2 The Effects of Inflammation on Stem Cells and their Niche

Inflammatory bowel diseases (IBD) such as CD or UC are characterised by inflammatory infiltrates into the mucosa driven and are perpetuated by bacteria (autologous or otherwise) or autoimmune factors, respectively. Infiltrating mucosal T cells (Hursting et al. 1997) are well known to produce factors such as proinflammatory cytokines such interferon- γ (IFN- γ) and tumour necrosis factor- α (TNF- α) as well as a plethora of others. The effects of these cytokines upon the crypt epithelium are profound; the mucosa thickens and the crypts elongate and become hyperplastic and there can be an eventual loss of crypts replaced by infiltrate if the inflammation is severe enough.

It has been reported that chronic inflammation can induce molecules such as P-cadherin which in turn cause crypt bifurcation perhaps through symmetric stem cell division (Milicic et al. 2008). Differentiated epithelial cells themselves react to proinflammatory factors. Enterocyte tight junction proteins are particularly sensitive to IFN- γ that induces a loss in barrier function or permeability (Beaurepaire et al. 2009). Goblet cells or mucodepletion is a common characteristic of UC, moreover, mice expressing mutations in MUC2 invariably develop a UC-like inflammatory bowel disease (van der Sluis et al. 2008). Paneth cells in the small intestine contain large concentrations of anti-microbial peptides called defensins, regulated by MyD88 activation of toll-like receptors on their surface. These are dramatically reduced during chronic inflammation, indeed, CD patients expressing the NOD2 mutation have almost absent defensin expression (Bevins et al. 2009).

There is a dearth of information on the direct effects of inflammation on crypt stem cells. It is unknown whether crypt hyperplasia is caused by an increase in stem cell number or an increase in the number of transit-amplifying cells

proliferating. Furthermore, it is unknown if the apparent loss of crypts in severe IBD is due to stem cell death. Assessing stem cell number in the normal human intestine has proved a trick too far for epithelial cell biologists, and therefore so has calculating stem cell numbers in chronic inflammation.

However, there is relatively more known about the effects of inflammation on the stem cell niche, which in turn would have effects on the stem cells themselves.

As previously stated the gastrointestinal stem cell niche is comprised of intestinal sub-epithelial myofibroblasts (ISEMFs), the stem cells themselves and surrounding differentiated epithelial cells such as Paneth cells (Sato et al. 2011). ISEMFs are important producers of matrix metalloproteinases (MMPs) which can digest extracellular matrix components and the basement membrane (Pender and MacDonald 2004). While no specific effect on intestinal stem cells has been documented, mice that are deficient in the matrixlysin have been shown to be resistant to tumour development (Wilson et al. 1997).

ISEMFs are also potent effectors of inflammation. They can express proinflammatory cytokines such as TNF- α , interleukin- (IL)-1 and can also proliferate in response to such cytokines, particularly in IBD (Andoh et al. 2002). Interestingly, IL-23 produced by ISEMFs has been shown to be important in the production of IL-17-producing cells (the so-called Th17 memory cell). Furthermore, IL-23 can induce IL-1 β and TNF- α production from surrounding macrophages in a synergistic fashion (Zhang et al. 2005). While there is a clear relationship between IL-17/IL-23 and IBD (Sarra et al. 2010), and they are potent inducers of intestinal pathology (Buonocore et al. 2010), there is no clear evidence as to the specific effect of such inflammatory mediators on the mammalian intestinal crypt stem cell.

Drosophila melanogaster has, however, yielded some interesting evidence on the control of stem cell proliferation by inflammatory mediators. Ren et al. (2010) in a recent paper have shown that a direct connection between intestinal stem cells and the basement membrane results in the activation of the Hippo (Hpo) pathway, which inhibits the transcriptional co-activator Yorkie (Yki). Dextran-sulphate sodium (a commonly used initiator of mucosal inflammation in mice) administration breaks this contact allowing activation of Yki and stem cell proliferation. Furthermore, the same group have shown that Yki can up-regulate expression of inflammatory cytokines such as the unpaired family (Upd1-3) which can also induce ISC proliferation through the JAK-STAT pathway (Beebe and Huttenlocher 2010). This pathway can also be negatively regulated by Notch inhibition of Upd cytokines (Liu et al. 2010). The balance between Notch and Hippo-mediated control of ISC proliferation is not yet fully understood. However, the JAK-STAT pathway is frequently employed in mammalian inflammatory cytokine signalling and it is logical to assume that mammalian ISC is also regulated by similar mechanisms. Indeed Andoh et al. (2009) have shown that the novel cytokine IL-24, an activator of the JAK1/STAT3 cascade is enhanced by proinflammatory cytokines in IBD.

3 Concluding Remarks

If there is one area of stem cell biology that has been under-researched it is that of the effects of inflammation on stem cells in the intestine. We assume that chronic inflammation is a potent carcinogen, and if we subscribe to the cancer stem cell theory of tumour development then our knowledge of the effects of inflammation on stem cells must improve. Recent developments in identifying stem cells within the crypt should allow thorough investigations of the effects of inflammatory mediators and potentially allow drug targets to be developed that specifically protect or control stem cell biology in these conditions.

References

- Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP (1998) Aging and DNA methylation in colorectal mucosa and cancer. *Cancer Res* 58:5489–5494
- Akazawa C, Ishibashi M, Shimizu C, Nakanishi S, Kageyama R (1995) A mammalian helix-loop-helix factor structurally related to the product of *Drosophila* proneural gene *atonal* is a positive transcriptional regulator expressed in the developing nervous system. *J Biol Chem* 270:8730–8738
- Andoh A, Fujino S, Bamba S, Araki Y, Okuno T, Bamba T, Fujiyama Y (2002) IL-17 selectively down-regulates TNF- α -induced RANTES gene expression in human colonic subepithelial myofibroblasts. *J Immunol* 169:1683–1687
- Andoh A, Shioya M, Nishida A, Bamba S, Tsujikawa T, Kim-Mitsuyama S, Fujiyama Y (2009) Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. *J Immunol* 183(1):687–695
- Andreu P, Colnot S, Godard C, Gad S, Chafey P, Niwa-Kawakita M, Laurent-Puig P, Kahn A, Robine S, Perret C, Romagnolo B (2005) Crypt-restricted proliferation and commitment to the Paneth cell lineage following *Apc* loss in the mouse intestine. *Development* 132:1443–1451
- Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegerbarth A, Korving J, Begthel H, Peters PJ, Clevers H (2007) Identification of stem cells in small intestine and colon by marker gene *Lgr5*. *Nature* 449:1003–1007
- Beaurepaire C, Smyth D, McKay DM (2009) Interferon- γ regulation of intestinal epithelial permeability. *J Interferon Cytokine Res* 29:133–144
- Beebe DJ, Huttenlocher A (2010) Introduction to the mechanisms of directed cell migration themed issue. *Integr Biol (Camb)* 2:559–560
- Bevins CL, Stange EF, Wehkamp J (2009) Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007 fs genotype. *Gut* 58:882–883 (discussion 883–884)
- Bjerknes M, Cheng H (1999) Clonal analysis of mouse intestinal epithelial progenitors. *Gastroenterology* 116:7–14
- Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. *Nature* 464:1371–1375
- Cai WB, Roberts SA, Potten CS (1997) The number of clonogenic cells in crypts in three regions of murine large intestine. *Int J Radiat Biol* 71:573–579
- Cairns J (1975) Mutation selection and the natural history of cancer. *Nature* 255:197–200
- Campbell F, Williams GT, Appleton MA, Dixon MF, Harris M, Williams ED (1996) Post-irradiation somatic mutation and clonal stabilisation time in the human colon. *Gut* 39:569–573

- Cheng H, Leblond CP (1974) Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. *Am J Anat* 141:537–561
- Crosnier C, Stamatakis D, Lewis J (2006) Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. *Nat Rev Genet* 7:349–359
- de Dombal FT, Price AB, Thompson H, Williams GT, Morgan AG, Softley A, Clamp SE, Unwin BJ (1990) The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. *Gut* 31:115–120
- Greaves LC, Preston SL, Tadrous PJ, Taylor RW, Barron MJ, Oukrif D, Leedham SJ, Deheragoda M, Sasieni P, Novelli MR, Jankowski JA, Turnbull DM, Wright NA, McDonald SA (2006) Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. *Proc Natl Acad Sci USA* 103:714–719
- Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM (1997) Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. *Cancer Res* 57:2843–2846
- Issa JP (2000) CpG-island methylation in aging and cancer. *Curr Top Microbiol Immunol* 249:101–118
- Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R, Guillemot F, Serup P, Madsen OD (2000) Control of endodermal endocrine development by Hes-1. *Nat Genet* 24:36–44
- Kim K-M, Shibata D (2002) Methylation reveals a niche: stem cell succession in human colon crypts. *Oncogene* 21:5441–5449
- Kimura M (1968) Evolutionary rate at the molecular level. *Nature* 217:624–626
- Loeffler M, Birke A, Winton D, Potten C (1993) Somatic mutation, monoclonality and stochastic models of stem cell organization in the intestinal crypt. *J Theor Biol* 160:471–491
- Liu W, Singh SR, Hou SX (2010) JAK-STAT is restrained by Notch to control cell proliferation of the *Drosophila* intestinal stem cells. *J Cell Biochem* 109(5):992–999
- Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. *Cancer Res* 64:7629–7633
- Meineke FA, Potten CS, Loeffler M (2001) Cell migration and organization in the intestinal crypt using a lattice-free model. *Cell Prolif* 34:253–266
- Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, Sieber O, Santander S, Pringle JH, Mandir N, East P, Obszynska J, Sanders S, Piazuelo E, Shaw J, Harrison R, Tomlinson IP, McDonald SAC, Wright NA, Jankowski J (2008) Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. *Cancer Res* 68:7760–7768
- Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science* 275:1787–1790
- Nicolas P, Kim K-M, Shibata D, Tavaré S (2007) The stem cell population of the human colon crypt: analysis via methylation patterns. *PLoS Comput Biol* 3:e28
- Novelli MR, Williamson JA, Tomlinson IP, Elia G, Hodgson SV, Talbot IC, Bodmer WF, Wright NA (1996) Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. *Science* 272:1187–1190
- Novelli M, Cossu A, Oukrif D, Quaglia A, Lakhani S, Poulson R, Sasieni P, Carta P, Contini M, Pasca A, Palmieri G, Bodmer W, Tanda F, Wright N (2003) X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. *Proc Natl Acad Sci USA* 100:3311–3314
- Nowell PC (1976) The clonal evolution of tumor cell populations. *Science* 194:23–28
- Park HS, Goodlad RA, Wright NA (1995) Crypt fission in the small intestine and colon. A mechanism for the emergence of G6PD locus-mutated crypts after treatment with mutagens. *Am J Pathol* 147:1416–1427

- Pender SL, MacDonald TT (2004) Matrix metalloproteinases and the gut—new roles for old enzymes. *Curr Opin Pharmacol* 4:546–550
- Pinto D, Gregorieff A, Begthel H, Clevers H (2003) Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. *Genes Dev* 17:1709–1713
- Ponder BA, Schmidt GH, Wilkinson MM, Wood MJ, Monk M, Reid A (1985) Derivation of mouse intestinal crypts from single progenitor cells. *Nature* 313:689–691
- Potten CS, Booth C, Pritchard DM (1997) The intestinal epithelial stem cell: the mucosal governor. *Int J Exp Pathol* 78:219–243
- Ren F, Wang B, Yue T, Yun EY, Ip YT, Jiang J (2010) Hippo signaling regulates *Drosophila* intestine stem cell proliferation through multiple pathways. *Proc Natl Acad Sci USA* 107:21064–21069
- Saleh M, Trinchieri G (2011) Innate immune mechanisms of colitis and colitis-associated colorectal cancer. *Nat Rev Immunol* 11:9–20
- Salzman NH, Underwood MA, Bevins CL (2007) Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. *Semin Immunol* 19:70–83
- Sarra M, Pallone F, Macdonald TT, Monteleone G (2010) IL-23/IL-17 axis in IBD. *Inflamm Bowel Dis* 16:1808–1813
- Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, Barker N, Shroyer NF, van de Wetering M, Clevers H (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. *Nature* 469:415–418
- Schmidt GH, Winton DJ, Ponder BA (1988) Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. *Development* 103:785–790
- Smith JM, Haigh J (1974) The hitch-hiking effect of a favourable gene. *Genet Res* 23:23–35
- Taylor RW, Barron MJ, Borthwick GM, Gospel A, Chinnery PF, Samuels DC, Taylor GA, Plusa SM, Needham SJ, Greaves LC, Kirkwood TB, Turnbull DM (2003) Mitochondrial DNA mutations in human colonic crypt stem cells. *J Clin Invest* 112:1351–1360
- van der Sluis M, Bouma J, Vincent A, Velcich A, Carraway KL, Buller HA, Einerhand AW, van Goudoever JB, Van Seuning I, Renes IB (2008) Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice. *Lab Invest* 88:634–642
- van Es JH, Clevers H (2005) Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. *Trends Mol Med* 11:496–502
- Williams ED, Lowes AP, Williams D, Williams GT (1992) A stem cell niche theory of intestinal crypt maintenance based on a study of somatic mutation in colonic mucosa. *Am J Pathol* 141:773–776
- Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. *Proc Natl Acad Sci USA* 94:1402–1407
- Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY (2001) Requirement of *Math1* for secretory cell lineage commitment in the mouse intestine. *Science* 294:2155–2158
- Yatabe Y, Tavaré S, Shibata D (2001) Investigating stem cells in human colon by using methylation patterns. *Proc Natl Acad Sci USA* 98:10839–10844
- Zhang Z, Andoh A, Yasui H, Inatomi O, Hata K, Tsujikawa T, Kitoh K, Takayanagi A, Shimizu N, Fujiyama Y (2005) Interleukin-1 β and tumor necrosis factor- α upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. *Int J Mol Med* 15:79–83

Acid Reflux and Oesophageal Cancer

Anna Nicholson and Janusz Jankowski

Abstract

Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas. One in 50 of the adult population develops Barrett's as a consequence of chronic gastro-oesophageal reflux. The mucosal inflammation seen within patients with gastro-oesophageal reflux seems likely to drive the growth of the metaplastic mucosa and also help direct further oncological change, yet the molecular events that characterize the pathway from inflammation to metaplasia to dysplasia and adenocarcinoma are poorly understood. There is hope that understanding the role of oesophageal inflammation will provide important insight into the development of Barrett's metaplasia and oesophageal cancer. This chapter will discuss the inflammation seen within context of Barrett's oesophagus and also clinical trials which hope to address this common premalignant disease. There are several ongoing clinical trials which are aiming to provide data using anti-inflammatory therapies to tackle this important premalignant condition. There is new data presented which suggests that data from the aspirin esomeprazole chemoprevention trial (AspECT) may hold the clue to disease treatment and that the cytokine TNF- α seems to be a key signalling molecule in the metaplasia-dysplasia-carcinoma sequence. Specifically it appears that both epigenetic and inherited genetics cooperate to modulate the prognosis.

A. Nicholson (✉) · J. Jankowski
Centre for Digestive Disease, Blizard Institute, Queen Mary University of London,
London, UK
e-mail: a.nicholson@qmul.ac.uk

J. Jankowski
University of Oxford, Oxford, UK

J. Jankowski
Royal Infirmary, Leicester, UK

J. A. Z. Jankowski (ed.), *Inflammation and Gastrointestinal Cancers*,
Recent Results in Cancer Research 185, DOI: 10.1007/978-3-642-03503-6_4,
© Springer-Verlag Berlin Heidelberg 2011

Keywords

Barrett's metaplasia • Oesophageal adenocarcinoma • Inflammation • Non-steroid anti-inflammatories • Proton pump inhibitors

Contents

1	Inflammation in GI Cancer	67
2	Gastro-Oesophageal Reflux Disease	68
3	Inflammation and Gastro-Oesophageal Reflux Disease	69
4	Inflammation and Barrett's Metaplasia	70
4.1	TNF- α	71
4.2	COX-2.....	71
4.3	NF- κ B	72
4.4	Interleukins	72
4.5	p53.....	73
4.6	CDX1 and CDX2	73
4.7	p16.....	74
4.8	Reactive Oxygen Species.....	74
4.9	Polymorphisms in Inflammatory Agents.....	74
5	Anti-Inflammatory Therapies and Clinical Management of Oesophageal Adenocarcinoma	76
5.1	Proton Pump Inhibitors	76
5.2	Non-Steroidal Anti-Inflammatories	76
6	Clinical Trials and Future Treatment of Acid Reflux and Oesophageal Cancer	77
6.1	Current Treatment for Oesophageal Adenocarcinoma.....	77
6.2	Anti-TNF Therapy	77
6.3	Aspirin and PPI's	77
6.4	Surveillance of Barrett's Patients	78
6.5	Other Studies	79
	References.....	79

Oesophageal Adenocarcinoma (OA) is a fatal cancer and is increasing in incidence in the western world. OA is currently fifth in the most common of fatal cancers with annual incidence and death rates increasing by 3% per year (Jankowski and Hawk 2006).

OA has a poor prognosis mainly because patients usually present at a late stage of the disease and the 5 year survival rates for the disease are about 16% (Jemal et al. 2008). Oesophageal Adenocarcinoma has been shown to be commonly associated with a premalignant condition called Barrett's Metaplasia (BM) in which the stratified squamous epithelium of the oesophagus is replaced by a metaplastic columnar epithelium (Lagergren 2005; Nandurkar and Talley 1999). BM is thought to develop as a result of gastro-oesophageal reflux disease in which acid and bile reflux into the oesophagus (Eisen et al. 1997; Zhang et al. 2009). It follows that OA is thought to be a microcosm of evolution, developing sequentially along the metaplasia-dysplasia-adenocarcinoma sequence (Jankowski et al. 2000). Progression is attributed to a series of genetic and epigenetic events that ultimately allow for clonal selection of Barrett's cells via subversion of intrinsic control mechanisms

Table 1 Examples of malignancies strongly associated with chronic inflammatory conditions

Malignancy	Associated chronic inflammatory condition
Nasopharyngeal carcinoma	Epstein-Barr virus
Oesophageal (<i>Barrett's</i>) adenocarcinoma	Duodeno-gastro-oesophageal reflux disease
Gastric cancer	<i>Helicobacter pylori</i> (<i>H. pylori</i>) and intestinal metaplasia of stomach
Hepatocellular carcinoma	Hepatitis C
Cholangiocarcinoma	Chinese liver fluke infestation
Pancreatic carcinoma	Chronic pancreatitis
Gallbladder cancer	Chronic cholecystitis
Small intestine and colon cancer	Chronic non-specific ulcerative colitis and Crohn's disease
Anogenital cancer	Human papilloma virus

regulating cellular proliferation and/or apoptosis (Jankowski et al. 1999). This section will look at the implications and associations of inflammation in this progression and how we can target inflammation to help treat this fatal disease.

1 Inflammation in GI Cancer

The link between inflammation and cancer was first suggested by Rudolph Virchow in 1863 and now the epidemiological data shows a clear association between the two (Balkwill and Mantovani 2001; Coussens and Werb 2002). In the GI tract, many inflammatory tumours are seen and the cause of the inflammation can be infective; such as a virus or caused by a non-infective irritant; such as a chemical. A list of the associated GI cancers can be seen in Table 1 (Balkwill and Mantovani 2001).

Inflammation as a response to tissue damage is seen commonly in GI cancers (Fig. 1). Inflammation is part of the body's immune system; the immune system is comprised of the innate and adaptive systems. The innate system is the body's first line of defense against pathogens and injury; it is a non-specific line of attack, comprised of inflammation, complement system and leukocytes and cells of the immune system. A more sustained and specific line of defense for the body is the adaptive immune system which comprises specific leukocytes called lymphocytes and antibody production. The adaptive immune system allows the immune system to recognise and remember specific pathogens and to mount a stronger attack next time the body comes into contact with it.

Inflammation is the very first response to damage or pathogens and is stimulated by chemical factors released by injured cells and serves to establish a physical barrier against the spread of infection. Also it promotes healing of any damaged tissue. Inflammation is normally self limiting; however, dysregulation of

The GI Tract and associated premalignant inflammatory conditions




Fig. 1 A diagram to show the structures of the gastrointestinal tract and areas where inflammatory conditions can lead to malignancy. 1 Nasopharyngeal carcinoma 2 Oesophageal carcinoma 3 Gastric cancer 4 Small bowel and colon cancer 5 Anogenital cancer

any of the converging factors can lead to abnormality and pathogenesis. During tissue injury associated with wounding, cell proliferation is enhanced while the tissue regenerates; proliferation and inflammation subside after the assaulting agent is removed or the repaired completed. In contrast, proliferating cells that sustain DNA damage and/or mutagenic assault continue to proliferate in micro-environments rich in inflammatory cells and growth/survival factors that support their growth. In a sense, tumours act as wounds that fail to heal (Dvorak 1986).

2 Gastro-Oesophageal Reflux Disease

Gastro-oesophageal reflux disease (GORD) is a common problem in western countries; it is thought that it is the most common complaint made to general physicians (Cameron et al. 1990). It is considered that around 50% of the population experience symptoms of heartburn or substantial burning sensation in the chest at least monthly and about 20% experience symptoms weekly (Dent et al. 2005). We know that obesity (El-Serag 2008), smoking and drinking alcohol are all considered risk factors associated with GORD (Friedenberg et al. 2008) and that any individual can make lifestyle choices such as healthy eating to help reduce their risk and improve their quality of life.

The causes of reflux disease can include one or more of the following;

- Transient relaxation of the lower oesophageal sphincter
- Decreased resting tone of the lower oesophageal sphincter
- Impaired oesophageal clearance
- Decreased salivation
- Bile/acid regurgitation from the duodenum into the stomach
- Delayed gastric emptying

More often than not patients also present with a hiatus or hiatal hernia, which prevents the efficient closing of the lower oesophageal sphincter, and thus leads to an increase in reflux of acid and bile salts into the oesophagus (Koek et al. 2008).

3 Inflammation and Gastro-Oesophageal Reflux Disease

As previously described reflux of caustic gastric contents into the oesophagus can cause symptoms such as heartburn and nausea, but these factors can also result in local tissue injury leading to erosive oesophagitis and stricture formation (Savarino and Dulbecco 2004). Upon injury, the damaged oesophageal cells start to release inflammatory mediators such as cytokines and chemokines, a list of the implicated substances are shown in Table 2. This leads to migration of inflammatory cells to the site of damaged tissue. Cells are recruited including T-lymphocytes, neutrophils and also there is the activation of inflammatory mediator nuclear factor kappa β (NF- $\kappa\beta$) (Balkwill and Mantovani 2001). The intended result of the inflammatory response is clearance of the causative agent which is subsequently followed by stem cell proliferation, mucosal remodelling and eventually healing (Jankowski et al. 2000). But if the causative agent is not removed and there is deregulation of these processes, it can lead to chronic inflammation and in around 10% of cases initiation of metaplasia (Jankowski et al. 2000). But why all patients experiencing GORD do not go onto develop metaplasia is still unclear, it is possible that the duration and severity of symptoms are important risk factors. The components of the inflammatory infiltrate have implications in deregulation of cellular proliferation as well as impacting on cellular adhesion and angiogenesis. The cytokine profile of Barrett's oesophagus differs from oesophagitis, with an anti-inflammatory response characterised by increased levels of T Helper 2 cytokines and a reduction in signalling through the transforming growth factor b (TGF-b) pathway (Fitzgerald et al. 2002; Fitzgerald et al. 2002). In addition, it has been shown that Barrett's oesophagus has a higher proportion of Th2 effector cells than Th1 effector cells when compared with reflux oesophagitis, demonstrating a shift to a humoral inflammatory response rather than the pro-inflammatory state that characterises oesophagitis (Moons et al. 2005). The importance of these changes is not fully understood. Additionally the inflammatory infiltrate may induce increased expression of FAS ligands on cells, which may protect them from immune surveillance and render them resistant to apoptosis (Younes et al. 2000).

Table 2 A Table to show cytokines and chemokines implicated in the metaplasia–dysplasia–adenocarcinoma sequence

Cytokine	Stage of disease progression implicated	Change in expression	Outcome
TNF- α	Non-dysplastic Barrett's	Increase in expression from oesophagitis to Barrett's	Shown to be expressed in base of Barrett's glands and may have effects on stem cells, also shown to effect oncogene transcription
COX-2	Early Barrett's	Increase in expression	Shown to be up-regulated by various stimuli including cytokines
NF- $\kappa\beta$	Barrett's and Adenocarcinoma	Activation of pathway	Acid has been shown to induce pathway, pathway has been linked to many cancers
Interleukin 1 β	Oesophagitis and Barrett's	Increase at new squamo-columnar junction	Inflammation is maximal at new developing tissue
Interleukin 4	Barrett's	Increase in protein and 100-fold increase in receptor compared to squamous	Directly modulates epithelial function in the intestine and increased in progression to adenocarcinoma
Interleukin 8	Oesophagitis and Barrett's	Increase at new squamocolumnar junction	Inflammation is maximal at new developing tissue
Interleukin 10	Barrett's	Increase at distal end of Barrett's	Increase seen in non-inflamed columnar epithelium
IFN- γ	Adenocarcinoma	Increase positively correlated with tumour progression	IFN regulatory factor 2 (IRF-2) can suppress IFNGR1 transcription in cancer cells by binding IFNGR1 promoter, lowering the sensitivity of cancer cells to IFN-gamma (Wang et al. 2008)

4 Inflammation and Barrett's Metaplasia

In Barrett's oesophagus, the native non-stratified squamous epithelium is replaced by a mucin-secreting columnar-lined intestinal-type epithelium, which is thought to be more resistant to continued duodeno-gastro-oesophageal reflux (Eksteen et al. 2001; Shaheen and Richter 2009). This change in cell type is hypothesised to be in response to a phenotypic change at the level of the pluripotent stem cells in the glands, native squamous oesophagus and oesophageal glands (Jankowski et al. 2000; Jankowski et al. 1999) and in response to stimulation by inflammatory cytokines and growth factors, some of which are detailed below. The stromal compartment of Barrett's oesophagus is increasingly being recognised to play a role in oesophageal carcinogenesis. A recent study by Saadi et al. (2009) showed




Fig. 2 TNF- α causes migration in Barretts cell lines (Qh-TERT), the effect is abrogated by the TNF- α inhibitor Infliximab. (a) Nitrocellulose membranes showing migrated cells. Cells cultured with low serum do not migrate through the membrane. Cells cultured in low serum with added TNF- α do migrate, an effect which is removed by the addition of the TNF- α inhibitor Infliximab, as a control cells cultured in 10% serum also migrate through the membrane. (b) Graphical representation of 4 experiments testing the migration of Barrett's cells cultured with TNF- α . TNF- α causes a significant increase in migration in Barretts cells ($p < 0.001$) and this effect is removed by Infliximab ($p < 0.001$)

that increased protein levels of inflammatory-related genes were significantly up-regulated in oesophageal adenocarcinoma.

4.1 TNF- α

Of the mediators of the NF- κ B pathway TNF- α , in particular, has been shown to increase along the metaplasia-dysplasia-carcinoma sequence leading to an increase in the proto-oncogene *c-myc* via the β -catenin mediated pathway (Tselepis et al. 2002). TNF- α has been shown also to be expressed in the base of the Barrett's glands, the proposed location of the stem cells (Tselepis et al. 2002). As well as having implications with increasing proliferation TNF- α and other pro-inflammatory cytokines are able to modulate the levels of both pro and anti-apoptotic proteins Bcl-2 and Bax. A study by the author (unpublished) has shown that TNF- α can cause migration in Barrett's cells (Fig. 2).

4.2 COX-2

Cyclooxygenase-2 (COX-2) is another inducible agent with carcinogenic properties. Activation of NF- κ B possibly via TNF- α signalling can also lead to an increase in COX-2. Expression of COX-2 has been shown to be significantly

increased in Barrett's oesophagus before dysplasia development, suggesting a role early on in the Barrett's malignancy (Wilson et al. 1998). COX-2 and derived prostaglandins including prostaglandin E2 (PGE2) can contribute to malignancy by inhibiting apoptosis, increasing proliferation and angiogenesis and inducing the production of matrix metalloproteinases (MMPs). Also COX-2 can be induced by other cytokines including IL-1 α and IL-1 β .

4.3 NF- κ B

The transcription factor NF- κ B is largely implicated in oesophageal carcinogenesis. Prior to activation most NF- κ B molecules are retained in the cytoplasm, bound to one of the I κ B (inhibitor of NF- κ B) proteins. Upon stimulation, the IKK (I κ B kinase) complex is activated which phosphorylates NF- κ B-bound I κ B and targets them for polyubiquitination and ultimately degradation. This allows NF- κ B to enter the nucleus and bind to κ B-regulatory elements and co-ordinate the transcriptional activation of many immune response genes (Baron et al. 2008; Mathers et al. 2003; Logan et al. 2008). This is known as the classical NF- κ B signalling pathway and is triggered in response to pro-inflammatory cytokines and micro-organisms. Once activated, NF- κ B regulates expression of over 200 genes, including genes encoding cell adhesion molecules and immune response genes including cytokines, and cell proliferation (Fitzgerald et al. 2002; O'Riordan et al. 2005). Barrett's cells have shown to activate the NF- κ B pathway as a way of avoiding apoptosis when they sustain damage, whereas normal squamous cells of the oesophagus undergo apoptosis when damaged by mutagens (Hormi-Carver et al. 2009). Most recently a study by Duggan et al. highlighted pseudokinase tribbles homolog 3 (TRB3) as a novel gene involved in the regulation of inflammation through modulation of NF- κ B function (Duggan et al. 2010).

4.4 Interleukins

This group of cytokines which are produced by a variety of the body cells, function to promote the development and differentiation of T, B, and haematopoietic cells. Within the development of Barrett's, interleukins 1b, 4, 8, and 10 have all been implicated in the disease progression. IL-1 β is a pro-inflammatory cytokine involved in immune defense against infection. Studies of the inflammatory gradient in Barrett's oesophagus show the levels of IL-1 β are significantly increased at the proximal end of the segment (closest to the new squamocolumnar junction) and were actually higher in the inflamed squamous than the distal Barrett's (Fitzgerald et al. 2002). IL-8, a chemokine produced by macrophages, was also up-regulated in the proximal Barrett's and has also been seen to be up-regulated in dysplasia and adenocarcinoma, however anti-reflux surgery can modulate its expression (Oh et al. 2007). IL-10, an anti-inflammatory cytokine, has been shown to be increased distally to the leading edge of the Barrett's, and its expression

up-regulated in association with adenocarcinoma (Fitzgerald et al. 2002). Finally alongside IL-10, IL-4 has been shown to be expressed specifically in Barrett's and characterised by a distinct Th2 predominant cytokine profile not seen in oesophagitis. In a study by Nguyen et al., several interleukins were each associated with poor prognosis in oesophageal adenocarcinoma and profiling these genes in tissues may have clinical utility as predictors of prognosis (Nguyen et al. 2010).

It is thought that to become cancerous a cell must undergo approximately four to seven genetic alterations in either up-regulation of oncogenes or down regulation of tumour suppressor genes. Although acid and bile have a role to play in remodelling the mucosa, such as inducing DNA damage or affecting tissue differentiation, evidence showing that once reflux disease is corrected by acid suppression drugs, Barrett's never totally regresses points to maintenance of the metaplasia and promotion to adenocarcinoma by the mild chronic inflammatory infiltrate (Fukata and Abreu 2008).

4.5 p53

The inflammatory response and reactive oxygen species have been shown to cause mutations in genes which play an important role in carcinogenesis, one very important tumour suppressor gene involved in Barrett's carcinogenesis is p53. p53 mutations have been shown in Barrett's oesophagus and in low grade dysplasia, although these mutations are thought not to be the ones seen to clonally expand to progress to carcinoma. Although in High-grade dysplasia and cancer the frequency of mutations increases dramatically, with an even high rate of allelic loss of the p53 locus. A few prospective studies of p53 immunohistochemistry have shown that patients with p53 over-expression in low-grade dysplasia have an increased risk of progressing to high-grade dysplasia and cancer (Kim et al. 1997; Weston et al. 2001; Younes et al. 1997).

Although p53 is mutated early in Barrett's there is an increase in expression as tissue becomes dysplastic. p53 is a tumour suppressor protein which has shown to be inactivated by a two-hit mechanism involving loss of heterozygosity of one allele and mutation or methylation of the second (Chao et al. 2008; Wong et al. 1997). It is also thought that it is the mutational changes occurring late in the dysplastic sequence which clonally expand throughout the region and drive the dysplasia to carcinoma.

4.6 CDX1 and CDX2

The embryonic gut is glandular throughout and CDX1 and CDX2 are homeobox proteins which play major roles in the development of the intestine, CDX2 expression arises in the proximal intestine and declines distally, whereas CDX1 expression arises in the distal intestine with overlap of both in the mid-gut. It is possible that in humans, injurious agents present in GORD activate ectopic

expression of CDX1 through NF- κ signalling which in turn initiates the development of the intestinal phenotype seen with Barrett's oesophagus. Wong et al. (2005) have found CDX1 mRNA and protein expression in all samples of Barrett's metaplasia tested but not in normal oesophageal squamous or gastric body epithelia. Conjugated bile salts and inflammatory cytokines tumour necrosis factor alpha (TNF-alpha) and interleukin 1b (IL-1b) were found to increase CDX2 mRNA expression in vitro through NF- κ B signalling. CDX2 may cooperate with CDX1 in inducing and maintaining a complete intestinal phenotype.

4.7 p16

p16 (CDKN2a/INK4a) is a cyclin dependant kinase inhibitor that regulates the cell cycle at G1/S control. Germ line mutations in p16 have been shown in melanomas but also somatic mutations in the gene have been implicated in many cancers including oesophageal adenocarcinoma. Alterations in the gene can occur as mutations, loss of heterozygosity and promoter hypermethylation (Barrett et al. 1999). p16 alterations occur early in the MDA sequence and mutated lesions have the ability to undergo clonal expansion, creating a field in which other abnormalities can arise that can lead to adenocarcinoma (Wong et al. 2001). In detail, growth advantages result in preferential expansion of a mutated clone and a mutation is said to have "gone to fixation" when it expands throughout an entire field, extinguishing all competing clones. A "selective sweep" is the process of natural selection driving a mutation to fixation. It has been suggested that loss of each of the two p16 alleles predisposes to a selective sweep, and that p16 mutation fixation occurs early in the progression of Barrett's oesophagus (Maley et al. 2004).

4.8 Reactive Oxygen Species

The inflammatory cells including neutrophils produce reactive oxygen species (ROS) whose primary role is to remove the damaged cells but they can also induce genetic mutations, which can contribute to DNA damage (Clemons et al. 2007; Jaiswal et al. 2001). While most of these changes will lead to cell death, others may confer a survival advantage and lead to a clonal expansion of the premalignant Barrett's cell type (Atherfold and Jankowski 2006). High levels of ROS have been identified in ulcerated gastro-oesophageal mucosa. The production of ROS can also lead to the further increase in NF- κ B activity, thus enhancing the overall inflammatory response (Fig. 3).

4.9 Polymorphisms in Inflammatory Agents

There has been little work into finding polymorphisms implicated in the oesophagus but some have been identified to affect cancer risk in other GI diseases. In *H. pylori* induced gastric cancer individuals with the IL-1B-31*C or -511*T and




Fig. 3 The cell, an overview of mechanisms of inflammation associated carcinogenesis arising from Barrett’s oesophagus. ROS—reactive oxygen species, NF-κB—nuclear factor kappa-light-chain-enhancer of activated B cells, COX-2—Cyclooxygenase 2

IL-1RN*2/*2 genotypes are at increased risk of developing hypochlorhydria and gastric atrophy in response to *H. pylori* infection. In addition to IL-1 gene cluster polymorphisms, pro-inflammatory genotypes of TNF-α and IL-10 have also been identified as risk factors for gastric cancer (El-Omar et al. 2000; Figueiredo et al. 2002).

With these genetic changes and new microenvironment produced by the infiltrating inflammatory cells, the pluripotent stem cells in Barrett’s glands/native oesophagus/oesophageal glands are able to acquire the mutations they need to result in the observed metaplastic change while avoiding cell apoptosis or atrophy. Although all these changes occur when the normal squamous oesophagus changes into Barrett’s oesophagus, only a small percentage (0.5–2%) of patients with Barrett’s will progress to adenocarcinoma there is a need to identify biomarkers to identify these patients at risk (Tischoff and Tannapfel 2008; Fitzgerald 2005). There are a few biomarkers which have been investigated but none have yet to be taken into the clinic (Kerkhof et al. 2007). Most recently a large scale genome wide association study is being undertaken in patients with Barrett’s oesophagus, this work is being carried out by the Eagle consortium as part of the WTCCC2. It is hoped that this study will identify common variants in alleles which predispose people to developing Barrett’s oesophagus.

5 Anti-Inflammatory Therapies and Clinical Management of Oesophageal Adenocarcinoma

5.1 Proton Pump Inhibitors

Reflux associated diseases including Barrett's are treated with proton pump inhibitors (PPI's) to help reduce the reflux and prevent neoplastic change associated with the infiltrate, although it has been shown that there are patients who do not respond to PPI's (Fass and Sifrim 2009). PPI's have numerous beneficial effects including symptoms control, reduction of inflammation and promotion of the development of squamous islands (Shaheen 2005). However even with these benefits PPI therapy has been shown to cause hypergastrinemia and has not prevented recent increase in the incidence of oesophageal cancer.

5.2 Non-Steroidal Anti-Inflammatories

Aspirin and other non-steroidal anti-inflammatory drugs are increasingly used in the treatment of the disease and are thought to be implicated early in the disease progression. The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce the incidence of several cancers associated with chronic inflammation. The principle target of NSAIDs is cyclo-oxygenase (COX).

5.2.1 COX

COX converts arachidonic acid to prostaglandins and exists as two isoforms, COX-1 is expressed on many tissues and maintains physiological functions, whereas COX-2 is expressed at low levels in normal tissues and is up-regulated by pro-inflammatory cytokines, growth factors and tumour promoters. COX-2 has been shown to be over-expressed in patients with Barrett's metaplasia and oesophageal adenocarcinoma (Fullard et al. 2006) and also tumours with high expression have been shown to have a more aggressive phenotype (Buskens et al. 2002). Recent advances in the understanding of the cellular and molecular mechanisms of the anti-cancer effects of NSAIDs and COX-2 inhibitors have demonstrated that these drugs target both tumour cells and the tumour vasculature.

5.2.2 Studies into Using NSAID's

Aspirin is commonly used as an NSAID in chemoprevention (Bosetti et al. 2009), it has multiple effects on the inflammatory process, and several studies have tried to assess whether users of aspirin or other NSAIDs have an associated reduced risk of oesophageal cancers. Most importantly, a recent meta-analysis performed by Rothwell and colleagues showed that daily aspirin can reduce the risk of death in several common cancers (Rothwell et al. 2011).

A large study by Thun et al. (Jemal et al. 2008) showed a reduced risk reduction by 40% for oesophageal cancer in recurrent users of aspirin. From a meta-analysis

undertaken by Corley et al. (Corley et al. 2003) it was observed that the overall protective effect of aspirin is 50% compared to 25% for other NSAIDs, but the use of these drugs has to be frequent to achieve this association. There are thoughts that the patients who take aspirin frequently will also be undertaking other lifestyle choices such as vitamins and that this may be having additional effects, also there are concerns over the toxicity of NSAIDs, which are associated with GI bleeds. This shows that evidence from prospective studies such as the one by Thun and Rothwell can give limited data and what is really required is a large scale clinical trial (Moayyedi et al. 2010).

6 Clinical Trials and Future Treatment of Acid Reflux and Oesophageal Cancer

6.1 Current Treatment for Oesophageal Adenocarcinoma

The main treatment options for patients presenting with high-grade dysplasia or Oesophageal adenocarcinoma is currently surgery but this has a low 5 year survival rate.

Observational studies have shown that NSAID use reduces the risk of disease progression in Barrett's Oesophagus (Vaughan et al. 2005). There are still concerns over the use of anti-inflammatories after the Victor trial was ended after a significant increase in the cardiovascular adverse events (Kerr et al. 2007). Although aspirin has been shown to be effective in colorectal adenomas in patients with a history of lesions (Cole et al. 2009).

6.2 Anti-TNF Therapy

Previously in this report TNF- α has been shown to be implicated in Oesophageal adenocarcinoma by upregulating oncogene transcription, TNF- α is shown to be a possible therapeutic target for cancer and in 2004 the first clinical trial using TNF-anatagonists in cancer treatment were undertaken in Breast cancer (Madhusudan et al. 2004), the trial showed safety and biological activity of the treatment and further trials in other advanced cancers have confirmed this (Harrison et al. 2007; Brown et al. 2008). There is now a potential to investigate the use of anti-TNF therapy in the treatment of Barrett's metaplasia/barrett's adenocarcinoma.

6.3 Aspirin and PPI's

The AsPECT trial got underway in 2005 with recruitment reaching its target of 2500 patients in February 2009. It is a national, multi-centred, phase III clinical trial recruiting Barrett's patients to one of four arms, consisting of low or high dose PPI's and aspirin or no aspirin long term. The trial aims to follow-up patients for 10 years and will report on the incidence of end points including high-grade

Table 3 A table to show the clinical trials underway to investigate the effects of anti-inflammatory therapy on GI cancers

Trial	Years of recruitment	GI disease	Years of follow-up	Patients recruited	Drugs studied
AspECT (Jankowski and Barr 2006)	Aug 2005	Barrett's oesophagus	10 years	2513	Aspirin and PPI's
Victor (Pendlebury et al. 2003)	April 2002	Colorectal cancer	7 years	2327	Rofecoxib and placebo
Fischbach et al. (Fischbach et al. 2001)	1993	Gastritis	16 weeks	374	Metronidazole, amoxicillin bismuth subsalicylate
CALGB 9270	1993	Previous colorectal cancer	7 years	635	Aspirin and placebo
APPROVe (Baron et al. 2008)	2000	Colorectal adenomas	4 years	2587	Rofecoxib and placebo
(CAPP 1) (Mathers et al. 2003)	Jan 1993	Familial adenomatous polyposis	8 years	40	Aspirin and corn-starch
CAPP 2	Jan 1999	Hereditary nonpolyposis colorectal cancer	4 years	400	Aspirin and corn-starch
ukCAP (Logan et al. 2008)	Dec 1997	Colorectal adenomas	4 years	939	Aspirin, folic acid and placebo
AFPPS	1994	Colorectal adenomas	4 years	1121	Aspirin, folic acid and placebo
APACC (Benamouzig et al. 2001, 2003)	1997	Colorectal adenocarcinomas	4 years	272	Aspirin or placebo
CBET (Heath et al. 2003, 2007)	April 2000	Barrett's oesophagus and dysplasia	2 years	222	Celecoxib or placebo

dysplasia or adenocarcinoma. After 3 years more than 85% of patients tolerated their initial dose of medicine and the drop out rate has been 7%, an interim analysis is expected in 2011 (Das et al. 2009).

6.4 Surveillance of Barrett's Patients

There are questions being asked about the surveillance of Barrett's patients and how we can better manage this condition (Armstrong 2008; Barritt and Shaheen 2008).

Since only 0–2% of Barrett's patients go on to develop adenocarcinoma there is a question over the need for constant endoscopy, better data are required to determine whether patients with mild gastro-oesophageal reflux disease would benefit from increased surveillance (Fullard et al. 2006) and linked to the AspECT trial, the BOSS study will challenge this question in Barrett's patients (Jankowski and Barr 2006).

6.5 Other Studies

There are several other clinical trials which are investigating the effects of anti-inflammatories in GI cancer (Jankowski and Hawk 2006) (Table 3). As well as Victor there were other studies which showed an increase in cardiovascular events after taking anti-inflammatories but none have been seen in the AspECT trial. Hopefully a combined therapy of aspirin and PPI's can be shown to have a significant effect on the development of adenocarcinoma and therefore we can be able to control the increase in cases of these cancers being seen in the west.

In this regard it is possible that PPI therapy may abrogate the GI ulcer complications seen with low dose aspirin therapy (Cuzick et al. 2009; Jankowski and Hunt 2008). Recently an expert independent review has nominated aspirin as the first choice chemoprevention agent for testing in the clinic (Cuzick et al. 2009).

References

- Armstrong D (2008) Should patients with Barrett's oesophagus be kept under surveillance? The case for. *Best Pract Res Clin Gastroenterol* 22(4):721–739
- Atherfold PA, Jankowski JA (2006) Molecular biology of Barrett's cancer. *Best Pract Res Clin Gastroenterol* 20(5):813–827
- Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? *Lancet* 357(9255):539–545
- Baron JA et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. *Lancet* 372(9651):1756–1764
- Barrett MT et al (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. *Nat Genet* 22(1):106–109
- Barritt AS, Shaheen NJ (2008) Should patients with Barrett's oesophagus be kept under surveillance? The case against. *Best Pract Res Clin Gastroenterol* 22(4):741–750
- Benamouzig R et al (2001) APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. *Eur J Cancer Prev* 10(4):327–335
- Benamouzig R et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. *Gastroenterology* 125(2):328–336
- Bosetti C, Gallus S, La Vecchia C (2009) Aspirin and cancer risk: a summary review to 2007. *Recent Results Cancer Res* 181:231–251
- Brown ER et al (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. *Ann Oncol* 19(7):1340–1346
- Buskens CJ et al (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. *Gastroenterology* 122(7):1800–1807

- Cameron AJ et al (1990) Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. *Gastroenterology* 99(4):918–922
- Chao DL et al (2008) Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. *Clin Cancer Res* 14(21):6988–6995
- Clemons NJ, McColl KE, Fitzgerald RC (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. *Gastroenterology* 133(4):1198–1209
- Cole BF et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomised trials. *J Natl Cancer Inst* 101(4):256–266
- Corley DA et al (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. *Gastroenterology* 124(1):47–56
- Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* 420(6917):860–867
- Cuzick Jack, Otto Florian, Baron John A, Brown Powel H, Burn John, Greenwald Peter, Jankowski Janusz, Vecchia Carlo La, Meyskens Frank, Senn Hans Jörg, Thun Michael (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. *Lancet Oncol* 10:501–507
- Das D, Chilton AP, Jankowski JA (2009) Chemoprevention of oesophageal cancer and the AspECT trial. *Recent Results Cancer Res* 181:161–169
- Dent J et al (2005) Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 54(5):710–717
- Duggan SP et al (2010) An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid response gene, which regulates NF-kappaB activation and cytokine levels. *Carcinogenesis* 31(5): 936–945
- Dvorak HF (1986) tumours: wounds that do not heal Similarities between tumour stroma generation and wound healing. *N Engl J Med* 315(26):1650–1659
- Eisen GM et al (1997) The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. *Am J Gastroenterol* 92(1):27–31
- Eksteen JA et al (2001) Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFalpha. *Eur J Cancer Prev* 10(2):163–166
- El-Omar EM et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 404(6776):398–402
- El-Serag H (2008) Role of obesity in GORD-related disorders. *Gut* 57(3):281–284
- Fass R, Sifrim D (2009) Management of heartburn not responding to proton pump inhibitors. *Gut* 58(2):295–309
- Figueiredo C et al (2002) Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J Natl Cancer Inst* 94(22):1680–1687
- Fischbach LA et al (2001) Anti-inflammatory and tissue-protectant drug effects: results from a randomised placebo-controlled trial of gastritis patients at high risk for gastric cancer. *Aliment Pharmacol Ther* 15(6):831–841
- Fitzgerald RC (2005) Genetics and prevention of oesophageal adenocarcinoma. *Recent Results Cancer Res* 166:35–46
- Fitzgerald RC et al (2002a) Inflammatory gradient in Barrett's oesophagus: implications for disease complications. *Gut* 51(3):316–322
- Fitzgerald RC et al (2002b) Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. *Gut* 50(4):451–459
- Friedenberg FK et al (2008) The association between gastroesophageal reflux disease and obesity. *Am J Gastroenterol* 103(8):2111–2122
- Fukata M, Abreu MT (2008) Role of toll-like receptors in gastrointestinal malignancies. *Oncogene* 27(2):234–243
- Fullard M et al (2006) Systematic review: does gastro-oesophageal reflux disease progress? *Aliment Pharmacol Ther* 24(1):33–45

- Harrison ML et al (2007) Tumour necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. *J Clin Oncol* 25(29):4542–4549
- Heath EI et al (2003) Chemoprevention for Barrett's esophagus trial. Design and outcome measures. *Dis Esophagus* 16(3):177–186
- Heath EI et al (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomised trial. *J Natl Cancer Inst* 99(7):545–557
- Hormi-Carver K et al (2009) Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappa B pathway. *Cancer Res* 69(2):672–677
- Jaiswal M, LaRusso NF, Gores GJ (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. *Am J Physiol Gastrointest Liver Physiol* 281(3):G626–G634
- Jankowski J, Barr H (2006) Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. *Bmj* 332(7556):1512
- Jankowski JA, Hawk ET (2006) A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. *Nat Clin Pract Gastroenterol Hepatol* 3(2):101–111
- Jankowski J, Hunt R (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention; better the devil you know. *Cancer Epidemiol Biomarkers Prev* 17:1858–1861
- Jankowski JA et al (1999) Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. *Am J Pathol* 154(4):965–973
- Jankowski JA et al (2000) Barrett's metaplasia. *Lancet* 356(9247):2079–2085
- Jemal A et al (2008) Cancer statistics, 2008. *CA Cancer J Clin* 58(2):71–96
- Kerkhof M et al (2007) Biomarkers for risk stratification of neoplastic progression in Barrett esophagus. *Cell Oncol* 29(6):507–517
- Kerr DJ et al (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. *N Engl J Med* 357(4):360–369
- Kim R et al (1997) Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. *Dig Dis Sci* 42(12):2453–2462
- Koek GH et al (2008) Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. *Gut* 57(8):1056–1064
- Lagergren J (2005) Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? *Gut* 54(Suppl 1):i1–i5
- Logan RF et al (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. *Gastroenterology* 134(1):29–38
- Madhusudan S et al (2004) A phase II study of etanercept (Enbrel), a tumour necrosis factor alpha inhibitor in patients with metastatic breast cancer. *Clin Cancer Res* 10(19):6528–6534
- Maley CC et al (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. *Cancer Res* 64(10):3414–3427
- Mathers JC et al (2003) Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. *Proc Nutr Soc* 62(1):51–57
- Moayyedi P, Jankowski JA (2010) Does long-term aspirin prevent cancer? *BMJ* 341
- Moons LM et al (2005) Barrett's oesophagus is characterised by a predominantly humoral inflammatory response. *J Pathol* 207(3):269–276
- Nandurkar S, Talley NJ (1999) Barrett's esophagus: the long and the short of it. *Am J Gastroenterol* 94(1):30–40
- Nguyen GH et al (2010) Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. *Clin Cancer Res* 16(23):5824–5834

- O’Riordan JM et al (2005) Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. *Am J Gastroenterol* 100(6):1257–1264
- Oh DS et al (2007) Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett’s esophagus with antireflux surgery. *Arch Surg* 142(6):554–559 (discussion 559–560)
- Pendlebury S et al (2003) A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. *Clin Colorectal Cancer* 3(1):58–60
- Rothwell PM et al (2011) Effect of daily Aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 377(9759):31–41
- Saadi A et al (2009) Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. *PNAS* 107(5):2177–2182
- Savarino V, Dulbecco P (2004) Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease. *Digestion* 69(Suppl 1):9–16
- Shaheen NJ (2005) Advances in Barrett’s esophagus and esophageal adenocarcinoma. *Gastroenterology* 128(6):1554–1566
- Shaheen NJ, Richter JE (2009) Barrett’s oesophagus. *Lancet* 373(9666):850–861
- Tischoff I, Tannapfel A (2008) Barrett’s esophagus: can biomarkers predict progression to malignancy? *Expert Rev Gastroenterol Hepatol* 2(5):653–663
- Tselepis C et al (2002) Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. *Oncogene* 21(39):6071–6081
- Vaughan TL et al (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. *Lancet Oncol* 6(12):945–952
- Wang Y et al (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. *Cancer Res* 68(4):1136–1143
- Weston AP et al (2001) p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistochemical marker predictive of progression. *Am J Gastroenterol* 96(5):1355–1362
- Wilson KT et al (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. *Cancer Res* 58(14):2929–2934
- Wong DJ et al (1997) p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. *Cancer Res* 57(13):2619–2622
- Wong DJ et al (2001) p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. *Cancer Res* 61(22):8284–8289
- Wong NA et al (2005) CDX1 is an important molecular mediator of Barrett’s metaplasia. *Proc Natl Acad Sci USA* 102(21):7565–7570
- Younes M et al (1997) p53 Protein accumulation is a specific marker of malignant potential in Barrett’s metaplasia. *Dig Dis Sci* 42(4):697–701
- Younes M et al (2000) Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett’s esophagus. *Hum Pathol* 31(4):434–438
- Zhang HY, Spechler SJ, Souza RF (2009) Esophageal adenocarcinoma arising in Barrett esophagus. *Cancer Lett* 275(2):170–177

Helicobacter pylori and Gastric Cancer

Michael Rathbone and Barrie Rathbone

Abstract

Gastric cancer remains a major cause of cancer death worldwide. The discovery of *Helicobacter pylori* and its association with gastric cancer has opened up new insights into its pathogenesis. Gastric cancer pathogenesis is the result of a complex interplay between bacterial, host and environmental factors resulting in a step wise histological progression to neoplasia. *H. pylori* is a major factor in the early stages of cancer development and the mechanism of action of its virulence factors are being steadily unravelled. It is also now recognised that host genetic polymorphisms also play a complex role interacting synergistically with the bacterial virulence factors. The role of *H. pylori* in the causation of gastric cancer also raises the possibility of cancer prevention through screening and eradication, actions which may improve outcomes in high risk populations but which may not be cost-effective in areas of low risk. Ultimately, despite the vast improvements in knowledge, as yet there has not been a corresponding improvement in terms of gastric cancer survival rates.

Contents

1	Introduction.....	84
2	Pathogenesis.....	85
2.1	Bacterial Factors.....	87
2.2	Host Factors.....	90
2.3	Environmental Factors.....	91

M. Rathbone
St George's, University of London, London, UK

B. Rathbone (✉)
University Hospitals of Leicester, Leicester, UK
e-mail: barrie.rathbone@uhl-tr.nhs.uk

3	Treatment	92
4	Conclusion	93
	References	93

1 Introduction

Although gastric cancer rates appear to be declining worldwide, it is still a huge problem. It was estimated as the fourth most common cancer in 2002 and the second most common cause of cancer-related mortality (Parkin et al. 2005). There is considerable geographical variation in rates of gastric cancer, demonstrating higher rates in East Asia, Eastern Europe and parts of Central and South America. The lower risk areas are South Asia, North and East Africa, North America, Australia and New Zealand (Parkin et al. 2005).

The vast majority of stomach tumours are gastric adenocarcinomas (90%) which can be classified according to position (cardia or more distal tumours) and according to histological appearance (diffuse or intestinal). Tumours of the cardia are more likely to be diffuse type tumours with more distal tumours being intestinal type.

The bacterium *Helicobacter pylori* (*H. pylori*) is now known to be the predominant cause of chronic gastritis. Colonisation of the gastric epithelium by ‘unidentified curved bacilli’ and the association with chronic inflammation was first brought to the attention of the medical world by (Marshall 1983; Warren 1983) who also isolated the organism. Their achievement earned them the Nobel Prize in Physiology or Medicine in 2005. In addition to its role in chronic gastritis and peptic ulceration, *H. pylori* was recognised as a carcinogenic agent for gastric cancer by the International Agency for Research on Cancer (IARC 1994).

The bacterium itself is a spiral or slightly curved gram-negative rod, 2.4–4.0 µm in length, with 2–5 unipolar flagella which play a role in motility.

This microaerophilic organism colonises the gastric mucus gel and adheres to the epithelium. While generally thought to be non-invasive there is evidence that intra- and inter-cellular invasion occurs (Necchi et al. 2007). It has exceptional urease activity helping it survive in an acidic environment. The organism is mainly contracted in childhood predominantly by the gastric-oral route. The faecal–oral or the oral–oral route together with indirect transmission through contaminated food or water may be possible (Go 2002). A large study from the north of England showed that the most important factors for contracting *H. pylori* infection in the UK were worse socioeconomic conditions in childhood and number of siblings. The risk of infection rose with an increasing number of siblings (Moayyedi et al. 2002).

The prevalence of *H. pylori* infection in middle-aged adults was estimated as 74% in developing countries and 58% in developed countries (Parkin 2006). The same study suggested that 63.4% of gastric cancer cases worldwide were attributable to the bacterium, which translated to 5.5% of all cancers. *H. pylori* is most strongly associated with the non-cardia intestinal type adenocarcinoma and the rare gastric mucosa-associated lymphoid tissue-type (MALT) lymphoma (Wotherspoon et al. 1991).




Fig. 1 Normal gastric mucosa (H & E 300× kindly supplied by Dr. Kevin West)

Other major risk factors for gastric cancer independent of *H. pylori* include pernicious anaemia, Epstein-Barr Virus (EBV) and previous gastric surgery. The following discussion relates to the complex interrelationship between *H. pylori*, inflammation and other associated risk factors in the pathogenesis of gastric adenocarcinoma.

2 Pathogenesis

Prior to the discovery of *H. pylori* it was well recognized that gastric inflammation and hypochlorhydria were associated with gastric cancer. Careful biopsy follow-up studies in high-risk populations had demonstrated the slow development of gastric atrophy over years and identified the importance of gastric body atrophy and intestinal metaplasia as risk factors for gastric cancer development (Siurala et al. 1966). Correa et al. (1975) developed the hypothesis that gastric cancer development was a slow and complex multistep process.

Fundamental to the model was the progression from normal gastric mucosa to non-atrophic gastritis, multifocal atrophic gastritis, and then the development of intestinal metaplasia and dysplasia before invasive cancer (Figs. 1, 2, 3, 4, 5, 6) (Correa et al. 1975).

Helicobacter pylori gastritis is fundamentally the host immune response to the bacteria with neutrophils, lymphocytes and macrophages. Despite the pronounced host humoral and cell-mediated response, colonisation persists for decades. The immune response is thus ineffective, raising issues regarding immune evasion (reviewed by Wilson and Crabtree 2007). Although *H. pylori* is the cause of the initial gastric inflammation only a tiny proportion of infected individuals will ultimately progress to cancer. An important determinant of cancer risk relates to the phenotype of the *H. pylori* gastritis. Subjects with an antral predominant gastric




Fig. 2 *H. pylori* gastritis (H & E 300× kindly supplied by Dr. Kevin West)




Fig. 3 *H. pylori* and polymorpholeukocyte in gastric pit (modified Giemsa stain 600× kindly supplied by Dr. Judy Wyatt)

inflammation maintain acid secretion and are not at risk of gastric cancer but are at risk of duodenal ulcer disease. Those individuals who develop an *H. pylori* pan-gastritis are at risk of developing multifocal atrophy, reduced acid secretion and an increased risk of gastric cancer. With decreasing acid secretion *H. pylori* colonisation may itself be lost.

Prior to the discovery of *H. pylori*, environmental factors were considered of utmost importance for gastric cancer pathogenesis. With the initial discovery of *H. pylori* the role of the bacterium took prominence. Recent studies have emphasised the importance of bacterial, host and environmental factors, and their complex interrelationship.




Fig. 4 Gastric intestinal metaplasia (H & E 300× kindly supplied by Dr. Kevin West)




Fig. 5 Gastric low-grade dysplasia (H & E 300× kindly supplied by Dr. Kevin West)

2.1 Bacterial Factors

There is considerable heterogeneity in terms of *H. pylori* strains. A number of putative virulence factors have been identified and recently reviewed (Amieva and El-Omar 2008). Currently most interest centres on membrane proteins related to adherence, the cytotoxin associated gene A (CagA) and the cytotoxin VacA.

CagA is a 120–130 kDa protein initially identified by studies investigating the gastric humoral response to *H. pylori*. Only a proportion of colonised subjects had an immune response to this protein and the presence of such a response was associated with the degree of inflammatory activity and mucosal damage (Crabtree et al. 1991). Many studies have subsequently demonstrated that subjects with CagA positive




Fig. 6 Intestinal type gastric adenocarcinoma (H & E 300× kindly supplied by Dr. Kevin West)

strains are more associated with peptic ulcer disease and gastric cancer. The *CagA* gene is part of a large pathogenicity island (*cag* PAI). Genes from this island encode the *CagA* protein and a type IV secretion system. Following bacterial adhesion the secretion system is responsible for the translocation of *CagA* bacterial protein into the host cell (Segal et al. 1999; Odenbreit et al. 2000). Once translocated into host cytoplasm, *CagA* has complex effects on the host cell both directly and following phosphorylation.

CagA phosphorylation occurs on tyrosine residuals at its five amino acid EPIYA (Glu-Pro-Ile-Tyr-Ala) repeat region by host cell kinases. The tyrosine phosphorylated *CagA* interacts with a number of host proteins which can activate the ERK/MAPK pathway (Keates et al. 1999; Ding et al. 2008). The effect is to alter cellular signalling, cell proliferation and differentiation, programmed death, cytoskeletal organisation, stress and inflammatory responses (Backert et al. 2001; Chang et al. 2006).

The N-terminus of unphosphorylated *CagA* can complex with several junction proteins (*E-cadherin*, *ZO1* and *JAM*) resulting in disruption of the epithelial cell apical junction complex, loss of polarity and proinflammatory and mitogenic responses (Bagnoli et al. 2005; Amieva et al. 2003). This may include the development of intestinal metaplasia (Murata-Kamiya et al. 2007).

CagA is a complex protein associated with dramatic effects on epithelial cells and associated with an increased risk of gastric cancer, yet the majority of subjects colonised with *CagA* positive strains will never develop gastric cancer.

The *H. pylori* bacterial cytotoxin *VacA* was initially described by Leunk et al. (1988) who demonstrated that *H. pylori* broth supernatants caused vacuolisation of cultured cells. The *VacA* gene occurs in all strains but has considerable variability in terms of cytotoxin activity. The major variations occur in the *VacA* signal region (types *s1* and *s2*), the mid region (types *m1* and *m2*) and the more recently described intermediate region (*i1* and *i2*) (Atherton et al. 1995; Rhead et al. 2007).




Fig. 7 Modified Correa gastric cancer pathway

When the toxin is secreted, approximately 50% remains associated with the bacterial cell surface and gains access to the epithelium with bacterial adherence (Ilver et al. 2004). The VacA toxin has multiple toxigenic properties. By affecting endosome maturation and function it causes cytoplasmic vacuolisation and impairment of antigen presentation (Molinari et al. 1998). Other effects include apoptosis, inhibition of T cell activation, disruption of tight junctions and cytochrome c release (Gebert et al. 2003; Galmiche et al. 2000; Papini et al. 1998; Willhite and Blanke 2004). The s1 m1 strains are the most toxigenic and the most associated with gastric cancer (Basso et al. 2008). Information on the intermediate type is limited although the i1 type has been associated with cancer risk in an Iranian population (Rhead et al. 2007).

Adherence seems a critical step with regard to *H. pylori* virulence with the highest density of adherence around intercellular junctions (Steer 1984). Several outer membrane proteins appear to act as adhesins. One of the most studied is BabA which is a 78 kDa outer membrane protein which binds through Lewis b blood antigens on the gastric epithelium (Ilver et al. 1998). Subjects expressing BabA have a higher density of colonisation which is associated with an enhanced mucosal inflammatory response (Rad et al. 2002). Two genes are associated with the encoding of BabA, although only BabA2 is functionally active. The expression of BabA2 is associated with the s1 VacA subtype and when associated with CagA it is associated with an enhanced risk of cancer formation (Gerhard et al. 1999).

The bacterial virulence factors described above are byzantine and intriguing in terms of benefit to the bacteria and cancer risk for the host. Adherence would appear to be a necessary prerequisite for significant mucosal damage. The BabA2, CagA and s1/m1 VacA virulence factors appear to act synergistically in promoting inflammation and the development of intestinal metaplasia (Zamboni et al. 2003). An attempt to quantify the relative risk of the CagA and VacA bacterial factors confirmed the previously described CagA and VacA polymorphisms with disease but found that the single most important factor was the number of EPIYA-C segments and hence the magnitude of CagA phosphorylation (Basso et al. 2008).

The risk factors described above are all associated with an increased risk of gastric cancer and detailed studies are unravelling the mechanisms of increased risk.

Subjects colonised with the highest risk bacterial genotype are still unlikely to develop gastric cancer, again emphasising the multifactorial nature of this disease.

2.2 Host Factors

Helicobacter pylori colonisation is responsible for the increased mucosal expression of many cytokines, including several interleukins (IL-1 β , IL-6, IL-8), tumour necrosis factor- α (TNF α) and interferon- γ (IFN- γ) (Calam 1999). These have all been described as affecting the parietal cells of the stomach, inhibiting acid secretion. There are multiple polymorphisms in inflammation-associated genes, for example in the IL-1 gene cluster that results in an increased expression of IL-1 β , and in the TNF-A gene, resulting in increased expression of TNF- α (Kusters et al. 2006). Polymorphisms present in the interferon- γ receptor 1 (IFN-NGR1) gene have been found to increase host susceptibility to *H. pylori*-associated gastric cancer development (Canedo et al. 2008), and it was postulated that an increased receptor presence would result in increased number of proinflammatory cytokines. IL-8 is an important cytokine responsible for activating and attracting neutrophils and lymphocytes and for the induction of proinflammatory cytokines. The IL-8-251 gene polymorphism is associated with increased IL-8 production in *H. pylori*-associated gastric mucosa with an increased risk of premalignant change (Li et al. 2010). The presence of three or four proinflammatory gene polymorphisms in association with *H. pylori* infection has been shown to increase the risk of gastric cancer substantially (El-Omar et al. 2003).

In addition to the cytokine polymorphisms described above, other polymorphisms have been associated with an increased risk of gastric cancer in association with *H. pylori*. These include polymorphisms of the Toll-like receptor TLR4, a type I transmembrane protein expressed in the gastric epithelium which acts as a lipopolysaccharide (LPS) receptor and activates proinflammatory pathways. Certain polymorphisms in TLR4 have been shown to increase the risk of premalignant and malignant change in *H. pylori* colonised individuals (Hold et al. 2007; Hishida et al. 2009). The gene selenoprotein S (SEPS1) encodes a protein in

the endoplasmic reticulum which protects cells from oxidative damage and has a role in cytokine release (Curran et al. 2005).

A promoter polymorphism which results in reduced expression of SEPS1 has recently been associated with gastric cancer in a Japanese population (Shibata et al. 2009).

There is increasing interest in the potential role of bone marrow derived cells (BMDCs) as cancer stem cells in gastric neoplasia, reviewed by Correa and Houghton (2007). The bacterial and host factors resulting in ongoing inflammation and atrophy theoretically produce a situation where local stem cells are depleted. Mouse studies have demonstrated tissue stem cell depletion with ongoing inflammation and injury, and recruitment of bone marrow cells into the tissue stem cell niche. With continued inflammation and injury the BMDC-derived gastric mucosa developed metaplasia and dysplasia and subsequent invasive neoplasia (Houghton et al. 2004). The relevance and implications of these studies for human disease are as yet unclear.

2.3 Environmental Factors

Similar to other parts of the GI tract, the stomach has prolonged contact with ingested food material. The varying rates of gastric cancer geographically and chronologically have promoted an interest in the potential role of diet. Characteristically populations at high risk of gastric cancer have diets low in animal fats and proteins, low in fresh fruit and vegetables, high in starches and carbohydrates and high in salt and nitrates (Judd 1988). Particular interest has been paid to N-nitroso compounds as these have been found to induce tumours in the glandular stomachs of experimental animals and to the antioxidant vitamin C (ascorbic acid) as a potential protective factor.

Dietary N-nitroso compounds are typically found in cured meat, fish and beers, and have been associated with populations at an increased risk of gastric cancer (Judd 1988). There is also the potential for the formation of N-nitroso compounds in the stomach itself with gastric nitrate-reducing bacteria acting on dietary nitrates. *H. pylori* is not nitrate reducing, but if the *H. pylori* related inflammation involves the gastric body and results in decreased acid secretion, progressive atrophy can occur, raising the gastric pH. In these circumstances a range of other bacteria can colonise the stomach including nitrate-reducing bacteria and as a result higher levels of potentially carcinogenic N-nitroso compounds can be detected in gastric juice.

The recent EPIC-EUROGAST study demonstrated an association between endogenous formation of N-nitroso compounds and gastric cancer risk (Jakszyn et al. 2006). Paradoxically as the gastric pH rises, *H. pylori* colonisation is often lost, which could be due to a less favourable environment or competition from other bacteria. In practice *H. pylori* is absent from the stomach in most patients at the time when their cancer is diagnosed, emphasising the potential for varying factors to be important at different points in the natural history of gastric cancer.

Dietary ascorbic acid as an antioxidant has the potential to reduce carcinogenic *N*-nitrosamine formation in the stomach. Studies looking at gastric juice vitamin C levels demonstrated higher concentrations than would be expected from simple oral intake. These high levels are due to active gastric secretion of vitamin C. The mechanism for the secretion is unclear but like acid secretion it decreases with inflammation and atrophy (Rathbone et al. 1989; Sobala et al. 1989). Furthermore as the gastric luminal pH rises the proportion of the vitamin C available in its active form decreases thus increasing the risk of potentially carcinogenic *N*-nitroso compounds formation.

Another often overlooked environmental factor for gastric cancer is smoking with the EPIC study estimating that 17.6% of gastric cancer is related to smoking (González et al. 2003). A study looking at *H. pylori* status and smoking demonstrated a strongly increased risk of gastric cancer in those patients who were infected with CagA positive *H. pylori* and smoked, although the mechanism is unclear (Brenner et al. 2002).

3 Treatment

Both gastric cancer incidence and *H. pylori* infection rates are declining in many countries with the most probable reasons relating to improved living conditions. Important factors for this almost certainly include improved sanitation, water quality, food hygiene and a reduction in smoking. Despite the well-described association of gastric cancer risk with diets poor in vegetables and fruit, related intervention studies have failed to show a convincing benefit (Forman and Burley 2006).

A Cochrane analysis of randomised trials of anti-oxidant supplementation failed to demonstrate any evidence for a preventative effect against gastric cancer (Bjelakovic et al. 2008).

One of the sad facts regarding gastric cancer is the poor improvement in survival figures with treatment over the past 50 years. Clinical symptoms of gastric cancer generally occur late when the tumour is advanced and treatment options are limited. In the USA, Europe and China survival rates are only 20–25% whereas in Japan the equivalent survival rate is 52% (Parkin 2001). This difference is largely attributable to Japanese screening programmes to detect early disease. The current position regarding different treatment modalities has recently been well reviewed by Hartgrink et al. (2009).

With the important role *H. pylori* has in the early stages of the pathogenesis of gastric cancer it is compelling to believe that eradication programmes would be beneficial. The major problem here is that approximately 50% of the world's population is infected with *H. pylori*, and only a tiny minority of these are at risk of gastric cancer. Certainly in low-risk populations such as the UK and most of Europe, broad-based screening and treatment programmes are unlikely to be cost effective. In high-risk populations such as Japan and Columbia the cost benefit ratios are much better and the Asia–Pacific consensus guidelines on gastric cancer

prevention recommend screening and eradication in high-risk populations (Fock et al. 2008).

Current treatment regimens are not perfect with major problems regarding drug resistance which dramatically alters eradication rates. Where population treatment intervention studies have been carried out the results have been conflicting (Fuccio et al. 2007; Ito et al. 2009). For those with established atrophy and intestinal metaplasia, eradication is not so reliable in reducing cancer risk and endoscopic-histological screening is necessary to detect progression. This is demonstrated in a study on early gastric cancer patients treated by endoscopic mucosal resection and then treated with *H. pylori* eradication or placebo. At three years 3.3% of the eradicated patients had developed a metachronous gastric cancer compared to 8.8% of the placebo-treated patients (Fukase et al. 2008).

Clearly, advances in treatment regimens may alter the cost effectiveness of potential population treatment strategies but the development of an effective vaccine would be the best option for the future, but concerns remain regarding *H. pylori*'s immune evasion.

4 Conclusion

Gastric cancer remains a major health problem and is paradigmatic of a cancer which develops from inflamed mucosa. There is a clear pathway of development with many different factors operating. Despite a steady decline in the western world it remains a very significant cause of cancer deaths worldwide. Our understanding of the pathogenesis as described above has improved dramatically over the past thirty years however this has not translated into improved outcomes as yet.

The Correa pathway was an important concept in understanding the stepwise histological progression leading to invasive gastric cancer. Since this was described, the most fundamental breakthrough was the discovery of *H. pylori* and its role in causing histological chronic gastritis. Intensive research across the world has uncovered an astonishingly complex host-bacterial interaction and identified a number of interrelated factors pertinent to cancer risk (Fig. 7). The presence of *H. pylori* causes chronic mucosal inflammation early in the pathway. In the stepwise histological progression there appears to be a point of no return after which *H. pylori* plays no role and indeed colonisation is often lost. Eradication of or vaccination programmes against *H. pylori* in high-risk populations potentially offer a reduction in gastric adenocarcinoma and therefore the worldwide burden of cancer.

References

- Amieva MR, El-Omar EM (2008) Host-bacterial interactions in *Helicobacter pylori* infection. *Gastroenterology* 134(1):306–323
- Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S (2003) Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science* 300(5624):1430–1434

- Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL (1995) Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific *vacA* types with cytotoxin production and peptic ulceration. *J Biol Chem* 270(30):17771–17777
- Backert S, Moese S, Selbach M, Brinkmann V, Meyer TF (2001) Phosphorylation of tyrosine 972 of the *Helicobacter pylori* CagA protein is essential for induction of a scattering phenotype in gastric epithelial cells. *Mol Microbiol* 42(3):631–644
- Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR (2005) *Helicobacter pylori* CagA induces a transition from polarized to invasive phenotypes in MDCK cells. *Proc Natl Acad Sci USA* 102(45):16339–16344
- Basso D, Zamboni CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Ruge M, Plebani M, Atherton JC (2008) Clinical relevance of *Helicobacter pylori* *cagA* and *vacA* gene polymorphisms. *Gastroenterology* 135(1):91–99
- Bjelakovic G, Nikolova D, Simonetti RG, Gluud C (2008) Antioxidant supplements for preventing gastrointestinal cancers. *Cochrane Database Sys Rev* 16(3):CD004183
- Brenner H, Arndt V, Bode G, Stegmaier C, Ziegler H, Stümer T (2002) Risk of gastric cancer among smokers infected with *Helicobacter pylori*. *Int J Cancer* 98(3):446–449
- Calam J (1999) *Helicobacter pylori* modulation of gastric acid. *The Yale J Biol Med* 72(2–3):195–202
- Canedo P, Corso G, Pereira F, Lunet N, Suriano G, Figueiredo C, Pedrazzani C, Moreira H, Barros H, Carneiro F, Seruco R, Roviello F, Machado JC (2008) The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. *Gut* 57(11):1504–1508
- Chang YJ, Wu MS, Lin JT, Pestell RG, Blaser MJ, Chen CC (2006) Mechanisms for *Helicobacter pylori* CagA-induced cyclin D1 expression that affect cell cycle. *Cell Microb* 8(11):1740–1752
- Correa P, Houghton J (2007) Carcinogenesis of *Helicobacter pylori*. *Gastroenterology* 133(2):659–672
- Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M (1975) A model for gastric cancer epidemiology. *Lancet* 2(7924):58–60
- Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross TM, Tompkins DS, Rathbone BJ (1991) Mucosal IgA recognition of *Helicobacter pylori* 120 kDa protein, peptic ulceration, and gastric pathology. *Lancet* 338(8763):325–332
- Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, Abel Azim DM, Cai G, Mahaney MC, Comuzzie AG, Dyer TD, Walder KR, Zimmet P, MacCluer JW, Collier GR, Kissebah AH, Blangero J (2005) Genetic variation in selenoprotein S influences inflammatory response. *Nat Genet* 37(11):1234–1241
- Ding SZ, Smith MF Jr, Goldberg JB (2008) *Helicobacter pylori* and mitogen-activated protein kinases regulate the cell cycle, proliferation and apoptosis in gastric epithelial cells. *J Gastroenterol Hepatol* 23(7 Pt 2):e67–e78
- El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 124(5):1193–1201
- Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J (2008) Asia-Pacific consensus guidelines on gastric cancer prevention. *J Gastroenterol Hepatol* 23(3):351–365
- Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. *Best Pract Res Clin Gastroenterol* 20(4):633–649
- Fuccio L, Zagari RM, Minardi ME, Bazzoli F (2007) Systematic review: *Helicobacter pylori* eradication for the prevention of gastric cancer. *Aliment Pharmacol Ther* 25(2):133–141
- Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M (2008) Effect of eradication of *Helicobacter pylori* on incidence of metachronous

- gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 372(9636):392–397
- Galmiche A, Rassow J, Dove A, Cagnol S, Chambard JC, Contamin S, de Thillot V, Just I, Ricci V, Solcia E, Van Obberghen E, Boquet P (2000) The N-terminal 34 kDa fragment of *Helicobacter pylori* vacuolating cytotoxin targets mitochondria and induces cytochrome c release. *EMBO J* 19(23):6361–6370
- Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R (2003) *Helicobacter pylori* vacuolating cytotoxin inhibits T lymphocyte activation. *Science* 301(5636):1099–1102
- Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehle S, Classen M, Prinz C (1999) Clinical relevance of the *Helicobacter pylori* gene for blood-group antigen-binding adhesion. *Proc Natl Acad Sci USA* 96(22):12778–12783
- Go MF (2002) Review article: natural history and epidemiology of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 16(Suppl 1):3–15
- González CA, Pera G, Agudo A, Palli D, Krogh V, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nvrén O, Agren A, Martinez C, Dorrnsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Bingham S, Day N, Miller A, Nagel G, Boeing H, Overvad K, Tionneland A, Bueno-De-Mesquita HB, Boshuizen HC, Peeters P, Numans M, Clavel-Chapelon F, Helen I, Agapitos E, Lund E, Fahey M, Saracci R, Kaaks R, Riboli E (2003) Smoking and the risk of gastric cancer in the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer* 107(4):629–634
- Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ (2009) Gastric cancer. *Lancet* 374(9688):477–490
- Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, Wakaj K, Tajima K, Hamajima N (2009) Toll-like receptor 4 +3725 G/C polymorphism, *Helicobacter pylori* seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. *Helicobacter* 14(1):47–53
- Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF Jr, El-Omar EM (2007) A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. *Gastroenterology* 132(3):905–912
- Houghton J, Stoioy C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC (2004) Gastric cancer originating from bone marrow-derived cells. *Science* 306(5701):1568–1571
- Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Borén T (1998) *Helicobacter pylori* adhesion binding fucosylated histo-blood group antigens revealed by retagging. *Science* 279(5349):373–377
- Ilver D, Barone S, Mercati D, Lupetti P, Telford JL (2004) *Helicobacter pylori* toxin VacA is transferred to host cell via a novel contact-dependent mechanism. *Cell Microbiol* 6(2):167–174
- International Agency for Research on Cancer (1994) IARC monographs on the evaluation of carcinogenic risks to humans: Schistosomes, liver flukes and *Helicobacter pylori*, vol 61. Lyon, IARC
- Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y, Takamura A, Kitamura S, Matsuo T, Tanaka S, Haruma K, Chayama K (2009) Clinical prevention of gastric cancer by *Helicobacter pylori* eradication therapy: a systematic review. *J Gastroenterol* 44(5):365–371
- Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, Palli D, Saieva C, Krogh V, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Sanchez MJ, Larrañaga N, Barricarte A, Chirlaque MD, Quiros JR, Key TJ, Allen N, Lund E, Carneiro F, Linseisen J, Nagel G, Overvad K, Tionneland A, Olsen A, Bueno-de-Mesquita HB, Ocké MO, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Fenger C, Stenling R, Ferrari P, Jenab M, Norat T, Riboli E, González CA (2006) Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European prospective investigation into cancer and nutrition (EPIC-EURGAST) study. *Carcinogenesis* 27(7):1497–1501

- Judd PA (1988) Dietary factors in the aetiology of gastric cancer. In: Gastric carcinogenesis, proceedings of the 6th annual symposium of the European organisation for cooperation in cancer prevention studies. Amsterdam, Excerpta Medical
- Keates S, Keates AC, Warny M, Peek RM Jr, Murray PG, Kelly CP (1999) Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag- *Helicobacter pylori*. *J Immunol* 163(10):5552–5559
- Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev* 19(3):449–490
- Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR (1988) Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J Med Microbiol* 26(2):93–99
- Li ZW, Wu Y, Sun Y, Liu LY, Tian MM, Feng GS, You WC, Li JY (2010) Inflammatory cytokine gene polymorphisms increase the risk of atrophic gastritis and intestinal metaplasia. *World J Gastroenterol* 16(14):1788–1794
- Marshall B (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1(8336):1273–1275
- Moayyedi P, Axon AT, Feltbower R, Duffett S, Crocombe W, Braunholtz D, Richards ID, Dowell AC, Forman D (2002) Relation of adult lifestyle and socioeconomic factors to the prevalence of *Helicobacter pylori* infection. *Int J Epidemiol* 31(3):624–631
- Molinari M, Salio M, Galli C, Norais N, Rappuoli R, Lanzavecchia A, Montecucco C (1998) Selective inhibition of II-dependent antigen presentation by *Helicobacter pylori* toxin VacA. *J Exp Med* 187(1):135–140
- Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr, Azuma T, Hatakeyama M (2007) *Helicobacter pylori* CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. *Oncogene* 26(32):4617–4626
- Necchi V, Candusso ME, Tava F, Luinetti O, Ventura U, Fiocca R, Ricci V, Solcia E (2007) Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by *Helicobacter pylori*. *Gastroenterology* 132(3):1009–1023
- Odenbreit S, Püls J, Sedlmaier B, Gerland E, Fischer W, Haas R (2000) Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science* 287(5457):1497–1500
- Papini E, Satin B, Norais N, de Bernard M, Telford JL, Rappuoli R, Montecucco C (1998) Selective increase of the permeability of polarized epithelial cell monolayers by *Helicobacter pylori* vacuolating toxin. *J Clin Invest* 102(4):813–820
- Parkin DM (2001) Global cancer statistics in the year 2000. *Lancet Oncol* 2(9):533–543
- Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 118(12):3030–3044
- Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. *CA Cancer J Clin* 55(2):74–208
- Rad R, Gerhard M, Lang R, Schöniger M, Rösch T, Schepp W, Becker I, Wagner H, Prinz C (2002) The *Helicobacter pylori* blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. *J Immunol* 168(6):3033–3041
- Rathbone BJ, Johnson AW, Wyatt JI, Kelleher J, Heatley RV, Losowsky MS (1989) Ascorbic acid: a factor concentrated in human gastric juice. *Clin Sci* 76(3):237–241
- Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh Hosseini M, Atherton JC (2007) A new *Helicobacter pylori* vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. *Gastroenterology* 133(3):926–936
- Segal ED, Cha J, Lo J, Falkow S, Tompkins LS (1999) Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by *Helicobacter pylori*. *Proc Natl Acad Sci USA* 96(25):14559–14564
- Shibata T, Arisawa T, Tahara T, Ohkubo M, Yoshioka D, Maruyama N, Fujita H, Kamiya Y, Nakamura M, Nagasaka M, Iwata M, Takahama K, Watanabe M, Hirata I (2009) Selenoprotein S (SEPS1) gene -105G > A promoter polymorphism influences the susceptibility to gastric cancer in the Japanese population. *BMC Gastroenterology* 9:2

- Siurala M, Varis K, Wiljasalo M (1966) Studies of patients with atrophic gastritis: a 10–15 year follow-up. *Scand J Gastroenterol* 1(1):40–48
- Sobala GM, Schorah CJ, Sanderson M, Dixon MF, Tompkins DS, Godwin P, Axon AT (1989) Ascorbic acid in the human stomach. *Gastroenterology* 97(2):357–363
- Steer HW (1984) Surface morphology of the gastroduodenal mucosal in duodenal ulceration. *Gut* 25(11):1203–1210
- Warren JR (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1(8336):1273
- Willhite DC, Blanke SR (2004) *Helicobacter pylori* vacuolating cytotoxin enters cells, localizes to the mitochondria, and induces mitochondrial membrane permeability changes correlated to toxin channel activity. *Cell Microbiol* 6(2):143–154
- Wilson KT, Crabtree JE (2007) Immunology of *Helicobacter pylori*: insights into the failure of the immune response and perspectives on vaccine studies. *Gastroenterology* 133(1):288–308
- Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG (1991) *Helicobacter pylori*-associated gastritis and primary B-cell gastric lymphoma. *Lancet* 338(8776):1175–1176
- Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M (2003) *Helicobacter pylori* babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. *J Clin Pathol* 56(4):287–291

Inflammatory Bowel Disease and Colon Cancer

Noor Jawad, Natalie Direkze and Simon J. Leedham

Abstract

The inflammatory bowel diseases (IBD); Crohn's and Ulcerative colitis, result from an altered host response to intestinal flora. Recurrent inflammation with ulceration and tissue restitution confers an increased risk of cancer in both UC and Crohns, and genome wide searches have identified a number of disease susceptibility alleles. The carcinogenesis pathway in colitis-associated colorectal cancer (CACRC) is less clearly understood than it's sporadic counterpart. Clonal ordering experiments have indicated the order and timing of chromosomal instability and common genetic mutations. Epigenetic changes such as DNA methylation and histone modification are thought to play an increasingly important role in inflammation induced carcinogenesis. Clonal expansion of procarcinogenic mutations can lead to large fields of mutant tissue from which colitis associated cancers can arise (field cancerisation). Endoscopic screening is the mainstay of surveillance in high-risk patients although the development of appropriate, clinically applicable biomarkers remains a research priority. Despite the expanding field of biological therapy in inflammatory bowel

N. Jawad
Blizard Institute of Cell and Molecular Science,
Bart's and The London School of Medicine and Dentistry,
Queen Mary, University of London,
London, UK

N. Direkze
Frimley Park Hospital NHS Foundation Trust, Portsmouth Road,
Frimley, Surrey, GU16 7UJ, UK

S. J. Leedham (✉)
Wellcome Trust Centre for Human Genetics, University of Oxford,
Roosevelt Drive, Oxford, OX3 7BN, UK
e-mail: simon.leedham@cancer.org.uk

disease the ASA compounds remain the best-studied and most efficacious chemopreventive agents. Colitis associated CRC appears to have a different aetiology, carcinogenesis pathway and clinical course to its sporadic counterpart. Further research including long-term follow up of patient cohorts taking biological therapies will improve the detection and treatment of these important, inflammation-induced malignancies.

Contents

1	Introduction.....	100
2	Genetic Epidemiology of IBD Aetiology.....	101
2.1	Genetic Variation in Inflammation-Related Genes.....	101
3	Comparison of Carcinogenesis Pathways in Sporadic and Colitis-Associated Colorectal Cancer.....	104
3.1	Genetic Instability.....	104
3.2	Role of Inflammation in Cancer Epigenetics.....	106
4	Mutator Phenotype versus Clonal Expansion.....	107
5	Field Cancerisation.....	108
6	Screening and Detection.....	109
6.1	Endoscopic Screening.....	109
6.2	Biomarkers.....	109
7	Chemoprevention.....	109
8	Future Perspectives.....	110
8.1	Biological Therapies and Cancer.....	110
8.2	Stem Cell Therapy.....	110
	References.....	111

1 Introduction

Ulcerative colitis (UC) and Crohn's disease (CD) both have a prevalence of two per 1,000 people in northern Europe, with an incidence of 10 and 6 per 100,000 people per year, respectively, in Western countries (Shivananda et al. 1996). Clinically the conditions are characterised by chronic, relapsing inflammation affecting the colon only in UC or any portion of the gut in CD. The aetiology of these conditions is unclear, but it is often presumed that they result from an altered host response to normal intestinal flora.

Inflammatory bowel disease (IBD) confers a high risk of development of a number of malignancies especially colorectal cancer, with a standardised incidence ratio of 2.4 (95% CI 0.6–6.0) in patients with extensive or pan UC. This risk is associated with longer disease duration, an earlier age of onset (Ekbom et al. 1990) the greater the severity of inflammation (Rutter et al. 2004), and the presence of concomitant inflammatory conditions such as primary sclerosing cholangitis (PSC). This suggests that the acquired cancer risk is a consequence of the inflammatory process which results in cycles of recurrent ulceration and tissue restitution. It is now accepted that the cancer risk in both Crohn's disease and UC is approximately

the same if similar disease patterns are compared (Gillen et al. 1994), and this is further evidence for similar inflammation-related tumour biology.

2 Genetic Epidemiology of IBD Aetiology

Genetic and environmental factors both appear to be important in the development of IBD. At least 13 genome-wide linkage studies have been completed since 1996, but the results have varied widely. The most frequently reported linkages were designated the IBD loci (Table 1).

A recent genome-wide association study (GWAS) of UC has recently identified susceptibility loci that provides the first genetic link between UC and colorectal cancer (Barrett et al. 2009). The strongest new association intervals include *CDH1* on chromosome 16q22, which encodes E-cadherin, a transmembrane glycoprotein and one of the main components of the adherens junction. It is a key mediator of intercellular adhesion in the intestinal epithelium and also plays a key role in epithelial restitution and repair following mucosal damage. The observation of correlated association signals at the *CDH1* locus in both colorectal cancer and UC is significant.

This is the first time that variants within genetic loci encoding epithelial barrier genes have shown association with IBD at rigorous genome-wide significant thresholds and provide further evidence for the re-emerging concept that altered epithelial barrier function and may be a strategic factor in UC pathogenesis. Additional fine mapping and functional studies are undoubtedly necessary to explore this association; however this study provides strong scientific rationalisation for the investigation of novel therapeutic targets pertinent to epithelial barrier function.

2.1 Genetic Variation in Inflammation-Related Genes

Associations between CRC and genetic variation in genes involved in inflammation-related pathways provide support to the mounting body of evidence that suggests inflammation-related pathways are important in the aetiology of CRC. Of potential importance are genes such as *IL6*, which is a critical regulator of inflammation signalling (Slattery et al. 2007). Polymorphisms in the *IL6* gene promoter have been found to be associated with levels of circulating C-reactive protein, an important biomarker for pro-inflammatory status in several diseases (Ferrari et al. 2003). A study by Slattery et al. (2007) suggests that *IL6* genotype may influence risk of CRC. Individuals with the C allele of the c.572G > C SNP and the GG genotype for the c.174G > C polymorphism were at a slightly reduced risk of colon cancer, but possibly at a slightly increased risk of rectal cancer. Associations were comparable for men and women and for all age groups and appeared to be modified by use of aspirin or non-steroidal anti-inflammatory drugs

Table 1 Genetic aetiology of IBD

IBD locus	Chromosome location	Condition	Candidate genes	References
IBD1	16q12	CD	<i>NOD2/CARD15</i>	Hugot et al. (1996)
IBD2	12q13	UC	<i>VDR, IFN-γ</i>	Satsangi et al. (1996)
IBD3	6q13	CD, UC	<i>MHC I, II, TNF-α</i>	Hampe et al. (1999)
IBD4	14q11	CD	<i>TCR α/δ complex</i>	Ma et al. (1999)
				Duerr et al. (2000)
IBD5	5q31–33	CD	<i>IL-3, -4, -5, -13, CSF-2</i>	Rioux et al. (2000)
IBD 6	19p13	CD, UC	<i>ICAM-1, C3, TBXA2R, LTB4H</i>	Rioux et al. (2000)
Other loci (pre GWAS)	1p36	CD, UC	<i>TNF-R family, CASP9</i>	Cho et al. (1998)
	7q	CD, UC	<i>MUC-3</i>	Satsangi et al. (1996)
	3p	CD, UC	<i>HGFR, EGFR, GNA12</i>	Satsangi et al. (1996)
	8q	CD	<i>Beta 2 defensins</i>	Fellermann et al. (2006)
GWAS 2008	Multiple loci	UC, CD	<i>IL23R, IL12B, HLA-DQ/DR, NKX2-3, MST1</i>	Fisher et al. (2008)
GWAS 2008	Multiple loci	UC, CD	<i>HERC2, CCNY</i>	Franke et al. (2008)
		UC	<i>STAT3, PTPN2</i>	
GWAS 2009	Multiple loci	UC	Multiple genes including <i>HNF4A, CDH1, LAMB1</i>	Barrett et al. (2009)
GWAS 2009	Multiple loci	UC	Genes including <i>IL-27, SULT1A1, SULT1A2, EIF3C</i>	Imielinski et al. (2009)

(continued)

Table 1 (continued)

IBD locus	Chromosome location	Condition	Candidate genes	References
GWAS 2009	Multiple loci	UC	Multiple genes including: <i>FCGR2A, SLC26A3, INSL6, INSL4, JAK2</i>	Asano et al. (2009)
<p>Summary table of the major IBD susceptibility loci detected by linkage and genome-wide association studies since 1996. Abbreviations—<i>IL23R</i>—interleukin 23 receptor; <i>IL-12B</i>—interleukin 12 B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40; <i>HLA DQ/DR</i>—human leucocyte antigens DQ/DR; <i>NKY2-3</i>—NK2 transcription factor related, locus 3; <i>MST1</i>—macrophage stimulating 1 (hepatocyte growth factor-like); <i>HERC2</i>—hect domain and RLD2; <i>CCNY</i>—cyclin Y; <i>STAT3</i>—signal transducer and activator of transcription 3 (acute phase response factor); <i>PTPN2</i>—protein tyrosine phosphatase, non-receptor type 2; <i>HNF4A</i>—hepatocyte nuclear factor 4, alpha; <i>CDH1</i>—cadherin 1, type 1, E-cadherin (epithelial); <i>LAMB1</i>—laminin, beta 1; <i>IL-27</i>—interleukin 27; <i>SULT1A1</i>—sulfotransferase family, cytosolic 1A, phenol-preferring, member 1; <i>SULT1A2</i>—sulfotransferase family, cytosolic 1A, phenol-preferring, member 2; <i>EIF3C</i>—eukaryotic initiation factor 3, carrier subunit C; <i>FCGR2A</i>—Fc fragment of IgG, low affinity IIa, receptor (CD32); <i>SLC26A3</i>—solute carrier family 26, member 3; <i>INSL6</i>—insulin-like 6; <i>INSL4</i>—insulin-like 4 (placenta); <i>JAK2</i>—Janus kinase 2</p>				

(NSAIDs): especially for colon cancer (Macarthur et al. 2005). In addition, if users had a C allele in either IL6 polymorphism, they had a greater reduction in risk of colon cancer (Slattery et al. 2007). Although these data are supportive of genetic involvement in an inflammation-related pathway, additional work is necessary that will encompass more genes in this pathway to obtain a better understanding of the associations between inflammation and genetic factors and CRC development.

3 Comparison of Carcinogenesis Pathways in Sporadic and Colitis-Associated Colorectal Cancer

There are several distinguishing clinical features when comparing colitis-associated colorectal cancer (CACRC) to sporadic colorectal carcinoma (SCRC). Firstly, CACRC arises in a younger population, often from flat, not polyploid dysplasia and has a more proximal distribution. Furthermore, there is a greater frequency of mucinous or signet cell histology and a higher incidence of multiple synchronous lesions (Itzkowitz and Yio 2004). From a histological perspective, sporadic tumours tend to follow the adenoma-carcinoma sequence (Vogelstein et al. 1988), whereas CACRC progresses from no dysplasia to indefinite dysplasia, usually through low (LGD) and high-grade dysplasia (HGD) to carcinoma. The stepwise accumulation of genetic mutations in onco- and tumour suppressor genes that underpins the SCRC carcinogenesis pathway is well established and has significantly altered worldwide clinical practice (Vogelstein et al. 1988). The CACRC carcinogenesis pathway is less explored and significantly differs in the requirement and timing of genetic and epigenetic alterations (Fig. 1).

3.1 Genetic Instability

3.1.1 Chromosomal Instability

In sporadic cancer carcinogenesis, chromosomal instability leading to aneuploidy, detectable by both image and flow cytometry, is rare in established precursor lesions before the development of high-grade dysplasia or cancer (Sieber et al. 2002). Yet, in ulcerative colitis, chromosomal instability (CIN) can be detected in histologically non-dysplastic tissue from high-risk patients (extensive disease distribution and long duration of disease), by comparative genomic hybridisation (Willenbacher et al. 1997), image (Keller et al. 2001) or flow cytometry and is thought to precede the development of dysplasia in these patients (Rubin et al. 1992; Lofberg et al. 1992; Befrits 1994). It has been suggested that CIN occurs as a consequence of the effect of inflammation and reactive oxygen species encouraging telomere shortening, permitting chromosomal end fusion. This results in cycles of chromatin bridge breakage and fusion, promoting the accumulation of chromosomal aberrations (O'Sullivan et al. 2002).




Fig. 1 Comparison of Colitis Associated and Sporadic Colorectal Cancer Pathways. Both types of cancer show multistep development with sequential mutation in tumour suppressor and oncogenes. The main differences between the pathways are in the timing of these mutations. Abbreviations: APC, Adenomatous Polyposis Coli; DCC, Deleted in Colon Cancer; LOH, loss of heterozygosity; MSI, Microsatellite instability

3.1.2 Initiating Genetic Mutations

In sporadic CRC carcinogenesis, mutations in *APC* are found in about 60% of sporadic adenomas and 80% of tumours (Powell et al. 1992) and are considered to be the gate-keeping, initiating mutations (Kinzler and Vogelstein 1996). It is now becoming clear that the inflammation and restitution processes that underly IBD, select for alternative initiating genetic mutations in CACRC. A recent clonal ordering study determining the spatial distribution of shared mutations in UC-associated neoplasia allowed insight into the timing of genetic mutations (Leedham et al. 2009). *p53* was the most common single founding mutation with *K-RAS* mutations as the only other detected unique gate-keeping mutation. *APC*

mutations were uncommon suggesting that *APC* is unlikely to have a gatekeeper function in colitis. This is consistent with other work. Point mutations in the *p53* gene can be detected in non-dysplastic tissue from patients with UC preceding the development of aneuploidy and LOH, and appear to be linked to the presence of inflammation (Brentnall et al. 1994; Hussain et al. 2000). Additionally, LOH for *p53* correlates with malignant progression, occurring in 6% of non-dysplastic biopsies, 33% of LGD, 63% of HGD and 85% of cancers (Burmer et al. 1992). The mutation spectrum in *p53* is dominated by transition mutations (Yin et al. 1993; Hussain et al. 2000; Yoshida et al. 2003), and this is likely to reflect the effect of the inflammatory process causing oxidative DNA damage and deamination of 5-methylcytosine, promoting G:C to A:T transitions (Hussain et al. 2000; Seril et al. 2003). It is simple to comprehend why *p53* may act as an initiating mutation in colitis. If underlying chromosomal instability throughout the colon is the main tumourigenic driving force in colitis (Chen et al. 2003, 2005), early *p53* would be selected for, on the basis that disruption of a mitotic checkpoint would permit the survival and selection of clones with gross chromosomal changes.

3.2 Role of Inflammation in Cancer Epigenetics

One of the many potential processes by which inflammation can contribute to carcinogenesis includes alterations in epigenetic events and subsequent inappropriate gene expression.

3.2.1 DNA Methylation and Transcriptional Silencing

CpG island hypermethylation often starts in normal mucosa as a function of age and is markedly increased in cancer (Issa et al. 2001). Such silencing is clonal and is thought to be physiologically irreversible in somatic cells. Neoplastic cells often display aberrant promoter region methylation with epigenetic silencing of multiple genes including genes that regulate critical processes such as cell cycle control, DNA repair and angiogenesis. In the colon, CpG islands methylated in cancer have been divided into two groups: those that display cancer-restricted methylation (type C), and those that are methylated initially in aging normal epithelial cells (type A). It has been proposed that age-related methylation contributes to an acquired predisposition to colorectal neoplasia because methylation alters the physiology of aging cells and tissues (Issa et al. 2001). This hypothesis predicts that higher levels of age-related methylation are associated with a heightened susceptibility to developing colorectal cancer, and it may be present in conditions of rapid cell turnover that mimic premature aging such as IBD.

Issa et al. (2001), investigated the methylation status of 4 genes in patients with UC versus controls (*ER*, *MYOD1*, *CSPG2* and *p16*). All four genes were highly methylated in dysplastic epithelium from patients with colitis-associated HGD or cancer. In addition, three of the four genes (*ER*, *MYOD* and *p16*) were also highly methylated in the normal appearing (non-dysplastic) epithelium from these same HGD/cancer patients, indicating that methylation precedes dysplasia and is

widespread in these patients. These results are consistent with the hypothesis that age-related methylation marks (and may lead to) the field defect that reflects acquired predisposition to colorectal neoplasia. More recently, Kukitsu et al. (2008) identified hypermethylation and subsequently reduced *p16* gene expression in aberrant crypt foci (ACF) in UC. These are the earliest detectable lesions in the CACRC pathway and suggest that aberrant methylation of tumour suppressor genes may be an early event in CACRC carcinogenesis.

3.2.2 Histone Modification

A well-proven epigenetic mechanism of gene expression control involves chromatin remodelling via histone modification. Transcriptional regulation of a variety of cancer-related genes are controlled by two contrasting classes of enzymes—histone deacetylase (HDAC) and histone acetyl transferases (HATs). The acetylation of lysine residues on the N-terminus of histones by HATs activates gene transcription, while removal of an acetyl group from lysine residues in histone tails by HDACs results in transcriptional repression. Therefore, HDACs and HATs, in general, act as transcriptional co-repressors and co-activators, respectively. In chronic inflammatory responses and carcinogenesis the inappropriate activation/inactivation of HDACs and HATs has been implicated. In a study by Cao et al. (2007), the exposure of human bronchial epithelial cells (BEAS-2B) to the diesel exhaust particulate matter induced the transcriptional activation of a representative pro-inflammatory gene cyclooxygenase-2 (COX-2) by promoting acetylation of histone-4 by degradation of HDAC-1. Similarly, the activation of NF- κ B and expression and release of IL-8 and IL-6 in human alveolar (A549) cells by H₂O₂ were associated with augmented acetylation of histone-4 and diminished expression and activity of HDAC-2 (Cao et al. 2007). Thus histone modification and the ensuing upregulation of COX-2 and NF- κ B demonstrates that inflammation induced modification in cellular epigenetic apparatus may also contribute to the genetic instability of cancer cells.

4 Mutator Phenotype versus Clonal Expansion

Multiple aneuploidy detection techniques have shown gross chromosomal changes occurring in non-dysplastic tissue in UC (see Sect. 3.1). Chen et al. (2003, 2005) used arbitrarily-primed (AP-PCR) and inter-simple-sequence repeat PCR (ISSR-PCR) genetic fingerprinting techniques to further analyse genomic instability in colitis. The identification of DNA fingerprint abnormalities throughout normal and dysplastic areas of the colon allowed the subdivision of patients with IBD into UC progressors: patients with identifiable genomic instability who are likely to progress to dysplasia or cancer, and UC non-progressors, patients with normal DNA fingerprints who are not (Chen et al. 2003). The authors proposed that this colon-wide genomic instability in UC progressors provides a field from which dysplasia develops, and is evidence of a mutator phenotype where mutations in genes maintaining genetic stability result in an increased mutation rate driving

colitis-associated tumorigenesis (Chen et al. 2003, 2005; Loeb and Loeb 1999). This is a controversial subject and proponents of an evolutionary theory of carcinogenesis argue that the mutator phenotype theory underestimates the power of natural selection (Tomlinson and Bodmer 1999; Bodmer 2008). The recent identification of colitis-associated neoplasia clonality with *p53* as the commonest initiating mutation (Leedham et al. 2009) lends weight to a Darwinian model where natural selection and clonal expansion are the dominant forces driving CACRC evolution—the somatic mutation theory of carcinogenesis. The close association between the cell cycle and DNA repair suggests that a number of genes involved in the cellular response to DNA damage, such as *p53* may have a two-fold responsibility in controlling DNA repair and growth. Consequently mutations in these genes may provide both a selective growth advantage and an increased mutation rate driving selection and the mutator phenotype simultaneously, although evolutionary geneticists argue that the mutator phenotype component is a coincidental by-product of direct selection of mutation of these genes for their anti-apoptotic effects (Bodmer 2008). The debate continues!

5 Field Cancerisation

The term field cancerisation was proposed by Slaughter et al. (1953) to explain the presence of multifocal head and neck cancers developing out of a field of pre-cancerous change that had developed following carcinogen exposure. Braakhuis et al. (2003) expanded this theory and proposed that the field was actually a clonally expanded area of mutated cells. Clonally expanded mutated patches have been documented previously in dysplastic and phenotypically normal mucosa of colitis patients (Lyda et al. 1998, 2000). Leedham et al. (2009) identified field cancerisation in one interesting patient when they demonstrated that three left-sided tumours and some of the intervening chronically inflamed but phenotypically non-dysplastic mucosa shared the same founder mutation, suggesting widespread clonal expansion of a progenitor clone from which the three spatially independent tumours arose. Niche succession and crypt fission are likely to be the mechanisms behind clonal expansion in CACRC. Occasional symmetrical division of individual crypt stem cells results in the extinction or amplification of one cell lineage (Kim and Shibata 2002). This process will occur faster if the mutation provides a growth advantage. Crypt fission has been shown to be responsible for the spread of individual clones into daughter crypts in the colon (Greaves et al. 2006) and this process is a histological feature of colitis and dysplasia (Park et al. 1995). Chen et al. (2005) used a fluorescent in situ hybridisation technique to demonstrate the spread of *p53* mutations into the daughter crypts of a crypt in the process of fission in UC. The suggestion of field cancerisation in this condition has possible clinical implications, raising questions about the use of molecular genetic analysis of non-dysplastic tissue in high-risk cancer patients to detect fields from which future tumours may arise.

6 Screening and Detection

6.1 Endoscopic Screening

Early detection and screening is the mainstay of reducing cancer morbidity and mortality in the IBD population. As the risk of CRC is influenced by the extent and duration of the disease current European guidelines suggest an initial assessment colonoscopy 8–10 years after the onset of symptoms in UC (Moum et al. 1999). The development of PSC is an independent risk factor and patients should be offered yearly surveillance as soon as PSC is diagnosed. Many dysplastic lesions in colitis are flat rather than polypoid (Allen et al. 1985). These are more difficult to detect endoscopically, which leads us to the question of how many random biopsies to take to maximise the chance of detecting dysplasia? Current recommendations suggest that four biopsies should be taken every 10 cm with additional biopsies in strictured, raised or other abnormal areas of the colon; however this is time consuming for patients, nurses, colonoscopists and histopathologists. There are gradual moves towards a more focused approach to obtain targeted biopsies aided by the use of chromendoscopy with indigo carmine or methylene blue. This has shown to give a superior yield in the detection of dysplasia (Biancone et al. 2008; Eaden and Mayberry 2002; Winawer et al. 2003). The role of other methods of targeting biopsies—such as trimodal, autofluorescence and narrow band imaging are also being studied and may feature in future recommendations (East et al. 2006; van den Broek et al. 2008; Dekker et al. 2007).

6.2 Biomarkers

A biomarker is an indicator of a pathological process that may be measured or used to assess the response to therapeutic intervention. At present the histological detection of dysplasia in a biopsy sample is the only marker that has entered widespread clinical practice, and the detection of high-grade dysplasia is an indication for endoscopic resection or colectomy. The discomfort, difficulty and expense of obtaining histological samples mean that the development of a biomarker detectable in stool is a research priority. As yet studies on calprotectin (von Roon et al. 2007) and SFRP2 hypermethylation (Huang et al. 2007) from stool samples have failed to show the sensitivity and specificity required for clinical applicability.

7 Chemoprevention

Prevention is the best strategy to minimise the impact of cancer and may be theoretically achieved by good disease control and reduction of modifiable risk factors. A number of pharmacological agents have been proposed to have a chemopreventive role and these include 5-amino salicylic acid (5-ASA) compounds.

The efficacy of these agents may only be partially explained by anti-inflammatory effects of these drugs as other more potent anti-inflammatory agents such as glucocorticoids and immunomodulators such as azathioprine have a less significant cancer protective effect. Additional chemopreventative effects of 5-ASA compounds include; modulation of inflammatory cytokine production (Zimmerman and Jewell 1996), inhibition of cyclooxygenase (Allgayer 2003), inducible NO synthase (Hasko et al. 2001; Kennedy et al. 1999) and nuclear factor KB (Greten et al. 2004; Wahl et al. 1998) as well as activation of peroxisome proliferator activated receptor (PPAR) gamma (Dubuquoy et al. 2006; Rousseaux et al. 2005). In addition to this 5-ASA's scavenge oxygen free radicals and have an antimicrobial action (Swidsinski et al. 2005). 5-ASA compounds can also act as an inhibitor of protein phosphatase 2A—which can reduce the activity of the Wnt pathway (Bos et al. 2006). Although, theoretically these mechanisms could help to prevent cancer, there are no prospective randomised controlled trials to confirm the protective effect of 5-ASA in cancer chemoprevention in colitis. The best evidence to support their use comes from the meta-analysis by Velayos et al. (2008) that revealed a reduced risk of the development of cancer or dysplasia in UC patients on regular 5-ASA (pooled odds ratio of 0.51 (95% CI 0.38–0.69)).

8 Future Perspectives

8.1 Biological Therapies and Cancer

With the advent of the use of biological therapies, we have seen the medical management of IBD patients who are refractory to steroids and revolutionised immunomodulators (Rutgeerts et al. 2009). As yet there is no evidence to suggest that biologics offer any cancer chemoprevention. In fact, data from the British Society of Rheumatology Biologics Registry show that patients with pre-existing cancer have an increased risk of recurrence with the use of biologics, and those without pre-existing cancer have no increased incidence except in two cohorts—teenagers and young adolescents (in particular with the risk of hepatosplenic T-cell lymphoma) (Rosh et al. 2007). There remains many unanswered questions about the mechanism of action, appropriate time to use biologics and their long-term safety profile and as more long-term data emerges, our understanding of these novel therapies will expand.

8.2 Stem Cell Therapy

It is now appreciated that bone marrow-derived stem cells have a dynamic role in inflammation and cancer throughout the body. Bone marrow-derived cells contribute to myofibroblast populations in the colon and small intestine of mice and humans (Brittan et al. 2002) as well as in mouse models of colitis where they also contribute to vascular lineages (Brittan et al. 2005). Not only this, but also in the

IL-10 knock-out model, the colitis that develops can be ameliorated by transplantation of wild-type bone marrow (Bamba et al. 2006). Bone marrow has been shown to contribute to stromal cell populations in cancer (Direkze et al. 2004) and this may offer an alternative route to target therapies to control not only IBD itself but also CACRC, a finding that has been seen in mouse cancer models (Studeny et al. 2002; Nakamizo et al. 2005). In the human, case reports of amelioration of IBD in haematopoietic stem cell (HSC) transplant recipients for co-incident haematologic malignancy prompted interest in stem cell therapy for IBD (reviewed in (Lanzoni et al. 2008)). More recently adipose-derived mesenchymal stem cells have been successfully used in the treatment of refractory perianal fistulae (Garcia-Olmo et al. 2005) and a European-wide phase III trial on the effect of autologous stem cell transplantation in CD is underway (ASTIC trial). Whether the beneficial effect of stem cell therapy arises from concomitant immunosuppressive therapy or from a 'resetting' of the colonic stem cell niche remains to be seen.

There is increasing evidence that CACRC has a different aetiology, carcinogenesis pathway and clinical course to its sporadic counterpart. Genome-wide association studies have revealed new susceptibility loci and opened up new lines of investigation. The recognition that intestinal immune system dysregulation provokes chronic inflammation with resultant carcinogenesis has already shifted the focus of management of the IBD. The development of further biological treatments including stem cell therapy promises further tantalising insight into the pathogenesis of these, and other chronic inflammatory conditions.

References

- Allen DC, Biggart JD, Pyper PC (1985) Large bowel mucosal dysplasia and carcinoma in ulcerative colitis. *J Clin Pathol* 38:30–43
- Allgayer H (2003) Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. *Aliment Pharmacol Ther* 18(suppl 2):10–14
- Asano K, Matsushita T, Umeno J et al (2009) A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. *Nat Genet* 41:1325–1329
- Bamba S, Lee CY, Brittan M et al (2006) Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. *J Pathol* 209:265–273
- Barrett JC, Lee JC, Lees CW et al (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. *Nat Genet* 41:1330–1334
- Befrits R, Hammarberg C, Rubio C et al (1994) DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. *Dis Colon Rectum* 37:313–319 discussion 319–20
- Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S et al (2008) European evidence-based consensus on the management of ulcerative colitis: special situations. *J Crohn's Colitis* 2:63–92
- Bodmer W (2008) Genetic instability is not a requirement for tumor development. *Cancer Res* 68:3558–3560 discussion 3560–1
- Bos CL, Diks SH, Hardwick JC et al (2006) Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. *Carcinogenesis* 27:2371–2382

- Braakhuis BJ, Tabor MP, Kummer JA et al (2003) A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. *Cancer Res* 63:1727–1730
- Brentnall TA, Crispin DA, Rabinovitch PS et al (1994) Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. *Gastroenterology* 107:369–378
- Brittan M, Hunt T, Jeffery R et al (2002) Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. *Gut* 50:752–757
- Brittan M, Chance V, Elia G et al (2005) A regenerative role for bone marrow following experimental ulceritis: contribution to neovascuogenesis and myofibroblasts. *Gastroenterology* 128:1984–1995
- Burmer GC, Rabinovitch PS, Haggitt RC et al (1992) Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. *Gastroenterology* 103:1602–1610
- Cao D, Bromberg PA, Samet JM (2007) COX-2 expression induced by diesel particles involves chromatin modification and degradation of HDAC1. *Am J Respir Cell Mol Biol* 37:232–239
- Chen R, Rabinovitch PS, Crispin DA et al (2003) DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. *Am J Pathol* 162:665–672
- Chen R, Bronner MP, Crispin DA et al (2005a) Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions. *Cancer Genet Cytogenet* 162:99–106
- Chen R, Rabinovitch PS, Crispin DA et al (2005b) The initiation of colon cancer in a chronic inflammatory setting. *Carcinogenesis* 26:1513–1519
- Cho JH, Nicolae DL, Gold LH et al (1998) Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. *Proc Natl Acad Sci USA* 95:7502–7507
- Dekker E, van den Broek FJ, Reitsma JB et al (2007) Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. *Endoscopy* 39:216–221
- Direkze NC, Hodiava-Dilke K, Jeffery R et al (2004) Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. *Cancer Res* 64:8492–8495
- Dubuquoy L, Rousseaux C, Thuru X et al (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. *Gut* 55:1341–1349
- Duerr RH, Barmada MM, Zhang L et al (2000) High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11–12. *Am J Hum Genet* 66:1857–1862
- Eaden JA, Mayberry JF (2002) Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. *Gut* 51(Suppl 5):V10–V12
- East JE, Suzuki N, von Herbay A et al (2006) Narrow band imaging with magnification for dysplasia detection and pit pattern assessment in ulcerative colitis surveillance: a case with multiple dysplasia associated lesions or masses. *Gut* 55:1432–1435
- Ekobom A, Helmick C, Zack M et al (1990) Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 323:1228–1233
- Fellermann K, Stange DE, Schaeffeler E et al (2006) A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. *Am J Hum Genet* 79:439–448
- Ferrari SL, Ahn-Luong L, Garnero P et al (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. *J Clin Endocrinol Metab* 88:255–259
- Fisher SA, Tremelling M, Anderson CA et al (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. *Nat Genet* 40:710–712
- Franke A, Balschun T, Karlsen TH et al (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. *Nat Genet* 40:1319–1323
- Garcia-Olmo D, Garcia-Arranz M, Herreros D et al (2005) A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. *Dis Colon Rectum* 48:1416–1423

- Gillen CD, Walmsley RS, Prior P et al (1994) Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. *Gut* 35:1590–1592
- Greaves LC, Preston SL, Tadrous PJ et al (2006) Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. *Proc Natl Acad Sci USA* 103:714–719
- Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 118:285–296
- Hampe J, Schreiber S, Shaw SH et al (1999) A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. *Am J Hum Genet* 64:808–816
- Hasko G, Szabo C, Nemeth ZH et al (2001) Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. *Immunology* 103:473–478
- Huang Z, Li L, Wang J (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. *Dig Dis Sci* 52:2287–2291
- Hugot JP, Laurent-Puig P, Gower-Rousseau C et al (1996) Mapping of a susceptibility locus for Crohn's disease on chromosome 16. *Nature* 379:821–823
- Hussain SP, Amstad P, Raja K et al (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. *Cancer Res* 60:3333–3337
- Mielinski M, Baldassano RN, Griffiths A et al (2009) Common variants at five new loci associated with early-onset inflammatory bowel disease. *Nat Genet* 41:1335–1340
- Issa JP, Ahuja N, Toyota M et al (2001) Accelerated age-related CpG island methylation in ulcerative colitis. *Cancer Res* 61:3573–3577
- Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *Am J Physiol Gastrointest Liver Physiol* 287:G7–G17
- Keller R, Foerster EC, Kohler A et al (2001) Diagnostic value of DNA image cytometry in ulcerative colitis. *Dig Dis Sci* 46:870–878
- Kennedy M, Wilson L, Szabo C et al (1999) 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. *Int J Mol Med* 4:437–443
- Kim KM, Shibata D (2002) Methylation reveals a niche: stem cell succession in human colon crypts. *Oncogene* 21:5441–5449
- Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. *Cell* 87:159–170
- Kukitsu T, Takayama T, Miyanishi K et al (2008) Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. *Clin Cancer Res* 14:48–54
- Lanzoni G, Roda G, Belluzzi A et al (2008) Inflammatory bowel disease: moving toward a stem cell-based therapy. *World J Gastroenterol* 14:4616–4626
- Leedham SJ, Graham TA, Oukrif D et al (2009) Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. *Gastroenterology* 136:542–506
- Loeb KR, Loeb LA (1999) Genetic instability and the mutator phenotype. *Studies in ulcerative colitis. Am J Pathol* 154:1621–1626
- Lofberg R, Brostrom O, Karlen P et al (1992) DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. *Gastroenterology* 102:1149–1154
- Lyda MH, Noffsinger A, Belli J et al (1998) Multifocal neoplasia involving the colon and appendix in ulcerative colitis: pathological and molecular features. *Gastroenterology* 115:1566–1573
- Lyda MH, Noffsinger A, Belli J et al (2000) Microsatellite instability and K-ras mutations in patients with ulcerative colitis. *Hum Pathol* 31:665–671
- Ma Y, Ohmen JD, Li Z et al (1999) A genome-wide search identifies potential new susceptibility loci for Crohn's disease. *Inflamm Bowel Dis* 5:271–278

- Macarthur M, Sharp L, Hold GL et al (2005) The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. *Cancer Epidemiol Biomarkers Prev* 14:1613–1618
- Moum B, Ekbom A, Vatn MH et al (1999) Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. *Am J Gastroenterol* 94:1564–1569
- Nakamizo A, Marini F, Amano T et al (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. *Cancer Res* 65:3307–3318
- O’Sullivan JN, Bronner MP, Brentnall TA et al (2002) Chromosomal instability in ulcerative colitis is related to telomere shortening. *Nat Genet* 32:280–284
- Park HS, Goodlad RA, Wright NA (1995) Crypt fission in the small intestine and colon. A mechanism for the emergence of G6PD locus-mutated crypts after treatment with mutagens. *Am J Pathol* 147:1416–1427
- Powell SM, Zilz N, Beazer-Barclay Y et al (1992) APC mutations occur early during colorectal tumorigenesis. *Nature* 359:235–237
- Rioux JD, Silverberg MS, Daly MJ et al (2000) Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. *Am J Hum Genet* 66:1863–1870
- Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? *Inflamm Bowel Dis* 13:1024–1030
- Rousseaux C, Lefebvre B, Dubuquoy L et al (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. *J Exp Med* 201:1205–1215
- Rubin CE, Haggitt RC, Burmer GC et al (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. *Gastroenterology* 103:1611–1620
- Rutgeerts P, Vermeire S, Van Assche G (2009) Biological therapies for inflammatory bowel diseases. *Gastroenterology* 136:1182–1197
- Rutter M, Saunders B, Wilkinson K et al (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 126:451–459
- Satsangi J, Parkes M, Louis E et al (1996) Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. *Nat Genet* 14:199–202
- Seril DN, Liao J, Yang GY et al (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. *Carcinogenesis* 24:353–362
- Shivananda S, Lennard-Jones J, Logan R et al (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). *Gut* 39:690–697
- Sieber OM, Heinemann K, Gorman P et al (2002) Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC. *Proc Natl Acad Sci USA* 99:16910–16915
- Slattery ML, Wolff RK, Herrick JS et al (2007) IL6 genotypes and colon and rectal cancer. *Cancer Causes Control* 18:1095–1105
- Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. *Cancer* 6:963–968
- Studeny M, Marini FC, Champlin RE et al (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. *Cancer Res* 62:3603–3608
- Swidsinski A, Weber J, Loening-Baucke V et al (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. *J Clin Microbiol* 43:3380–3389
- Tomlinson I, Bodmer W (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. *Nat Med* 5:11–12
- van den Broek FJ, Fockens P, van Eeden S et al (2008) Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and

- autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. *Gut* 57:1083–1089
- Velayos F (2008) Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices. *Expert Rev Gastroenterol Hepatol* 2:817–825
- Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. *N Engl J Med* 319:525–532
- von Roon AC, Karamountzos L, Purkayastha S et al (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. *Am J Gastroenterol* 102:803–813
- Wahl C, Liptay S, Adler G et al (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. *J Clin Invest* 101:1163–1174
- Willenbacher RF, Zelman SJ, Ferrell LD et al (1997) Chromosomal alterations in ulcerative colitis-related neoplastic progression. *Gastroenterology* 113:791–801
- Winawer S, Fletcher R, Rex D et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. *Gastroenterology* 124:544–560
- Yin J, Harpaz N, Tong Y et al (1993) p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. *Gastroenterology* 104:1633–1639
- Yoshida T, Mikami T, Mitomi H et al (2003) Diverse p53 alterations in ulcerative colitis-associated low-grade dysplasia: full-length gene sequencing in microdissected single crypts. *J Pathol* 199:166–175
- Zimmerman MJ, Jewell DP (1996) Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. *Aliment Pharmacol Ther* 10 (suppl 2):93–98 discussion 99

Primary Sclerosing Cholangitis

Piotr Milkiewicz and Ewa Wunsch

Abstract

Primary sclerosing cholangitis (PSC) is a chronic liver condition which may affect both intra and extrahepatic biliary tree. Etiology of PSC remains to be fully elucidated but genetic, autoimmune, inflammatory and possibly infective factors could all contribute to its development. More than two-thirds of patients are males and the most commonly associated condition is an inflammatory bowel disease which occurs in up to 70% of affected subjects. Endoscopic cholangiopancreatography (ERCP) and magnetic resonance cholangiopancreatography (MRCP) remain a gold standard in the diagnosis of this condition. No curative treatment of PSC exists and a proportion of patients who develop liver failure or suffer from recurrent episodes of cholangitis requires liver transplantation. PSC is associated with increased risk of malignancies, in particular cholangiocarcinoma which may arise in 12% of patients. The main aim of this chapter is to review the current knowledge on pathogenesis and clinical aspects of PSC as well as its associated malignancies.

Keywords

Primary sclerosing cholangitis · Cholangiocarcinoma · Colorectal cancer

P. Milkiewicz (✉) · E. Wunsch
Department of Hepatology and Liver Transplantation,
M.Curie Hospital, Arkonska 4, 71-455 Szczecin, Poland
e-mail: p.milkiewicz@wp.pl

P. Milkiewicz
Liver Research Laboratories, Pomeranian Medical School,
Powstancow Wlkp. 72, 70-111 Szczecin, Poland

J. A. Z. Jankowski (ed.), *Inflammation and Gastrointestinal Cancers*,
Recent Results in Cancer Research 185, DOI: 10.1007/978-3-642-03503-6_7,
© Springer-Verlag Berlin Heidelberg 2011

Contents

1	Introduction.....	118
2	Epidemiology.....	118
3	Aetiopathogenesis.....	119
4	Clinical Features and Diagnosis.....	120
5	Malignancies in PSC.....	122
5.1	Cholangiocarcinoma.....	122
5.2	Other Malignancies in PSC.....	123
5.3	Chemoprevention.....	125
5.4	Treatment.....	126
	References.....	128

1 Introduction

Sclerosing cholangitis comprises a group of chronic, progressive cholestatic liver diseases which may affect both intra and extrahepatic biliary tree. Secondary and rare causes of IgG4 related sclerosing cholangitis include portal bilopathy, sclerosing cholangitis, inflammatory hepatic pseudotumours, autoimmune pancreatitis, mast cell cholangiopathy or AIDS related cholangiopathy. The main focus of this chapter is primary sclerosing cholangitis (PSC), the commonest cause of sclerosing cholangitis. PSC is one of the most fascinating and challenging conditions in the contemporary hepatology. Its aetiology remains a mystery and although underlying immunological mechanisms play an important role, for many reasons PSC can not be called a typical autoimmune condition. In terms of diagnosis and treatment neither reliable serum markers to diagnose PSC exist nor is curative medical therapy available. Liver transplantation potentially cures the disease in many patients however the disease may recur after surgery even leading to graft loss. Significantly increased risk of both biliary and extrahepatic malignancies pose a real challenge in the management of this condition.

2 Epidemiology

Incidence of PSC seems to be higher in northern Europe and United States than in southern Europe or Asia. Unfortunately, the data on the epidemiology of PSC are scanty with only a few population-based studies existing in the literature. Boberg et al. (1998) in their study on Norwegian population found the mean annual incidence to be of 1.3/100000 and the point prevalence of 8.5/100.000. Bambha et al. (2003) who studied American population living in Minnesota showed an age-adjusted incidence of PSC of 1.25/100000 in males and 0.54/100.000 in females with the prevalence of 20.9/100.000 in males and 6.3/100000 in females. In another, population-based, Canadian study, Kaplan et al. (2007) found an annual incidence to be of 0.92/100.000 and more specifically for the small-duct variant of

PSC of 0.15/100000. A more recent study from the UK where the incidence rates during the period between 1991 and 2001 were analysed showed the rate of the disease to be 0.41/100000 person-years and the prevalence in 2001 of 3.85/100000. Authors found that the incidence of PSC over the analyzed period increased by 50% (Card et al. 2008).

3 Aetiopathogenesis

Without a doubt the aetiology of PSC is multifactorial with genetic, autoimmune, inflammatory and possibly infective factors all playing their role.

An increased prevalence of PSC has been found in first degree relatives (Bergquist et al. 2005) and recent, Swedish study on 678 patients with PSC showed the risk (with the hazard ratio and 95% confidence interval) of cholangitis in off spring, siblings and parents of these patients to be 11.5; 11.1 and 2.3, respectively when compared to the relatives of the control group (Bergquist et al. 2008).

HLA haplotypes B8 and DR3 which are both associated with autoimmune conditions occur with an increased frequency in patients with PSC. MICA genes are localised between HLA-B and TNFA in the MHC class I region and MCA*008 homozygosity showed the most significant association with PSC, reaching an odds ratio of 5.01 (Norris et al. 2001). It has also been postulated that haplotypes DRB1*0701, DRB1*0401 and MICA*002 may be related to decreased risk of PSC (Spurkland et al. 1999). With regard to non-MHC genes data are conflicting and almost as a rule are not reproducible (Kitiyakara and Chapman 2008).

An autoimmune background for PSC is suggested by its common coexistence with typical autoimmune conditions and inflammatory bowel diseases, predominantly ulcerative colitis. PSC is associated with various autoantibodies, including antinuclear antibodies (ANA), smooth muscle antibodies (SMA) or perinuclear-staining antineutrophil cytoplasmic antibodies (p-ANCA). They occur with various frequencies but are unlikely to be directly involved in the pathogenesis of this condition (Angulo et al. 2000).

A potential role of infection as a possible trigger of an immune-mediated inflammation has been considered since the late 1980's. Several studies have shown a high prevalence of various microorganisms obtained from either bile or bile ducts tissues (Kahana et al. 2003; Fox et al. 1998; Olsson et al. 1998; Kulaksiz et al. 2006). However, these organisms have been found mainly in patients with immunodeficiency syndromes or PSC-like secondary cholangitis. On the other hand Olsson et al. reported a significant prevalence of hepatobiliary infection in patients with PSC caused by colonic bacteria, predominantly α -haemolytic Streptococci (1998). A potential role of infectious agents can also be suggested by the fact that combined therapy with metronidazole and ursodeoxycholic acid (UDCA) improves both liver biochemistry and histology in patients with PSC (Farkkila et al. 2004).

Well known close linkage between PSC and chronic inflammatory bowel disease (IBD) led to the hypothesis that portal bacteremia associated with increased permeability of the inflamed colon could be a potential source of biliary inflammation. This hypothesis is strengthened by the works on animal models where hepatic injury similar to PSC were observed after intraportal injection of intestinal non-pathogenic bacteria (Kono et al. 1988) or in experimental small bowel bacterial overgrowth (Lichtman et al. 1990). These findings, however, do not explain why PSC occurs more frequently in patients with ulcerative colitis than with Crohn's disease and also human studies have not confirmed portal bacteraemia or portal vein phlebitis in patients with ulcerative colitis. However, recently published studies support the idea that intestinal permeability, secondary to IBD could play a role in the pathogenesis of PSC. According to this hypothesis, colonic bacteria or bacterial antigens can trigger ANCA formation and autoimmune reaction in the genetically susceptible host by molecular mimicry in a cross-reaction with human autoantigens (O'Mahony and Vierling 2006). In this context induction of bile duct inflammation neither require a direct microbial presence in the biliary ducts nor the portal bacteraemia. However, unlike in primary biliary cirrhosis (PBC) where ubiquitous, xenobiotic-metabolising bacteria, *Novosphingobium aromaticivorans* has been suggested as a source of molecular mimicry (Selmi et al. 2003), there is no conclusive evidence which bacterial antigens might cross-react with human autoantigens and thereby play the trigger's role of autoimmunity phenomena in PSC. Recently, the bacterial cell division protein FtsZ has been proposed as a potential antigen for p-ANCA in patients with PSC and AIH (Terjung and Spengler 2009).

In patients who undergo proctocolectomy for ulcerative colitis symptoms of PSC may occur many years later. This fact led to the hypothesis that PSC can be triggered by/through long-lived memory cells, primary recruited during active inflammation of the colon (Grant et al. 2002). These T lymphocytes undergo enterohepatic circulation and can cause an organ specific immune response. The described lymphocyte tropism is a result of the unique expression of many adhesion molecules restricted to the particular locations. It has been shown that there is an overlapping expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and vascular adhesion protein-1 (VAP-1) between the mucosal and hepatic endothelium, especially during episode of inflammation (Grant et al. 2001). It may suggest that mucosal memory cells may be able to enter the liver using both VAP-1 and MAdCAM-1 and, when activated by the particular stimulus or stimuli, can trigger the chronic liver inflammation even after resolution of colitis.

4 Clinical Features and Diagnosis

Up to 71% of patients are male. A significant proportion (between 21 and 44%) of affected subjects are asymptomatic at the diagnosis and their disease is diagnosed as a consequence of further investigations of accidentally found disturbance of




Fig. 1 **a** Primary sclerosing cholangitis with typical multiple stenoses seen in the biliary tree leading to a beaded pattern (*arrows*). **b** cholangiocarcinoma (CCA) of the common bile duct (*arrow*)

liver biochemistry. The most common complaints in those who are symptomatic are abdominal pain, icterus, skin itching and recurrent episodes of fever (Weismuller et al. 2008). The prevalence of chronic fatigue, an extremely troublesome symptom in chronic cholestasis, (Milkiewicz and Heathcote 2004) is controversial. Bjornson et al. found it to be lower than in general population (Bjornsson et al. 2004) whereas in most recent study Al-Harty et al. were able to detect it in more than 90% of patients (Al-Harthy et al. 2009).

Inflammatory bowel disease (IBD) is the most commonly associated condition which can occur in up to 73% of patients. Ulcerative colitis is diagnosed in majority of affected subjects and colonic Crohn's disease comprises between 1 and 14%. Among other associated diseases of an autoimmune background, most common are insulin dependent diabetes mellitus (IDDM), thyroid conditions and psoriasis.

Liver biochemistry demonstrates cholestasis with elevated alkaline phosphatase (ALP). Mild/moderate elevation of serum transaminases can also be commonly seen. Bilirubin levels tend to fluctuate and increase during episodes of cholangitis. In patients who developed liver cirrhosis features of impaired synthetic function with decreased levels of albumin and prolonged prothrombin time can be seen. Autoantibodies, with an exception of p-ANCA (36) play neither diagnostic nor prognostic role (Terjung and Spengler 2005).

ERCP remains a gold standard in the diagnosis of PSC. As ERCP can be associated with complications such as pancreatitis or cholangitis, MRCP is a modality of choice in an early assessment, particularly in patients without clinical and biochemical symptoms suggesting the necessity of endoscopic intervention. Except non-invasiveness of MRCP, its clear advantage is a visualisation of bile ducts localised after significant stenoses where contrast medium may not penetrate. However, interpretation of MRCP scans requires advanced radiological expertise, for sure not available in all hospitals thus ERCP with its ability of direct

diagnostic (brush cytology) and therapeutic (stenting) interventions holds its role as a gold standard. Typical ERCP image in patient with PSC is shown in Fig. 1a.

It has been recently shown that overall complications rate after ERCP in patients with PSC was comparable to these without PSC. However the risk of cholangitis was significantly higher and the duration of the procedure was significantly longer in subjects with PSC (Bangarulingam et al. 2009).

Unlike in many other liver disorders, histology plays a minor role in the diagnosis of PSC as it shows significant variability and it affects clinical management in just 1.3% of patients (Olsson et al. 1995; Burak et al. 2003). It is however useful in the assessment of the stage of fibrosis and for confirming cirrhotic. A small proportion of patients have normal ERCP/MRCP, suffer from IBD and have histology compatible with PSC. This variant is called small-duct PSC and carries significantly better prognosis in terms of progression of the disease and the risk of CCA (Bjornsson et al. 2002). It has been recently shown that unlike in PSC with typical ERCP/MRCP picture the presence of IBD exerts no significant effect on the long-term prognosis in patients with small-duct variant (Bjornsson et al. 2008).

PSC can be overlapped with AIH, more commonly in children (Gregorio et al. 2001). Also in adults it has been postulated that all patients with AIH who have elevated ALP or GGT should be screened for PSC with MRCP (Abdalian et al. 2008). This approach permits detection of PSC in 10% of adult patients with AIH (Abdalian et al. 2008).

5 Malignancies in PSC

5.1 Cholangiocarcinoma

Cholangiocarcinoma (CCA) is a tumour with extremely bad prognosis and has similar incidence and mortality rates (Khan et al. 2008). Incidence shows geographical relationship with the highest rates observed in Thailand and being 100 higher than in Europe. In East Asia CCA is associated with infestation with hepatobiliary flukes, in particular *Opisthorchis viverrini* and *Clonorchis sinensis* (Shaib and El-Serag 2004; Watanapa 1996) and in Japan and Taiwan with hepatolithiasis (Okuda et al. 2002). In Europe, PSC is the most common risk factor. Over last decades mortality rates of CCA show a significant increase of intrahepatic CCA and no increase or even fall in extrahepatic form. These data have to be interpreted with caution due to a potential error related to misclassification of hilar (Klatskin) tumour which in terms of its localisation is extrahepatic but in ICD-0-2 classification it received a code of an intrahepatic one.

In terms of pathogenesis, CCA is clearly related to processes induced by inflammation and cholestasis. Undoubtedly, like in many other tumours, interleukin-6 (IL-6) is a key signalling cytokine involved in the pathogenesis of CCA (Wise et al. 2008). Its receptor subunit gp-130 is overexpressed in CCA (Yokomuro et al. 2000) and production facilitated by other inflammatory agents

(Park et al. 1999). Increased IL-6 not only causes CCA resistance to cytotoxic treatments (Isomoto et al. 2007; Kobayashi et al. 2005) but also leads to an activation of the family of mitogen activated protein kinases (MAPK) such as p44, p42 and p38 playing a crucial role in proliferation of CCA cells (Park et al. 1999). IL-6 produced by CCA cells in an autocrine fashion upregulates anti-apoptotic molecule Mcl-1 via STAT3 and AKT cascades (Kobayashi et al. 2005).

Various other cytokines enhanced by both inflammation and cholestasis in PSC trigger the cascade of inducible nitric oxide synthase (iNOS) activation followed by reactive nitrogen oxide species (RNOS) production which leads to DNA damage and mutagenesis (Blechacz and Gores 2008). Persistent activation of epidermal growth factor receptor (EGFR) by bile salts has been observed in CCA (Werneburg et al. 2003). This phenomenon facilitates proliferation of CCA cells. EGFR phosphorylation (along with the effect of bile acids, oxysterol and iNOS) triggers MAPK leading to increased expression of cyclooxygenase-2 (COX-2) in CCA cells and inhibition of apoptosis (Endo et al. 2002; Han et al. 2004). Growth of CCA cells is also affected by various other factors such as estrogens, neuropeptides or neuroendocrine hormones. 17 beta estradiol, one of the most toxic metabolites of estradiol (Milkiewicz et al. 2001) facilitates proliferation of CCA cells, an effect clearly inhibited by tamoxifen (Sampson et al. 1997). On the other hand stimulation of alpha2 receptors, gamma-aminobutyric acid and gastrin seem all decrease proliferation of CCA cells via various mechanisms (Wise et al. 2008; Kanno et al. 2002; Fava et al. 2005). Figure 2 shows in a simplified scheme of the development of CCA.

A large study on the relationship between PSC and CCA comprising about 400 patients from 5 European centres showed that 12.2% of patients with PSC were found to have CCA (Boberg et al. 2002). In 50% of them CCA was diagnosed within first year of the diagnosis of PSC and in a further 27% CCA was found during liver transplant assessment. Typical ERCP image of CCA is shown in Fig. 1b. Interestingly, although symptoms of jaundice, pruritus or abdominal pain were more pronounced in these who developed CCA, this relation was not seen when these patients were excluded from the analysis. Also, patients who developed CCA suffered from ulcerative colitis significantly longer than those who did not (17.4 years vs. 9 years). More recently a Dutch study found the 10 and 20 year rate of CCA in patients with PSC to be of 9% and 9%, respectively (Claessen et al. 2009a). Detailed description of diagnosis, staging and treatment of CCA is not an aim of this chapter. Authors would recommend recent review on it by Blechacz and Gores (Blechacz and Gores 2008).

5.2 Other Malignancies in PSC

5.2.1 Colorectal Cancer

An increased risk of colorectal dysplasia and cancer in patients with PSC and IBD has been demonstrated in several studies with their cumulative risk being 9, 31 and 50% after 10, 20 and 25 years as compared to 2, 5 and 10%, respectively for




Fig. 2 Processes involved in the pathogenesis of cholangiocarcinoma in PSC (detailed description in the text). Inflammation and cholestasis with accumulation of several toxic agents lead to activation of various signaling cascades promoting inhibition of apoptosis, proliferation and mutagenesis of biliary epithelial cells. Abbreviations: interleukin-6 (IL-6), mitogen activated protein kinases (MAPK); inducible nitric oxide synthase (iNOS); reactive nitrogen oxide species (RNOS); cyclooxygenase-2 (COX-2); epidermal growth factor receptor (EGFR)

patients with UC only (Broome et al. 1995). In patients who underwent liver transplantation for PSC cumulative risk of developing colonic cancer was 14 and 17% after 5 and 10 years, respectively as compared to 0% at 10 years in these who have PSC without IBD (Vera et al. 2003). The natural history of colitis seems to be different in patients with PSC where it presents itself more frequently as pancolitis with less active course (Joo 2009). Thus the duration of colitis may be longer in these subjects, increasing the risk of colorectal carcinogenesis (Sokol et al. 2008). Also colonic cancer in patients with PSC and IBD is more frequently localised to the right colon (Claessen et al. 2009b). It is now widely recommended that patients with PSC and IBD should undergo colonoscopies on an annual basis (Kitiyakara and Chapman 2008). Those who do not have symptoms of colitis should undergo initial colonoscopy at their diagnosis of PSC but no clear guidelines exist as to the further follow-up in this subgroup of patients.

5.2.2 Gallbladder Cancer

When compared to general population, gallbladder polyps represent an increased risk of neoplastic transformation in patients with PSC, with as many as 57% of polyps found malignant in one series (Buckles et al. 2002). In another study, gallbladder adenocarcinomas were found in 14% of patients with PSC and an increased risk of gallbladder neoplasia in subjects with coexisting IBD or intra-hepatic biliary cancer was also observed (Lewis et al. 2007). Thus regular examination of the gallbladder in PSC patients has been recently suggested and cholecystectomy recommended when gallbladder lesion is found, regardless of its diameter (Said et al. 2008).

5.2.3 Other Malignancies in PSC

Increased risk of two other gastrointestinal tract tumours, namely pancreatic (standard incidence ratio 9.7) and stomach cancer (standard incidence ratio 2.5) were observed in a large study from Sweden comprising more than 600 patients with PSC (Bergquist et al. 2002).

5.3 Chemoprevention

In patients with PSC and UC colonic cancer is more frequently localised to the right side of the colon suggesting a potential pathogenic role of agents to which proximal colon is exposed first. Among good candidates are secondary bile salts such as deoxycholate, a metabolite of primary bile salt (cholate), synthesised in the gut after the exposure of cholate to intestinal bacteria. Deoxycholate has a well proven toxic and cancerogenic properties (Bernstein et al. 2005; Rosignoli et al. 2008). In this context, a potential, chemopreventive role of UDCA, a hydrophilic, secondary bile acid, commonly prescribed in PSC may be of importance. UDCA expresses several hepatoprotective properties not only by replacing toxic bile salts from a total bile acid pool but also inducing choleresis by triggering various intracellular signalling pathways (Paumgartner and Beuers 2004; Beuers et al. 2001; Milkiewicz et al. 1999, 2002; Wimmer et al. 2008). Our recent study applying gene array technique showed that UDCA is a potent modulator of genes involved in cell cycle and apoptosis (Chen et al. 2008). In terms of a potential chemopreventive effect of UDCA on the development of CCA the literature is equivocal (Olsson et al. 2005; Brandsaeter et al. 2004) but certainly it is affected by the fact that majority of CCA manifests itself shortly after the diagnosis of PSC thus the preventive effect of UDCA is difficult to prove. However, clear trends towards positive effect of UDCA have been seen by some authors with one study showing that no single case of CCA has been diagnosed in patients treated with UDCA longer than 8 years (Rudolph et al. 2007). More convincing evidence exists for chemoprevention of UDCA on colonic cancer (Wolf et al. 2005; Tung et al. 2001; Pardi et al. 2003). Additionally, these data is strengthened by the study on patients with another chronic, cholestatic liver condition, PBC where significant reduction of colonic polyps was observed in

Table 1 Studies on chemoprevention with ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC)

Author/year of publication	Tumour/lesion	Type of study	Results/conclusions
Tung et al. 2001	Colonic dysplasia	Cross-sectional	Significant decrease of colonic dysplasia in patients using UDCA
Pardi et al. 2003	Colonic dysplasia/cancer	Prospective	Significant reduction of the risk of colonic dysplasia/cancer in patients taking UDCA
Wolf et al. 2005	Colonic dysplasia/cancer	Retrospective	1. Not significant reduction of the incidence of colonic dysplasia/cancer in patients taking UDCA 2. Significant reduction of overall mortality in patients taking UDCA
Brandsaeter et al. 2004	Hepatobiliary tumours	Prospective	Increased risk of hepatobiliary cancers in patients who did not take UDCA
Olsson et al. 2005	CCA	Randomised, placebo-controlled	Not significant effect of high dose of UDCA on the incidence of CCA but study did not reach an enrolment target
Rudolph et al. 2007	CCA	Prospective	Annual incidence of CCA lower than expected in patients taking UDCA

these who took UDCA (Serfaty et al. 2003). Literature data on the chemopreventive studies with UDCA in patients with PSC is summarised in Table 1.

5.4 Treatment

5.4.1 Medical

Historically, several agents have been assessed for the treatment in PSC. These include colchicine, cyclosporine A, methotrexate, *D*-penicillamine, budesonide, mycophenolate mofetil, pentoxifylline, pirfenidone, tacrolimus and prednisone (Cullen and Chapman 2006). Almost all these therapies are now considered ineffective or associated with significant side effects. The only exception is perhaps steroids. Boberg et al. (2003) have shown that a subgroup of patients with PSC may benefit from steroids in terms of long-term survival. They comprised a group of young subjects with significantly higher levels of ALT and some histological features of AIH. Nevertheless, all subjects from these study had their PSC confirmed with cholangiography.

Ursodeoxycholic acid (UDCA) has been widely used in patients with PSC however recent study has shown that long-term, high-dose therapy with this compound did not improve survival and was in fact associated with higher rates of

serious adverse events (Lindor et al. 2009). Following these findings American Association for the Study of Liver Disease (AASLD) has recommended against using UDCA in patients with PSC (Chapman et al. 2010) and most recent European Association for the Study of Liver Disease (EASL) Guidelines suggested that UDCA may be used in patients with PSC but in these who also suffer from advanced colitis (EASL Clinical Practice Guidelines 2009). Despite these controversies many experts may still consider using UDCA in a lower dose (13–15mg/kg b.w.) recommended in patients with PBC (Chapman 2009).

A recent, pilot study showed a significant improvement of alkaline phosphatase and Mayo risk score in patients treated with minocycline (Silveira et al. 2009). This effect was attributed to anti-inflammatory and immunomodulatory rather than antimicrobial properties of minocycline. Certainly, these results have to be validated in larger cohorts of patients.

Major steps in our understanding of the pathogenesis of cholestasis and elucidation of the role of nuclear orphan receptors such as PXR, FXR, VDR, CAR or PPAR may have an important therapeutic consequences in future, however at this point the data is limited to experimental works on laboratory animals (Beuers et al. 2009).

5.4.2 Endoscopic

Endoscopic treatment plays an important role in the management of patients with PSC. Unfortunately, due to a lack of randomised studies comparing different endoscopic approaches no guidelines on applying therapeutic endoscopy in PSC exist. In principle, endoscopy is of particular use in restoring a bile flow in patients who developed a dominant stricture, especially in a common bile duct. Most commonly this can be managed with either balloon dilatation or stenting (Bjornsson et al. 2004; Bjornsson and Olsson 2004; Baluyut et al. 2001). As CCA may manifest itself as a dominant stricture material for cytology and if possible histology should be taken during the procedure (Weismuller et al. 2008). A recent, retrospective study on a large cohort of patients treated endoscopically showed that their survival at 3 and 4 years was significantly better than the one predicted by Mayo model (Gluck et al. 2008).

5.4.3 Liver Transplantation

PSC is a good indication for liver transplantation however the timing of the operation poses a significant challenge. This is mostly due to the high risk of CCA which once developed is a contraindication for the transplantation in a majority of centres. Patients with PSC usually comprise a population of relatively young and frequently clinically stable subjects thus liver transplantation on the grounds of the fact that 10–15% of them will develop CCA is not justified. As effective surveillance for CCA does not exist the decision of transplantation is difficult. There is no doubt that patients with recurrent episodes of cholangitis in whom endoscopic management is not effective are good candidates. Patients with Candida positive bile cultures may be at particular risk and should be referred for liver

transplantation early (Rudolph et al. 2009). Also those who developed liver cirrhosis with features of end stage liver disease should be considered for transplantation according to the same principles applied in other patients with cirrhosis. On occasion, intractable pruritus can be in itself an indication for surgery, but this is more common in PBC than in PSC.

A recent study, based on UNOS database obtained between 1995 and 2006 showed that despite the constant increase of the overall number of liver transplants in the US, the number of transplants for PSC showed no change over the analysed period (Lee et al. 2007). Interestingly, a clear trend towards a decrease of placing patients with PSC on the waiting list was seen. Interpretation of these phenomena is difficult as the static number of transplants performed for PSC may be related to the low MELD (Model of End Stage Liver Disease) scores of these patients and, in terms of numbers on the waiting list, it may reflect better pre-transplant treatment (UDCA, endoscopic methods). Prognosis after transplantation is favourable with 5 and 10 years survivals of 79 and 78% (European liver transplant registry 2009). PSC may recur after surgery in up to 37% of patients. Data are accumulating that the presence of intact colon poses a significant risk of the recurrence. Vera et al. (2002) have shown that cumulative, 10 years risk of PSC recurrence after grafting in patients in whom their colons were removed before or during transplantation was 0.1 as compared to 0.7 in those who had their colons intact. They also showed that in small number of patients, recurrence may lead to graft loss and re-grafting. These findings have been recently confirmed by the same group on a significantly larger cohort of patients (Alabraba et al. 2009).

As already mentioned, the presence of CCA is a clear contraindication for transplantation in PSC. However, authors from Mayo Clinic designed protocols which include meticulous staging and neoadjuvant chemoradiation which permit transplantation in carefully selected patients with PSC and CCA reaching 5 years survivals in 82% of patients as compared to 21% in these who underwent resection (Rea et al. 2005).

References

- Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ (2008) Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. *Hepatology* 47(3):949–957
- Alabraba E, Nightingale P, Gunson B et al (2009) A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. *Liver Transpl* 15(3):330–340
- Al-Harthy N, Kumagi T, Parasar S, Coltescu C, Heathcote EJ, Hirschfield GM (2009) High prevalence of fatigue in patients with sclerosing cholangitis. *J Hepatol* 50:S241
- Angulo P, Peter JB, Gershwin ME et al (2000) Serum autoantibodies in patients with primary sclerosing cholangitis. *J Hepatol* 32(2):182–187
- Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N (2001) Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. *Gastrointest Endosc* 53(3):308–312
- Bambha K, Kim WR, Talwalkar J et al (2003) Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. *Gastroenterology* 125(5):1364–1369

- Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD (2009) Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. *Am J Gastroenterol* 104(4):855–860
- Bergquist A, Ekblom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. *J Hepatol* 36(3):321–327
- Bergquist A, Lindberg G, Saarinen S, Broome U (2005) Increased prevalence of primary sclerosing cholangitis among first-degree relatives. *J Hepatol* 42(2):252–256
- Bergquist A, Montgomery SM, Bahmanyar S et al (2008) Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. *Clin Gastroenterol Hepatol* 6(8):939–943
- Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H (2005) Bile acids as carcinogens in human gastrointestinal cancers. *Mutat Res* 589(1):47–65
- Beuers U, Bilzer M, Chittattu A et al (2001) Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. *Hepatology* 33(5):1206–1216
- Beuers U, Kullak-Ublick GA, Pusch T, Rauws ER, Rust C (2009) Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? *Clin Rev Allergy Immunol* 36(1):52–61
- Bjornsson E, Olsson R (2004) Dominant strictures in patients with primary sclerosing cholangitis-revisited. *Am J Gastroenterol* 99(11):2281
- Bjornsson E, Boberg KM, Cullen S et al (2002) Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. *Gut* 51(5):731–735
- Bjornsson E, Simren M, Olsson R, Chapman RW (2004a) Fatigue in patients with primary sclerosing cholangitis. *Scand J Gastroenterol* 39(10):961–968
- Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R (2004b) Dominant strictures in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 99(3):502–508
- Bjornsson E, Olsson R, Bergquist A et al (2008) The natural history of small-duct primary sclerosing cholangitis. *Gastroenterology* 134(4):975–980
- Blechacz B, Gores GJ (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. *Hepatology* 48(1):308–321
- Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. *Scand J Gastroenterol* 33(1):99–103
- Boberg KM, Bergquist A, Mitchell S et al (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. *Scand J Gastroenterol* 37(10):1205–1211
- Boberg KM, Egeland T, Schrupp E (2003) Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. *Scand J Gastroenterol* 38(9):991–995
- Brandsaeter B, Isoniemi H, Broome U et al (2004) Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. *J Hepatol* 40(5): 815–822
- Broome U, Lofberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. *Hepatology* 22(5):1404–1408
- Buckles DC, Lindor KD, LaRusso NF, Petrovic LM, Gores GJ (2002) In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. *Am J Gastroenterol* 97(5):1138–1142
- Burak KW, Angulo P, Lindor KD (2003) Is there a role for liver biopsy in primary sclerosing cholangitis? *Am J Gastroenterol* 98(5):1155–1158
- Card TR, Solaymani-Dodaran M, West J (2008) Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. *J Hepatol* 48(6):939–944
- Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010) Diagnosis and management of primary sclerosing cholangitis. *Hepatology* 51:660–678
- Chapman RW (2009) High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? *Hepatology* 50:671–673

- Chen L, Borozan I, Milkiewicz P et al (2008) Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. *Liver Int* 28(7):997–1010
- Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR (2009a) High lifetime risk of cancer in primary sclerosing cholangitis. *J Hepatol* 50(1):158–164
- Claessen MM, Lutgens MW, van Buuren HR et al. (2009b) More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. *Inflamm Bowel Dis* 15(9):1331–1336.
- Cullen SN, Chapman RW (2006) The medical management of primary sclerosing cholangitis. *Semin Liver Dis* 26(1):52–61
- Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW (2008) High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. *J Hepatol* 48(5):792–800
- EASL (2009) Clinical Practice Guidelines: Management of cholestatic liver diseases. *J Hepatol* 51:2009 237–267
- Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE (2002) ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. *Hepatology* 36(2):439–450
- European liver transplant registry 2009. <http://www.eltr.org>
- Farkkila M, Karvonen AL, Nurmi H et al (2004) Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. *Hepatology* 40(6): 1379–1386
- Fava G, Marucci L, Glaser S et al (2005) Gamma-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. *Cancer Res* 65(24):11437–11446
- Fox JG, Dewhirst FE, Shen Z et al (1998) *Hepatic Helicobacter* species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. *Gastroenterology* 114(4):755–763
- Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA (2008) A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. *J Clin Gastroenterol* 42(9):1032–1039
- Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH (2001) MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). *Hepatology* 33(5):1065–1072
- Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH (2002) Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. *Lancet* 359(9301):150–157
- Gregorio GV, Portmann B, Karani J et al (2001) Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16 year prospective study. *Hepatology* 33(3):544–553
- Han C, Leng J, Demetris AJ, Wu T (2004) Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. *Cancer Res* 64(4):1369–1376
- Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. *Am J Gastroenterol* 96(5):1558–1562
- Isomoto H, Mott JL, Kobayashi S et al (2007) Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. *Gastroenterology* 132(1): 384–396
- Joo M, Abreu-e-Lima P, Farraye F et al (2009) Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. *Am J Surg Pathol* 33(6):854–862
- Kahana DD, Cass O, Jessurun J, Schwarzenberg SJ, Sharp H, Khan K (2003) Sclerosing cholangitis associated with trichosporon infection and natural killer cell deficiency in an 8-year-old girl. *J Pediatr Gastroenterol Nutr* 37(5):620–623

- Kanno N, Lesage G, Phinizy JL, Glaser S, Francis H, Alpini G (2002) Stimulation of alpha 2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. *Hepatology* 35(6):1329–1340
- Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS (2007) The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *Am J Gastroenterol* 102(5):1042–1049
- Khan SA, Toledano MB, Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. *HPB (Oxford)* 10(2):77–82
- Kitiyakara T, Chapman RW (2008) Chemoprevention and screening in primary sclerosing cholangitis. *Postgrad Med J* 84(991):228–237
- Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ (2005) Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. *Gastroenterology* 128(7):2054–2065
- Kono K, Ohnishi K, Omata M et al (1988) Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic *Escherichia coli* in rabbits. *Gastroenterology* 94(3):787–796
- Kulaksiz H, Rudolph G, Kloeters-Plachky P, Sauer P, Geiss H, Stiehl A (2006) Biliary candida infections in primary sclerosing cholangitis. *J Hepatol* 45(5):711–716
- Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N (2007) Transplantation trends in primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 5(11):1313–1315
- Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC (2007) Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. *Am J Surg Pathol* 31(6):907–913
- Lichtman SN, Sartor RB, Keku J, Schwab JH (1990) Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. *Gastroenterology* 98(2):414–423
- Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology* 50:808–814
- Milkiewicz P, Heathcote EJ (2004) Fatigue in chronic cholestasis. *Gut* 53(4):475–477
- Milkiewicz P, Mills CO, Roma MG, Ahmed-Choudhury J, Elias E, Coleman R (1999) Tauroursodeoxycholate and S-adenosyl-L-methionine exert an additive ameliorating effect on tauroolithocholate-induced cholestasis: a study in isolated rat hepatocyte couplets. *Hepatology* 29(2):471–476
- Milkiewicz P, Roma MG, Cardenas R, Mills CO, Elias E, Coleman R (2001) Effect of tauroursodeoxycholate and S-adenosyl-L-methionine on 17 beta-estradiol glucuronide-induced cholestasis. *J Hepatol* 34(2):184–191
- Milkiewicz P, Roma MG, Elias E, Coleman R (2002a) Pathobiology and experimental therapeutics in hepatocellular cholestasis: lessons from the hepatocyte couplet model. *Clin Sci (Lond)* 102(6):603–614
- Milkiewicz P, Roma MG, Elias E, Coleman R (2002b) Hepatoprotection with tauroursodeoxycholate and beta muricholate against tauroolithocholate induced cholestasis: involvement of signal transduction pathways. *Gut* 51(1):113–119
- Norris S, Kondatis E, Collins R et al (2001) Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. *Gastroenterology* 120(6):1475–1482
- O'Mahony CA, Vierling JM (2006) Etiopathogenesis of primary sclerosing cholangitis. *Semin Liver Dis* 26(1):3–21
- Okuda K, Nakanuma Y, Miyazaki M (2002) Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. *J Gastroenterol Hepatol* 17(10):1049–1055
- Olsson R, Hagerstrand I, Broome U et al (1995) Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. *J Clin Pathol* 48(10):933–935
- Olsson R, Björnsson E, Backman L et al (1998) Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. *J Hepatol* 28(3):426–432

- Olsson R, Boberg KM, de Muckadell OS et al (2005) High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5 year multicenter, randomized, controlled study. *Gastroenterology* 129(5):1464–1472
- Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterology* 124(4):889–893
- Park J, Tadlock L, Gores GJ, Patel T (1999) Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. *Hepatology* 30(5):1128–1133
- Paumgartner G, Beuers U (2004) Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. *Clin Liver Dis* 8(1):67–81 vi.
- Rea DJ, Heimbach JK, Rosen CB et al (2005) Liver transplantation with neoadjuvant chemotherapy is more effective than resection for hilar cholangiocarcinoma. *Ann Surg* 242(3):451–458
- Rosignoli P, Fabiani R, De BA, Fuccelli R, Pelli MA, Morozzi G (2008) Genotoxic effect of bile acids on human normal and tumour colon cells and protection by dietary antioxidants and butyrate. *Eur J Nutr* 47(6):301–309
- Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A (2007) The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. *Eur J Gastroenterol Hepatol* 19(6):487–491
- Rudolph G, Gotthardt D, Kloeters-Plachky P, Kulaksiz H, Rost D, Stiehl A (2009) Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. *J Hepatol* 51(1):149–155
- Said K, Glaumann H, Bergquist A (2008) Gallbladder disease in patients with primary sclerosing cholangitis. *J Hepatol* 48(4):598–605
- Sampson LK, Vickers SM, Ying W, Phillips JO (1997) Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. *Cancer Res* 57(9):1743–1749
- Selmi C, Balkwill DL, Invernizzi P et al (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. *Hepatology* 38(5):1250–1257
- Serfaty L, De LA, Rosmorduc O et al (2003) Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. *Hepatology* 38(1):203–209
- Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. *Semin Liver Dis* 24(2):115–125
- Silveira MG, Torok NJ, Gossard AA et al (2009) Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. *Am J Gastroenterol* 104(1):83–88
- Sokol H, Cosnes J, Chazouilleres O et al (2008) Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. *World J Gastroenterol* 14(22):3497–3503
- Spurkland A, Saarinen S, Boberg KM et al (1999) HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. *Tissue Antigens* 53(5):459–469
- Terjung B, Spengler U (2005) Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. *Clin Rev Allergy Immunol* 28(2):115–133
- Terjung B, Spengler U (2009) Atypical p-ANCA in PSC and AIH: a hint toward a “leaky gut”? *Clin Rev Allergy Immunol* 36(1):40–51
- Tung BY, Emond MJ, Haggitt RC et al (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Ann Intern Med* 134(2):89–95
- Vera A, Moledina S, Gunson B et al (2002) Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. *Lancet* 360(9349):1943–1944
- Vera A, Gunson BK, Ussatoff V et al (2003) Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. *Transplantation* 75(12):1983–1988

- Watanapa P (1996) Cholangiocarcinoma in patients with opisthorchiasis. *Br J Surg* 83(8):1062–1064
- Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP (2008) The challenges in primary sclerosing cholangitis—etiopathogenesis, autoimmunity, management and malignancy. *J Hepatol* 48(Suppl 1):S38–S57
- Werneburg NW, Yoon JH, Higuchi H, Gores GJ (2003) Bile acids activate EGF receptor via a TGF- α -dependent mechanism in human cholangiocyte cell lines. *Am J Physiol Gastrointest Liver Physiol* 285(1):G31–G36
- Wimmer R, Hohenester S, Pustl T, Denk GU, Rust C, Beuers U (2008) Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC α -/PKA-dependent mechanism in rat liver. *Gut* 57(10):1448–1454
- Wise C, Piliathananon M, Perry BF, Alpini G, McNeal M, Glaser SS (2008) Mechanisms of biliary carcinogenesis and growth. *World J Gastroenterol* 14(19):2986–2989
- Wolf JM, Rybicki LA, Lashner BA (2005) The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. *Aliment Pharmacol Ther* 22(9):783–788
- Yokomuro S, Lunz JG III, Sakamoto T, Ezure T, Murase N, Demetris AJ (2000) The effect of interleukin-6 (IL-6)/gp 130 signalling on biliary epithelial cell growth, in vitro. *Cytokine* 12(6):727–730

Chronic Inflammation and Hepatocellular Carcinoma

Malcolm R. Alison, Linda J. Nicholson and Wey-Ran Lin

Abstract

Hepatocellular carcinoma (HCC) invariably develops within a setting of chronic inflammation caused by either hepatotropic viruses, toxins, metabolic liver disease or autoimmunity. Mechanisms that link these two processes are not completely understood, but transcription factors of the NF- κ B family and signal transducer and activator of transcription 3 (STAT3), cytokines such as IL-6 and IL-1 α and ligands of the epidermal growth factor receptor (EGFR) family are clearly pivotal players. HCC may have its origins in either hepatocytes or hepatic progenitor cells (HPCs), and HCCs, like other solid tumours appear to be sustained by a minority population of cancer stem cells.

Keywords

Cell senescence · Chronic inflammation · STAT3 · NF- κ B · Fibrosis · Cirrhosis · Hepatic progenitor cells · Hepatocytes · Oval cells · Stem cells

Contents

1	Introduction.....	136
2	Hepatitis B virus.....	136
3	Hepatitis C virus.....	138

M. R. Alison (✉) · W.-R. Lin
Centre for Diabetes, Barts and The London School of Medicine and Dentistry,
BICMS, 4 Newark Street, London, E1 2AT, UK
e-mail: m.alison@qmul.ac.uk

L. J. Nicholson
Division of Cancer Studies, King's College London, London, UK

W.-R. Lin
Chang Gung Memorial Hospital, Chang Gung University College, Taipei, Taiwan

J. A. Z. Jankowski (ed.), *Inflammation and Gastrointestinal Cancers*,
Recent Results in Cancer Research 185, DOI: 10.1007/978-3-642-03503-6_8,
© Springer-Verlag Berlin Heidelberg 2011

4	Signalling Pathways Linking Inflammation and HCC Development	138
5	Obesity	142
6	Liver Regeneration and Carcinogenesis	143
7	Conclusions.....	146
	References.....	146

1 Introduction

Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide and the 3rd most common cause of cancer death with approximately 600,000 deaths annually. Most HCCs (70–90%) arise in a cirrhotic liver, i.e., a situation where there has been repetitive hepatocyte damage leading to regenerative hyperplasia and chronic inflammation (hepatitis) leading to fibrosis and cirrhosis (Fig. 1) (Schutte et al. 2009; Neuveut et al. 2010). Hepatic fibrosis leading to cirrhosis is the liver's connective tissue response to iterative hepatocyte injury, mediated by activated hepatic stellate cells (Bataller and Brenner 2005). Both HBV and HCV infection cause increased hepatic production of Hh ligands that can stimulate stellate cells to produce collagen and hepatic progenitor cells (HPCs) to divide (Pereira et al. 2010). Cell proliferation is of course a necessary pre-requisite for successful tumour initiation, which together with inflammation-induced oxidative stress makes a fertile background for genomic mutation. There are huge geographical variations in the incidence of HCC, with the highest incidence in areas such as Eastern Asia and sub-Saharan Africa where chronic hepatitis B virus (HBV) infection is a major risk factor (Brechot 2004). In Europe and the USA, the incidence of HCC is low but slowly increasing, probably due to the rise in people infected with HCV. Apart from hepatotropic viruses, the other major risk factors for HCC are other factors leading to cirrhosis such as alcohol abuse and metabolic liver disease, and mutagens such as aflatoxins that are toxic metabolites of the food mould *Aspergillus species*.

Cholangiocarcinomas (CC) are believed to arise from biliary epithelium that is either within the liver (intrahepatic) or extrahepatic. The tumour is much less common than HCC, but its incidence and associated mortality has been increasing steadily over the past 2–3 decades, with most tumours arising in persons over 50 years of age, suggesting carcinogenesis is a protracted and (possibly) multistep process (Sirica 2005). Injury to the biliary epithelium with chronic inflammation, together with impedance of bile flow, are common factors in high-risk conditions for CC such as primary sclerosing cholangitis, hepatolithiasis (gall stones) and liver fluke infestation by *Opisthorchis viverrini* and *Clonorchis sinensis*.

2 Hepatitis B virus

Worldwide, Hepatitis B virus (HBV) infection is a major problem with between 350 and 400 million people chronically infected. After acute hepatitis B infection, about 90% of adults achieve complete immune clearance of the virus, but 10%




Fig. 1 Simplified overview of events leading to HCC development

develop chronic infection. Viral hepatitis plays a key role in up to 80% of all HCC, with HBV being responsible for two-thirds of all cases. Areas of high risk for HCC are mostly endemic for HBV, though the relevance of HBV infection is waning with the introduction of universal prophylactic vaccination programmes for infants, pioneered in Taiwan. Chronic active hepatitis occurs because viral hepatitis B surface antigen (HBsAg) is expressed on the hepatocyte's cell surface, stimulating the host's immune system and triggering inflammation thus generating reactive oxygen species (ROS) leading to oxidative DNA damage (Hussain et al. 2003), probably the main factor driving liver carcinogenesis (Kremsdorf et al. 2006; Brechot et al. 2010). Nuclear factor erythroid2-related factor (Nrf2), the transcription factor that positively up-regulates the expression of a large number of cytoprotective genes (detoxifying enzymes, biotransformation enzymes and transporters) by binding to antioxidant response elements, protects liver cells from such oxidative/electrophilic stress (Klaassen and Reisman 2010).

The carcinogenic process will of course be aided by a host of chemokines and cytokines produced by the inflammatory cell infiltrate that foster cell survival and proliferation (Coussens and Werb 2002). Other drivers of the carcinogenic process may well include direct viral DNA integration into the host genome leading to the likes of genomic instability, chromosomal loss and inappropriate gene activation (insertional mutagenesis) (reviewed in Brechot et al. 2010), while the virally encoded pleiotropic Hepatitis B virus X protein (HBx) has been implicated in anti-apoptotic pathways by blocking p53 function and transactivating promoters and enhancers with NF- κ B binding sites. HBx also causes DNA re-replication by de-regulating expression of the DNA replication licensing factors Cdt1 and Cdc6, and geminin, the inhibitor of re-replication, so leading to an aberrant DNA content that propagates genomic instability and up-regulation of cell cycle genes such as the mitotic kinase called polo-like kinase (Plk1) (Studach et al. 2009), whose activity is required for entry into mitosis. The importance of these mechanisms other than the immune response to HbsAg in the carcinogenic process is illustrated by the fact that patients who spontaneously clear HBsAg can still develop HCC many years later, albeit at a lower rate than persistent carriers (Simonetti et al. 2010).

Treatments that delay or block disease progression include interferons and anti-viral nucleoside analogues that block viral DNA replication.

3 Hepatitis C virus

Globally, 25% of HCC deaths can be attributed to Hepatitis C virus (HCV) (McGivern and Lemon 2009). In contrast to HBV-associated HCC, HCV-associated HCC has been increasing steadily since the 1960s mainly because of contaminated blood supplies and widespread intravenous drug abuse (shared syringe needles). HCV is the leading cause of end-stage liver disease worldwide and the most common indication for liver transplantation in the United States and Europe. Unlike HBV-associated acute hepatitis, acute hepatitis C resolves in only about 10–40% of cases and effective vaccination against HCV is currently not available. The sequelae of histological changes are broadly similar to those associated with HBV infection, namely hepatocyte death, inflammation, steatosis and progressive fibrosis leading to cirrhosis and HCC, thus regenerative hyperplasia in the setting of oxidative stress leading to DNA damage is likely to be a major cause of malignant transformation (reviewed in Bartosch et al. 2009; Castello et al. 2010). The HCV genome is a single stranded RNA molecule of approximately 9600 nucleotides in length, but lacks a reverse-transcriptase, so with no DNA intermediate, does not integrate into the host genome, so mechanisms of hepatocarcinogenesis by HCV proteins are likely to be indirect, perhaps activating cell signalling pathways such as STAT3, PI3 K and NF- κ B or by direct interaction with key cell cycle regulators such as pRb and p53. In HCV core transgenic mice, both spontaneous and diethylnitrosamine (DEN)-induced HCC hepatocarcinogenesis can be effectively abolished by knockdown of c-Jun (AP-1) and STAT3, transcription factors that are collectively required for stimulating cell proliferation, suppressing apoptosis and impairing oxidative DNA damage repair (Machida et al. 2010). Additionally there are many pro-carcinogenic co-factors such as co-infection with HBV, obesity linked to non-alcoholic steatohepatitis (NASH) and insulin resistance that lead to more inflammation favouring hepatocarcinogenesis. In a murine model of HCV hepatocarcinogenesis, enteric bacteria promote tumourigenesis related to NF- κ B signalling in both the intestine and liver, seemingly associated with activation of the innate and Th1-type adaptive immunity (Fox et al. 2010). Treatments for HCV infection centre on pegylated interferon- α and ribavirin (a nucleoside analogue) that interfere with viral replication among other things.

4 Signalling Pathways Linking Inflammation and HCC Development

Apart from infectious agents with their own transforming oncoproteins, bacteria and viruses can activate cells of the innate immune system (particularly macrophages) through pattern recognition receptors (PRRs), specifically those belonging




Fig. 2 Some of the intracellular signaling pathways linking hepatocyte cell death with inflammatory cells and hepatocyte survival and proliferation. COX-2, cyclooxygenase 2; MMPs, matrix metalloproteinases; SOD, superoxide dismutase (see text for further details)

to the Toll-like receptor (TLR) family. Receptor occupancy triggers the production of chemokines and cytokines to amplify the response, while others, notably IL-6 and TNF- α can stimulate normal and malignant liver cell proliferation (Fig. 2).

Among the signalling pathways, the one controlled by NF- κ B appears pre-eminent. NF- κ B can be activated downstream of TLRs through the adaptor molecule, myeloid differentiation primary response gene 88 (MyD88) or by TNF- α or IL-1 β . NF- κ B provides a mechanistic link between inflammation and cancer, being a major factor in determining the ability of normal, preneoplastic and malignant cells to avoid apoptosis (Karin and Greten 2005; Karin 2006; Elsharkawy and Mann 2007). Before stimulation most NF- κ B dimers are retained in the cytoplasm bound to specific inhibitors—the inhibitors of NF- κ Bs (I κ Bs) (Moynagh 2005) (Fig. 3). Cell stimulation activates the I κ B kinase (the IKK complex) composed of two catalytic subunits (IKK α and IKK β) and a regulatory subunit (IKK γ /NEMO). Activated IKK phosphorylates the NF- κ B-bound I κ B protein, targeting it for polyubiquitination and ultimately proteasomal destruction; freed NF- κ B dimers translocate to the nucleus where they coordinate transcriptional activation of several hundred target genes.

A prototype of inflammation-associated HCC is the *Mdr2*^{-/-} mouse with homozygous deletion of the multidrug resistance 2 gene that encodes a P-glycoprotein. This animal model develops cholestatic hepatitis leading to dysplasia and eventually




Fig. 3 Simplified diagram illustrating just one of the pathways involved in promoting NF- κ B signaling

HCC after 8–10 months, and here TNF- α produced by adjacent inflammatory cells and endothelial cells leads to up-regulation of NF- κ B signalling in hepatocytes, thereby promoting HCC formation, while an anti-TNF α treatment suppressed HCC formation (Pikarsky et al. 2004). The pro-tumourigenic effect of NF- κ B appeared to be related to a suppression of apoptosis in premalignant and malignant hepatocytes through up-regulation of inhibitors of apoptosis such as Bcl-X_L and IAPs. Tumour development could also be blocked by over-expression of the degradation-resistant form of the so-called I κ B super repressor.

However, while NF- κ B inactivation late on in the process of tumour progression appears to **impede** growth because the tumour cells need the pathway for cell survival, inactivation of the pathway at an early stage in some models actually **promotes** hepatocarcinogenesis, seemingly because normal hepatocytes are now more sensitive to apoptosis which triggers a compensatory hyperplasia under inflammatory and oxidative stress, thus increasing the risk of malignant transformation. For example, mice (*Nemo/Ikk γ ^{Δhep}*) lacking IKK γ /NEMO, the regulatory subunit of the upstream kinase, have spontaneous liver damage, with enhanced steatohepatitis and HCC development (Luedde et al. 2007). Likewise, mice lacking IKK β specifically in hepatocytes (*Ikk β ^{Δhep}* mice) also show enhanced HCC formation following DEN exposure, thought to be linked to increased ROS production, more hepatocyte death and thus more regenerative hyperplasia (Maeda et al. 2005). In both these latter two murine models, liver injury is a key event, and

with hepatocyte-specific deletion of IKK γ /NEMO it appears that this is mediated by NK cell damage via TRAIL/DR5 signalling leading to the familiar cascade of cellular events, inflammation, steatohepatitis, fibrosis, cirrhosis and HCC development (Beraza et al. 2009). On the other hand, in the *Mdr*^{-/-} mouse, HCC development depends on low-grade chronic inflammation with no liver injury, and in this situation NF- κ B signalling is pro-tumourigenic, however if hepatocyte injury is superimposed upon this model by a two-thirds partial hepatectomy then long-term tumourigenesis is enhanced, probably because hepatocytes harbouring DNA damage replicate increasing genomic instability (Barash et al. 2010).

An equally important inflammation-associated signalling pathway is that controlled by STAT3 triggered by cytokines such as IL-6 that bind to cytokine receptor-associated Janus family kinases (JAKs). The pathway is negatively regulated through transcriptional up-regulation of SOCS3 (suppressor of cytokine signaling 3), a molecule that prevents further interaction of JAKs with STAT3, thus blocking further JAK-mediated phosphorylation (activation) of STAT3. The importance of STAT3 to inflammation-associated hepatocarcinogenesis is illustrated by the fact that hepatocyte-specific deletion of SOCS3 in a mouse model of DEN-induced HCC results in larger and more numerous tumours (Ogata et al. 2006). Interestingly, up to 60% of hepatic adenomas associated with inflammation can have gain-of-function mutations in the *IL6ST* gene that encodes the signaling co-receptor gp130 (Rebouissou et al. 2009); these mutants can activate STAT3 in the absence of ligand. IL-6/STAT3 also promotes survival in established HCC cells, and blocking STAT3 can sensitise cells to doxorubicin (Liu et al. 2010). Blocking c-Met specifically in hepatocytes also results in increased sensitivity to potentially damaging bile duct obstruction (Giebeler et al. 2009).

As highlighted, signalling via NF- κ B is complex, being anti-tumourigenic in *Nemo/Ikk γ ^{Δhep}* and *Ikk β ^{Δhep}* mice where liver injury occurs (and is needed for initiation via compensatory regeneration), but being pro-tumourigenic in *Mdr*^{-/-} mice that depend upon chronic low-grade inflammation for tumour progression. But, NF- κ B signalling can also be anti-tumourigenic in the context of tumour progression. In a further twist, NF- κ B signalling has been found to negatively regulate STAT3 by preventing accumulation of ROS (He et al. 2010). Transplanting DEN-initiated hepatocytes into a mouse liver with ongoing indigenous hepatocyte loss, it was found that deletion of IKK β in the transplanted cells caused increased accumulation of ROS leading to JNK and STAT3 activation and accelerated tumour development. As noted by the authors, human hepatocarcinogenesis is likely to involve both inflammatory and injury/regeneration responses, thus all of the above model systems probably have some relevance to human HCC development.

Other promoters of HCC development include the cytokines lymphotoxin (LT) α and β produced by CD3⁺ and CD20⁺ lymphocytes that act primarily on hepatocytes expressing the LT β R, resulting in the release of chemokines that cause an influx of inflammatory cells that then contribute to hepatocyte death. These molecules are notably up-regulated in HBV- and HCV-induced hepatitis and HCC, and LT β R inhibition in LT $\alpha\beta$ -transgenic mice with hepatitis suppresses HCC formation (Haybaeck et al. 2009). Signalling through EGFR ligands is a further




Fig. 4 **a** The principal cellular events linking obesity with the promotion of HCC development. **b** Summary of how a high fat diet (HFD) leads to liver inflammation, hepatocyte damage and compensatory hyperplasia rendering the liver at greater risk of neoplastic transformation

stimulus to the growth of premalignant and malignant hepatocytes (Berasain et al. 2009).

5 Obesity

The relative risk of death from HCC increases dramatically with obesity (men with a BMI of 35–40 have a 4.5-fold increase in relative HCC risk), particularly in those patients who develop non-alcoholic steatohepatitis (NASH) and cirrhosis. Increases in intracellular lipid puts a heavy metabolic demand on the endoplasmic reticulum (ER) leading to ER dysfunction and production of excessive ROS leading to oxidative stress and activation of inflammatory pathways (e.g., NF- κ B). Studies in mice suggest that IL-6 and TNF- α are the main molecular triggers linking obesity with hepatocarcinogenesis (Fig. 4a). Mice treated with the carcinogen diethylnitrosamine (DEN) and fed with a high fat diet (HFD) have a higher tumour burden than those fed with a normal diet after DEN injection, seemingly linked to the abnormal proliferation of hepatocytes with damaged DNA (Park et al. 2010). It was thought unlikely that this effect resulted from carcinogens or tumour promoters in the HFD since leptin-deficient mice (*Lep^{Ob}*) that spontaneously develop obesity, also had a higher tumour burden after DEN than wild-type mice when both are fed on a low fat diet. Obesity was associated with elevated levels of the inflammatory cytokines IL-6 (and associated STAT3 activation), TNF- α and IL-1 β in the liver, produced by the likes of Kupffer cells, hepatocytes and inflammatory cells, and an ingress of inflammatory cells (macrophages and neutrophils); moreover studies with IL-6 knock-out mice confirmed the requirement for IL-6 for tumour promotion in

this scenario. In turn, TNF signalling was required for IL-6 expression since TNFR1 ablation almost completely abolished obesity-induced tumour promotion, and both IL-6 and TNF were required to trigger NASH. Thus, either dietary or genetic obesity seems to be a *bona fide* liver tumour promoter, at least in mice (summarised in Fig. 4b).

6 Liver Regeneration and Carcinogenesis

In postnatal animals and humans, hepatocytes are highly differentiated cells with multiple synthetic and metabolic functions. Notwithstanding, hepatocytes are the cells that normally shoulder the burden of regenerative growth after liver damage, so they can be considered as the functional stem cells under most circumstances. Normally the liver exhibits a very low level of cell turnover, but when hepatocyte loss occurs, a rapid regenerative response is elicited from all cell types in the liver to restore the organ to its pristine state (Alison et al. 2009). More severe liver injury, particularly long-standing iterative injury in the context of chronic inflammation (e.g., chronic viral hepatitis leading to fibrosis) is often associated with replicative senescence (Marshall et al. 2005; Ikeda et al. 2009), activating a facultative stem cell compartment located within the intrahepatic biliary tree, giving rise to cords of bipotential transit amplifying cells (named oval cells in rodents and hepatic progenitor cells [HPCs] in man), that can ultimately differentiate into hepatocytes and biliary epithelial cells.

As already noted, chronic liver injury is invariably accompanied by progressive fibrosis, involving the activation of hepatic stellate cells (HpSCs) that proliferate and synthesise and secrete interstitial collagens. HpSCs express α smooth muscle actin (α -SMA), the histological hallmark of myofibroblasts, and they are thought to be the pivotal in the pathogenesis of liver fibrosis. As in other responses, Kupffer cells seem to be key cells, activating HpSCs by secretion of TGF- β , and bacterial products such as lipopolysaccharide (LPS) engage Toll-like receptors on stellate cells, down-regulating the inhibitory TGF- β pseudoreceptor Bambi, allowing unrestricted activation of HpSCs by the Kupffer cells (Seki et al. 2007). Regenerative nodules, a key feature of cirrhosis, have been traditionally considered to be formed through the simple fibrotic dissection of the liver parenchyma by the deposition of collagens, but we have proposed an alternative explanation (Lin et al. 2010). It is well recognised that the fibrotic septae in cirrhosis also harbour HPCs, derived from biliary ducts, that comprise the ductular reaction (schematically illustrated in Fig. 5a), and by using mitochondrial DNA (mtDNA) mutations in the cytochrome *c* oxidase gene as clonal markers we have found that the regenerative nodules are invariably monoclonal and derived from HPCs (Fig. 5b).

So are HPCs, the cells that are so common in circumstances of chronic inflammation in the liver, the founder cells for HCC? Certainly, hepatocytes are implicated in some instances of HCC, for example, in some mouse models of HCC, oncogenic transgenes are driven by albumin promoters. The direct involvement of hepatocytes




Fig. 5 Scheme for the development of regenerative nodules in the chronically inflamed human liver. **a** Chronic hepatocyte damage leads to the replacement of the liver parenchyma by fibrous tissue; commonly a ductular reaction composed of hepatic progenitor cells is located within these fibrous septae. **b** If these hepatic progenitor cells differentiated into hepatocytes they could form the nidus of a regenerative nodule. Hepatic progenitor cells could also be the founder cells for HCC (see text for experimental details)

in hepatocarcinogenesis has been established in rats. Gournay et al. (2002) found that some preneoplastic foci (expressing gamma glutamyl transpeptidase and the placental form of glutathione-S-transferase) were directly descended from hepatocytes. This was established by stably labelling hepatocytes at day one after a two-third partial hepatectomy (PH) with β -galactosidase using a recombinant retroviral vector containing the β -galactosidase gene; subsequent feeding with 2-acetylaminofluorene

lead to foci, some of which were composed of β -galactosidase-expressing cells. Using the same labelling protocol, Bralet et al. (2002) observed that 18% of hepatocytes expressed β -galactosidase at the completion of regeneration after a two-third PH; subsequent chronic treatment with diethylnitrosamine (DEN) resulted in many HCCs of which 17.7% of the tumours expressed β -galactosidase, leading to the conclusion that a random clonal origin of HCC from mature hepatocytes was operative in the model.

As discussed above, there is now compelling evidence that HPCs are capable of giving rise to both hepatocytes and cholangiocytes. The fact that the ductular cell reaction precedes the development of HCC in almost all models of hepatocarcinogenesis and invariably accompanies chronic liver damage in humans makes it almost certain that the mature hepatocyte is not the cell of origin of all HCCs, indeed perhaps only a small minority of HCCs are derived from mature hepatocytes. An origin of HCC from HPCs is often inferred from the fact that many tumours contain an admixture of mature cells and cells phenotypically similar to HPCs (Alison et al. 2009). Cells with an HPC phenotype have also been noted in a relatively rare subset of hepatic malignancies where there are clearly two major components, an HCC component and a cholangiocarcinoma component, again suggestive of an origin from a bipotential progenitor (Theise et al. 2003).

Direct evidence of a role for HPCs in the histogenesis of HCC can be found; Dumble et al. (2002) isolated HPCs from p53 null mice and when the cells were transplanted into athymic nude mice they produced HCCs. If tumours do arise from HPCs, then this would suggest a block in HPC differentiation, a process termed 'stem cell maturation arrest'. Along these lines of thought, in humans four prognostic subtypes of HCC have been identified, corresponding to a hierarchy of liver cell lineages (Yamashita et al. 2008). Those with the poorest prognosis possessed a sizeable proportion of either EpCAM⁺AFP⁺ cells (hepatoblast-like) or EpCAM⁻AFP⁺ cells (HPC-like), whereas those with EpCAM⁻AFP⁻ cells (mature hepatocyte-like) or EpCAM⁺AFP⁻ cells (cholangiocyte-like) had a more favourable outcome. Moreover, gene expression profiling has identified a subset of HCCs with a poor prognosis that have a profile consistent with an origin from HPCs (Lee et al. 2006), and simple enumeration of CK19-positive cells in HCC can identify a patient group who have a shorter time to disease recurrence (Durnez et al. 2006).

There is a growing realisation that many, if not all cancers contain a minority population of self-renewing stem cells, the *cancer stem cells* (CSCs) which are entirely responsible for sustaining the tumour as well as giving rise to proliferating but progressively differentiating cells that are responsible for much of the cellular heterogeneity that is so familiar to histopathologists (Alison et al. 2011). We have suggested that many liver tumours probably have their origins in normal liver stem cells, particularly HPCs, but do liver tumours have CSCs? The answer is probably yes, with CD133, CD90, ALDH and the side population being variously advocated as liver CSC markers (Alison et al. 2011).

7 Conclusions

This chapter has summarised our current knowledge of how the liver responds to chronic liver damage, regenerating after both acute and more chronic iterative damage. Under normal circumstances the differentiated parenchymal cells (hepatocytes) are the functional stem cells, but in more extreme circumstances a 'potential' stem cell compartment can be recruited into action, providing HPCs from the intrahepatic biliary system that can differentiate into hepatocytes. Most cases of HCC arise within a cirrhotic setting, a scenario associated with hepatocyte replicative senescence and HPC activation. The signaling pathways centred on NF- κ B and STAT3 appear to be central to the hepatocarcinogenic process. Observation and experimental evidence points to a possible origin of HCC from either HPCs or hepatocytes, and HCC itself appears to have a minority population of CSCs.

References

- Alison MR, Islam S, Lim S (2009) Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. *J Pathol* 217(2):282–298
- Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: problems for therapy? *J Pathol* 223(2):147–161
- Barash H, Gross E, Edrei Y, Ella E, Israel A, Cohen I et al (2010) Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. *Proc Natl Acad Sci USA* 107(5):2207–2212
- Bartosch B, Thimme R, Blum HE, Zoulim F (2009) Hepatitis C virus-induced hepatocarcinogenesis. *J Hepatol* 51(4):810–820
- Battaller R, Brenner DA (2005) Liver fibrosis. *J Clin Invest* 115(2):209–218
- Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA (2009) Inflammation and liver cancer new molecular links. *Steroid Enzymes and Cancer. Ann NY Acad Sci* 1155: 206–221
- Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D et al (2009) Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. *J Exp Med* 206(8):1727–1737
- Bralet MP, Pichard V, Ferry N (2002) Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. *Hepatology* 36:623–630
- Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. *Gastroenterology* 127(5 Suppl 1):S56–S61
- Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P et al (2010) Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms. *Pathol Biol (Paris)* 58(4):278–287
- Castello G, Scala S, Palmieri G, Curley SA, Izzo F (2010) HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. *Clin Immunol* 134(3):237–250
- Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* 420(6917):860–867
- Dumble ML, Croager EJ, Yeoh GC, Quail EA (2002) Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. *Carcinogenesis* 23:435–445
- Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J et al (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. *Histopathology* 49:138–151

- Elsharkawy AM, Mann DA (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. *Hepatology* 46(2):590–597
- Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JL, Doernte AL et al (2010) Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. *Gut* 59(1):88–97
- Giebeler A, Boekschoten MV, Klein C, Borowiak M, Birchmeier C, Gassler N et al (2009) c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. *Gastroenterology* 137(1):297–308 e1–4
- Gournay J, Auvigne I, Pichard V, Ligeza C, Bralet MP, Ferry N (2002) In vivo cell lineage analysis during chemical hepatocarcinogenesis in rats using retroviral-mediated gene transfer: evidence for dedifferentiation of mature hepatocytes. *Lab Invest* 82:781–788
- Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO et al (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. *Cancer Cell* 16(4):295–308
- He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T et al (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. *Cancer Cell* 17(3):286–297
- Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. *Nat Rev Cancer* 3(4):276–285
- Ikeda H, Sasaki M, Sato Y, Harada K, Zen Y, Mitsui T et al (2009) Large cell change of hepatocytes in chronic viral hepatitis represents a senescent-related lesion. *Hum Pathol* 40(12):1774–1782
- Karin M (2006) Nuclear factor-kappaB in cancer development and progression. *Nature* 441(7092):431–436
- Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 5(10):749–759
- Klaassen CD, Reisman SA (2010) Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. *Toxicol Appl Pharmacol* 244(1):57–65
- Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C (2006) Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. *Oncogene* 25(27):3823–3833
- Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF et al (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. *Nat Med* 12:410–416
- Lin WR, Lim SN, McDonald SA, Graham T, Wright VL, Peplow CL et al (2010) The histogenesis of regenerative nodules in human liver cirrhosis. *Hepatology* 51(3):1017–1026
- Liu Y, Li PK, Li C, Lin J (2010) Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. *J Biol Chem* 285(35):27429–27439
- Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. *Cancer Cell* 11(2):119–132
- Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, Lai MM et al (2010) c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. *Hepatology* 52(2):480–492
- Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell* 121(7):977–990
- Marshall A, Rushbrook S, Davies SE, Morris LS, Scott IS, Vowler SL et al (2005) Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. *Gastroenterology* 128(1):33–42
- McGivern DR, Lemon SM (2009) Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. *Annu Rev Pathol* 4:399–415
- Moynagh PN (2005) The NF-kappaB pathway. *J Cell Sci* 118(Pt 20):4589–4592
- Neuveut C, Wei Y, Buendia MA (2010) Mechanisms of HBV-related hepatocarcinogenesis. *J Hepatol* 52:594–604

- Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y et al (2006) Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. *Gastroenterology* 131(1):179–193
- Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* 140(2):197–208
- Pereira TA, Witek RP, Syn WK, Choi SS, Bradrick S, Karaca GF et al (2010) Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. *Lab Invest* 90(12):1690–1703
- Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* 431(7007):461–466
- Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C et al (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. *Nature* 457(7226):200–204
- Schutte K, Bornschein J, Malfertheiner P (2009) Hepatocellular carcinoma—epidemiological trends and risk factors. *Dig Dis* 27:80–92
- Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med* 13:1324–1332
- Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S et al (2010) Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. *Hepatology* 51(5):1531–1537
- Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. *Hepatology* 41:5–15
- Studach LL, Rakotomalala L, Wang WH, Hullinger RL, Cairo S, Buendia MA et al (2009) Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. *Hepatology* 50(2):414–423
- Theise ND, Yao JL, Harada K, Hytioglou P, Portmann B, Thung SN et al (2003) Hepatic ‘stem cell’ malignancies in adults: four cases. *Histopathology* 43:263–271
- Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. *Cancer Res* 68:1451–1461

Gastrointestinal Cancer: Current Screening Strategies

Hugh Barr

Abstract

The prevention and chemoprevention of cancer is based on identifying a pre-neoplastic lesion and altering the outcome by early intervention. Many of the gastrointestinal epithelial cancers are related to chronic inflammatory conditions for many years prior to cancer development. It is clear that treatment of the inflammatory condition can prevent and indeed reverse changes that predispose to cancer. This is most notable for helicobacter pylori infection of the stomach. Screening for Barrett's oesophagus and other conditions are more controversial and the results of large scale clinical trials are awaited. Nevertheless preventive strategies are highly attract health care interventions and are being actively considered.

Contents

1	Introduction.....	150
2	Oesophageal Cancer.....	150
3	Screening for Oesophageal Squamous Cancer.....	151
4	Screening for Oesophageal Adenocarcinoma (Barrett's Cancers).....	152
5	Screening for Adenocarcinoma and Lymphoma of the Stomach.....	153
6	Small Intestine Inflammation: Crohns Disease.....	154
7	Inflammatory Bowel Disease: Colorectal Adenocarcinoma.....	155
8	Conclusions.....	156
	References.....	156

H. Barr (✉)
Cranfield Health, Gloucestershire Royal NHS Foundation Trust,
Great Western Road, Gloucester, GL13NN, UK
e-mail: hugh.barr@glos.nhs.uk

1 Introduction

The association between chronic inflammation and cancer in the gastrointestinal tract now has a very strong scientific basis (Marx 2004; Quante and Wang 2008; Clemons et al. 2007). Inflammatory cells, in particular macrophages, infiltrate tumours and promote tumour growth liberating TNF- α , NF- κ B and COX-2. Cytokines can also influence and indeed instruct cell lineage choice (Rieger et al. 2009). The evidence base remains incomplete but data is accumulating that the progression to cancer may be preventable, if patients are detected early and measures are put in place to detect and control inflammation, and screening for pre-invasive neoplasia in those with chronic inflammatory conditions (Velayos et al. 2006).

There is now accumulating evidence, from epidemiological studies, that regular usage of aspirin and non-steroidal anti-inflammatory drugs reduces the risk of developing and also progressing to cancer. These trends are so important that they are being explored in large, long-term clinical trials of secondary chemoprevention at the present time (Raj and Jankowski 2004; Wong and Fitzgerald 2005; Jankowski and Barr 2006; Jankowski and Hawk 2006). However, these issues are complex, and it is important to note that there is some data to indicate that if the sequence of inflammation to cancer is very advanced, then chemopreventative strategies may not help. For example, a recent multicentre, randomised, placebo-controlled trial explored the effect of long-term administration of a COX-2 inhibitor in patients with Barrett's oesophagus who had with established diagnosis of dysplasia. This anti-inflammatory intervention did not appear to prevent progression to cancer after 48 months of therapy (Heath et al. 2007).

Nevertheless, the purpose of screening of patients with chronic inflammatory conditions is to detect the degeneration to cancer at a pre-invasive histopathological stage and at an appropriately early clinical stage. The premise is that early intervention will alter the clinical course and prevent premature mortality from invasive cancer. Therefore the strategies of screening and subsequent intervention must be well tolerated and without substantial risk. Repeated assessment may be necessary and required over prolonged time scales and the health care resource required must be measured.

2 Oesophageal Cancer

The outcomes from this disease are very poor with incidence paralleling to mortality and very little evidence that intervention for symptomatic disease has had much impact on overall disease mortality. Despite these dreadful outcomes, any screening programme must be completely informed by the very marked geographic and ethnic variation in the incidence of oesophageal cancer. In the white population of the USA the incidence per 100,000 is 5.8, in the United Kingdom it is 4.8, and in the Netherlands it is 2.5. In the West, there are some areas of moderately high occurrence including parts of France (25.5), and among the black population of Southern USA (20.5). However, in many of the

low-incidence countries, adenocarcinoma of the gastro-oesophageal is increasing dramatically. Adenocarcinoma in white Americans has increased 463% and 335% in men and women, respectively, over the past three decades (Brown et al. 2008).

The biggest problem appears to be in the United Kingdom with marked regional variation with a particular problem in Scotland around Glasgow (Wong and Fitzgerald 2005).

Overall, in the worldwide problem is that of squamous cell cancer, which predominates, particularly in the Caspian area and in Kazakhstan, where the recorded incidence reaches 547.2 per 100,000; also in the Transkei region of South Africa (357.2 per 100,000) and in Linxian Province in China (379 per 100,000). The other main high-risk groups include those with the rare autosomal dominant condition tylosis, which is associated with a 70% chance of developing a squamous cell carcinoma. Some 3–7% patients with achalasia, develop squamous cell carcinoma. Similarly, patients with an aerodigestive tract squamous cell carcinoma are more prone to develop further cancers in the region with a cumulative risk of 25% at 5 years (Barr 2008).


3 Screening for Oesophageal Squamous Cancer

Inflammation in the oesophagus caused by fumonisin, (a maize fungal toxin) nitrosamines and aflatoxins are the probable causative inflammation producing agents in Chinese patients. There is a programme for screening occurrence in the high-risk regions of China. It is based on the use of the lawang (a balloon covered with a mesh, when swallowed, it is inflated and pulls up the oesophagus) to obtain cells for cytological analysis. Those found to have neoplastic cells proceed to confirmatory endoscopy and biopsy. This regimen has a sensitivity of 80% and cure is possible in 90% of patients with early asymptomatic cancer (Barr 2008).

Food stasis and bacterial infection in achalasia cause chronic inflammation in the squamous mucosa, leading to a sequence through dysplasia to invasive cancer. Screening of these patients has demonstrated that early detection and cure is possible. The overall incidence of squamous carcinoma is 3.4/100 patients per year, being a 33-fold increase over controls (0.104/1,000 patients a year) (Katz 2008). A population-based study of 1,062 patients followed for 9,864 patient years showed a 16-fold increase in cancer. However, it was calculated that 406 endoscopies would be required to detect one cancer in men and 2,220 endoscopies for the detection of cancer in women (Sandler 1992). Therefore, endoscopic screening is left to the clinician's discretion, but it is recommended by the American Society for Gastrointestinal Endoscopy in patients with untreated achalasia for 15 years at 1–2 years intervals. If patients have had successful treatment then screening and surveillance is not recommended.

It is now becoming established that screening for early neoplastic lesion after treatment of squamous cancer can detect lesions at an early stage, and screening occurs in those interested in early detection and therapy but is not fully established

Fig. 1 Endoscopic picture of an segment of Barrett's oesophagus with the development of multiple areas of intramucosal cancer. Patient had a history of over 30 years of gastro-oesophageal reflux




(Grosjean and Monnier 1998). Certainly the few patients found to have tylosis should be screened.

4 Screening for Oesophageal Adenocarcinoma (Barrett's Cancers)

There is a clear link between gastro-oesophageal reflux disease producing chronic mucosal inflammation at the gastro-oesophageal junction progressing to adenocarcinoma. A very influential case-control Swedish study showed that recurrent reflux symptoms had an odds ratio of 7.7 for oesophageal adenocarcinoma and two for adenocarcinoma of the gastric cardia when compared with asymptomatic patients. Severe prolonged symptoms produced an odds ratio of 43.5 and 4.4 for oesophageal and cardia adenocarcinoma, respectively (Lagergren et al. 1999). The proposed sequence is of inflammation leading to metaplasia (Barrett's oesophagus), dysplasia and cancer. The aetiology of the intense inflammation at the gastro-oesophageal junction in these patients is a subject of intense study. It is now apparent that there is a highly toxic inflammatory mixture based on nitrosative chemistry that is produced may be the driver of the inflammatory mutagenesis (Suzuki et al. 2005) (Figs. 1 and 2).

Adenocarcinoma in Barrett's oesophagus has an incidence of 800 per 100,000, and should be compared with an incidence of lung cancer in men over 65, of 500 per 100,000. There is continued intense controversy over the need for screening and surveillance to detect oesophagitis, Barrett's oesophagus and early cancer, and the subsequent management of any detected pre-neoplastic lesions and early cancers (Fernando et al. 2009). More importantly national guidelines indicate that there is no evidence that screening or surveillance will save lives (Wang and Sampliner 2008).

Fig. 2 Histopathological section of an area of Barrett's oesophagus showing inflammation and dysplasia



It is now clear that many patients will have no reflux symptoms prior to the diagnosis of an oesophageal adenocarcinoma (Tomizawa and Wang 2009). The two issues of whether protocol surveillance with 2 yearly endoscopy and biopsy, and if chemoprevention with aspirin and proton pump inhibitors are being addressed by large United Kingdom randomised trials. The Aspirin and Esomeprazole chemoprevention trial (ASPECT) has successfully recruited over 2,500 patients and the Barrett's Oesophagus surveillance Study (BOSS) is open and recruiting well and both will report in a few years (Jankowski and Barr 2006). Currently patients should be entered into studies and screening and surveillance is left to clinicians and patient's choice but it is suggested to occur every 2 years with protocol biopsy. Certainly in the United Kingdom there is little conviction and adherence to protocol surveillance until randomised evidence is forthcoming (Das et al. 2008).

5 Screening for Adenocarcinoma and Lymphoma of the Stomach

In worldwide terms gastric adenocarcinoma is still a common cancer. There is also marked geographical variation. The epidemic is based in Japan (70 per 100,000), with a cumulative risk of developing this cancer by the age of 75 as high as 11%. The incidence is falling in the United Kingdom and USA (age-adjusted mortality for men is 10 per 100,000). The anatomical location is also changing with carcinoma occurring at the cardia rather than more distally in the stomach. Infection and chronic gastric inflammation with *Helicobacter pylori* (*H. pylori*) is a clear causative agent (Graham and Shiotani 2005). The mechanism is through chronic inflammation, metaplastic change and then gastric atrophy. Screening by using antibody status to detect *Helicobacter* and serum pepsinogen as a marker for gastric atrophy has been examined. A group of 9,293 participants were assessed in a mass health appraisal programme and 6,983 were followed up and gastric cancer

was detected by annual endoscopy. Those with normal pepsinogen and negative for *H. pylori* had an annual incidence rate of 0.04% (0.02–0.09) compared with 0.35 (0.23–0.57) for those with ‘atrophic’ pepsinogen and *H. pylori* positive, and those with ‘atrophic’ pepsinogen and negative for *H. pylori* 0.60 (0.34–1.05). Thus screening may be possible using this combination to identify high-risk groups (Watabe et al. 2005).

In Japan, gastric cancer caused 50,562 deaths (15.85% of all cancer deaths) in 2004. The Health Service Law for the Aged was introduced in 1983 with the support of the national government. This is a mass programme of radiographic and endoscopic screening, available for all residents aged 40 or over. The method of initial screening is photofluorography. However, only 25% of cancers detected are as a result of this programme. Most cancers and early cancers are detected by an aware population requesting endoscopy in response to symptoms or health screening. The number of cancers detected at as early gastric cancer has risen from 2 to 63%, and after 25 years of the programme there has been a corresponding fall in the death rate (Hamashima et al. 2008).

In a study population of 1,625 patients over 40 in the National Cancer Screening Survey in Korea there is a preference (67%) for endoscopy when compared with radiology (33%) (Choi et al. 2009). Overall in Asia gastric cancer is the second most common cause of death, and few countries have national screening programmes. Most will adopt opportunistic screening of high-risk groups and there is few quality data to recommend changing practice (Leung et al. 2008). Prophylactic eradication of *Helicobacter* is to be recommended in patients after an endoscopic resection of an early gastric cancer as an important preventative for developing metachronous lesions (Fukase et al. 2008). Overall 2–8% of gastric malignancies are lymphomas. *Helicobacter* infection causes inflammation followed by the excessive development of mucosal associated lymphoid tissue (MALT), and lymphoma. Screening and eradication of *H. pylori* is essential. In the United Kingdom routine screening and surveillance does not form part of guidelines. However, in high-risk groups annual screening endoscopy should be considered for patients who have atrophic gastritis, dysplasia and adenomatous polyps (Allum et al. 2002).

6 Small Intestine Inflammation: Crohns Disease

The two chronic inflammatory conditions that progress to cancer are coeliac and Crohns disease. Long standing ileal inflammation is the major risk factor.

Patients with small bowel Crohns disease have an increased risk of small bowel adenocarcinoma but all series are very small and have wide variability, often including other areas of the gastrointestinal tract (3–91 fold) (Friedman 2006). The Olmsted data indicates an increased risk of 40.6 (95% CI, 8.4–118) in patients with small bowel disease (Jess et al. 2006). A meta-analysis of population-based studies reported the risk as 33.2 (95% CI, 15.9–60.9) (Canavan et al. 2006). There is perhaps a borderline increase in lymphoma and leukaemia but the data is conflicting and may be related to treatment. There is an increased risk of anal squamous cell cancers in

patients with chronic inflammation related to Crohns disease of the perineum and anal fistulae (Friedman 2006). No screening or surveillance programme is placed.

For over 40 years it has been recognised that the chronic inflammation associated with coeliac disease is associated with enteropathy-associated T-cell lymphoma (EATL). These neoplastic lesions are usually diagnosed symptomatically and after a clinical relapse and the overall survival is poor with most patients dying within 3 years. The risk of malignancy is 40–100 times higher than in the general population (Logan 2009). Recent data from a large population-based survey in Finland of 8,000 subjects demonstrated no difference in the overall risk of malignancy in the prognosis in undiagnosed coeliac subjects compared with known patients (Lohi et al. 2009). There is no basis at present for a mass screening programme to detect celiac disease at an earlier stage.

7 Inflammatory Bowel Disease: Colorectal Adenocarcinoma

The extent of the colitis is clearly an independent risk factor for the development of colorectal cancer although most cancers occur in the sigmoid colon and rectum. Pancolitis or extensive disease (variably defined as beyond hepatic flexure) has a standardised incidence ratio for developing colorectal cancer of 14.8% (95% CI, 11.4–18.9) compared with 2.8 (95% CI, 1.6–4.4) for left-sided colitis (Ekbom et al. 1990; Rubin and Kavitt 2006).

The risk of colorectal cancer in patients with inflammatory bowel disease is also related to the duration of the disease. The overall prevalence is estimated to be 3.7% (95% CI, 3.2–4.2%). For the first 10 years the incidence rate is 2/1,000 patient years, for the second decade 7/1,000 patient years, for the third decade 12/1,000 patient years. The geographical variation is important being 2/1,000 patient years in Scandinavia, 4/1,000 patient years in the United Kingdom and 5/1,000 patient years in the United States (Eaden et al. 2001).

Primary sclerosing cholangitis (PSC) confers a five-fold increase risk. This estimate follows a meta-analysis of 16,844 patients with ulcerative colitis and 560 patients with PSC (Soetikno et al. 2002; Konda and Duffy 2008). Ureterosigmoidoscopy is associated with increased incidence of colorectal cancer by 2–15%, and annual sigmoidoscopies should be performed starting 10 years after the surgery (Konda and Duffy 2008). Patients with asymptomatic HIV infection have a higher incidence of neoplastic lesions odds ration 3 (95% CI, 1.83–4.93) (Bini et al. 2009).

In the United Kingdom recommendations are for patients with ulcerative colitis and Crohns colitis. Screening should be by colonoscopy with the initial screening at 8 years for patients with pancolitis and 15 years for left sided colitis; timings are from the onset of symptoms. The frequency is 3 yearly in the second decade and 2 yearly in the third decade. If the patient has PSC and colitis, colonoscopy should be annually at the diagnosis of PSC with biopsy for every 10 cm. Following uretero-sigmoidoscopy a flexible sigmoidoscopy should be performed annually,

10 years post surgery (Cairns and Scholefield 2002). Patients who have an ileoanal pouch may be at increased risk of neoplasia in the pouch following pouchitis, and in any retained mucosal rectal cuff. In the latter circumstance should have repeated biopsies (Rubin and Kavitt 2006).

8 Conclusions

The prospect of secondary cancer prevention by intervention to control inflammation is very attractive. Trials are underway that will inform the decisions as to whether screening for and of these inflammatory conditions will prevent mortality from cancer. Ultimately the answer may well be prevention with control of inflammation at an early stage.

References

- Allum WH, Griffin SM, Watson A, Colin-Jones D (2002) Guidelines for the management of oesophageal and gastric cancer. *Gut* 50 (suppl V):v1–v23
- Barr H (2008) Squamous cell carcinoma of the oesophagus. In: Jankowski J, Sampliner RE, Kerr DJ, Fung Y (eds) *Gastrointestinal oncology: a critical multidisciplinary team approach*. Oxford University Press, Oxford
- Bini EJ, Green B, Poles MA (2009) Screening colonoscopy for detection of neoplastic lesions in asymptomatic HIV-infected subjects. *Gut* 58:1129–1134
- Brown L, Devesa S, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. *J Natl Cancer Inst* 100:1184–1187
- Cairns S, Scholefield JH (2002) Guidelines for colorectal cancer screening in high risk groups. *Gut* 51(Suppl V):v1–v2
- Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohns disease. *Aliment Pharmacol Ther* 23:1097–1104
- Choi KS, Kwak M-S, Lee H-Y, Jun JK, Hahm M, Par E-C (2009) Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. *Cancer Epidemiol Biomarkers Prev* 18:1390–1398
- Clemons NJ, McColl KE, Fitzgerald R (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett's carcinogenesis via distinct mechanisms. *Gastroenterology* 133:1198–1209
- Das D, Ishaq S, Harrison R, Kosuri K, Harper E, deCaestecker J, Sampliner R, Barr H, Watson P, Moayyedi PJ, Jankowski J (2008) Management of Barrett's esophagus in the UK: over treated and under biopsied but improved by the introduction of a national randomised trial. *AJG* 103:1079–1089
- Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 48:526–535
- Ekbom A, Helmick C, Zack M et al (1990) Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 323:1228–1233
- Fernando HC, Murthy SC, Hofstetter W et al (2009) The society of thoracic surgeons practice guideline series: Guidelines for the management of Barrett's esophagus with high-grade dysplasia. *Ann Thorac Surg* 87:1993–2002
- Friedman S (2006) Cancer in Crohns disease. *Gastroenterol Clin N Am* 35:621–639
- Fukase K, Kato M, Kikuchi S et al (2008) Effect of eradication of helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of gastric cancer: an open-label, randomised controlled trial. *Lancet* 372:392–397

- Graham DY, Shiotani A (2005) The time to eradicate gastric cancer is now. *Gut* 54:735–738
- Grosjean P, Monnier P (1998) Photodynamic therapy and mucosectomy for early squamous cell carcinomas in the oesophagus and tracheobronchial tree. *Eur J Surg Oncol* 24:234
- Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, Sobue T (2008) The Japanese guidelines for gastric cancer screening. *Jpn J Clin Oncol* 38:259–267
- Heath EI, Canto MI, Piantadosi S et al (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. *J Natl Cancer Inst* 99:545–557
- Jankowski J, Barr H (2006) Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. *BMJ* 332:1512
- Jankowski J, Hawk E (2006) A methodological analysis of chemoprevention in the gastrointestinal tract. *Nat Clin Pract Gastro Hep* 3:101–111
- Jess T, Loftus E, Velayos F et al (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted, Minnesota. *Gastroenterology* 130:1039–1046
- Katz P (2008) Esophageal carcinoma and achalasia: another call for screening? *Achalasia complicated by squamous cell carcinoma: A prospective study in 195 patients.* *AJG* 88:783–793
- Konda A, Duffy MC (2008) Surveillance of patients at increased risk of colorectal cancer: inflammatory bowel disease and other conditions. *Gastroenterol Clin N Am* 37:191–213
- Lagergren J, Bergstrom R, Lindgren A, Myren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 18:825–831
- Leung WK, Wu M, Kakugawa Y et al (2008) Screening for gastric cancer: current evidence and practice. *Lancet Oncol* 9:279–287
- Logan RFA (2009) Malignancy in unrecognised coeliac disease: a nail in the coffin for mass screening? *Gut* 58:618–619
- Lohi S, Mäki M, Montonen J, Knekt P, Pukkala E, Reunanen A, Kaukinen K (2009) Malignancies in cases with screening—identified evidence of celiac disease: a long-term population-based cohort study. *Gut* 58:643–647
- Marx J (2004) Inflammation and cancer: the link grows stronger. *Science* 306:966–968
- Quante M, Wang TC (2008) Inflammation and stem cells in gastrointestinal carcinogenesis. *Physiology* 23:350–359
- Raj A, Jankowski J (2004) Acid suppression and chemoprevention in Barrett's oesophagus. *Dig Dis* 22:171–180
- Rieger MA, Hoppe PS, Smejkal BM, Eitelhuber AC, Schroeder T (2009) Hematopoietic cytokines can instruct lineage choice. *Science* 325:217–218
- Rubin DT, Kavitt RT (2006) Surveillance for cancer and dysplasia in inflammatory bowel disease. *Gastroenterol Clin N Am* 35:581–604
- Sandler RS, Nyren O, Ekholm A et al (1992) The risk of esophageal cancer in patients with achalasia: a population based study. *JAMA* 274:1359–1362
- Soetikno RM, Lin OS, Heidenreich PA et al (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc* 56:48–54
- Suzuki H, Iijima K, Scobie C, Fyfe V, Mc Coll KEL (2005) Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. *Gut* 54:1527–1535
- Tomizawa Y, Wang KK (2009) Screening, surveillance, and prevention for esophageal cancer. *Gastroenterol Clin N Am* 38:59–73
- Velayos FS, Loftus EV Jr, Jess T et al (2006) predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-controlled study. *Gastroenterology* 130:1941–1949
- Wang K, Sampliner R (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. *AJG* 103:788–797
- Watabe H, Mitsushima T, Yamaji Y et al (2005) Predicting the development of gastric cancer from combining *Helicobacter pylori* antibodies and serum pepsinogen status: a prospective endoscopic cohort study. *Gut* 54:764–768
- Wong A, Fitzgerald RC (2005) Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. *Clin Gastroenterol Hepatol* 3:1–10

Targeted Drug Therapies and Cancer

K. L. Yim and D. Cunningham

Abstract

With the progress of research in molecular biology and greater understanding of cell signalling systems emerge an increasing array of potential targets for the therapy of cancer. While traditional chemotherapy aims to elicit tumour cell death, it also produces undesirable side effects on physiologically proliferating cells. By isolating cell surface receptors which link specific intracellular secondary messenger pathways, researchers are increasingly able to define the biological network which drives cellular function. Of importance are routes involved in malignant transformation, proliferation, survival and angiogenesis. Thus targeted therapy is directed to specific differential growth processes particular to malignant tumours. The principle mode of action generally involves the “lock-and-key” mechanism and identifying the “Achilles’ heel” for drug action. Various targeted agents have been studied and many have translated into significant clinical benefit. This chapter will describe some examples which illustrate the role of this approach in gastrointestinal cancers.

Contents

1	Cell Signalling Networks and Potential Targets.....	160
2	Targeted Therapies in Gastrointestinal Cancers.....	160
2.1	Tyrosine Kinase Cell Receptor Families.....	160
2.2	VEGF Inhibitor.....	164
2.3	Small Molecule TK Inhibitor.....	165

K. L. Yim (✉) · D. Cunningham
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
e-mail: yimkl2000@hotmail.com, kein.yim@rmh.nhs.uk

D. Cunningham
e-mail: david.cunningham@rmh.nhs.uk

J. A. Z. Jankowski (ed.), *Inflammation and Gastrointestinal Cancers*,
Recent Results in Cancer Research 185, DOI: 10.1007/978-3-642-03503-6_10,
© Springer-Verlag Berlin Heidelberg 2011

3	Network Interactions and Resistance to Targeted Therapies	167
4	Conclusion	168
	References.....	168

1 Cell Signalling Networks and Potential Targets

Examples of potential targets include: (1) cell surface receptors, (2) receptor tyrosine kinase (RTK), (3) intracellular downstream signalling proteins and (4) anti-angiogenic agents.

Targeted therapies may thus be directed towards inhibition of the receptor-intracellular signalling axis via:

1. Inactivation of ligands by preventing binding to receptors triggering signalling pathways.
2. Binding of extracellular receptor domain and interfering with activation by the effector ligand.
3. Inhibition of intracellular tyrosine kinase domain by interrupting phosphorylation and downstream messenger initiation.
4. Disruption of intracellular signalling pathways by disrupting the downstream signal transfer circuit.

Principle of therapy extends to treatments which may also trigger apoptotic pathways and modify inflammation pathways. The range of potential targets is wide but in this chapter clinical data is highlighted to illustrate the translational approach using selected targeted therapies in the management of gastrointestinal cancer (Fig. 1).

2 Targeted Therapies in Gastrointestinal Cancers

2.1 Tyrosine Kinase Cell Receptor Families

2.1.1 EGF Receptor Inhibitor

EGFR is a member of the ErbB family of trans-membrane tyrosine kinase receptors which consists of ErbB1 (HER1, EGFR), ErbB2 (HER2, neu), Erb3 (HER3) and ErbB4 (HER4). Investigation into signal transduction processes involving EGF receptors has linked these receptors to the Ras-Raf-MEK-MAPK, PI3 K-Akt and STAT pathways leading to DNA transcription, cell cycle progression and cellular proliferation. Overexpression of EGFR occurs in a variety of tumours including head and neck, colorectal, pancreatic, lung, breast, kidney, prostate and bladder carcinomas; and HER2 in breast and gastric cancers.

Drugs which target EGFR are monoclonal antibodies (mAb) which competitively bind to the extracellular domain, inhibiting receptor activation and downstream signalling. Cetuximab and panitumumab are two mAb EGFR inhibitors which are commonly investigated in clinical trials.




Fig. 1 Simplified example of cell surface receptors and their interaction with intracellular signalling pathways

EGFR inhibitors have been investigated in several large phase III metastatic colorectal cancer (mCRC) trials, initially in the chemo-refractory setting and more recently as part of first-line therapy. However, activating somatic *KRAS* mutation occurs in around 40% of cases and commonest mutations occur in codons 12, 13 and 61 (approximately 82, 17 and 8%, respectively) (Edkins et al. 2006). Sub-group analyses of the major randomised EGFR-therapy trials demonstrate lack of clinical benefit in tumours with *KRAS* mutation due to the evasion of upstream

EGFR blockade (Karapetis et al. 2008). This highlighted the importance of an intact receptor-signalling axis and illustrates the proof of concept in targeted therapies.

The synergistic effect of cetuximab when used in combination with chemotherapy was first reported in the BOND trial which compared single agent cetuximab with cetuximab in combination with irinotecan for patients who had progressed on irinotecan-based regimens. Significant improvement in response rate (22.9 vs. 10.8%), median time to progression (4.1 vs. 1.5 months) and median survival (8.6 vs. 6.9 months) (Cunningham et al. 2004) was achieved, demonstrating the ability of cetuximab to reverse irinotecan-resistance and also for monotherapy activity in patients resistant to conventional lines of treatment. In the EPIC (Sobrero et al. 2008) trial, cetuximab was used in combination with irinotecan in the second-line treatment of patients with mCRC. Compared to irinotecan alone, statistically significant improved response rate and progression-free survival (PFS) were achieved (16.4 vs. 4.2% and 4.0 vs. 2.6 months, respectively), reinforcing the concept of reversal of chemo-resistance. However, there was no difference in overall survival (OS). This may have been due to treatment cross over between the arms.

The importance of *KRAS* mutation emerged from subsequent trials. When treatment with cetuximab monotherapy plus best supportive care (BSC) was compared to BSC alone, patients with *KRAS* wild-type (wt) tumours had significantly better median OS (9.5 vs. 4.8 months, $p < 0.0001$) and median PFS (3.7 vs. 1.9 months, $p < 0.0001$) (Karapetis et al. 2008) with EGFR therapy. Similar improvement in PFS but not OS was also found in *KRAS* wt patients treated with panitumumab monotherapy versus BSC (3.0 vs. 1.8 months, $P < 0.001$) (Amado et al. 2008).

Subsequent trials incorporated EGFR-targeted therapy with combination chemotherapy in the first-line treatment of patients with mCRC. The CRYSTAL trial (Van Cutsem et al. 2009a) randomised 599 chemotherapy-naïve patients with mCRC to FOLFIRI with cetuximab versus 599 patients to FOLFIRI alone. Treatment with EGFR inhibition led to an improved hazard ratio for PFS in patients with *KRAS* wt (0.68; 95% CI, 0.50–0.94) but not *KRAS* mutant (mt) tumours. The OPUS trial randomised 337 patients to cetuximab in combination with FOLFOX-4 versus FOLFOX-4 alone. Benefit was again limited to the *KRAS* wt, but not *KRAS* mt group confirming an improved chance of response (ORR = 61 vs. 37%; odds ratio = 2.54; $p = 0.011$) and a lower risk of disease progression (HR 0.57; $p = 0.0163$) in favour of anti-EGFR therapy.

However, no significant survival benefit from the addition of cetuximab to FOLFOX was seen in the UK MRC COIN trial (Adams 2009). Early data suggested a trend to inferior survival in patients with *KRAS* mt tumours treated in the cetuximab combination arm. Together with a significantly shortened PFS in the subgroup of patients with *KRAS* mt tumours from the OPUS trial, this suggests a possible negative interaction between oxaliplatin and anti-EGFR-targeted therapy not seen with irinotecan-based combination chemotherapy (see Sect. 3).

Resection of liver-only metastases in CRC improves survival (Giacchetti et al. 1999; Adam et al. 2004). In patients with unresectable hepatic metastases, cetuximab was shown to increase response rate when added to FOLFIRI (59.3%) (Van Cutsem et al. 2009a). However, when added to FOLFOX, overall response rate of up to 85% was achieved in the randomised phase II CELIM trial, leading to a resection rate of 40%. Activity in *KRAS* wt tumours was 79% with cetuximab. In the UK, the use of cetuximab combined with chemotherapy in patients with liver-only metastases has been approved by NICE.

2.1.2 HER2 Receptor Inhibitor

It is estimated that between 6 and 35% of oesophageal and gastric malignancies overexpress HER2. In the first phase III prospective randomised ToGA trial (Van Cutsem et al. 2009b) investigating HER2 inhibition in locally advanced or metastatic gastroesophageal and gastric adenocarcinomas, histological samples were found to be HER2 positive in 22.1% of 3,807 patients (Bang et al. 2009). A modified HER2 score was used and HER2 positivity was defined as IHC 3+ and/or FISH positive.

Five hundred and ninety two patients with HER2 positive tumours were randomised to receive 3-weekly fluoropyrimidine (5-fluorouracil or capecitabine) with cisplatin alone or in combination with trastuzumab. Results were in favour of the trastuzumab arm showing a significant improvement in OS of 2.4 months (13.5 vs. 11.1 months, respectively) with no unexpected adverse events or difference in symptomatic congestive cardiac failure. Results of this trial suggest the benefit of anti-HER2 targeted therapy as a treatment option in the management of these patients.

2.1.3 IGFR-1 Receptor Inhibitor

Another class of tyrosine kinase transmembrane receptor is the IGF-1R which is activated by IGF-1 and 2 ligands. It is structurally similar to the insulin receptor and share the IRS-1 and 2 substrate transmission proteins. However, IGF-1R has been shown to trigger the Ras-Raf-MEK-MAPK and PI3 K-Akt pathways leading to a wide range of cellular activity including growth, differentiation and survival. IGF-1R is known to be overexpressed in gastric, colorectal and pancreatic cancers leading to increased risk of metastases and worse clinical outcome.

In gastric cancer, a positive correlation between overexpression of IGF-1R and rate of nodal metastases in gastric cancer was found (Guo et al. 1995). IGF-1R is also implicated in the pathogenesis of colorectal cancers (Guo et al. 1995; Zecevic et al. 2006). The risk of developing bowel malignancy is known to be increased in patients with acromegaly. This is associated with high growth hormone and IGF-1 levels. IGF-1 may be overexpressed in up to two-thirds of colorectal cancer and can independently affect tumour progression (Scartozzi et al. 2009).

Various IGF-1R receptor antibodies and tyrosine kinase inhibitors (TKI) have been developed and are undergoing clinical trials. In vitro study using IR3 antibody directed to IGF-1R in gastric carcinoma resulted in a reduction of cell colony count (Pavelic et al. 2002). In colorectal cancer, a current phase II/III trial investigates anti-IGFR antibody MK-0646 in conjunction with cetuximab and irinotecan.

This combination was found to be tolerated and further results on PFS and correlation with *KRAS* status is pending (Watkins et al. 2009). In pancreatic cancer, a dose-response relationship was found in cell line studies when treated with single agent IGF-1R antibody and synergistic effect was observed when IGF-1R blockade was combined with gemcitabine and panitumumab (Beltran et al. 2009).

IGF-1R also interacts with other receptors involved in malignant transformation including EGFR and VEGF. A study on surgical specimens demonstrated correlation between membrane-dominant dominant EGFR/cytoplasmic-dominant IGF receptor with lower grade and prognosis, and cytoplasmic-dominant EGFR/membrane-dominant IGF receptor with higher grade and worse prognosis. In addition, IGF-1R and EGFR overexpression was also more frequent in liver metastases compared to pancreatic primaries (Ueda et al. 2006).

2.2 VEGF Inhibitor

With tumour cell proliferation, angiogenesis is essential for continued growth. This process is mediated by the VEGF family of circulating angiogenic ligands (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor PlGF). The ligands exert its effect on corresponding VEGF receptors VEGF-R1 (migration, invasion), VEGF-R2 (proliferation, survival) and VEGF-R3 (lymphangiogenesis). These processes are not only involved in inflammation and wound healing, but are also activated in malignant angiogenesis. In addition, VEGF plays an important role in the orchestration of tumour survival including inhibition of apoptosis, migration and invasion.

Bevacizumab is an antibody to VEGF-A. Curbing the development of tumour blood vessels, it also normalises vessel blood flow through vasoconstriction, reducing hypoxia and expression of HIF-1. It was one of the earliest to be studied in colorectal cancer improving median survival from 15.6 to 20.3 months when used in combination with first-line 5-fluorouracil and irinotecan (Hurwitz et al. 2004). A recent Cochrane analysis showed overall benefit of bevacizumab (Wagner and Moehler 2009). Although it has little efficacy as monotherapy, improvement in PFS and OS was evident when used in combination with chemotherapy. The benefit of anti-VEGF therapy was also found in patients ≥ 65 years old (Kabbavar et al. 2009). Allowing for heterogeneity in treatment duration and chemotherapy platform using oxaliplatin-based regimens, improvement in HR for PFS (0.61; 95% CI 0.45–0.83) and OS (0.81; 95% CI 0.73–0.90) was demonstrated in the first-line setting. The value of continuing bevacizumab beyond progression was suggested by the observational BRiTE study. Although not randomised, median OS rates were 12.6 months in patients who stopped treatment, 19.9 months in those who continued chemotherapy without bevacizumab and 31.8 months in those who continued chemotherapy with bevacizumab (Grothey et al. 2008). In the second-line setting, a large trial using FOLFOX with bevacizumab demonstrated a in HR for PFS (0.61; 95% CI 0.51–0.73) and OS (0.75; 95% CI 0.63–0.89) (Giantonio et al. 2007).

However, early data on bevacizumab in the adjuvant scenario showed it to be of little advantage. The NSABP-C08 phase III trial comprising of 2,672 patients with stage II or III colorectal cancer did not demonstrate benefit in terms of PFS after a year of anti-VEGF treatment in addition to FOLFOX (Wolmark et al. 2009).

2.3 Small Molecule TK Inhibitor

Signal transduction occurs at the intracellular domain when the receptor is triggered by their complementary ligand. This leads to downstream phosphorylation of substrate proteins and subsequently activates the network of signal transduction pathways which regulate important cell functions. TKI block this key activation process and were the forerunners of targeted therapy in cancer.

2.3.1 Imatinib

Kit and PDGFR display extensive structural homology and are members of the type III tyrosine kinase receptor family. TKIs which act on these sites were among the earliest described and provided the initial proof of concept. STI-571 (Imatinib mesylate) has binding activity to sites including Kit, Bcr-Abl and PDGF domains. It was tested in advanced GIST tumours which express the kit (Hirota et al. 1998) mutation. Early studies showed a response rate exceeding 80% and median PFS of over 24 months could be achieved. The commonest mutation occurs at the exons 11 (70%) and 9 (15%) but other sites including exons 13, 14, 17 as well as PDGFRA (exons 12, 18) (Heinrich et al. 2003) have been reported. Exon 11 encodes for the intracellular autoinhibitory juxta-membrane domain, while exon 9 encodes for the distal part of the extracellular domain. In addition, exons 13/14 and 17 encode for the drug/ATP binding pocket and activation loop, respectively. Differential mutations at these sites predict for objective response—71.7% for exon 11 versus 44.4% for exon 9, as well as clinical outcome where presence of exon 11 mutation led to a 5-year recurrence-free survival of $89 \pm 10\%$, but only $40 \pm 8\%$ if other mutations were found ($p = 0.03$) (Singer et al. 2002). Doubling the dose of imatinib to 800 mg improved PFS for patients with exon 9 mutation (Verweij et al. 2004; Van Glabbeke et al. 2007). Secondary mutations in exons 13/14 and 17/18 led to resistance. Clinical observation suggested that abrupt withdrawal of the drug could result in accelerated progression. This may reflect heterogeneity of the tumour where previously imatinib sensitive malignant clones encounter resurgence.

2.3.2 Sunitinib

Sunitinib is a TKI with activity against Kit (CD117), PDGF-R β and VEGFR. In patients with GIST who progress on imatinib, sunitinib has shown to be effective as second line therapy (Demetri et al. 2006, 2009; Heinrich et al. 2008). Although it demonstrated in vitro activity in wild-type, exons 11 and 9 mutated tumours, benefit in clinical trials translated into the exon 9 group. This is

postulated to be due to dimerisation of the receptor as a distinct mechanism of activation compared to exon 11 mutations (Dibb et al. 2004; Yuzawa et al. 2007). However, clinical trials will be required to test sunitinib TKI naïve GIST to exclude selection bias.

2.3.3 Sorafenib

Sorafenib is active against Raf kinase, PDGFR, VEGF receptor 2 and 3 kinases and c-Kit. Targeting signalling through the Ras-Raf-MAPK-Erk pathway, it has been studied in a phase III trial (Llovet et al. 2008) in advanced hepatocellular carcinoma (HCC). Patients were randomised to receive sorafenib or placebo. In the treated group, a significant improvement in median OS and median time to radiological progression was found (10.7 vs. 7.9 months, 5.5 vs. 2.8 months, respectively).

A separate analysis of signalling pathway proteins in HCC tumour samples show activation of Erk pathway correlated with low levels of nuclear β -cat and high levels of *p*-mTOR, distinguishing them from normal liver parenchyma. Better survival of 6 months or more in patients treated with sorafenib was linked to tumours with a high level of nuclear *p*-Erk with low level of *p*-Akt and *p*-GSK3 β in tumour cells. In addition, high levels of VEGFR, *p*-Erk and *p*-Src in endothelial cells were associated with high microvessel density and micrometastases (Ji et al. 2009).

2.3.4 Erlotinib

Erlotinib was the first targeted therapy to show survival benefit in a phase III trial involving advanced pancreatic cancer. Compared to gemcitabine alone, it led to a modest but statistically significant improvement in survival at 12 months (23 vs. 17%) and HR for OS (0.82; 95% CI, 0.69–0.99, $p = 0.038$) (Moore et al. 2007).

However, interesting questions remain relating to the mechanism of action. *KRAS* mutation was found in 79% of patients in the trial and analysis of subgroups shows advantage irrespective of EGFR expression, given variation in laboratory testing techniques. One hypothesis is anti-EGFR therapy targets EGFR expressing endothelial cells in the tumour microenvironment stimulated by EGF-like peptides expressed at high levels in pancreatic cancer (Bruns et al. 2000; Normanno and De Luca 2007; Salomon et al. 1995). Although erlotinib may play a part in angiogenesis, it may be an early indirect effect on cellular proliferation that limits the condition conducive to VEGF production. This may explain the negative results in large phase III clinical trials where the addition of bevacizumab to gemcitabine and erlotinib did not result in OS benefit (Vervenne et al. 2008; Van Cutsem et al. 2009c). An on-going phase I/II TARGET trial addresses the efficacy and safety of gemcitabine and capecitabine together with erlotinib and bevacizumab.

2.3.5 Gefitinib

Overexpression of EGFR has been found to be a negative prognostic factor in oesophageal carcinoma (Yacoub et al. 1997). Several non-randomised phase II trials investigating gefitinib in patients with advanced oesophageal carcinoma

demonstrated an overall response rate between 30 and 58% (Janmaat et al. 2006; Ferry et al. 2004, 2007). Currently the UK COG trial is underway randomising patients between gefitinib and placebo in patients with relapsed advanced oesophageal cancer.

3 Network Interactions and Resistance to Targeted Therapies

The interaction of various signalling networks suggests that tumours may escape interruption of downstream signalling by TKI through by-passing blocked channels. This re-routing of messaging system enables continued progression despite disabling a known target. The interplay of signalling pathways is more elaborate than initially thought and appears to contribute to tumour progression and resistance to therapy.

However, current trials show that efficacy is not necessarily improved by combining targeted drugs. For example, two CRC trials using VEGF together with EGFR-directed mAbs and chemotherapy demonstrate a detrimental effect on survival (Hecht et al. 2009; Tol et al. 2009). Apart from increased toxicity, combining targeted agents worsened survival especially in patients with *KRAS* mt tumours as confirmed on meta-analysis (Zhou et al. 2009). The choice of chemotherapy platform may also have a negative impact. In the OPUS trial where FOLFOX-4 was used in combination with cetuximab, patients with *KRAS* mt tumours had a trend to reduced median PFS compared to FOLFOX-4 alone (5.5 vs. 8.6 months, HR 1.83; 95% CI, 1.095–3.056, $p = 0.192$) (Bokemeyer et al. 2009). A negative effect of reduced median PFS was again seen when FOLFOX was added to panitumumab in the PRIME study (7.3 months in chemotherapy-only arm vs. 8.8 months for combination treatment; HR 1.29; 95% CI, 1.04–1.62, $p = 0.0227$) (Douillard 2009). Early results from the COIN study (Adams 2009) investigating FOLFOX or CAPOX in combination with cetuximab suggested a worse outcome with the capecitabine combination. These trials indicate a negative interaction between targeted agents and oxaliplatin or capecitabine. The mechanism of interaction is of considerable interest and remains to be elicited.

Forty to seventy percentage of *KRAS* wt tumours do not benefit from EGFR inhibition. The varied permutation and interaction between signalling pathways is only beginning to be understood. In a report investigating chemorefractory mCRC found mutations in *KRAS*, *BRAF* and *NRAS* were mutually exclusive and occur independently in over 47% of cases (Lambrechts et al. 2009). *BRAF* wt also conferred a significantly better PFS and OS. Mutation in *BRAF* and *NRAS* occurred in 9.8 and 5% of *KRAS* wt CRC tumours, respectively. Best outcome was associated with *KRAS/BRAF/NRAS* wt. Twelve percentage carried the independent PI3 K mutation but this was not correlated with tumour response or outcome. In advanced gastric cancer, however, *KRAS* and *BRAF* status was not predictive of response to cetuximab (Stella et al. 2009). In addition, mutation rates of *KRAS*

were lower compared to colorectal tumours at 11.4 and 2.3%, respectively. Similarly *KRAS* mutation was found in only 12% of cholangiocarcinoma and did not impact on treatment response to EGFR inhibition (Gruenberger et al. 2009).

Interaction between receptors may also impact on prognosis. In a study of 66 patients with mCRC receiving irinotecan and cetuximab, partial response rate was 50% in *KRAS* wt and IGF-R1 tumours but 5% with a co-existent IGF-R1 mutation. A statistically significant difference in time to tumour progression was also found (11 vs. 3.2 months). Thus IGF-R1 status is implicated as a predictive factor for resistance in tumours treated with anti-EGFR therapy (Scartozzi et al. 2009).

Mutations in exons 13/14 may be coexpressed with exon 17 in GIST tumours. Although both are involved in signal transduction, they occur in distinct parts of the pathway. The former involves changes in the ATP binding site and the latter in the ATP activation loop. However, they are linked by a common primary mutation (V560D). Thus stopping treatment directed at one arm of the mutational defect due to development of a second defect at the first sign of resistance may also disinhibit activity in the second mutational site leading to rapid tumour growth. For example, although tumours resistant to imatinib due to secondary mutation in exons 13/14 were sensitive to second-line sunitinib, this mutation was coexpressed as a mutation in exon 17 (V560D) which was not susceptible to either drugs (Heinrich et al. 2008). Therefore removing collateral inhibition may result in tumour flare.

4 Conclusion

The role of targeted treatment in cancer has developed rapidly in recent years. With greater understanding of the biology of various cancers, new drugs have been developed and tested in the clinical setting demonstrating efficacy and extending the treatment paradigm beyond that of traditional chemotherapy. Current data bridging in vitro studies and clinical trials demonstrate the mechanism of action of targeted therapy is more than just a proof of concept in translational cancer research. However, understanding the interplay between numerous receptor-signalling pathways has presented to us a bigger challenge than simply addressing individual targets. More research is warranted both to greater understand the basic molecular biology of cancer as well as to develop further randomised clinical trials in addressing the potential of targeted therapy in this era of biological treatment in cancer.

References

- Adam R et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. *Ann Surg* 240:644–657
- Adams R (2009) Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). *Eur J Cancer Suppl* 7:10

- Amado RG et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 26:1626–1634
- Bang Y et al (2009) Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. *J Clin Oncol (Meeting Abstracts)* 27:4556
- Beltran PJ et al (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. *Mol Cancer Ther* 27:5800–5807
- Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 27:663–671
- Bruns CJ et al (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. *Cancer Res* 60:2926–2935
- Cunningham D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 351:337–345
- Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 368:1329–1338
- Demetri GD et al (2009) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clin Cancer Res* 15:5902–5909
- Dibb NJ, Dilworth SM, Mol CD (2004) Switching on kinases: oncogenic activation of BRAF and the PDGFR family. *Nat Rev Cancer* 4:718–727
- Douillard J (2009) Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: the PRIME trial. *Eur J Cancer Suppl Abstr* 10LBA 7:6
- Edkins S et al (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. *Cancer Biol Ther* 5:928–932
- Ferry DR et al (2004) Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. *J Clin Oncol (Meeting Abstracts)* 22:4021
- Ferry DR et al (2007) A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. *Clin Cancer Res* 13:5869–5875
- Giacchetti S et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. *Ann Oncol* 10:663–669
- Giantonio BJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 25:1539–1544
- Grothey A et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). *J Clin Oncol* 26:5326–5334
- Gruenberger B et al (2009) K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study. *J Clin Oncol (Meeting Abstracts)* 27:4586
- Guo YS et al (1995) Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions. *J Am Coll Surg* 181:145–154
- Hecht JR et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol* 27:672–680
- Heinrich MC et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 299:708–710

- Heinrich MC et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 26:5352–5359
- Hirota S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 279:577–580
- Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 350:2335–2342
- Janmaat ML et al (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. *J Clin Oncol* 24:1612–1619
- Ji Y et al (2009) Analysis of signal pathway activation in hepatocellular carcinoma: association with clinical outcomes to sorafenib in Chinese patients. *J Clin Oncol (Meeting Abstracts)* 27:e15529
- Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. *J Clin Oncol* 27:199–205
- Karapetis CS et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 359:1757–1765
- Lambrechts D et al (2009) The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. *J Clin Oncol (Meeting Abstracts)* 27:4020
- Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 359:378–390
- Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 25:1960–1966
- Normanno N, De Luca A (2007) Erlotinib in pancreatic cancer: are tumor cells the (only) target? *J Clin Oncol* 25:5836–5837
- Pavelic K, Bukovic D, Pavelic J (2002) The role of insulin-like growth factor 2 and its receptors in human tumors. *Mol Med* 8:771–780
- Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol* 19:183–232
- Scartozzi M et al (2009) Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. *J Clin Oncol (Meeting Abstracts)* 27:4017
- Singer S et al (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. *J Clin Oncol* 20:3898–3905
- Sobrero AF et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. *J Clin Oncol* 26:2311–2319
- Stella G et al (2009) KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. *J Clin Oncol (Meeting Abstracts)* 27:e15503
- Tol J et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med* 360:563–572
- Ueda S et al (2006) Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. *Mod Pathol* 19:788–796
- Van Cutsem E et al (2009a) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 360:1408–1417
- Van Cutsem E et al (2009b) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). *J Clin Oncol (Meeting Abstracts)* 27:zLBA4509

- Van Cutsem E et al (2009c) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol* 27:2231–2237
- Van Glabbeke MM et al (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts). *J Clin Oncol (Meeting Abstracts)* 25:10004
- Vervenne W et al (2008) A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. *J Clin Oncol (Meeting Abstracts)* 26:4507
- Verweij J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 364:1127–1134
- Wagner AD, Moehler M (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. *Curr Opin Oncol* 21:381–385
- Watkins DJ et al (2009) A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer. *J Clin Oncol (Meeting Abstracts)* 27:4127
- Wolmark N et al (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. *J Clin Oncol (Meeting Abstracts)* 27:LBA4
- Yacoub L, Goldman H, Odze RD (1997) Transforming growth factor- α , epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. *Mod Pathol* 10:105–112
- Yuzawa S et al (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. *Cell* 130:323–334
- Zecevic M et al (2006) IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. *J Natl Cancer Inst* 98:139–143
- Zhou Z, Walsh WV, Bathini VG, Piperdi B (2009) Anti-VEGF and anti-EGFR monoclonal antibodies (Mabs) in the first-line therapy for metastatic colorectal cancer: a meta-analysis. *J Clin Oncol (Meeting Abstracts)* 27:e15012

Genetics of Inflammation in the Gastrointestinal Tract and How it Can Cause Cancer

Mairi H. McLean and Emad M. El-Omar

Abstract

Genetic epidemiology is an important discipline that is helping to unravel the aetiology and pathogenesis of complex human diseases. In the context of gastrointestinal malignancy, the paradigm model of host genetic influence on disease outcome is *H. pylori*-associated gastric adenocarcinoma. This cancer represents a classic example of an inflammation-induced malignancy and highlights the importance of host genetics in disease development. This chapter gives an insight into how genetic epidemiology can play an important role in the development of gastric cancer. Increasing our understanding of host genetics in cancer development may allow particularly susceptible individuals to be targeted for screening or treatment to reduce risk of future malignant transformation.

Contents

1	<i>Helicobacter pylori</i> and Gastric Cancer	174
2	Role of IL-1 β in Gastric Cancer Risk	175
3	Confirmation of the Role of IL-1 β in Gastric Cancer Pathogenesis	177
4	Tumour Necrosis Alpha (TNF- α)	177
5	Interleukin-8.....	177
6	COX-2 and MMP-9.....	178
7	Role of Innate Immune Response Genes	179
8	Genome-Wide Association Studies and Gastric Cancer.....	180
9	Overall Contribution of a Host Pro-Inflammatory Genetic Makeup to Pathogenesis of Gastric Cancer.....	180
10	Conclusion	181
	References.....	181

M. H. McLean · E. M. El-Omar (✉)
Gastrointestinal Research Group, Division of Applied Medicine,
School of Medicine and Dentistry, Institute of Medical Sciences,
Aberdeen University, Foresterhill, Aberdeen, Scotland, AB25 2ZD, UK
e-mail: e.el-omar@abdn.ac.uk

Almost 150 years ago, Rudolf Virchow identified leucocytes within neoplastic lesions and hypothesised that malignant change arose within areas of chronic inflammation. This was assumed to be a consequence of the cancer process per se. The last few decades, however, have seen a surge in research interest in the relationship between inflammatory pathways and malignancy (Balkwill and Mantovani 2001; Coussens and Werb 2002; Macarthur et al. 2004). Certainly, the understanding of the mechanisms of inflammatory activity and its role in development of disease has escalated and there can be no doubt that carcinogenesis in a variety of body sites are related to tissue inflammation. Concentrating on the gastrointestinal tract, this is particularly evident in *Helicobacter pylori* (*H. pylori*)-associated gastric cancer, chronic hepatitis C-associated hepatocellular carcinoma and inflammatory bowel disease associated colorectal cancer. This chapter is focussed on discussing the influence of genetic makeup on the process of inflammatory linked cell transformation to cancer.

It must be appreciated that genetic epidemiology is only one part of the jigsaw, a contributing part of the complex web of multifactorial influences determining outcome in human disease processes. A strategy employing population-based genetic epidemiology calculates risk of developing a particular disease in relation to host genotype, and has a particular role in unravelling the complexities of common chronic diseases with strong environmental influences. Specifically, single nucleotide polymorphisms of pro-inflammatory genes in the context of host susceptibility have been extensively studied. SNP's are 'common' mutations, occurring at >1% within the general population, and describes the variation in DNA sequence between the two alleles of a particular gene. Differing genotypes can manipulate phenotypic character and therefore be associated with risk of developing overt pathology, in specific racial groups. Overall, it is estimated that there are over 10 million SNPs within the human genome and this is probably just the tip of the iceberg, with a large number not identified as yet. Luckily, the majority of these will not have functional consequence, occurring either in non-coding sections of DNA or having no influence on the final protein product. However, it is appreciated that carriage of a particular genotype can lead to downstream functional consequences, either silencing or promoting the expression of downstream gene targets that can positively influence pathogenesis of disease.

1 *Helicobacter pylori* and Gastric Cancer

In the context of gastrointestinal malignancy, the paradigm model of host genetic influence on disease outcome is *H. pylori*-associated gastric adenocarcinoma. This cancer represents a classic example of an inflammation-induced malignancy, and highlights the importance of host genetics in disease development. For this reason, this chapter will focus on *H. pylori*-induced gastric cancer to illustrate the role of host genetics in the pathogenesis of disease. Gastric adenocarcinoma remains a major health problem worldwide, with 900,000 new cases diagnosed in 2002, mainly in Eastern Asia and with increasing incidence in the developing world

(Parkin et al. 2005). Eight thousand new cases are diagnosed each year in the UK, and despite advances in treatment, the prognosis remains poor. Clearly, this disease carries significant burden in terms of patient morbidity, mortality and healthcare economics. A major advance in the fight against this malignancy came with the recognition of the role of *H. pylori* infection in its pathogenesis. *H. pylori* is a Gram-negative, urease-positive bacillus, acquired during childhood, probably via the faecal–oral or gastric–oral routes. This infection persists throughout life unless treated with an antibiotic-based eradication regime. The bacteria mainly reside on the surface mucus gel layer, with little invasion of the gastric glands (Amieva and El-Omar 2008). Despite this, the host responds with an impressive humoral and cell-mediated immune response. In most cases, spontaneous clearance is rare leading to chronic carriage of the bacteria. Persistent carriage of the bacteria in itself does not necessarily lead to development of gastric malignancy, at least in the majority of cases. It is now well established that three separate phenotypic outcomes exist. The majority of individuals colonised with *H. pylori* will be asymptomatic and will not develop clinically significant disease. In this group, carriage of the bacteria could be described as commensal. In contrast, chronic carriage can be pathogenic, resulting in one of two significant disease phenotypes. The first of these is antral-predominant gastritis, associated with high gastric acid secretion and duodenal ulceration, the so called ‘duodenal ulcer phenotype’. Alternatively, an infected individual may develop corpus predominant chronic inflammation, associated with gastric atrophy and hypochlorhydria, a pre-malignant phenotype, associated ultimately with the development of gastric adenocarcinoma (Amieva and El-Omar 2008).

These diverse clinical outcomes of chronic *H. pylori* infection are mutually exclusive with the development of the ‘duodenal ulcer’ phenotype protective against subsequent gastric malignancy (Hansson et al. 1996). Therefore, it is clear that infection with *H. pylori* can lead to several diverse disease phenotypes and it is now known that host genetic factors play a key role in determining outcome. Specifically, the course and magnitude of cytokine driven inflammatory response, induced and perpetuated by chronic *H. pylori* colonisation is largely dependent on genetic susceptibility. Overall, genetic variation in important cytokine genes, both pro- and anti-inflammatory, impart an important influence on the final outcome.

2 Role of IL-1 β in Gastric Cancer Risk

The pro-inflammatory cytokine IL-1 β is recognised as an important candidate in the development of gastric malignancy, reflecting profound pro-inflammatory action, up-regulation in response to *H. pylori* infection, and potent gastric acid suppression (El-Omar et al. 2001). The IL-1 gene cluster lying within a 430 kb region on chromosome 2q contains three related genes, namely, *IL-1A*, *IL-1B* and *IL-1RN*, which encode for pro-inflammatory cytokines IL-1 α and IL-1 β as well as their endogenous receptor antagonist IL-1ra, respectively. Three diallelic polymorphisms at the *IL-1B* loci have been reported, all representing C–T or T–C transitions, at positions –511, –31, and +3,954 bp from the transcriptional start

site (Bidwell et al. 2001). The *IL-1RN* gene has a penta-allelic 86 bp tandem repeat (VNTR) in intron 2.

In a Caucasian population of gastric cancer relatives, polymorphisms in the *IL-1* gene cluster were found to be associated with increased risk of developing pre-malignant gastric changes of gastric atrophy and hypochlorhydria, in response to *H. pylori* infection (El-Omar et al. 2000). Specifically, carriage of the *IL-1B*-31*C or -511*T and *IL-1RN**2/*2 genotypes were associated with these pre-malignant gastric changes. This association also extends into the development of overt non-cardia gastric adenocarcinoma, with an estimated odds ratio of 1.6 (95% CI, 1.2–2.2) and 2.9 (95% CI, 1.9–4.4) for carriage of *IL-1β*-31*C/-511*T and *IL-1RN**2/*2, respectively (El-Omar et al. 2000). In terms of other upper gastrointestinal tract malignancies, this pro-inflammatory genotype was not associated with gastric cancer of the cardia, or oesophageal malignancy of either glandular or squamous origin (El-Omar et al. 2003). This is in keeping with the underlying physiological consequence of enhanced *IL-1β* signalling and particularly, reflects its potent acid inhibitory action. These findings have been confirmed independently in both Caucasian (Figueiredo et al. 2002; Machado et al. 2001) and other ethnic groups, specifically Asian (Furuta et al. 2002; Zeng et al. 2003) and Hispanic (Garza-Gonzalez et al. 2005) populations. Machado et al. were the first to confirm the association between *IL-1* gene markers and gastric cancer in Caucasians and reported similar results to those reported by the initial study. They then later investigated the combined influence of pro-inflammatory *IL-1* genotypes and *H. pylori* bacterial virulence factors (*cagA* positive, *VacA s1* and *VacA m1*), highlighting a potentially important interaction between host and bacterium in the pathogenesis of gastric cancer. Specifically, combination of high-risk bacterial/host genotype conferred the greatest risk of developing gastric malignancy (Figueiredo et al. 2002).

Not all studies, however, have confirmed the association between genetic variability of the *IL-1* loci and gastric cancer. There are a number of reasons why this may be the case. Firstly, the reported discrepancies may reflect issues with study design, such as use of inappropriate controls or an underpowered study population. Overall, within the last few years, meta-analyses of *IL-1B* genotype as a risk factor for gastric cancer have been published (Wang et al. 2007; Camargo et al. 2006; Kamangar et al. 2006) and these suggest that genetic variation in the pro-inflammatory gene, *IL-1β*, is a risk factor for developing gastric malignancy. However, it is likely that there are other influences. Positive associations between genotype and disease appear to be demonstrated more readily in low incidence compared with high incidence areas, suggesting that background prevalence of gastric cancer in a population is an important factor when carrying out these studies. The haplotype context is also an important consideration for genetic risk associations. This describes the relationship between haplotype structure and gene regulation. Specifically, the question of whether individual SNPs within a gene promoter region (*IL-1β* in this case) might affect promoter function was raised. It has also recently been recognised that potential synergy between two or more genetic markers may influence phenotypic outcome. For example, association between carriage of *IL-1B*-31C allele and gastric cancer was identified but only in individuals with *GTF2A1* GG genotype (Lee et al. 2007).

3 Confirmation of the Role of IL-1 β in Gastric Cancer Pathogenesis

A crucial piece of evidence that confirmed the apparent role of IL-1 β in *H. pylori*-induced gastric carcinogenesis came from a transgenic mouse model in which IL-1 β overproduction was targeted to the stomach by the H⁺/K⁺ ATPase beta promoter (Tu et al. 2008). With overexpression of IL-1 β confined to the stomach, these transgenic mice had a thickened gastric mucosa, produced lower amounts of gastric acid and developed severe gastritis followed by atrophy, intestinal metaplasia, dysplasia and adenocarcinoma. Crucially, these IL-1 β transgenic mice proceeded through a multistage process that mimicked human gastric neoplasia. These changes occurred even in the absence of *H. pylori* infection, which when introduced led to an acceleration of these abnormalities. Most interestingly, the pathological changes including the progression to gastric cancer were prevented by infusion of interleukin-1 receptor antagonist, proving beyond doubt that IL-1 β is responsible for the pathological effects (Tu et al. 2008).

From these initial studies, interest in the role of host genetics in the pathogenesis of gastric cancer escalated to include other key inflammatory genes. The target candidate genes under investigation mirror the cytokine response evoked by *H. pylori* infection and included potent pro-inflammatory cytokines, such as TNF α , IL-8 and IL-6 and also genes encoding for key inflammatory mediators such as COX-2 and MMP-9. There have been many other studies. The list of genes investigated is extensive and we have chosen to expand on a few of these to illustrate the expanding knowledge base in this field.

4 Tumour Necrosis Alpha (TNF- α)

TNF was recognised as a potentially important cytokine in the development of gastric malignancy, due to its powerful pro-inflammatory action and acid-inhibitory effect, albeit weaker than that of IL-1 β . The G > A polymorphism at position -308 within the TNF- α gene was identified as significant, with carriage of the pro-inflammatory A allele associated with a 2-fold increase in malignant phenotype (El-Omar et al. 2003). This finding was subsequently reproduced in a population of similar ethnicity (Machado et al. 2003), and a recent meta-analysis confirmed the role of *TNF-A* polymorphisms in gastric cancer risk (Gorouhi et al. 2008).

5 Interleukin-8

Interleukin-8 (IL-8) is a potent pro-inflammatory cytokine, involved not only in recruitment of neutrophils and macrophages at the site of inflammatory activity, but also exerting a multitude of additional functional capabilities, many central to

tumour biology. IL-8 is mitogenic and angiogenic, through linked expression of MMP's, namely MMP-2 and 9, influences tumour cell motility so that tumour invasion is enhanced. IL-8 has been found to be increased in a number of cancers, including those of the GI tract (Xie 2001). There is a well defined promoter T > A polymorphism on the IL-8 gene at position -251. Functionally, carriage of the A allele results in enhanced IL-8 expression within the gastric mucosa of *H. pylori* infected individuals. The association of this genotype to overt gastric malignancy however, remains under debate, with both positive and negative associations reported across different ethnic groups (Ohyauchi et al. 2005; Savage et al. 2006; Taguchi et al. 2005) .

6 COX-2 and MMP-9

Cyclo-oxygenase (COX) is the key rate limiting enzyme in arachidonic acid metabolism, resulting in the production of many active prostaglandins, prostacyclins and thromboxanes. There are two recognised isoforms. COX-1 is constitutively expressed in normal cellular homeostasis. In contrast, COX-2 is inducible and expressed in response to mainly inflammatory stimuli, growth factors and mitogens. It is now widely recognised that COX-2 activity is implicated in a wide range of cell processes that are central to cell function and life cycle, such as angiogenesis, cell proliferation, inflammatory response and apoptosis (Wang and DuBois 2006). Clearly, this could play an important role in the development of malignancy. COX-2 is known to be up-regulated in gastric carcinoma. Sitarz et al. (2008) found a positive association between gastric cancer and carriage of the G allele at position -765 of the COX-2 gene in a Dutch population. Overall, a systematic review published recently, assessing the role of 17 SNP's within the COX-2 gene on gastrointestinal malignancy, concluded that the polymorphisms found at positions -1329A, -899C and *429TT were associated with up to a 3-fold increased risk of gastric cancer (Pereira et al. 2010).

MMP-9 is a key inflammatory mediator released from neutrophils and macrophages within areas of inflammatory activity and has been implicated in carcinogenesis at a number of body sites, mainly due to breakdown of collagen matrix, supporting tumour cell invasion and exerting a positive influence on angiogenesis. MMP-9 has been associated with pathobiological behaviour of gastric malignancy, including tumour size, invasion and lymphatic metastasis (Zheng et al. 2006). Recently, a study on a Chinese population identified a 3-fold increase risk of developing lymph node metastasis from primary gastric cancer with carriage of 2 SNP's within the MMP-9 gene (Tang et al. 2008).

When concurrent carriage of pro-inflammatory alleles in up to four genes (*IL-1B*, *IL-1-RN*, *TNF-A* and *IL-10*) was assessed in relation to risk of gastric cancer, the risk progressively increased along with an increasing pro-inflammatory genotype, such that, when three or four of the pro-inflammatory alleles were present, risk increased to 27-fold (El-Omar et al. 2003).

7 Role of Innate Immune Response Genes

Overall, in considering the pathogenesis of this disease and the role of genetic variation within this process, researchers have investigated both bacterial variability within microbial virulence factors as well as the host cytokine response to persistent infection. In addition, the investigative focus has included the initial contact between bacterium and host, and it is now clear that genetic variation within the adaptive immune response involved in this initial interaction is an important consideration. Lipopolysaccharide (LPS) is found in the cell membrane of Gram-negative bacteria, including *H. pylori*, and binds to trans-membranous pattern-recognition receptor, *TLR-4*, expressed on immune cells of the adaptive immune system, namely macrophages. Binding to this receptor activates a signalling cascade involving MyD88, IL-1 receptor associated kinase and TRAF6, to activate NF κ B and mitogen-activated protein kinase pathways, which results in a plethora of cytokines and pro-inflammatory mediators being released into the environment. There are functionally relevant polymorphisms in the *TLR-4* gene that profoundly alters host response to bacterial challenge. In particular, an A–G transition at position +896 on exon 4 leads to change in protein sequence, specifically replacement of aspartic acid to glycine at position 299. This ultimately alters the extracellular domain of the receptor and its overall function, renders the cell hyporesponsive to an LPS challenge through inhibition of ligand binding, inhibition of protein binding and by altering transport of the receptor to the cell membrane, reducing capacity of the cell to deal with pathogenic challenges. Initially, the immune response is jaded. However, overall, due to a reduction in IL-10 secreting regulatory cells, the immune response that is able to be activated through alternative signalling mechanisms becomes overwhelming and exaggerated in magnitude. Not surprisingly, it was hypothesised that defective signalling through *TLR-4/H. pylori* interaction associated with carriage of genetic variation could lead to an exaggerated immune response to this organism and contribute to the development of gastric malignancy. Indeed, it has been found that carriage of *TLR-4* +896G confers an 8-fold increase for pre-malignant change in 3 Caucasian populations, with profound corporeal inflammation and gastric atrophy. In terms of malignancy per se, carriage of the variant allele conveys a doubling of risk (Hold et al. 2007).

Santini et al. (2008) showed that another *TLR4* polymorphism increases risk of intestinal-type gastric cancer. Thus, the *TLR4* Thr399Ile was associated with an increased hazard ratio of 5.38, 95% CI 1.652–8.145, $p = 0.006$. More work is required on elucidating the full impact of polymorphisms within the toll-like receptors and their associated pathways.

There are other reports of innate immune response gene polymorphisms being associated with increased risk of gastric cancer. Mannose binding lectin is an antigen-recognition molecule involved in systemic and mucosal innate immunity. It is able to bind to a range of microbes and subsequently kill them by activating the complement system and promoting complement-independent opsonophagocytosis.

Baccarelli et al. (2006) showed that polymorphisms in the mannose binding lectin-2 gene (*MBL2*) were associated with increased risk of gastric cancer. In haplotype analysis, the HYD haplotype was associated with increased risk of stomach cancer when compared with HYA, the most common haplotype (OR = 1.9, 95% CI 1.1–3.2; $p = 0.02$). Further analyses to examine the joint effect of *MBL2* and *IL-1B* polymorphisms indicated that the combination of at-risk *IL-1B* genotypes (CT or TT at location –511) and HYD *MBL2* haplotype was associated with a 3.5-fold risk (OR = 3.5, 95% CI 1.6–7.6; $p = 0.001$). The findings suggest that the codon 52 D *MBL2* variant causing a cysteine > arginine replacement is specifically associated with gastric cancer risk.

8 Genome-Wide Association Studies and Gastric Cancer

Genotyping technology has advanced dramatically in the past 5 years and it is now possible to study hundreds and thousands of SNP's simultaneously. This approach, termed genome-wide association studies, was recently used by Sakamoto et al. (2008) to study gastric cancer in the Japanese population. Employing a two-stage genome-wide association study (stage 1: 85,576 SNPs on 188 cases and 752 references; stage 2: 2,753 SNPs on 749 cases and 750 controls) identified a significant association between an intronic SNP (rs2976392) in *PSCA* (prostate stem cell antigen) and diffuse-type gastric cancer (allele-specific OR = 1.62, 95% CI = 1.38–1.89, $P = 1.11 \times 10^{-9}$). Interestingly, the association was far less significant in intestinal-type gastric cancer. The *PSCA* gene is possibly involved in regulating gastric epithelial-cell proliferation and it will be very interesting to find out how it influences susceptibility to diffuse-type gastric cancer.

9 Overall Contribution of a Host Pro-Inflammatory Genetic Makeup to Pathogenesis of Gastric Cancer

It appears that subjects with a pro-inflammatory genetic makeup based on a combination of markers from cytokine/chemokine genes (e.g. *IL-1B*, *TNF-A*, *IL-10*, *IL-8*) and the innate immune response (e.g. *TLR4*, *MBL2*), respond to *H. pylori* infection by creating a gastric environment that is chronically inflamed and with reduced acidity. The damage is exacerbated if the infecting organisms are particularly virulent, and particularly if CagA positive. This bacterial protein has recently been shown to act as an oncoprotein and there is no doubt that its presence heightens the inflammatory process further (Ohnishi et al. 2008). This environment is conducive to the growth of other non-*H. pylori* bacteria within the gastric milieu, leading to sustained inflammation and oxidative/genotoxic/oncogenic stress. Subjects with the same pro-inflammatory polymorphisms may respond in the same exaggerated manner to these non-*H. pylori* bacteria, thus maintaining the pro-neoplastic drive. This may explain why *H. pylori* is not required in the later stages of gastric carcinogenesis and why it is often absent from gastric tumor tissue.

10 Conclusion

Overall, this chapter has given a brief insight into how host genetics can play an important role in the development of malignancy. Clearly, this is only part of the story, yet an important strand of the complex web of disease pathogenesis. Increasing our understanding of host genetics in cancer development may allow particularly susceptible individuals to be targeted for screening or treatment to reduce risk of future malignant transformation, for example, targeting those people who may benefit from *H. pylori* eradication therapy in an attempt to reduce gastric cancer prevalence. However, this benefit may be theoretical as the outcome in altering the natural progression of this disease is unknown. In addition, the currently recognised genetic risk markers are very common and do not carry the necessary degree of specificity required for a screening test. As the genetic revolution continues and technology advances, it will be possible to define a much more robust genetic profile that could be used for screening. This would certainly be a worthwhile achievement.

References

- Amieva MR, El-Omar EM (2008) Host-bacterial interactions in *Helicobacter pylori* infection. *Gastroenterology* 134:306–323
- Baccarelli A, Hou L, Chen J, Lissowska J, El Omar EM, Grillo P, Giacomini SM, Yaeger M, Bernig T, Zatonski W, Fraumeni JF Jr, Chanock SJ, Chow WH (2006) Mannose-binding lectin-2 genetic variation and stomach cancer risk. *Int J Cancer* 119:1970–1975
- Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? *Lancet* 357: 539–545
- Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S (2001) Cytokine gene polymorphism in human disease: on-line databases, supplement 1. *Genes Immun* 2:61–70
- Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG (2006) Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 15:1674–1687
- Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* 420:860–867
- El-Omar EM, Oien K, Murray LS, El Nujumi A, Wirz A, Gillen D, Williams C, Fullarton G, McColl KE (2000a) Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of *H. pylori*. *Gastroenterology* 118:22–30
- El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2000b) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 404: 398–402
- El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2001) The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. *Nature* 412:99
- El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 124:1193–1201

- Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, Van Doorn LJ, Carneiro F, Sobrinho-Simoes M (2002) Helicobacter pylori and Interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J Natl Cancer Inst* 94:1680–1687
- Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimurra H (2002) Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. *Gastroenterology* 123:92–105
- Garza-Gonzalez E, Bosques-Padilla FJ, El-Omar E, Hold G, Tijerina-Menchaca R, Maldonado-Garza HJ, Perez-Perez GI (2005) Role of the polymorphic IL-1B, IL-1RN and TNF-A genes in distal gastric cancer in Mexico. *Int J Cancer* 114:237–241
- Gorouhi F, Islami F, Bahrami H, Kamangar F (2008) Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. *Br J Cancer* 98:1443–1451
- Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, Fraumeni JF Jr, Adami HO (1996) The risk of stomach cancer in patients with gastric or duodenal ulcer disease. *N Engl J Med* 335:242–249
- Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF Jr, El-Omar EM (2007) A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. *Gastroenterology* 132:905–912
- Kamangar F, Cheng C, Abnet CC, Rabkin CS (2006) Interleukin-1B polymorphisms and gastric cancer risk—a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 15:1920–1928
- Lee KA, Park JH, Sohn TS, Kim S, Rhee JC, Kim JW (2007) Interaction of polymorphisms in the interleukin 1B-31 and general transcription factor 2A1 genes on the susceptibility to gastric cancer. *Cytokine* 38:96–100
- Macarthur M, Hold GL, El-Omar EM (2004) Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. *Am J Physiol Gastrointest Liver Physiol* 286:G515–G520
- Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simoes M (2001) Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. *Gastroenterology* 121:823–829
- Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Castro AC, Campos ML, Van Doorn LJ, Caldas C, Seruca R, Carneiro F, Sobrinho-Simoes M (2003) A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. *Gastroenterology* 125:364–371
- Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M (2008) Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. *Proc Natl Acad Sci USA* 105:1003–1008
- Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosegawa T (2005) The polymorphism interleukin 8–251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. *Gut* 54:330–335
- Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. *CA Cancer J Clin* 55:74–108
- Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, nis-Ribeiro M (2010) COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. *Eur J Gastroenterol Hepatol* 22:607–613
- Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, Matsuda N, Nakamura T, Hyodo I, Nishina T, Yasui W, Hirose H, Hayashi M, Toshiro E, Ohnami S, Sekine A, Sato Y, Totsuka H, Ando M, Takemura R, Takahashi Y, Ohdaira M, Aoki K, Honmyo I, Chiku S, Aoyagi K, Sasaki H, Ohnami S, Yanagihara K, Yoon KA, Kook MC, Lee YS, Park SR, Kim CG, Choi IJ, Yoshida T,

- Nakamura Y, Hirohashi S (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. *Nat Genet* 40:730–740
- Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, Calvieri A, Pizzagalli F, Graziano N, Ferraro E, Lorino G, Altomare A, Magnani M, Graziano F, Tonini G (2008) Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. *Clin Exp Immunol* 154:360–364
- Savage SA, Hou L, Lissowska J, Chow WH, Zatonski W, Chanock SJ, Yeager M (2006) Interleukin-8 polymorphisms are not associated with gastric cancer risk in a Polish population. *Cancer Epidemiol Biomarkers Prev* 15:589–591
- Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ, Milne AN (2008) The COX-2 promoter polymorphism-765 G > C is associated with early-onset, conventional and stump gastric cancers. *Mod Pathol* 21:685–690
- Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2005) Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. *Cancer Epidemiol Biomarkers Prev* 14:2487–2493
- Tang Y, Zhu J, Chen L, Chen L, Zhang S, Lin J (2008) Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. *Clin Cancer Res* 14:2870–2877
- Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC (2008) Overexpression of interleukin-1[beta] induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. *Cancer Cell* 14:408–419
- Wang D, DuBois RN (2006) Prostaglandins and cancer. *Gut* 55:115–122
- Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ (2007) Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. *Int J Cancer* 120:552–562
- Xie K (2001) Interleukin-8 and human cancer biology. *Cytokine Growth Factor Rev* 12:375–391
- Zeng ZR, Hu PJ, Hu S, Pang RP, Chen MH, Ng M, Sung JY (2003) Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. *Gut* 52:1684–1689
- Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y (2006) Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. *Anticancer Res* 26:3579–3583

Endoscopic Methods

Gaius Longcroft-Wheaton and Pradeep Bhandari

Abstract

Endoscopic methods to recognise and treat early gastrointestinal malignancies have increased in recent years. This has resulted in more lesions being diagnosed at an early stage and a shift away from invasive surgery towards endoscopic resection. However, it is necessary for the endoscopist to understand the key principles behind advanced endoscopic diagnosis and the new therapeutic options available. This chapter will review the advances in endoscopic techniques and methods which are changing the way we diagnose and treat these cancers. It will examine the general principles behind advanced endoscopy and then examine their application in Barrett's neoplasia, gastric cancer and the dysplasia associated lesions or masses associated with ulcerative colitis. It will focus on the best techniques for each of the above pathology.

Contents

1	Endoscopic Methods	186
2	Inflammation and Cancer	186
3	Fundamental Endoscopic Principles	186
3.1	Preparation	186
3.2	Basic Concepts	187
3.3	Philosophy of Endoscopy	187
3.4	Oesophageal Cancer	187
3.5	Treatment	190
4	The Stomach	191

G. Longcroft-Wheaton · P. Bhandari (✉)
Department of Gastroenterology, Queen Alexandra Hospital,
Cosham, Portsmouth, PO6 3LY, UK
e-mail: pradeep.bhandari@porthosp.nhs.uk

G. Longcroft-Wheaton
e-mail: gaius@gaius.wanadoo.co.uk

4.1 Treatment	192
5 The Colon	193
6 Endoscopic Resection of DALMS.....	194
7 Conclusions.....	195
References.....	195

1 Endoscopic Methods

Gastrointestinal malignancies represent a significant health burden, with the three main malignancies, colon, oesophageal and stomach cancer, representing the 3rd, 9th and 10th most common malignancies in the UK. With the exception of pancreatic cancer, survival has improved significantly over the last three decades, with survival rates doubling for oesophageal and colonic malignancies. This chapter will look at the advancing endoscopic techniques which are contributing to this, both in terms of diagnosis, staging and new novel treatments.

2 Inflammation and Cancer

As most gastrointestinal cancers develop on a background of inflammation it is important to differentiate inflammation from dysplasia. This is not always possible for the endoscopist or for the pathologist and is a common cause for confusion. The best approach is to always ensure that inflammation is completely treated prior to assessment of the mucosa for cancer. The diagnostic value of endoscopy for the detection of early cancer or dysplasia is very low in the presence of oesophagitis, gastritis or colitis. When these conditions are encountered a decision to fully treat inflammation and rescope at a later date should be made to assess for early neoplasia.

3 Fundamental Endoscopic Principles

3.1 Preparation

Good preparation is central to quality endoscopy, and the process starts before performing the endoscopy. In the upper gastrointestinal tract a mucolytic drink is recommended to enable subtle abnormalities to be evaluated. Pronase and Gascon ingested as a drink prior to gastroscopy has been shown to significantly improve mucosal visibility (Bhandari et al. 2010). Improving mucosal visibility should translate into improving early detection of cancers but that remains to be proven. Pronase is not licensed for ingestion, so a 50 ml solution containing 5 ml of 10% *N*-acetyl cysteine (NAC) with 5 ml of infacol can be used as an alternative in Western countries. This should be given as a drink 5 min prior to the procedure. Likewise, in the colon bowel preparation is central to visualising lesions. It is important that patients are informed of the importance of the bowel preparation,

including the timing of the sachets and the importance of consuming a significant volume of water with most of the commonly available preparations. When performing the procedure any residual debris should be washed away and the lens kept clean. Mucous and bubbles hinder the use of advanced techniques like spectral imaging and dye spray. A cap on the end of the endoscope can improve image quality when examining a lesion by stabilising the mucosa.

3.2 Basic Concepts

When visualising the oesophagus, stomach and colon, the mucosa should be inspected after insufflation and then again as the organ is deflated. It is during deflation of the lumen that many abnormalities become visible. Therefore, if inspection is only performed with complete inflation pathology will be missed. All areas should be visualised, with particular care taken to look beneath folds. There are key areas in each organ where pathology is most likely to be found, which will be discussed later. It is becoming recognised that a rapid procedure is not necessarily a good procedure. This has been demonstrated in studies looking at polyp detection in the colon, where a withdrawal time of >6 min is mandatory, and the same principle applies to the upper gastrointestinal tract. Likewise use of hyoscine during gastroscopy and colonoscopy can flatten the folds and help improve the pickup rate of early neoplasia.

3.3 Philosophy of Endoscopy

Most patients have an endoscopy because they are symptomatic and the endoscopist performs the procedure to look for a cause for the patient's symptoms. These causes are likely to be due to findings like peptic ulcer, oesophagitis or cancer in gastroscopy, and colitis or cancer during colonoscopy. However, these are very obvious findings during the procedure so endoscopists should pay special attention when no gross findings are seen. They should spend enough time to look at the fine details of the mucosa to identify subtle mucosal changes suggestive of the presence of early cancerous changes. Endoscopists in Japan have a very good understanding of these changes and also pay special attention looking for the changes. This might explain the higher incidence of early cancers detected in Japan. We believe that the endoscopist should spend more time looking at the mucosa and spend less time taking random untargeted biopsies.

3.4 Oesophageal Cancer

Oesophageal cancer is the ninth most common cancer in the UK, with 7,800 people diagnosed every year, accounting for 5% of all cancer deaths in the UK. Rates have increased by 50% over the last 30 years. It is more common in men

than women, with an incidence of 8.8–14.1 per 100,000 in men, and 4.8–5.7 per 100,000 in women (Barr 2007). The vague early symptoms have traditionally led to late diagnosis, leading to an overall 5 year survival of 9% (Hellier et al. 2006). However, recent endoscopic advances have made it easier to diagnose the condition at an earlier stage.

A significant risk factor for adenocarcinoma of the oesophagus is Barrett's epithelium, an acquired pre-malignant condition, caused by reflux of gastric contents into the oesophagus. The gastric acid damages the normal squamous epithelium, becoming replaced by a columnar epithelium. The newly updated definition by the British society of Gastroenterology defines Barrett's as 'an endoscopically apparent area above the oesophagogastric junction that is suggestive of Barrett's which is supported by the finding of columnar lined oesophagus on histology' (Playford 2006; Watson et al. 2005).

Barrett's oesophagus affects up to 1.6% of the general population (Ronkainen et al. 2005). It is found in 15–20% of gastrointestinal endoscopies performed for symptoms of reflux. The incidence is increasing in the West (Blot et al. 1991; Pera et al. 1993). It has the potential to progress into adenocarcinoma. Risk factors for this include male gender, age >45, extended segment (>8 cm) disease, duration of reflux history, early age of onset of GORD, duodeno-gastrooesophageal reflux, mucosal damage and family history (Watson et al. 2005).

There is not a national screening policy for the detection of upper gastrointestinal malignancy or for Barrett's. However, once Barrett's is detected patients are entered into a surveillance programme. The benefits of this are controversial, as the absolute risk of malignant transformation is low, 0.8–1.5% per annum. Some studies have concluded that because of this there is no benefit to surveillance (Watson et al. 2005). Computer modelling has been used to predict an effective balance point for surveillance intervals, and a widely used interval for surveillance endoscopy is 2 years (Watson et al. 2005). Quadrantic random biopsies every 2 cm are part of the standard protocol. The cost per life year saved is around £19,000.

Random biopsies are not ideal for identifying neoplasia within Barrett's. There are a range of techniques available for examining the oesophagus in detail, and can help improve neoplasia pickup rate. Chromo endoscopy can be used to identify areas of Barrett's metaplasia and dysplasia. Several dyes have been used, with most of the research examining methylene blue (MB), indigo carmine (IC) and acetic acid (AA).

Methylene blue 0.5% is an absorptive stain which highlights areas of specialised columnar epithelium (Canto et al. 1996, 2001). Dysplasia and cancer are detected more frequently than with random four quadrant biopsies (Canto et al. 2000). Unfortunately MB is inconvenient to use. It must be left in contact with the mucosa for 3 min followed by vigorous washing to clear away excess dye. As a result the endoscopic appearances are unpredictable and subjective (Dacosta et al. 2002). There have been recent concerns about DNA toxicity with MB so it is falling out of favour. IC 0.4% is not absorbed but accumulates in pits and valleys between cells highlighting the architecture (Hetil 2002) and has been shown to help in the detection of dysplasia (Sharma et al. 2003, 2006).




Fig. 1 Oesophagus: **a** routine endoscopic appearances, **b** post acetic acid chromoendoscopy

AA 2.5% when sprayed onto Barrett's mucosa causes a reversible acetylation of nuclear proteins to occur. This leads to an acetowhitening reaction, with increased opacity of the mucosal surface (Lambert et al. 2003). The associated vascular congestion improves visualisation of the surface vasculature (Lambert et al. 2003). It also enhances the surface pattern assessment allowing early recognition of neoplasia (see Fig. 1).

AA has been successfully used in the detection of neoplasia of the cervix during colposcopy (Guelrud and Herrera 1998; Van Le et al. 1993). While no randomised controlled trials for its use in the oesophagus exist, cohort studies have demonstrated effectiveness in the identification of dysplasia. The sensitivity for the identification of neoplasia has been suggested to be 71–100%, with a specificity between 80 and 99% (Vázquez-Iglesias et al. 2007; Gossner et al. 2005; Fortun et al. 2006; Longcroft-Wheaton et al. 2010). We believe that this is the dye of the future in the evaluation of Barrett's. It is cheap, effective and universally available.

Narrow band imaging (NBI) is a form of 'digital virtual chromo endoscopy'. It carries the potential advantage that it can be activated at the press of a button on the endoscope. It highlights mucosal vascular patterns to enhance abnormal dysplastic areas. A prospective cohort study has demonstrated that a sensitivity of 100%, specificity of 98.7% and positive predictive value of 95.3% for HGD could be achieved. Another tandem endoscopy study involving 65 patients compared standard resolution endoscopy to NBI. It found that NBI directed biopsies detected dysplasia in more patients (57%) compared to biopsies taken using standard resolution endoscopy (43%) (Wolfsen et al. 2008). Auto-fluorescence imaging (AFI) is another novel technique which is based on the principle of variable fluorescence between tissues. Normal mucosa when exposed to light emits a green fluorescence as compared to magenta/pink fluorescence in neoplastic areas within the mucosa. This principle is exploited by the technique of AFI to detect early

neoplasia. Early studies without NBI suggested that while detection rates were very good (91%) a 51% false positive rate limited its use without NBI (Kara et al. 2005). AFI is now being used as a 'red flag' technique to highlight points of concern in wide areas followed by detailed scrutinising using NBI (Curvers et al. 2008).

Fujinon has developed a technology for vascular enhancement, known as FICE. Rather than using filters it utilises a post processor technology to digitally reconstruct spectral data to enhance particular wavelengths. When compared with random biopsy in patients with suspected high grade intraepithelial neoplasia or early cancer, a sensitivity of 83% for FICE was achieved (Pohl et al. 2007). There was high grade dysplasia or early cancer in 24/57 patients. Due to its nature as a post processor technology, FICE can utilise a wide range of different frequencies for lesion enhancement. Therefore it has the potential to develop into a very powerful tool for examining Barrett's for neoplasia, perhaps with specific settings for the purpose. This is an area for future research.

All of the 'virtual chromo endoscopy' techniques (NBI, FICE and i-scan) produce different appearances. Although some of the skills are transferrable additional training is normally required to transfer between systems.

Confocal endomicroscopy is a new technology for obtaining true *in vivo* histology. Studies in Barrett's surveillance have suggested that Barrett's oesophagus with associated neoplasia could be predicted with a sensitivity of 96.4% (Trovato et al. 2008). It has been shown that confocal endomicroscopy improves the yield of neoplasia in apparent Barrett's oesophagus compared to a four quadrant random biopsy protocol (Dunbar et al. 2009). There is limited evidence that it is also effective in the identification of gastric cancers (Yeoh et al. 2005). This technique only works once neoplasia has been identified by the endoscopist using other endoscopic techniques, so it does not help improve detection but can improve the confidence for diagnosis. We believe that this is an excellent experimental technique which has yet to find a major clinical role.

3.5 Treatment

Traditionally the only treatment for high grade dysplasia and intramucosal adenocarcinoma was an oesophagectomy. This is a highly invasive intervention, associated with significant mortality and morbidity, variable according to centre, with high volume units producing better results (Birkmeyer et al. 2002). Post-operative morbidity is accepted to be significant, with rates between 30 and 50%, with a mortality of 2–10% (Chang et al. 2008).

Endoscopic resection and ablation techniques are becoming increasingly popular due to low morbidity and mortality. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) involve removing the mucosal and submucosal layers of the oesophagus. EMR uses either a cap and snare kit from Olympus or Duette banding ligator from Cook to remove the abnormal tissue. This can be taken in one piece (May et al. 2002a, b; Pech et al. 2008) or, for larger areas,

piecemeal excision can be performed. EMR gives a better histological diagnosis as compared to biopsy. However, if a lesion is >1.5 cm then piecemeal resection can make it hard to determine completeness of the lateral resection margins. ESD uses a specialised endoscopic knife to dissect out neoplastic areas of any size in an en-block fashion. It can provide a clear resection margin but carries increased risks, including that of perforation. This can be combined with Argon plasma coagulation (APC), multipolar electrocautery (MPEC), which all aim to destroy any residual abnormal tissue through either ionised argon gas or an electric current.

Ablative photodynamic therapy (PDT) involves the use of a photosensitizing agent which is preferentially taken up by tumour tissue (Panjehpour et al. 2008). After a suitable time period an endoscopy is performed where the abnormal area is exposed to light at an appropriate wavelength. The neoplasia which has preferentially taken up the drug then undergoes cell death. Using this technique a randomised controlled trial has shown 98% efficacy at eliminating low grade dysplasia (Ackroyd et al. 2000). Success has also been demonstrated with HGD and superficial T1 cancers, with successful ablation of HGD as high as 93% in one prospective series (Overholt et al. 1999), although a more recent RCT by the same author has suggested that complete HGD ablation is achieved in 77% of cases over a mean follow up period of 24 months (Overholt et al. 2005). It can cause stricture formation and photosensitivity reactions. Radiofrequency ablation (RFA) is similar in concept. Radiofrequency electrodes deliver thermal energy through a focal device or balloon inflated to make contact with the oesophageal wall. This induces mucosal destruction. The depth of burn is less than with PDT which improves the safety profile of RFA over that of PDT, with a low oesophageal stricture rate of 6%, no deaths and no perforations seen in a large sham-controlled trial (Shaheen et al. 2008). RFA is a useful technique for multifocal dysplasia (Shaheen et al. 2009). It is not suitable for raised nodular areas which should first be removed by EMR. There have been no trials conducted to date which show whether RFA combined with EMR is any better than EMR alone.

4 The Stomach

The incidence of gastric cancer is falling in the west. This is attributed to the declining incidence of *Helicobacter pylori* (*H. pylori*) colonisation. Gastric cancer is therefore considered to develop on a background of inflammation (McNamara and El-Omar 2008; Ernst 1999). Eradication of *H. pylori* is probably effective in reducing risk and possibly cost effective (Parsonnett et al. 1996; Roderick et al. 2003). In practical terms in the west the incidence is falling anyway, so the gain from actively seeking to eradicate in an asymptomatic population may be small.

The most common areas for gastric cancer associated with *H. Pylori* is in the antrum or insura. In helicobacter negative patients it is more prevalent along the greater curve or in the body. It is very important therefore when examining patients to look closely in these areas.




Fig. 2 High grade dysplasia in the gastric cardia after indigo carmine dye spray

Screening for gastric cancer is controversial. A screening programme place is in Japan, which has been successful in reducing mortality. This has not been adopted in the west, where the lower prevalence of the condition makes the usefulness questionable. However, patients with atrophic gastritis are at increased risk, and yearly endoscopic screening has been suggested in this group of patients (Whiting et al. 2002).

The diagnosis of gastric cancer is predominately by endoscopy. A non-healing gastric ulcer is the classical appearance of gastric cancer. This however, typically represents advanced disease. The key problem is in detecting early, potentially treatable lesions. However, the Japanese have demonstrated that not only it is possible to find early gastric cancer, but that it is even possible to accurately stage the depth of lesion invasion in 95% early cancer and 86% for advanced cancer (Yin et al. 2009). This assessment is best made by indigocarmine assisted chromo endoscopy techniques (see Fig. 2). NBI has been utilised with some success. There is very limited evidence available regarding whether FICE is beneficial.

4.1 Treatment

Early gastric cancer in the west has traditionally been treated by gastrectomy. However, in Japan endoscopic resection is the standard treatment. The Japanese gastric cancer association (JGCA) released a series of recommendations for the management of gastric cancer in 2001, (Nakajima 2002) updated in 2008 to reflect the rapid advances in management options available. Endoscopic resection is indicated for lesions <2 cm in size with a differentiated histological type where there is no ulceration present (Tsujiyama et al. 1999). Recently the indications have been expanded further to include all intramucosal cancer regardless of size without ulceration, or intramucosal cancer <30 mm with ulceration.

EMR of mucosal cancer is indicated for lesions under 2 cm, where the risk of lymph node metastasis is very low. An enbloc resection should be performed whenever possible, and is important in reducing the risk of recurrence (Eguchi et al. 2003). A problem with both cap and snare and duette cap ligation devices is that the




Fig. 3 Dual and IT-2 knives being used to resect a gastric lesion. Note how a circumferential incision is made and the final specimen removed enbloc

maximum size lesion which can be resected in one piece is 15 mm (Ell et al. 2000; Tanabe et al. 2002). Using these techniques recurrence free survival can be achieved in up to 92% of cases (Oda et al. 2006), with the recurrence rate most often quoted in the literature as being between 2 and 32% (Gotoda 2007).

Because of the importance of enbloc resection on recurrence free survival and the inherent limitations imposed by EMR techniques. ESD has become increasingly popular in Japan. This enables a true R0 resection to be achieved in a greater proportion of cases, and allows larger lesions to be removed. It is used for all lesions over 2 cm in diameter or where there is ulceration seen. There are now a wide range of endoscopic knives available for performing ESD, and it is accepted that these techniques are technically challenging (Choi et al. 2005). The risk of serious complications, including bleeding and perforation, is higher than that with EMR, with a risk of delayed bleeding of 6% and perforation around 4% (Oda et al. 2005). It is generally accepted that it is necessary to perform between 30 and 40 resections in a closely supervised environment before becoming competent. However, the potential gain in disease free survival is clear, with a comparative multicentre study demonstrating a significant difference in the disease free survival rates between ESD and EMR (97.6 vs. 92.5%) (Oda et al. 2006). We believe that ESD is an excellent technique for lesions over 2 cm, but is very challenging and expertise outside of Japan in this technique remains limited (see Fig. 3).

5 The Colon

A major risk factor for inflammatory neoplasia in the colon is ulcerative colitis. This is an idiopathic inflammatory condition which affects the large bowel. It has a prevalence of 3–12 per 100,000 in Northern Europe and America, but is much less common in Asia and the Far East, with a prevalence between 1 and 6 per 100,000 (Loftus 2004).

Chronic ulcerative colitis increases the risk of colonic cancer. The cancer risk in patients with ulcerative colitis is dependent on the extent of disease and the frequency of attacks. It is generally accepted that the cumulative risk for patients with extensive disease between 7 and 15% at 20 years. Up to 15 years the risk is very low. Carcinoma is usually preceded by dysplasia. Because of this there is a national screening policy for patients with Ulcerative colitis. It is the general consensus that colonoscopic screening should start at 8–10 years for patients with a pan-colitis or after 15 years for disease restricted to the left side (Riddell 1990), with regular

follow up thereafter. The standard approach has been to take quadrantic biopsies every 10 cm. This is unfortunately time consuming and expensive. There is evidence that more dysplastic lesions are picked up using methylene blue or indigo carmine than with white light alone (Marion et al. 2008; Rutter et al. 2004). The most recent guidelines from the British Society of Gastroenterology are recommending the use of chromo endoscopy where there is appropriate expertise available. Unfortunately to date colonoscopy with NBI has not been shown to be effective (Dekker et al. 2007). Caution needs to be taken when interpreting these findings; however, as the amount of evidence available is very limited.

The aim of chromoendoscopy in ulcerative colitis is to pick up areas of dysplasia associated lesions or mass (DALMS) which could turn into cancer. These abnormalities can be very subtle. As a result it is not possible where pseudo-polyps predominate or there is significant active inflammation. Dye can be applied by a spray catheter or flushed directly down the endoscope, depending on the preferences of the endoscopist. It is important to note that at present the evidence is not there for abandoning random biopsies in these patients. Therefore if dye spray is used and no abnormalities are seen biopsies still need to be taken. This may change with time.

Confocal endomicroscopy has been used in the examination of patients with ulcerative colitis. Early studies have shown some promise, with yields for intra-epithelial neoplasia greater in the chromo endoscopically guided biopsies than those targeted by chromo endoscopy alone (Hurlstone et al. 2008; Kiesslich et al. 2007). This suggests that if a targeted area is examined by the confocal endomicroscope it has the potential to prove or disprove whether it needs to be biopsied, in doing so reducing the number of unnecessary biopsies taken.

6 Endoscopic Resection of DALMS

The traditional treatment of high grade dysplasia on a background of ulcerative colitis has been colectomy. However, this strategy was developed on the hypothesis that dysplasia could not be visualised. The traditional view was that colon cancers originating on a background of dysplasia associated lesion or mass (DALMS) do not follow the traditional adenoma-carcinoma sequence, with rapid progression being seen (Blackstone et al. 1981). This view is now being challenged. There have been two studies which have investigated the endoscopic resection of polyp like DALMS (Rubin et al. 1999; Engelskjerd et al. 1999). The principle behind removal is to distinguish between lesions which are close to turning into cancer from those which are likely to behave more like adenomatous polyps.

An adenomatous DALM is defined as a well-circumscribed, smooth or papillary, non-necrotic sessile or pedunculated lesion (Odze and Robert 2008). Non-adenoma like lesions appear as velvety patches, plaques, irregular bumps, stricturing lesions and broad based masses. A small long term outcome study has investigated the outcome of 34 patients who had DALMs, 28 resected

endoscopically and six by colonic resection. These were compared to 49 non-colic patients treated for sporadic adenomas. It showed that one patient developed adenocarcinoma 7.5 years after resection. However, she was a high risk patient with sclerosing cholangitis. Twenty patients developed further DALMS. This was no different to the rate of sporadic adenomas in the control group (Hornick et al. 2004).

The current American Gastroenterology Association guidelines are that adenomatous like DALMS can be removed provided they can be completely excised, with an absence of dysplasia at the resection margins, and that there is no flat dysplasia anywhere else in the colon. All patients with flat non-adenoma like dysplasia should be treated with total colectomy (Itzkowitz et al. 2010).

7 Conclusions

Neoplasia in the gastrointestinal tract can develop on a background of chronic inflammation or via a non-inflammatory pathway. These neoplasias can be recognised by an endoscopist at a very early stage. The prerequisites for early diagnosis are adequate luminal preparation, a high resolution endoscope and an endoscopist with an ability to recognise subtle mucosal changes indicative of neoplasia.

Endoscopic resection and ablation techniques can now cure patients with dysplasia or early cancerous lesions without the need for radical resectional surgery and its associated morbidity and mortality. However, the success of these techniques depends on the skills and experience of the endoscopist and we believe that these procedures should only be performed at high volume early cancer centres.

References

- Ackroyd R, Brown NJ, Davis MF et al (2000) Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. *Gut* 47: 612–617
- Barr Hugh (2007) The case against oesophageal resection. *Ann R Coll Surg Engl* 89(6):586–588
- Bhandari P, Green S, Hamanaka H, Nakajima T, Matsuda T, Saito Y, Oda I, Gotoda T (2010) Use of Gascon and Pronase either as a pre-endoscopic drink or as targeted endoscopic flushes to improve visibility during gastroscopy: a prospective, randomized, controlled, blinded trial. *Scand J Gastroenterol* 45:357–361
- Birkmeyer JD, Siewers AE, Finlayson EV et al (2002) Hospital volume and surgical mortality in the United States. *N End J Med* 346:1128–1137
- Blackstone MO, Riddell RH, Rodgers BHG, Levin B (1981) Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in longstanding colitis. An indication for colectomy. *Gastroenterology* 80:366–374
- Blot WJ, Devesa SS, Kneller RW et al (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA* 265:1287–1289
- Canto MI, Selrakian S, Petras RE et al (1996) Methylene Blue selectively stains intestinal metaplasia in Barrett's oesophagus. *Gastrointest Endosc* 44(1):1–7

- Canto MI, Selrakian S, Petras RE et al (2000) Methylene-blue directed biopsies improves detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. *Gastrointest Endosc* 51:560–568
- Canto MI, Setrakian S, Willis JE, Chak A, Petras RE, Sivak MV (2001) Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study. *Endoscopy* 33:391–400
- Chang AC, Ji H, Birkmeyer NJ et al (2008) Outcomes after transhiatal and transthoracic esophagectomy for cancer. *Ann Thorac Surg* 85:424–429
- Choi JJ, Kim CG, Chang HJ, Kim SG, Kook MC, Bae JM (2005) The learning curve for EMR with circumferential mucosal incision in treating intramucosal gastric cancer. *Gastrointest Endosc* 62(6):860–865
- Curvers WL, Singh R, Song LM, Wolfsen HC, Ragunath K, Wang K, Wallace MB, Fockens P, Bergman JJ (2008) Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. *Gut* 57:167–172
- Dacosta RS, Wilson BC, Marcon NE (2002) New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions. *J Gastroenterol Hepatol* 17:S85–S104
- Dekker E, van den Broek FJ, Reitsma JB, Hardwick JC, Offerhaus GJ, van Deventer SJ, Hommes DW, Fockens P (2007) Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. *Endoscopy* 39(3):216–221
- Dunbar KB, Okolo P III, Montgomery E, Canto MI (2009) Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. *Gastrointest Endosc* 70(4):645–654
- Eguchi T, Gotoda T, Oda I, Hamanaka H, Hasuike N, Saito D (2003) Is endoscopic one-piece mucosal resection essential for early gastric cancer? *Dig Endosc* 15:113–116
- Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G et al (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. *Gastroenterology* 118:670–677
- Engelsgjerd M, Farraye FA, Odze RD (1999) Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. *Gastroenterology* 117(6):1288–1294
- Ernst P (1999) Review article: the role of inflammation in the pathogenesis of gastric cancer. *Aliment Pharmacol Ther* 13(suppl 1):13–18
- Fortun P, Anagnostopoulos G, Kaye P et al (2006) Acetic acid enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus. *Aliment Pharmacol Ther* 23:735–742
- Gossner L, Pech O, May A, Rabenstein T et al (2005) Inter- and intraobserver variability in high resolution chromoendoscopy with acetic acid for the detection of intestinal metaplasia and early neoplasia in Barrett's esophagus (abstract). *Gastrointest Endosc* 61(5):AB132
- Gotoda Takuji (2007) Endoscopic resection of early gastric cancer. *Gastric Cancer* 10(1):1–11
- Guelrud M, Herrera L (1998) Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopic therapy. *Gastrointest Endosc* 47:512–515
- Hellier MD, Sanderson JD, Morris AL, Elias E, De Caestecker J (2006) Care of patients with gastrointestinal disorders in the United Kingdom: a strategy for the future. *British Society of Gastroenterology. Gut Online*, p 24
- Hetil O (2002) Indigo carmine contrast staining in combination with high resolution electronic endoscopy. *Gasztróenterológiai Osztály* 143(1):25–29
- Hornick J, Odze RD, Farraye FA, Hecht JL, Jason L (2004) Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. *Clin Gastroenterol Hepatol* 2(7): 534–541
- Hurlstone DP, Kiesslich R, Thomson M, Atkinson R, Cross SS (2008) Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis. *Gut* 57(2):196–204

- Itzkowitz SH, Farraye FA, Odze RD, Eaden J (2010) AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 38(2):738–745
- Kara MA, Peters FP, Ten Kate FJ, Van Deventer SJ, Fockens P, Bergman JJ (2005) Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. *Gastrointest Endosc* 61(6):679–685
- Kiesslich R, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M, Vieth M, Nafe B, Galle PR, Neurath MF (2007) Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. *Gastroenterology* 132:874–882
- Lambert R, Rey JF, Sankaranarayanan R (2003) Magnification and chromoscopy with the acetic acid test. *Endoscopy* 35:437–445
- Loftus EV (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 126(6):1504–1517
- Longcroft-Wheaton G, Duku M, Mead R, Poller D, Bhandari P (2010) Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in patients with Barrett's esophagus. *Clin Gastroenterol Hepatol* 8(10):843–847
- Marion JF, Wayne JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L (2008) Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. *Am J Gastroenterol* 103(9):2342–2349
- May A, Gossner L, Pech O, Müller H, Vieth M, Stolte M, Ell C (2002a) Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. *Endoscopy* 34:604–610
- May A, Gossner L, Pech O, Fritz A, Günter E, Mayer G, Müller H, Seitz G, Vieth M, Stolte M, Ell C (2002b) Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. *Eur J Gastroenterol Hepatol* 14:1085–1091
- McNamara D, El-Omar E (2008) Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. *Dig Liver disease* 40(7):504–509
- Nakajima T (2002) Gastric cancer treatment guidelines in Japan. *Gastric Cancer* 5(1):1–5
- Oda I, Gotoda T, Hamanaka H, Eguchi T, Saito Y, Takahisa M, Bhandari P, Emura F, Saito D, Hiroyuki O (2005) Endoscopic submucosal dissection for early gastric cancer: technical feasibility, operation time and complications from a large consecutive series. *Dig Endosc* 17:54–58
- Oda I, Saito D, Tada M, Iishi H, Tanabe S, Oyama T, Doi T, Otani Y, Fujisaki J, Ajioka Y, Hamada T, Inoue H, Gotoda T, Yoshida S (2006) A multicenter retrospective study of endoscopic resection for early gastric cancer. *Gastric Cancer* 9(4):262–270
- Odze RD (2008) What are the guidelines for treating adenoma-like DALMs in UC? *Inflamm Bowel Dis* 14(52):s243–s244
- Overholt BF, Panjehpour M, Haydek JM (1999) Photodynamic therapy for Barrett's esophagus: follow up in 100 patients. *Gastrointest Endosc* 49(1):1–7
- Overholt BF, Lightdale CJ, Wang KK et al (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomised phase III trial. *Gastrointest Endosc* 62(4):488–498
- Panjehpour M, Coppola D, Overholt BF, Vo-Dinh T, Overholt S (2008) Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment. *Anticancer Res* 28(1B):485–489
- Parsonnett J, Harris RA, Hack HM, Owens DK (1996) Modelling cost effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. *Lancet* 348(9021):150–154
- Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, Manner H, Guenter E, Huijsmans J, Vieth M, Stolte M, Ell C (2008) Long-term results and risk factor analysis for

- recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. *Gut* 57:1200–1206
- Pera M, Cameron AJ, Trastek VF et al (1993) Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. *Gut* 104:510–513
- Playford RJ (2006) New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. *Gut* 55(4):442
- Pohl J, May A, Rabenstein T, Pech O, Nguyen-Tat M, Fissler-Eckhoff A, Ell C (2007) Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett's esophagus. *Endoscopy* 39(7):594–598
- Riddell RH (1990) Screening strategies in gastrointestinal cancer. *Scand J Gastroenterol Suppl* 175:177–184
- Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, Bhandari P (2003) Cost-effectiveness of population screening for *Helicobacter pylori* in preventing gastric cancer and peptic ulcer disease, using simulation. *J Med Screen* 10(3):148–156
- Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agrés L (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. *Gastroenterology* 129(6):1825–1831
- Rubin PH, Friedman S, Harpaz N et al (1999) Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. *Gastroenterology* 117(6):1295–3000
- Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC (2004) Pancolonoscopic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. *Gut* 53(2):256–260
- Shaheen NJ, Sharma P, Overholt BF et al (2008) A randomised, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett's esophagus (BE) containing dysplasia: interim results of the AIM dysplasia trial. *Gastroenterology* 134:A37
- Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ (2009) Radiofrequency ablation in Barrett's esophagus with dysplasia. *New Engl J Med* 360(22):2277–2288
- Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE (2003) Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. *Gut* 52(1):24–27
- Sharma P, Marcon N, Wani S, Bansal A, Mathur S, Sampliner R, Lightdale C (2006) Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study. *Endoscopy* 38:1206–1212
- Tanabe S, Koizumi W, Mitomi H, Nakai H, Murakami S, Nagaba S et al (2002) Clinical outcome of endoscopic aspiration mucosectomy for early stage gastric cancer. *Gastro intestinal Endosc* 56(5):708–713
- Trovato C, Sonzogni A, Fiori G, Ravizza D et al (2008) Confocal Laser Endomicroscopy for in vivo diagnosis of Barrett's oesophagus and associated neoplasia: an ongoing prospective study. *Gastrointest Endosc* 67(5):AB 97
- Tsujitani S, Oka S, Saito H, Kondo A, Ikeguchi M, Maeta M et al (1999) Less invasive surgery for early gastric cancer based on the low probability of lymph node metastasis. *Surgery* 125(2):148–154
- Van Le L, Broekhuizen FF, Janzer-Steele R et al (1993) Acetic acid visualization of the cervix to detect cervical dysplasia. *Obstet Gynecol* 81:293–295
- Vázquez-Iglesias JL, Alonso-Aguirre P, Diz-Lois MT, Vázquez-Millán MA, Alvarez A, Lorenzo MJ (2007) Acetic acid allows effective selection of areas for obtaining biopsy samples in Barrett's esophagus. *Eur J Gastroenterol Hepatol* 19(3):187–193
- Watson A, Heading RC, Shepherd NA (2005) Guidelines for the diagnosis and management of Barrett's Columnar-lined oesophagus (CLO). A report of the working party of the British

Society of Gastroenterology, Q3 Print Project Management Limited, Loughborough, Leicestershire

- Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW (2002) The long term results of endoscopic surveillance of premalignant gastric lesions. *Gut* 50(3):378–381
- Wolfsen HC, Crook JE, Krishna M, Achem SR, Devault KR, Bouras EP, Loeb DS, Stark ME, Woodward TA, Hemminger LL, Cayer FK, Wallace MB (2008) Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. *Gastroenterology* 135(1):24–31
- Yeoh KG, Salto-Tellez M, Khor CJL et al (2005) Confocal laser endoscopy is useful for in vivo rapid diagnosis of gastric neoplasia and pre-neoplasia. *Gastroenterology* 128(4):A27 Suppl
- Yin JX, Oda I, Suzuki H, Gotoda T, Shimoda T, Saito D (2009) Endoscopic diagnosis of gastric cancer invasion depth. *Nippon Shokakibyō Gakkai Zasshi* 106(11):1603–1609